nct_id,phase,number_of_arms,brief_title,official_title,enrollment,start_date,completion_date,sponsor
NCT00031837,Phase 3,1,Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer,A Prospective Randomized Controlled Multicenter Study of the Effect of Dalteparin on Quality of Life in Unresectable Pancreatic Cancer,400,2002-10-01,2006-12-01,University of Rochester
NCT00045955,Phase 3,NA,Long-Term Safety Performance of Fexofenadine in Asthma,"A Multicenter, Open-Label, Randomized, Parallel Groups Study to Assess the Long-Term Safety Performance of Fexofenadine Compared to Montelukast in Subjects With Asthma",1200,2002-02-01,2003-11-01,Sanofi
NCT00048581,Phase 3,3,Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.,"A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 in Subjects With Active Rheumatoid Arthritis on Background Disease Modifying Anti-Rheumatic Drugs (DMARDS) Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy",738,2002-12-01,2009-09-01,Bristol-Myers Squibb
NCT00062582,Phase 3,NA,Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110),"A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)",1000,2003-06-01,NA,AstraZeneca
NCT00071266,Phase 3,NA,The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC,The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - a Matrix Design,870,2003-10-01,NA,Kos Pharmaceuticals
NCT00093886,Phase 3,2,Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG),Evaluation of Clevidipine in the Perioperative Treatment of Hypertension Assessing Safety Events (With Nitroglycerin as Active Comparator) (ECLIPSE-NTG),629,2004-04-01,2005-04-01,The Medicines Company
NCT00095082,Phase 3,NA,Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes,Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes,447,2004-09-01,2005-12-01,Novo Nordisk A/S
NCT00096954,Phase 4,2,"A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)","A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)",333,2006-02-01,2010-09-01,"Genentech, Inc."
NCT00100620,Phase 3,NA,Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis,Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis,802,2004-06-01,2007-04-01,Novartis
NCT00138515,Phase 3,NA,Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes,Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes,418,2004-11-01,2006-05-01,Novartis
NCT00153660,Phase 3,2,Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients,A Double-blind Randomized Comparison of Celecoxib Plus Esomeprazole Versus Naproxen Plus Esomeprazole for Prevention of Recurrent Ulcer Bleeding in Patients With Arthritis and Cardiothrombotic Diseases (NSAID#8 Study),514,2005-06-01,2016-12-01,Chinese University of Hong Kong
NCT00165737,Phase 3,NA,Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease,"A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease",974,2003-03-01,2006-06-01,Eisai Inc.
NCT00174785,Phase 3,2,A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation,"A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)",4628,2005-06-01,2008-03-01,Sanofi
NCT00182143,Phase 3,2,PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT),PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT),3659,2006-05-01,2010-06-01,McMaster University
NCT00200434,Phase 3,NA,A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension,"A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Mild to Moderate Hypertension",600,2002-10-01,2003-10-01,Mylan Bertek Pharmaceuticals
NCT00206154,Phase 3,NA,"A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients","A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT® pMDI 2 x 160/4.5 µg & 80/4.5 µg Bid Compared to Formoterol TBH, Budesonide pMDI (& the Combination) & Placebo in COPD Patients",1500,2005-04-01,2006-12-01,AstraZeneca
NCT00219076,Phase 3,NA,A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients,"A Six-week, Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren 150 mg and Amlodipine 5 mg Compared to Amlodipine 5 mg and 10 mg in Hypertensive Patients Not Adequately Responsive to Amlodipine 5 mg",504,2005-02-01,NA,Novartis
NCT00224146,Phase 4,NA,Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder,Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX),2878,2004-05-01,2005-05-01,Watson Pharmaceuticals
NCT00225264,Phase 3,2,Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.,"A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Atherosclerotic Disease as Measured by Carotid Intima-Media Thickness",458,2003-10-01,2006-05-01,Takeda
NCT00236717,Phase 3,NA,A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy,TOPAMAX (Topiramate) Monotherapy Comparison Trial to Standard Monotherapy in the Treatment of Newly Diagnosed Epilepsy (RWJ-17021-000); Phase IIIB,865,1997-09-01,2000-11-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00251927,Phase 3,2,Esomeprazole (NEXIUM) vs. Surgery,"An Open, Randomized, Multicenter, Phase IIIB Study During 5 Years to Assess Long-term Efficacy and Tolerability of Esomeprazole Compared to Laparoscopic Anti-reflux Surgery in Adult Subjects With Gastroesophageal Reflux Disease - LOTUS.",626,2001-10-01,2009-04-01,AstraZeneca
NCT00251966,Phase 3,NA,ASTERIX: Low Dose ASA and Nexium,A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 mg Once Daily for 26 Weeks.,960,2004-05-01,2005-09-01,AstraZeneca
NCT00259428,Phase 3,2,EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS),EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS),615,2001-11-01,2003-08-01,Sanofi
NCT00264849,Phase 4,2,Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma,"A Randomized, Open Label, Parallel-group, International, Multicenter Study Evaluating Persistency of Response to Omalizumab During 32 Weeks Treatment Given as Add on to Optimized Asthma Therapy in Adult and Adolescent Patients With Severe Persistent Allergic Asthma, Who Remain Inadequately Controlled Despite GINA (2004) Step 4 Therapy",406,2005-11-01,2008-09-01,Novartis
NCT00274053,Phase 3,NA,Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD,Effect of a 9-month Treatment of SPIRIVA® on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease. Validation of a New HRQoL Questionnaire Appropriate to Common Daily Practice. (TIPHON Study),555,2002-04-01,2004-04-01,Boehringer Ingelheim
NCT00279201,Phase 4,6,The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV),The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine When Added to Existing Oral Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control,2091,2005-12-01,2009-11-01,Eli Lilly and Company
NCT00294723,Phase 3,4,To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c,Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes,746,2006-02-01,2008-11-01,Novo Nordisk A/S
NCT00297115,Phase 3,2,Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125),Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The HERMES Study,1568,2006-03-01,2008-08-01,AstraZeneca
NCT00306644,Phase 4,1,Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes,Effect of Rosiglitazone and Placebo on Carotid Intima Media Thickness in Patients With Insulin Resistance Syndrome and/or Type 2 Diabetes,556,2002-05-01,2004-11-01,GlaxoSmithKline
NCT00311753,Phase 3,2,Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients,An Open-label Comparison of the Efficacy and Safety of the Low-molecular-weight Heparin (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-surgical Patients,342,2006-02-01,NA,Novartis
NCT00311818,Phase 4,NA,Insulin Glargine in Type 2 Diabetes Mellitus,"44-week, Parallel, Open, Randomized, Multinational, Multi-center Clinical Trial to Compare Efficacy and Safety of the Combination Therapy of an Oral Anti-diabetic Drug Treatment With Either HOE901 Insulin Once Daily or Lispro Insulin Analogue at Mealtime in Type 2 Diabetes Mellitus Patients Poorly Controlled With Oral Anti-diabetic Drug Treatment.",NA,2003-06-01,NA,Sanofi
NCT00324363,Phase 3,2,Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin,Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin,466,2006-01-01,2007-04-01,AstraZeneca
NCT00326053,Phase 3,NA,Prevention of Asthma Relapse After Discharge From Emergency,A Comparison of Budesonide/Formoterol Turbuhaler® 160/4.5 µg 2 Inhalations BID Plus as Needed to Budesonide Turbuhaler® 320 µg 2 Inhalations BID Plus Terbutaline Turbuhaler® 0.4 mg as Needed for the Prevention of Asthma Relapse,600,2006-05-01,2007-05-01,AstraZeneca
NCT00331851,Phase 3,NA,Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes,"Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine Added to Glimepiride and Metformin Combination Therapy in Subjects With Type 2 Diabetes.A Six-month Randomised, Double-blind, Parallel-group, Multi-centre, Multi-national Trial With an Open-label Treat-to-target Insulin Glargine Control Arm.",584,2006-05-01,2007-04-01,Novo Nordisk A/S
NCT00336336,Phase 3,4,GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF,A Large Scale Clinical Trial Testing the Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic Congestive Heart Failure,6975,2002-08-01,2008-05-01,Gruppo di Ricerca GISSI
NCT00338260,Phase 3,NA,Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133),"A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy",496,1995-06-01,2001-11-01,Merck Sharp & Dohme Corp.
NCT00397631,Phase 3,2,Initial Combination With Pioglitazone Study (0431-064),"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus",520,2006-12-19,2008-06-28,Merck Sharp & Dohme Corp.
NCT00398931,Phase 3,NA,FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051),"A 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial",1099,1998-02-01,2003-10-01,Merck Sharp & Dohme Corp.
NCT00425997,Phase 4,NA,Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension,"A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hypertension",480,2006-12-01,2007-10-01,Novartis
NCT00434967,Phase 3,4,Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo,"A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) 32 mg and Hydrochlorothiazide (HCT) 25 mg Compared With CC 32 mg, HCT 25 mg and Placebo in Hypertensive Adults",2207,2007-01-01,2008-01-01,AstraZeneca
NCT00462748,Phase 3,3,A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121),"A MC, DB, Rand, Study to Evaluate Efficacy, Safety and Tolerability of Eze/Simva 10/40 mg, Atorva 40 mg, Rosuva 10 mg in Achieving LDL-C <2 mmol/l in Pts With CVD...on Simva 40 mg With LDL-C ³2 mmol/l",786,2007-03-01,2008-06-01,Merck Sharp & Dohme Corp.
NCT00468546,Phase 3,2,A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy,"A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Alpha Therapies",520,2003-05-01,2012-07-01,Hoffmann-La Roche
NCT00488267,Phase 3,3,Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee,"A Randomized, Double-Blind, 12-Week Study to Evaluate the Efficacy of ThermoProfen™ in the Treatment of Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee (ZMK-301)",679,2007-06-01,2008-09-01,ZARS Pharma Inc.
NCT00500604,Phase 4,2,Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension,A Comparative Study of the Efficacy of Irbesartan/Hydrochlorothiazide 300/25 mg Versus Valsartan/Hydrochlorothiazide 160/25 mg Using Home Blood Pressure Monitoring in the Treatment of Mild to Moderate Hypertension,1617,2007-07-01,2010-01-01,Sanofi
NCT00523991,Phase 4,2,Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).,"A 24 Week, Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by HandiHaler Once-daily Plus PRN Albuterol (Salbutamol) vs. Placebo Plus PRN Albuterol (Salbutamol) in Chronic Obstructive Pulmonary Disease Subjects Naive to Maintenance Therapy",457,2007-04-01,NA,Boehringer Ingelheim
NCT00547300,Phase 3,NA,Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-Release (ER) for Hypertension,Tolerability of Nebivolol Compared With Metoprolol ER in Patients With Mild to Moderate Hypertension Taking Hydrochlorothiazide,400,2007-10-01,2008-10-01,Forest Laboratories
NCT00549757,Phase 3,2,Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases),"A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality",8606,2007-10-01,2013-02-01,Novartis
NCT00550953,Phase 3,NA,Filtered Trial for Telmisartan 40mg Non-responder,Filtered Trial for Telmisartan 40mg Non-responder,314,2007-10-01,NA,Boehringer Ingelheim
NCT00614120,Phase 3,4,Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes,Effect of Liraglutide or Glimepiride Added to Metformin on Glycaemic Control in Subjects With Type 2 Diabetes,929,2008-01-01,2009-02-01,Novo Nordisk A/S
NCT00625547,Phase 3,2,A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS,"A Double-Blind, Randomized, Active-Controlled Multicenter Efficacy Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)",361,2003-01-01,2004-12-01,Pfizer
NCT00666718,Phase 3,2,A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients,A Prospective Randomized Trial to Compare Basal Bolus Therapies That Use Either Insulin Lispro Protamine Suspension or Insulin Glargine Together With Lispro Insulin in Patients With Type 2 Diabetes,374,2008-04-01,2010-02-01,Eli Lilly and Company
NCT00694382,Phase 3,2,Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy,"A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy",3212,2008-06-01,2010-11-01,Sanofi
NCT00714597,Phase 3,2,Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility,"A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility",421,2008-07-01,2009-03-01,Sanofi
NCT00716547,Phase 3,4,Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA),"Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Study of Safety and Efficacy of Two Dosages of Epicutaneously Applied Diractin® (Ketoprofen in Transfersome® Gel) for the Treatment of Osteoarthritis of the Knee",1399,2008-05-01,2009-05-01,IDEA AG
NCT00717236,Phase 3,2,Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis,"A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.",1648,2008-07-01,2011-03-01,UCB Pharma
NCT00771394,Phase 4,3,Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride",638,2008-10-01,2010-01-01,Astellas Pharma Inc
NCT00806026,Phase 3,6,Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients,"Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome",731,2008-12-01,2011-05-01,Pfizer
NCT00863304,Phase 3,4,Tanezumab in Osteoarthritis of the Hip or Knee (2),"A Phase 3 Randomized, Double Blind Placebo And Naproxen Controlled Multicenter Study of the Analgesic Efficacy And Study of Tanezumab in Patients With Osteoarthritis Of The Hip or Knee",849,2009-05-01,2010-06-01,Pfizer
NCT00911534,Phase 3,2,"Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)","A Multicenter Randomized Double-Blind Study to Compare the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)",305,2009-01-01,2009-10-01,Eisai Inc.
NCT00923091,Phase 3,8,"Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension","Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination in Subjects With Hypertension",2689,2009-06-01,2011-03-01,"Daiichi Sankyo, Inc."
NCT00957047,Phase 3,5,Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy,"Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial",395,2004-07-01,2008-01-01,Bial - Portela C S.A.
NCT00968708,Phase 3,2,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome",5380,2009-09-01,2013-06-01,Takeda
NCT01034137,Phase 3,3,A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis,"U-ACT-EARLY: A Multi-center, Randomized, Double Blind, Placebo Controlled Study to Evaluate Remission in DMARD and Biological naïve Early Rheumatoid Arthritis (RA) Subjects Treated With Tocilizumab (TCZ) Plus Tight Control Methotrexate (MTX) , TCZ Monotherapy or Tight Control MTX Monotherapy",317,2010-01-01,2014-09-01,Hoffmann-La Roche
NCT01045447,Phase 3,2,"Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes","A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes (BOOST™ : INTENSIFY BASAL)",465,2010-01-01,2010-10-01,Novo Nordisk A/S
NCT01053988,Phase 3,5,A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD),1031,2009-10-05,2011-04-14,GlaxoSmithKline
NCT01059773,Phase 4,2,A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate,An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitiioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT),490,2009-10-01,2011-08-01,Janssen-Cilag International NV
NCT01070784,Phase 3,2,A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan,"An Open-label Phase III, Multi-centre 52-week , Parallel-group Study Evaluating the Safety and Efficacy of Symbicort Turbuhaler 320/9 Twice Daily Compared With Standard Treatment in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)",328,2010-01-01,2011-10-01,AstraZeneca
NCT01094457,Phase 4,2,Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation,NA,840,2009-03-01,2012-06-01,Shenyang Northern Hospital
NCT01134042,Phase 3,3,Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,"HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents",587,2010-06-01,2011-10-01,GlaxoSmithKline
NCT01147848,Phase 3,2,HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents,"A Randomised, Double-blind, Double-dummy, Parallel-group Multicentre Study to Assess Efficacy and Safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents",810,2010-06-01,2011-07-01,GlaxoSmithKline
NCT01206972,Phase 3,4,Dose-confirmatory Bridging Study in Total Knee Replacement,"Randomized, Double-blind, Parallel-group, Active-controlled, Dose-confirmatory Bridging Study of Rivaroxaban (BAY59-7939) 5 to 10 mg Once-daily Regimen With a Reference Drug of Enoxaparin in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement",302,2010-10-01,2011-06-01,Bayer
NCT01218100,Phase 4,4,Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension,"A Randomized, Double-blind, Parallel-Group Study to Evaluate the Effects of First-Line Treatment With a Free Combination of Nebivolol and Lisinopril Compared With Placebo and the Monotherapy Components on Blood Pressure in Patients With Stage 2 Diastolic Hypertension",664,2010-10-01,2011-06-01,Forest Laboratories
NCT01257451,Phase 3,2,Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin in Type 2 Diabetes Mellitus Patients ≥ 70 Years (Drug-naive or Inadequately Controlled on Oral Agents)",431,2010-12-01,2012-03-01,Novartis
NCT01346865,Phase 4,2,Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI),"A Randomized, Placebo Controlled, Double-blind, Phase 4 Study to Evaluate Efficacy and Safety of Triple Anti-platelet Therapy Compared With Dual Antiplatelet Therapy in Patients Treated With Drug Eluting Stent for Coronary Artery Disease",402,2011-05-01,2015-02-01,"CardioVascular Research Foundation, Korea"
NCT01350804,Phase 3,4,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)","A Randomized, Double-blind, Placebo- and Active-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 1 Year in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents (CAIN457F2309) and A Four Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis (CAIN457F2309E1)",551,2011-09-01,2015-02-01,Novartis
NCT01358175,Phase 3,3,16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis,"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis",371,2011-10-01,2014-12-01,Novartis
NCT01368081,Phase 3,3,Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus,"A 52-week, Randomised, Multi-centre, Parallel Group Study to Investigate the Safety and Efficacy of BI 10773 (10 mg or 25 mg Administered Orally Once Daily) as add-on Therapy to an Oral Antidiabetic Drug (Sulfonylurea, Biguanide, Thiazolidinedione, Alpha Glucosidase Inhibitor, DPP-IV Inhibitor, or Glinide) in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control",1162,2011-05-01,2013-04-01,Boehringer Ingelheim
NCT01371994,Phase 4,2,A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy,"A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multicenter Study to Assess Efficacy and Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy",640,2011-08-01,2013-10-01,Astellas Pharma Inc
NCT01396395,Phase 4,2,Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina,"A Prospective, Multi-center, Random, Open-label Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina",402,2011-09-01,2014-05-01,Merck KGaA
NCT01422434,Phase 3,3,LEO 90105 Ointment in Japanese Subjects With Psoriasis,Efficacy and Safety of LEO 90105 Ointment (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris,676,2011-07-01,2012-04-01,LEO Pharma
NCT01437995,Phase 4,3,Long-acting Beta Agonist Step Down Study,Long-acting Beta Agonist Step Down Study,459,2012-03-01,2015-10-01,Johns Hopkins University
NCT01455129,Phase 4,2,Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China,"Early Intervention With Tiotropium （Spiriva） in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled, Parallel, Multicentre Trial",841,2011-11-01,2016-08-01,The First Affiliated Hospital of Guangzhou Medical University
NCT01493557,Phase 4,3,"A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation","A Prospective, Open Label Study Evaluating the Efficacy of Two Management Strategies (Pantoprazole 40 mg q.a.m. and Taking Pradaxa® With Food (Within 30 Minutes After a Meal) on Gastrointestinal Symptoms (GIS) in Patients Newly on Treatment With Pradaxa® 150 mg b.i.d., 110 mg b.i.d. or 75 mg b.i.d. for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation (NVAF)",1067,2011-12-01,2014-07-01,Boehringer Ingelheim
NCT01541943,Phase 3,4,Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia,"A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, Clinical Trial Comparing HL-040XC With Single Component Therapies(Atorvastatin, Losartan) to Assess the Efficacy and Safety of HL-040XC in Patients With Essential Hypertension and Hyperlipidemia",356,2012-03-01,2014-11-01,"HanAll BioPharma Co., Ltd."
NCT01627327,Phase 3,2,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease,A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease,623,2012-04-01,2012-12-21,GlaxoSmithKline
NCT01638000,Phase 3,2,A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.,"A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy",1887,2012-06-12,2013-04-24,Astellas Pharma Inc
NCT01644175,Phase 3,2,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I),"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy",316,2012-07-01,2014-04-01,Sanofi
NCT01694771,Phase 3,2,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,"A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]",1134,2012-09-01,2013-08-01,Boehringer Ingelheim
NCT01707134,Phase 3,2,Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes,"An Open-labelled, Controlled, Multicentre, Multinational, Extension Study Assessing Safety and Efficacy of the Human Insulin Analogue Insulin Aspart (X14) and Human Soluble Insulin as Meal Related Insulin in a Multiple Injection Regimen in Type 1 Diabetic Subjects",753,1997-09-01,2000-05-01,Novo Nordisk A/S
NCT01885208,Phase 3,2,Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1),813,2013-12-02,2015-07-13,Novo Nordisk A/S
NCT01917656,Phase 4,2,Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes,Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes,343,2014-01-09,2014-09-04,Novo Nordisk A/S
NCT01970488,Phase 3,2,Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis,"A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of ABP 501 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis",350,2013-10-01,2015-03-01,Amgen
NCT01989754,Phase 4,2,A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus,"A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus",5813,2014-01-16,2017-02-23,"Janssen Research & Development, LLC"
NCT02098395,Phase 3,6,The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes,"A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial",835,2014-05-01,2015-04-01,Novo Nordisk A/S
NCT02240680,Phase 4,2,Linagliptin as Add on to Basal Insulin in the Elderly,"A 24 Week Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Trial of Once Daily Linagliptin, 5 Milligrams Orally, as Add on to Basal Insulin in Elderly Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control",302,2014-09-23,2017-04-25,Boehringer Ingelheim
NCT02343458,Phase 3,4,"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD","A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo",1759,2015-03-30,2017-08-31,"Pearl Therapeutics, Inc."
NCT02390375,Phase 3,2,Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia,NA,348,2014-11-01,2016-05-01,"Daewon Pharmaceutical Co., Ltd."
NCT02467452,Phase 3,2,Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD),"A Multinational, Multicentre, Randomised, Open-Label, Active-Controlled, 26-Week, 2-Arm, Parallel Group Study to Evaluate the Non-Inferiority of Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) Administered Via Pressurized Metered-dose Inhaler (pMDI) Versus Fixed Combination Of Fluticasone Furoate Plus Vilanterol Administered Via Dry Powder Inhaler (DPI) (Relvar®) Plus Tiotropium Bromide (Spiriva®) for the Treatment of Patients With Chronic Obstructive Pulmonary Disease",1479,2015-05-01,2017-01-01,Chiesi Farmaceutici S.p.A.
NCT02471404,Phase 4,3,Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea,"A 52-Week, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Active Controlled, Phase IV Study to Evaluate the Safety and Efficacy of Dapagliflozin or Dapagliflozin Plus Saxagliptin Compared With Sulphonylurea All Given as Add-on Therapy to Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Monotherapy",1359,2015-09-21,2017-03-13,AstraZeneca
NCT02546323,Phase 3,2,A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis,"A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects",543,2015-09-17,2019-01-31,AstraZeneca
NCT02648204,Phase 3,4,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes,1201,2016-01-06,2017-05-19,Novo Nordisk A/S
NCT02739984,Phase 3,2,A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercholesterolemia/Mixed Dyslipidemia",424,2016-05-17,2017-09-05,Amgen
NCT02863328,Phase 3,2,Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus,Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus,816,2016-08-10,2018-03-12,Novo Nordisk A/S
NCT03015220,Phase 3,4,Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes,Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD in Japanese Subjects With Type 2 Diabetes,455,2017-01-10,2018-07-16,Novo Nordisk A/S
NCT00007683,Phase 3,3,Warfarin and Antiplatelet Therapy in Chronic Heart Failure,CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH),1587,1998-10-01,2004-12-01,VA Office of Research and Development
NCT00047424,Phase 3,NA,Stop Atherosclerosis in Native Diabetics Study (SANDS),Stop Atherosclerosis in Native Diabetics Study (SANDS),NA,2002-09-01,2008-08-01,"National Heart, Lung, and Blood Institute (NHLBI)"
NCT00048425,Phase 3,NA,Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.,"Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure: the REVIVE II Study.",600,2002-09-01,2004-12-01,Abbott
NCT00048568,Phase 3,3,A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate",1250,2002-12-01,2009-10-01,Bristol-Myers Squibb
NCT00062556,Phase 3,NA,Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication,Effect of Niacin ER/Lovastatin on Peak Walking Time and Claudication Onset Time in Patients With Intermittent Claudication,366,2003-01-01,2006-03-01,Kos Pharmaceuticals
NCT00069784,Phase 3,4,The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention),"A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)",12537,2003-08-01,2011-12-01,Sanofi
NCT00082381,Phase 3,2,Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin,Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin,551,2003-06-01,2008-07-01,AstraZeneca
NCT00092157,Phase 3,NA,Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224),"A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Tolerability and Efficacy of the Co-Administration of Simvastatin 20 mg/Day and Fenofibrate 160 mg/Day Compared to Simvastatin 20 mg/Day Alone for 12 Weeks of Treatment in Patients With Combined Hyperlipidemia-Simvastatin and Fenofibrate Efficacy Trial (SAFARI)",571,2002-05-01,2003-03-04,Merck Sharp & Dohme Corp.
NCT00094302,Phase 3,2,Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function,Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT),3445,2006-08-01,2013-06-01,New England Research Institutes
NCT00095238,Phase 3,2,Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve),Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve),4128,2002-06-01,2008-07-01,Bristol-Myers Squibb
NCT00099216,Phase 3,NA,Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia,Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia,708,2001-08-01,2005-11-01,Novartis
NCT00102765,Phase 4,NA,Study Of Asthma In Patients Of African Descent,"A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® BID or Fluticasone Propionate 100mcg DISKUS® BID Alone",479,2004-11-01,2007-04-01,GlaxoSmithKline
NCT00106132,Phase 3,NA,Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage,The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study,1260,2005-03-01,2005-11-01,National Institutes of Health Clinical Center (CC)
NCT00123903,Phase 3,NA,COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria,"A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria",1220,2005-07-01,2006-05-01,GlaxoSmithKline
NCT00130039,Phase 4,2,Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II,Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel,457,2005-08-01,2009-01-01,Asan Medical Center
NCT00134979,Phase 4,NA,"Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease","Efficacy and Safety of Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease",847,2004-10-01,2005-11-01,Novartis
NCT00145301,Phase 3,NA,"52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine","A 52-week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability and Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid and Celecoxib 200 mg od in Patients With Primary Osteoarthritis of Hip, Knee, Hand or Spine",3036,2004-09-01,NA,Novartis
NCT00153023,Phase 4,NA,1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy,"A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy VIVALDI-Study",885,2003-04-01,2005-12-01,Boehringer Ingelheim
NCT00154219,Phase 3,NA,Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis,"A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial of Lumiracoxib (COX189) 100 mg o.d. in Patients With Primary Hip Osteoarthritis Using Celecoxib (200 mg o.d.) as a Positive Control",1200,2004-11-01,NA,Novartis
NCT00163319,Phase 3,NA,Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101),Comparison of Inhaled Ciclesonide (640 mcg/Day) and Fluticasone Propionate (1000 mcg/Day) in Patients With Moderate and Severe Persistent Asthma,500,2004-11-01,2005-11-01,AstraZeneca
NCT00185133,Phase 3,NA,Study of co-Administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension,"A Randomized, Double-Blind, Placebo-Controlled Factorial Study Evaluating the Efficacy and Safety of co-Administration of Olmesartan Medoxomil Plus Amlodipine Compared to Monotherapy in Patients With Mild to Severe Hypertension",1900,2005-05-01,2007-01-01,"Daiichi Sankyo, Inc."
NCT00185159,Phase 3,2,Olmesartan Medoxomil in Diabetes Mellitus,Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP),4449,2004-10-01,2009-07-01,"Daiichi Sankyo, Inc."
NCT00203580,Phase 4,NA,Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study),A Randomized Trial of the Effect of Low-Molecular-Weight Heparin Versus Warfarin Sodium on the Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (Main LITE Study),910,1994-12-01,2002-03-01,University of Calgary
NCT00219154,Phase 3,NA,A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine,"A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension",1125,2005-03-01,2006-01-01,Novartis
NCT00239408,Phase 4,NA,Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).,"Spiriva Assessment of FEV1 - (SAFE-Portugal). The Effect of Inhaled Tiotropium Bromide (18 Mcg Once Daily) on the Change in FEV1 During Treatment in Patients With COPD. A Three-month Parallel Group, Double-blind, Randomised, Placebo-controlled Study.",311,2002-12-01,2004-04-01,Boehringer Ingelheim
NCT00242606,Phase 3,2,Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy,"Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy: An Open, Prospective, Multicenter, Randomized Phase III Study",409,2005-03-01,2009-01-01,Philipps University Marburg Medical Center
NCT00250445,Phase 3,NA,A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066),"A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis",23498,2003-01-01,2006-05-01,Merck Sharp & Dohme Corp.
NCT00264901,Phase 4,NA,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,Impact of a Self-Adjusted Titration Guideline in Subjects With Type 2 Diabetes Mellitus: A Treat-to-Target of the Efficacy and Safety of Levemir® (Insulin Detemir [rDNA Origin] Injection) (PREDICTIVE™ 303),5652,2005-10-01,2006-11-01,Novo Nordisk A/S
NCT00267969,Phase 3,3,A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis",766,2005-12-01,2011-05-01,"Centocor Research & Development, Inc."
NCT00268697,Phase 3,3,Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.,"A Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg and Lapaquistat Acetate 100 mg Administered in Combination With Ezetimibe 10 mg vs Ezetimibe 10 mg in Subjects With Primary Dyslipidemia",1267,2005-10-01,2007-01-01,Takeda
NCT00286442,Phase 3,3,Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Metformin in Subjects With Type 2 Diabetes",527,2006-03-01,2007-06-01,Takeda
NCT00286455,Phase 3,3,Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) Compared With Placebo in Subjects With Type 2 Diabetes",329,2006-02-01,2007-07-01,Takeda
NCT00290030,Phase 3,NA,ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH,A Double-Blind Randomized Parallel Group Study of Alfuzosin 10mg OD Versus Placebo in the Management of Acute Urinary Retention in Patients With a First Episode Due to Benign Prostatic Hyperplasia (BPH),800,2001-05-01,2004-10-01,Sanofi
NCT00296218,Phase 3,NA,ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation,Randomized Comparison of a Two-month Regimen of Irbesartan Versus Enalapril on Cardiovascular Markers in Patients With Acute Coronary Syndrome Without ST Segment Elevation.,440,2006-02-01,NA,Sanofi
NCT00312013,Phase 3,2,"Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer","A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate",503,2006-05-01,2009-07-01,GlaxoSmithKline
NCT00329225,Phase 4,NA,Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Insulin",630,2002-09-01,2004-04-01,GlaxoSmithKline
NCT00331149,Phase 3,NA,A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's,"A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468) in Advanced Stage Parkinson's Disease Subjects Who Are Not Adequately Controlled on L-dopa.",343,2006-06-20,2007-08-29,GlaxoSmithKline
NCT00333112,Phase 4,2,A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Safety and Efficacy, Phase 4 Study of VESIcare® (Solifenacin Succinate) or Placebo in Combination With Tamsulosin HCl for the Treatment of Residual OAB Symptoms of Urgency and Frequency in Men VICTOR: VESIcare® In Combination With Tamsulosin in OAB Residual Symptoms",398,2006-05-01,2007-01-01,Astellas Pharma Inc
NCT00350168,Phase 3,NA,Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension,An 8-week Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combination Based Therapy Versus Amlodipine Monotherapy in Patients With Stage II Hypertension,647,2006-06-01,2007-04-01,Novartis
NCT00354458,Phase 3,2,PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects With Acute Heart Failure Syndrome and Renal Impairment Who Are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy",1102,2006-10-01,2009-07-01,"NovaCardia, Inc."
NCT00355667,Phase 4,2,Comparison of Long- and Short-acting Diuretics in Congestive Heart Failure,Japanese Multicenter Evaluation of Long- Versus Short-acting Diuretics in Congestive Heart Failure,320,2006-06-01,2010-08-01,Hyogo College of Medicine
NCT00361335,Phase 3,5,A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy",643,2006-09-01,2009-09-01,"Centocor, Inc."
NCT00379067,Phase 4,2,A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia",882,2005-10-01,2006-11-01,Astellas Pharma Inc
NCT00383552,Phase 3,4,Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED),A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids,746,2006-09-01,2008-08-01,Merck Sharp & Dohme Corp.
NCT00385593,Phase 3,NA,Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults,"A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 Micrograms, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-week, Randomised, Open-label, Parallel-group, Multicentre Study. Study SPAIN",654,2006-09-01,2008-10-01,AstraZeneca
NCT00385736,Phase 3,3,Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis,"A Multicenter, Randomized, Double-blind Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis",576,2006-11-01,2010-03-01,Abbott
NCT00390728,Phase 4,NA,"Insulin Glargine in Type I Diabetes Mellitus> Main Study ""AT.LANTUS"": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: ""HALT""(Hypoglycaemia Avoidance With Lantus Trial)","A Phase IIIb/IV, Multinational, Multicentre, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 1 Diabetes Mellitus/ ""HALT"" Sub-study: Multicentre, Open Clinical Trial to Assess the Effect of Insulin Glargine on Symptomatic Hypoglycaemia, Fear of Hypoglycaemia and Quality of Life in Patients With Type 1 Diabetes",2346,2002-04-01,2003-08-01,Sanofi
NCT00392002,Phase 4,NA,Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response,A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD Patients Utilizing the PPI Acid Suppression Symptom (PASS) Test for Response [EncomPASS].,2000,2005-10-01,2007-05-01,AstraZeneca
NCT00398606,Phase 3,NA,A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED),"A Triple-Blind, Randomized, Active-Controlled, Parallel-Group, Multicenter Study to Evaluate and Compare the Efficacy and Tolerability of Alendronate Sodium With Calcium Supplementation in the Treatment of Osteoporosis in Postmenopausal Women",650,1995-04-01,NA,Merck Sharp & Dohme Corp.
NCT00408512,Phase 4,2,Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study,Increasing Stay-on-therapy in Hypertensive Patients Treated With First-line Diuretics: An Active Pharmacosurveillance and Pharmacogenetic Study.,2500,2006-12-01,2010-03-01,Federico II University
NCT00439725,Phase 3,2,Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study,Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study,1197,2007-02-01,2009-09-01,Bayer
NCT00440193,Phase 3,2,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism,3449,2007-03-01,2010-04-01,Bayer
NCT00449605,Phase 3,2,A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes,"A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess Glycemic Control With Rimonabant in Comparison With Glimepiride Over 1 Year in Overweight/Obese Type2 Diabetic Patients Not Adequately Controlled With Metformin",508,2007-03-01,2009-03-01,Sanofi
NCT00463567,Phase 2/Phase 3,7,"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","A 26-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (Selected From 75, 150, 300 & 600 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 µg b.i.d.) and Open Label Tiotropium (18 µg o.d.) as Active Controls",2059,2007-04-01,2008-08-01,Novartis
NCT00472199,Phase 4,2,"Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)","A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term Efficacy, Safety and Tolerability in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome for 26 Weeks Followed by a 26 Week Open-label Extension Treatment Period",331,2007-05-01,NA,Boehringer Ingelheim
NCT00487240,Phase 3,2,Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes,Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Insulin Detemir) in Basal-Bolus Therapy for Patients With Type 1 Diabetes,387,2007-06-01,2008-08-01,Eli Lilly and Company
NCT00504881,Phase 3,2,Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (≥ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",480,2007-10-01,2008-12-01,UCB Pharma
NCT00513630,Phase 4,2,Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease,Phase 4 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease,304,2004-06-01,2010-07-01,Shanghai Jiao Tong University School of Medicine
NCT00519142,Phase 3,3,Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus,"A Rapid Onset and Short Duration Insulin Secretogogue, Mitiglinide, in Combination With Metformin Versus Metformin Alone in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-blind, Placebo-controlled Trial for 6 Months",367,2007-08-01,2008-10-01,Elixir Pharmaceuticals
NCT00558064,Phase 3,NA,Filtered Trial for Amlodipine Non-responder,Filtered Trial for Amlodipine Non-responder,531,2007-10-01,NA,Boehringer Ingelheim
NCT00563381,Phase 4,2,Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.,"Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).",7376,2008-01-01,NA,Boehringer Ingelheim
NCT00624286,Phase 3,2,Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD),"A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Indacaterol (150 μg o.d.) in Patients With Chronic Obstructive Pulmonary Disease",416,2008-02-01,2008-07-01,Novartis
NCT00630929,Phase 4,3,Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe),A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee,388,2003-01-01,2004-02-01,Pfizer
NCT00634114,Phase 3,2,Reflux Esophagitis Phase III Study (Maintenance Treatment),"A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg Once Daily Oral Administration With Omeprazole 10 mg and Esomeprazole 10 mg Once Daily Oral Administration in Maintenance Treatment in Patients With Healed Reflux Esophagitis",540,2008-01-01,2009-05-01,AstraZeneca
NCT00665431,Phase 3,3,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,"Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Study Evaluating the Efficacy of PN400 (VIMOVO) Twice Daily (Bid) and Celecoxib Once Daily (qd) in Patients With Osteoarthritis of the Knee",610,2008-04-01,2009-01-01,POZEN
NCT00688688,Phase 3,3,Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,"A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects With Symptoms of Overactive Bladder",2792,2008-04-25,2010-05-06,Astellas Pharma Inc
NCT00696384,Phase 3,3,A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,"An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension",418,2007-06-01,2009-04-01,Takeda
NCT00700856,Phase 4,2,Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial,Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin.,3371,2008-09-01,2018-12-01,Italian Society of Diabetology
NCT00755287,Phase 3,3,"A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.","A Multicenter, Randomized, Open-label, Active-controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin-naïve Type 2 Diabetic Patients Inadequately Controlled With Metformin and Sulphonylurea Combination Therapy",1072,2008-11-01,2010-12-01,Hoffmann-La Roche
NCT00760266,Phase 4,2,Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population,"An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Active-controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to HCTZ (25 mg) in Older Patients With Stage 2 Systolic Hypertension",451,2008-09-01,2009-04-01,Novartis
NCT00763815,Phase 3,2,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Pioglitazone in Patients With Type 2 Diabetes Not Adequately Controlled With Pioglitazone",484,2008-09-01,2011-06-01,Sanofi
NCT00781391,Phase 3,3,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,"A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48)",21105,2008-11-01,2013-05-01,"Daiichi Sankyo, Inc."
NCT00783263,Phase 3,4,A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139),"A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate the Efficacy and Safety of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia at Risk for Coronary Heart Disease",440,2008-11-01,2010-05-01,Merck Sharp & Dohme Corp.
NCT00793624,Phase 3,4,Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I,"A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)",906,2009-02-01,NA,Boehringer Ingelheim
NCT00798161,Phase 3,6,"Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design","A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Twice Daily Administration of the Free Combination of BI 1356 2.5 mg + Metformin 500 mg, or of BI 1356 2.5 mg + Metformin 1000 mg, With the Individual Components of Metformin (500 mg or 1000 mg Twice Daily), and BI 1356 (5.0 mg Once Daily) Over 24 Weeks in Drug Naive or Previously Treated (4 Weeks Wash-out and 2 Weeks Placebo run-in) Type 2 Diabetic Patients With Insufficient Glycaemic Control",857,2008-12-01,NA,Boehringer Ingelheim
NCT00801944,Phase 3,2,Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms,"Solifenacin in the Treatment of Urgency Symptoms of Overactive Bladder in a Rising Dose, Randomized, Placebo-controlled, Double-blind Trial",973,2004-04-01,2005-10-01,Astellas Pharma Inc
NCT00860262,Phase 3,3,Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension,"An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 mg & Amlodipine 10mg Versus Telmisartan 80 mg Monotherapy or Amlodipine 10 mg Monotherapy as First Line Therapy in Patients With Severe Hypertension (Grade 3).",858,2009-03-01,NA,Boehringer Ingelheim
NCT00891462,Phase 3,3,Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33),"Efficacy and Safety of Aclidinium Bromide at Two Dose Levels (200 μg Twice Daily, 400 μg Twice Daily) vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",561,2009-04-01,2009-11-01,AstraZeneca
NCT00902304,Phase 4,3,Valsartan Intensified Primary Care Reduction of Blood Pressure Study,A Phase IV Clinical Trial of Intensified Blood Pressure Management in Primary Care Using Valsartan Alone and as Combination Anti-Hypertensive Therapy,2337,2009-07-01,2011-07-01,Novartis
NCT00927394,Phase 4,2,Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus,"An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus",1143,2009-05-01,2011-10-01,Novartis
NCT00971165,Phase 3,2,Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension,A Comparison Between Diuretics and Angiotensin-receptor Blocker Agents in Patients With Stage I Hypertension: PREVER-treatment Study,655,2010-07-01,2014-09-01,Hospital de Clinicas de Porto Alegre
NCT01066676,Phase 4,2,Dexibuprofen 400 mg Sachet Versus Ibuprofen 400 mg Sachet in Patients With Osteoarthritis of the Hip or Knee,"Prospective, Clinical Trial to Investigate Safety, Tolerability and Efficacy of Dexibuprofen Gebro 400 mg Powder for Oral Suspension (Test) Compared to Ibuprofen 400 mg Powder for Oral Suspension (Reference) in Patients Suffering From Osteoarthritis of the Hip or Knee",482,2009-10-01,2012-06-01,Gebro Pharma GmbH
NCT01072448,Phase 3,2,12-week Efficacy of Indacaterol,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Indacaterol in Patients With Chronic Obstructive Pulmonary Disease",323,2010-01-01,2010-07-01,Novartis
NCT01075698,Phase 4,2,A Trial of Telmisartan Prevention of Cardiovascular Disease,A Trial of Telmisartan Prevention of Cardiovascular Disease,1228,2009-07-01,2016-03-01,Kumamoto University
NCT01130025,Phase 3,2,Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer,Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT,900,2010-08-01,2014-05-01,LEO Pharma
NCT01191268,Phase 3,3,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4),The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4),884,2010-11-01,2012-09-01,Eli Lilly and Company
NCT01281787,Phase 3,3,PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer,Prevention of Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer,320,2008-04-01,2013-10-01,European Institute of Oncology
NCT01289119,Phase 3,6,Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes,"An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Determine the Efficacy and Safety of SYR-322 When Used in Subjects With Type 2 Diabetes",506,2010-12-01,2011-12-01,Takeda
NCT01316380,Phase 3,3,Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma,"A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 ug and 5 ug Once Daily) Compared to Placebo Over 12 Weeks in Mild Persistent Asthma",465,2011-03-01,2012-04-01,Boehringer Ingelheim
NCT01316887,Phase 3,3,"A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",A 52 Week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg Once-daily Alone and in Combination With GW642444 25mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Subjects With Chronic Obstructive Pulmonary Disease,563,2011-01-01,2012-07-21,GlaxoSmithKline
NCT01364220,Phase 3,2,The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke,"An Investigator-Sponsored,Double Blind,Placebo-controlled,Randomised,Multi-centre Study to Assess the Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke",318,2010-08-01,2013-04-01,Severance Hospital
NCT01381900,Phase 3,3,"A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea","A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 18-Week Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea",678,2011-08-01,2012-11-01,"Janssen Research & Development, LLC"
NCT01444430,Phase 3,2,A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents,"A 26 Week, Randomized, Double-blind, Parallel-group, Active Controlled, Multicenter, Multinational Safety Study Evaluating the Risk of Serious Asthma-related Events During Treatment With Symbicort®, a Fixed Combination of Inhaled Corticosteroid (ICS) (Budesonide) and a Long Acting β2-agonist (LABA) (Formoterol) as Compared to Treatment With ICS (Budesonide) Alone in Adult and Adolescent (≥12 Years of Age) Patients With Asthma",12460,2011-12-01,2015-10-01,AstraZeneca
NCT01445951,Phase 3,3,Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period,"A Phase 3, Multicenter, Open-label, Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With a Basal Insulin Versus Insulin Aspart in Combination With a Basal Insulin in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period",518,2011-09-01,2013-06-01,Mannkind Corporation
NCT01472185,Phase 3,2,Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus",465,2011-11-01,2013-10-01,Gilead Sciences
NCT01475721,Phase 4,6,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,"SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects With Asthma",11751,2011-11-18,2015-06-23,GlaxoSmithKline
NCT01475825,Phase 3,6,A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Continuation Period to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol",310,2011-12-01,2016-02-01,"Kastle Therapeutics, LLC"
NCT01494532,Phase 4,2,A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease,"A Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's Disease",352,2012-04-02,2014-11-18,GlaxoSmithKline
NCT01543555,Phase 3,2,Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose,Multicenter Randomized Controlled Trial of Loading Dose Statins for the Prevention of Cardiovascular Complications in High-Risk Non-Cardiac Surgery,648,2012-11-01,2015-06-01,Hospital do Coracao
NCT01558271,Phase 3,3,A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus,A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus,492,2012-03-01,2014-05-01,Eli Lilly and Company
NCT01583218,Phase 3,2,Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study),"(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients",7513,2012-03-01,2016-01-01,Portola Pharmaceuticals
NCT01604343,Phase 3,3,"A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)","A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite DMARD Therapy",1670,2012-08-15,2016-12-06,"Janssen Research & Development, LLC"
NCT01706328,Phase 3,2,A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),828,2012-10-15,2013-06-17,GlaxoSmithKline
NCT01709305,Phase 4,4,"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","A Multicenter, Randomized, Active-Controlled, Open-label Clinical Trial to Evaluate the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose as a Third OAHA on Top of Sitagliptin+Metformin Combination Therapy in Chinese Patients With Type 2 Diabetes Mellitus",5570,2012-11-08,2015-04-17,Merck Sharp & Dohme Corp.
NCT01729754,Phase 3,4,A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011),"A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011)",1090,2013-02-01,2019-06-01,Merck Sharp & Dohme Corp.
NCT01836523,Phase 3,6,The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes,"The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial",1398,2013-11-01,2015-06-01,Novo Nordisk A/S
NCT01926782,Phase 3,3,Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1),"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia",803,2013-09-01,2015-04-01,Regeneron Pharmaceuticals
NCT01958671,Phase 3,3,"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)","A Phase 3, Randomized, Double-blind, Placebo-controlled, 26-week Multicenter Study With a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise",461,2013-10-09,2016-07-28,Merck Sharp & Dohme Corp.
NCT02181985,Phase 3,3,"Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)","A Phase IIIb, Randomised, Open Label Trial With 3 Parallel Groups: Full Dose TNK-tPA Together With Heparin Sodium, Full Dose TNK-tPA Together With Enoxaparin, and Half Dose TNK-tPA Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction: ASSENT 3 (Assessment of the Safety and Efficacy of New Thrombolytic Regimens)",5989,2000-05-01,NA,Boehringer Ingelheim
NCT02203916,Phase 3,3,Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-491 in Korean Subjects With Essential Hypertension",328,2014-07-01,2016-02-01,Takeda
NCT02236611,Phase 4,2,A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",1036,2014-09-26,2015-06-02,GlaxoSmithKline
NCT02616497,Phase 4,2,ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS),Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events,1400,2015-09-01,2017-08-31,University of Ioannina
NCT02791490,Phase 3,2,A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin During Metformin Up-titration Compared With Metformin Up-titration Alone in Subjects With Type 2 Diabetes Mellitus",458,2016-06-16,2018-02-01,Merck Sharp & Dohme Corp.
NCT00029822,Phase 3,NA,Clinical Trial in Males With BPH (Enlarged Prostate),"Long-Term, Efficacy and Safety of Alfuzosin 10 MG OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients With BPH. A Two Year, Randomized, Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study.",1522,2001-05-01,2005-03-01,Sanofi
NCT00064389,Phase 3,2,Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma,Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma,746,2003-01-01,2005-07-01,Sunovion
NCT00085644,Phase 3,2,Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis,A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis,315,2004-01-01,2009-07-01,Abbott
NCT00089791,Phase 3,2,A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis,A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months),7808,2004-08-01,2008-07-01,Amgen
NCT00092040,Phase 3,NA,A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907),"A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis",936,2003-03-18,2005-09-28,Merck Sharp & Dohme Corp.
NCT00092560,Phase 3,NA,Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036),Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia,587,2002-12-01,2003-12-01,Merck Sharp & Dohme Corp.
NCT00092664,Phase 3,NA,An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled ""Factorial"" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia",1104,2003-01-01,2003-09-01,Merck Sharp & Dohme Corp.
NCT00092742,Phase 3,NA,Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072),"A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis",4086,2003-02-01,2005-12-01,Merck Sharp & Dohme Corp.
NCT00093912,Phase 3,2,Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP),Evaluation of Clevidipine in the Perioperative Treatment of Hypertension Assessing Safety Events (With Sodium Nitroprusside as Active Comparator) (ECLISPE-SNP),739,2004-06-01,2006-11-01,The Medicines Company
NCT00099905,Phase 3,NA,A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes,A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes,639,2004-04-01,2005-10-01,Novartis
NCT00109668,Phase 3,NA,Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids,NA,415,2004-07-01,2006-09-01,Teva Pharmaceutical Industries
NCT00147654,Phase 4,NA,Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction,"A Randomized, Double Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER Plus Tamsulosin) Study To Evaluate The Clinical Efficacy And Safety Of Tolterodine ER 4 mg In Men Who Have Frequency and Urgency, With Or Without Urinary Urge Incontinence, With Or Without Bladder Outlet Obstruction",830,2004-11-01,2006-05-01,Pfizer
NCT00163241,Phase 3,NA,Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression,"A Double-Blind, Placebo-Controlled, Randomized 24-Month Study, Assessing The Effect Of Celecoxib (Celebrex) Long Term Treatment On Hip Osteoarthritis (OA) Progression OSCARE",666,2004-06-01,2006-01-01,Pfizer
NCT00168805,Phase 3,3,RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery,RE-MODEL (Thromboembolism Prevention After Knee Surgery). Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With a Half Dose (i.e.75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 6-10 Days,2101,2004-11-01,NA,Boehringer Ingelheim
NCT00171366,Phase 3,NA,A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.,"A Multicenter, Group Study to Evaluate the Safety and Efficacy of Amlodipine and Benazepril Administered in Combination Compared to Amlodipine Monotherapy in Hypertensive Patients Not Adequately Controlled With Amlodipine Alone",1422,2004-07-01,2005-07-01,Novartis
NCT00174733,Phase 3,NA,Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160 μg Administered for Twelve Weeks Either in a Once-Daily Regimen in the Morning (160 μg qd AM) or in a Twice Daily Regimen (80 μg Bid) in Adults and Adolescents With Mild to Moderate Persistent Asthma Treated Previously With Inhaled Corticosteroids",456,2005-07-01,2006-02-01,Sanofi
NCT00200460,Phase 3,NA,A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients,"A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Dosing Study Evaluating the Effects of Nebivolol on Blood Pressure in Patients With Mild to Moderate Hypertension",825,2001-09-01,2003-03-01,Mylan Bertek Pharmaceuticals
NCT00213135,Phase 3,3,A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),"A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)",1326,2005-04-01,2008-11-01,EMD Serono
NCT00219167,Phase 3,NA,A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure,"An 8-week, Randomized, Double-blind, Parallel-group, Multicenter Study Assessing the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Patients With at Least 65 Years of Age With Essential Hypertension, Using 24-hour ABPM, With Lisinopril 10 mg as a Reference",355,2005-04-01,2006-02-01,Novartis
NCT00227318,Phase 3,NA,TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Long-term Trial of Preventing Hypertension Using Candesartan Cilexetil 16 mg in Patients With High Normal Blood Pressure (TROPHY)",1000,1998-07-01,2005-10-01,AstraZeneca
NCT00234065,Phase 4,2,Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2),Post-marketing Study of Cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison With Aspirin,2800,2003-12-01,2008-12-01,"Otsuka Pharmaceutical Co., Ltd."
NCT00235755,Phase 3,3,Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",539,2005-12-01,2008-04-01,GlaxoSmithKline
NCT00239421,Phase 4,NA,A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD),"A Six-Week, Randomized, Double-Blind, Quadruple-Dummy Parallel Group Multiple Dose Study Comparing the Efficacy and Safety of Tiotropium Inhalation Capsules Plus Formoterol Inhalation Capsules to Salmeterol Inhalation Aerosol Plus Fluticasone Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)",605,2003-11-01,2004-09-01,Boehringer Ingelheim
NCT00242307,Phase 2/Phase 3,NA,Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05),A Confirmatory Study of APTA-2217 in Adult Patients With Bronchial Asthma (A Placebo-controlled Double-blind Comparative Study),450,2004-05-01,2007-06-01,AstraZeneca
NCT00251706,Phase 3,NA,Amiodarone to Prevent Post-Operative Arrhythmias,"Prophylactic Amiodarone for the Prevention of Arrhythmias That Begin Early After Revascularization, Valve Replacement, or Repair - PAPABEAR",600,1999-02-01,2004-09-01,University of Calgary
NCT00251758,Phase 3,3,Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn,A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD),908,2005-12-01,2006-05-01,Takeda
NCT00256139,Phase 3,NA,CLEAR Study: Clinical Experience Acquired With Raptiva Study,NA,793,2003-03-01,2004-10-01,Merck KGaA
NCT00272454,Phase 4,NA,Cilostazol in Acute Ischemic Stroke Treatment (CAIST),"The Double-Blind, Randomized, Multi-Center, and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke",468,2006-01-01,2008-09-01,"Korea Otsuka Pharmaceutical Co., Ltd."
NCT00277472,Phase 4,2,Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension,"A 28-week, Multicenter Study to Evaluate the Effects of Valsartan/Hydrochlorothiazide (160/12.5 mg) in Comparison With Hydrochlorothiazide (25 mg) Monotherapy, for the Treatment of Patients With Hypertension, Uncontrolled by Hydrochlorothiazide (12.5 mg) Monotherapy",300,2005-11-01,NA,Novartis
NCT00280046,Phase 3,NA,Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes,Effect of Biphasic Insulin Aspart 30 on Glycaemic Control in Subjects With Type 2 Diabetes,307,2003-11-01,2004-07-01,Novo Nordisk A/S
NCT00280059,Phase 3,2,Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",660,2006-08-01,2010-04-01,Pfizer
NCT00280540,Phase 4,NA,Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension,"A 6-week Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose Valsartan Monotherapy (160 mg) or Combo Therapy (Valsartan + Hydrochlorothiazide, 160/12.5 mg) to Conventional Low-dose Valsartan Monotherapy (80 mg) in Managing Patients With Hypertension",648,2005-12-01,NA,Novartis
NCT00286429,Phase 3,3,Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Insulin in Subjects With Type 2 Diabetes",390,2006-02-01,2007-05-01,Takeda
NCT00290264,Phase 3,NA,SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma,"A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbohaler 160/4.5 μg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26-week, Randomised, Open-label, Parallel-group, Multi-centre Study (SALTO)",1000,2004-12-01,2006-08-01,AstraZeneca
NCT00299546,Phase 3,3,A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s),"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis and Previously Treated With Biologic Anti- TNFa Agent(s)",461,2006-02-01,2012-05-01,"Centocor, Inc."
NCT00303459,Phase 4,2,Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH),"Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study",334,2006-05-01,2013-12-01,Actelion
NCT00313001,Phase 3,NA,Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.,"Effects of NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) BID and QD vs. Byetta™ Exenatide) BID on Glycemic Control: A Multicenter, 24-Week, Open-Label, Parallel Group Study in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets With Metformin and a Sulfonylurea",373,2006-04-01,2007-07-01,Novo Nordisk A/S
NCT00318461,Phase 3,5,To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together,Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes,1091,2006-05-01,2008-11-01,Novo Nordisk A/S
NCT00329628,Phase 3,2,Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin,"RECORD 1 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement",4541,2006-02-01,2007-03-01,Bayer
NCT00333151,Phase 3,NA,Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes,Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes,576,2006-05-01,2007-08-01,Novo Nordisk A/S
NCT00387088,Phase 3,2,Tiotropium / Respimat One Year Study in COPD.,"Efficacy {FEV1, COPD Exacerbations & HRQoL} & Safety of 5mcg Tiotropium Respimat in COPD",3991,2006-09-01,NA,Boehringer Ingelheim
NCT00391872,Phase 3,2,A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome,"A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes]",18624,2006-10-01,2009-03-01,AstraZeneca
NCT00410384,Phase 3,3,A Study of Belimumab in Subjects With Systemic Lupus Erythematosus,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)",819,2006-12-01,2010-03-01,Human Genome Sciences Inc.
NCT00413413,Phase 3,3,Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension,"A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controled, Parallel Study, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Valsartan 80 mg and Valsartan 160 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 80 mg Monotherapy.",1134,2007-01-01,2007-11-01,Novartis
NCT00434954,Phase 3,2,Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes,Effect of Exenatide Plus Metformin vs. Premixed Human Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Inadequate Control of Type 2 Diabetes on Oral Antidiabetic Treatment,494,2007-02-01,2009-06-01,AstraZeneca
NCT00489424,Phase 4,3,"Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass","A Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group Study of Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an i.v. Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass",793,2007-06-01,2007-12-01,Novartis
NCT00501020,Phase 4,NA,Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin,"A 24-Week Randomized, Double-blind, Double-Dummy, Multicenter Study to Compare the Efficacy of AVANDIA When Added to Submaximal Doses of Metformin and to Compare the Tolerability of the Combination to Metformin Monotherapy When Administered to Subjects With Type 2 Diabetes Mellitus",750,2001-06-05,2003-02-13,GlaxoSmithKline
NCT00509262,Phase 3,2,Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1),"A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control",426,2007-10-09,2011-03-16,Merck Sharp & Dohme Corp.
NCT00540891,Phase 3,NA,"The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score","The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score",372,2003-02-01,2004-10-01,Sanofi
NCT00542789,Phase 3,2,Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID,"A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use",343,2007-08-01,2009-02-01,AstraZeneca
NCT00557921,Phase 3,2,Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1),"A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease",5000,2007-12-01,2009-11-01,Cogentus Pharmaceuticals
NCT00562952,Phase 2/Phase 3,2,Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients,Nt-proBNP Guided Prevention of Cardiovascular Events in a Population of Diabetic Patients Without a History of Cardiac Disease,300,2007-11-01,2011-12-01,Medical University of Vienna
NCT00570739,Phase 3,4,"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.","Effects of Metformin HCl in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, as Initial Therapy in Drug naïve Subjects With Type 2 Diabetes Mellitus, and the Effects of Colesevelam HCl on the Lipid Profile in Subjects With Pre Diabetes",502,2007-11-01,2009-05-01,"Daiichi Sankyo, Inc."
NCT00622284,Phase 3,2,Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes,"A Randomised Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 1356 ( 5.0 mg, Administered Orally Once Daily) Compared to Glimepiride Over Two Years in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy",1560,2008-02-01,NA,Boehringer Ingelheim
NCT00646542,Phase 3,2,Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency,"A Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency",525,2005-03-01,NA,Novartis
NCT00647491,Phase 2/Phase 3,4,A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis,NA,352,2004-02-01,2005-08-01,Abbott
NCT00659503,Phase 3,2,"Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older",420,2005-02-01,2005-11-01,AstraZeneca
NCT00678704,Phase 3,3,BAY38-9456 - Pivotal Trial for Diabetes Patient,"A Randomized, Placebo-controlled, Double-blind, Multi-centre, Parallel Group Study to Investigate the Efficacy and Safety of BAY 38-9456 in Males With Diabetes Suffering From Erectile Dysfunction",790,2004-01-01,2004-11-01,Bayer
NCT00689104,Phase 3,4,Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,"A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder",2336,2008-04-28,2009-03-24,Astellas Pharma Inc
NCT00712673,Phase 3,4,"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin",680,2008-06-01,2011-03-01,Sanofi
NCT00713830,Phase 3,2,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea","A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of a Sulfonylurea in Patients With Type 2 Diabetes Not Adequately Controlled With Sulfonylurea",859,2008-07-01,2011-01-01,Sanofi
NCT00720382,Phase 3,2,A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis,Active Controlled Trial of the Safety and Tolerability of MP 03-036 (Astepro 0.15%) in Patients With Perennial Allergic Rhinitis,703,2007-03-01,2008-07-01,Meda Pharmaceuticals
NCT00729430,Phase 3,2,Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging,"Prognostic, Anti-arrhythmic, and Ventricular Remodeling Effects of High Dose Fish Oil in Patients With a Recent Myocardial Infarction",358,2008-08-01,2014-07-01,Brigham and Women's Hospital
NCT00778921,Phase 3,3,Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone,"A Randomized, Eight Week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (150/10 mg and 300/10 mg) in Comparison With Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 10 mg Monotherapy",847,2008-10-01,2009-06-01,Novartis
NCT00784550,Phase 4,2,A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).,"A Randomized, Double-Blind, Parallel-Group, 24-Week Study to Evaluate the Efficacy and Safety of ADVAIR DISKUS (Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Inhalation Powder) BID Plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD Versus Spiriva QD Plus Placebo DISKUS BID in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",342,2008-12-01,2009-12-01,GlaxoSmithKline
NCT00789737,Phase 3,2,Welchol as Monotherapy for Type 2 Diabetes Mellitus,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Welchol as Monotherapy for Type 2 Diabetes Mellitus",357,2009-01-01,2011-12-01,"Daiichi Sankyo, Inc."
NCT00798434,Phase 4,2,A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.,"A 24-Week, Multi-Centre Trial, Comprising A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase Followed By A 12-Week Open-Label Phase, To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder.",794,2008-06-01,2010-09-01,Pfizer
NCT00839527,Phase 3,3,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus",685,2009-02-01,2013-04-01,GlaxoSmithKline
NCT00841672,Phase 3,2,Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension,"An 8-week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Amlodipine 10 mg Compared to Amlodipine 10 mg in Patients",485,2009-01-01,2009-09-01,Novartis
NCT00863707,Phase 4,2,A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment,"A Phase 4, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment",511,2009-04-01,2009-12-01,Astellas Pharma Inc
NCT00901368,Phase 4,2,FACTO Study (Foster® As Complete Treatment Option),"A PHASE 4, MULTINATIONAL, MULTICENTRE, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP, CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg pMDI WITH HFA-134A PROPELLANT (CHF1535, FOSTER®) VERSUS FLUTICASONE 250 µg PLUS SALMETEROL 50 µg DPI (SERETIDE® DISKUS®) AS MAINTENANCE TREATMENT IN CONTROLLED ASTHMATIC PATIENTS.",431,2009-05-01,2010-12-01,Chiesi Farmaceutici S.p.A.
NCT00920543,Phase 4,2,GSK BHR Study (Sont),"A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS Twice Daily or Fluticasone Propionate DISKUS Twice Daily (or Placebo BID if Asymptomatic)",464,2003-02-01,2004-10-01,GlaxoSmithKline
NCT00957060,Phase 4,2,Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients,"A Multicenter, Open, Randomized, 24 Weeks Study to Evaluate the Superiority of Glimepiride Over Sitagliptin for the Treatment of naïve Patients With Type 2 Diabetes Mellitus",400,2009-07-01,2010-10-01,Sanofi
NCT00977938,Phase 4,2,The Dual Antiplatelet Therapy Study (DAPT Study),"A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions",25682,2009-10-01,2014-06-01,Baim Institute for Clinical Research
NCT01006291,Phase 3,3,Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes,"A 26 Week Randomised, Controlled, Open Label, Multicentre, Multinational, Three-arm, Treat to Target Trial Comparing Efficacy and Safety of Three Different Dosing Regimens of Either Soluble Insulin Basal Analogue (SIBA) or Insulin Glargine With or Without Combination With OAD Treatment, in Subjects With Type 2 Diabetes Mellitus (BEGIN™ : FLEX)",687,2009-11-01,2010-09-01,Novo Nordisk A/S
NCT01106625,Phase 3,3,The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea),"A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy",469,2010-05-01,2012-04-01,"Janssen Research & Development, LLC"
NCT01131676,Phase 3,3,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,"A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk",7064,2010-07-01,2015-04-01,Boehringer Ingelheim
NCT01144338,Phase 3,2,Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus,"Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.",14752,2010-06-18,2017-04-24,AstraZeneca
NCT01154166,Phase 3,2,"A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa","A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa",347,2010-02-01,2011-09-01,GlaxoSmithKline
NCT01169779,Phase 3,2,Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin,"Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (With or Without Sulfonylurea): a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With 24-week Treatment Period",391,2010-07-01,2011-12-01,Sanofi
NCT01172821,Phase 3,4,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II,"A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma",1032,2010-08-01,2012-11-01,Boehringer Ingelheim
NCT01216072,Phase 4,2,"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis","A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Forms of Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)",1053,2010-08-01,2012-08-01,Novartis
NCT01232569,Phase 3,2,A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis,"A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis",656,2011-03-01,2013-11-01,Hoffmann-La Roche
NCT01316913,Phase 3,4,24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease,A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD,872,2011-03-01,2012-04-01,GlaxoSmithKline
NCT01336608,Phase 3,3,A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD,A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).,446,2011-03-04,2014-11-04,GlaxoSmithKline
NCT01342913,Phase 3,2,A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP)),A 12-week Study to Evaluate the 24 Hour Pulmonary Function of Fluticasone Furoate (FF)/Vilanterol Inhalation Powder (FF/VI Inhalation Powder) Once Daily Compared With Salmeterol/Fluticasone Propionate (FP) Inhalation Powder Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),528,2011-02-01,2011-10-01,GlaxoSmithKline
NCT01356602,Phase 3,3,Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients,"A Randomized, Double-blind, Active-controlled Study of Canakinumab Prefilled Syringes or Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients",397,2011-05-01,2012-09-01,Novartis
NCT01358578,Phase 3,6,"Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis","A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis",1306,2011-06-01,2013-07-01,Novartis
NCT01365455,Phase 3,5,Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year,"A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis",738,2011-06-01,2013-04-01,Novartis
NCT01425853,Phase 4,2,Study on Efficacy and Safety of Chondroitin Sulfate + Glucosamine Hydrochloride Versus Celecoxib in Knee Osteoarthritis,Non-Inferiority Clinical Trial On The Efficacy And Safety Of Chondroitin Sulfate And Glucosamine Hydrochloride In Combination Versus Celecoxib In Patients With Knee Osteoarthritis,606,2011-09-01,2013-05-01,Bioiberica
NCT01512108,Phase 3,2,Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone,"A 52-week, Multi-centre, Open-labelled, Randomised (2:1), Parallel-group Trial With an Active Control (Two OADs Combination Therapy) to Evaluate the Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Monotherapy",363,2012-01-10,2013-04-26,Novo Nordisk A/S
NCT01518855,Phase 4,2,Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension,Clinical Effect and Cost Effectiveness of Ca Antagonist in Combination With AII Receptor Antagonist in Patient With Essential Hypertension (PMS Study),514,2004-03-01,2005-04-01,Bayer
NCT01583374,Phase 3,3,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS",490,2012-05-02,2018-10-02,Celgene
NCT01687283,Phase 3,2,Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma,"A Multicenter, Randomized, Single Blind, Active Controlled, Parallel Group Study to Determine Efficacy and Safety of Nebulized Fluticasone Propionate 1mg BID Compared With Nebulized Budesonide 2mg BID Administered for 12 Weeks in Chinese Adult and Adolescent Patients With Severe Persistent Asthma",316,2012-09-27,2013-11-07,GlaxoSmithKline
NCT01854645,Phase 3,5,"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)","A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control",2103,2013-05-01,2015-02-01,"Pearl Therapeutics, Inc."
NCT01868061,Phase 3,3,A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication",1068,2013-07-31,2017-01-02,Hoffmann-La Roche
NCT01986881,Phase 3,3,"Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)","Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study",8000,2013-11-04,2019-10-31,Merck Sharp & Dohme Corp.
NCT02008682,Phase 4,2,"The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes","The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes.(LIRA-DPP-4 CHINA™)",368,2013-12-01,2014-11-01,Novo Nordisk A/S
NCT02009865,Phase 3,2,Epanova® for Lowering Very High Triglycerides II (EVOLVE II),"A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)",379,2013-12-01,2014-12-01,AstraZeneca
NCT02082769,Phase 3,3,Safety and Efficacy of Oral Febuxostat in Subjects With Gout,"A Phase 3, Randomized, Multicenter, Allopurinol-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout",504,2011-07-01,2013-10-01,Xijing Hospital
NCT02132767,Phase 3,2,Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation,Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation,523,2014-05-01,2015-09-01,Icahn School of Medicine at Mount Sinai
NCT02200640,Phase 4,4,A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM),"A Prospective, Randomized, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDIS® (Telmisartan) (40 & 80 mg QD) and COZAAR® (Losartan) (50 & 100 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring",333,2000-03-01,NA,Boehringer Ingelheim
NCT02308163,Phase 3,4,A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs,"Phase III Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs",509,2014-08-08,2017-11-22,Astellas Pharma Inc
NCT02452190,Phase 3,2,Study of Reslizumab in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils,"A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils",468,2015-09-28,2018-03-26,Teva Pharmaceutical Industries
NCT02473198,Phase 3,2,Femoral Nerve Block Compared to Exparel in Total Knee Replacement,A Prospective Randomized Trial Comparing Femoral Nerve Black to Intraoperative Local Anesthetic Injection of Liposomal Bupivacaine (Exparel) in Total Knee Replacement,312,2014-01-01,2017-02-01,The New England Baptist Hospital
NCT02477865,Phase 3,3,Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIIa Clinical Study Evaluating PEGylated Loxenatide Injection（PEX168）in Monotherapy of Type 2 Diabetes Mellitus",406,2014-03-23,2017-02-01,"Jiangsu Hansoh Pharmaceutical Co., Ltd."
NCT02738151,Phase 4,2,Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist,"A 24-week, Multicenter, Randomized, Open-label, Parallel-group StudyComparing the Efficacy and Safety of Toujeo® and Tresiba® in Insulin-NaivePatients With Type 2 Diabetes Mellitus Not Adequately Controlled With OralAntihyperglycemic Drug(s) GLP-1 Receptor Agonist",929,2016-05-19,2017-08-15,Sanofi
NCT02738879,Phase 3,2,Randomized Sitagliptin Withdrawal Study (MK-0431-845),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus",746,2016-05-09,2018-01-30,Merck Sharp & Dohme Corp.
NCT02746380,Phase 3,2,A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy,"Multi-center (in Korea and Japan), Double-blind, Randomized, Parallel-group Study to Evaluate the Similarity of Efficacy and Safety of LBAL 40mg Subcutaneous Biweekly Injection to Humira® 40mg Subcutaneous Biweekly Injection, as Adjunctive Therapy to Methotrexate (MTX), in Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to MTX",380,2016-04-01,2018-02-01,LG Life Sciences
NCT02777580,Phase 4,2,STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction,STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction,600,2017-08-01,2020-06-01,Katholieke Universiteit Leuven
NCT02788474,Phase 4,2,Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment,"A 12-week, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial Followed by a Single Active Arm Phase of 40 Weeks Evaluating the Effect of Oral Nintedanib 150 mg Twice Daily on Change in Biomarkers of Extracellular Matrix (ECM) Turnover in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Limited Forced Vital Capacity (FVC) Impairment.",347,2016-06-09,2018-06-11,Boehringer Ingelheim
NCT00000556,Phase 3,NA,Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM),NA,NA,1995-03-01,2002-09-01,"National Heart, Lung, and Blood Institute (NHLBI)"
NCT00076089,Phase 3,NA,OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111),"Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.",1100,2003-12-01,2005-12-01,AstraZeneca
NCT00089895,Phase 3,2,EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED),"Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)",9406,2004-11-01,2008-11-01,Merck Sharp & Dohme Corp.
NCT00091793,Phase 3,2,Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis,"A Randomized, Double-Blind Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis",332,2004-08-01,2009-03-01,Amgen
NCT00092352,Phase 3,NA,A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219),"A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee",395,2003-04-29,2003-12-01,Merck Sharp & Dohme Corp.
NCT00092573,Phase 3,NA,Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED),Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia,576,2003-04-01,2004-11-01,Merck Sharp & Dohme Corp.
NCT00104182,Phase 3,NA,"Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes","Efficacy and Safety Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening as Add-on to Oral Antidiabetic Drug(s) in Patients With Type 2 Diabetes",503,2005-02-01,2006-02-01,Novo Nordisk A/S
NCT00106522,Phase 3,3,A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy,"A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to Anti-TNF Therapy",499,2005-05-01,2007-11-01,Hoffmann-La Roche
NCT00106574,Phase 3,2,A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis,"A Randomized, Double-blind Study of the Effect of Tocilizumab on Reduction in Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to DMARD Therapy",1220,2005-04-01,2007-12-01,Hoffmann-La Roche
NCT00110422,Phase 4,2,Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome,Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome,400,2005-11-01,2007-02-01,Bristol-Myers Squibb
NCT00116831,Phase 3,2,Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes,"A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)",672,2005-01-01,2008-08-01,GlaxoSmithKline
NCT00127179,Phase 3,NA,A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140),MK0906 Phase III Double-Blind Comparative Study - Benign Prostate Hyperplasia,600,2004-01-01,2005-07-25,Merck Sharp & Dohme Corp.
NCT00129545,Phase 2/Phase 3,3,WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation,WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF),800,2005-02-01,2014-05-01,Boston Scientific Corporation
NCT00135226,Phase 4,4,ASCEND: A Study of Cardiovascular Events iN Diabetes,"A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes",15480,2005-03-01,NA,University of Oxford
NCT00141778,Phase 2/Phase 3,3,"Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)","RAAS, Inflammation, and Post-operative AF",455,2005-04-01,2010-08-01,Vanderbilt University
NCT00144339,Phase 3,NA,Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients,"A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).",5993,2002-12-01,NA,Boehringer Ingelheim
NCT00163423,Phase 3,NA,Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142),Comparison of Ciclesonide (80 mcg Once Daily in the Evening) and Fluticasone Propionate (100 mcg Twice Daily) in Patients With Mild to Moderate Asthma,480,2004-11-01,2006-01-01,AstraZeneca
NCT00163436,Phase 3,NA,Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145),Comparison of the Efficacy and Safety of 160 mcg Ciclesonide Administered Once Daily in the Evening With or Without Different Spacer Types in Patients With Asthma,450,2005-09-01,2006-01-01,AstraZeneca
NCT00170924,Phase 4,NA,"To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.","A Multi-center, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effect of the Angiotensin II Antagonist Valsartan on Diastolic Function in Patients With Hypertension and Diastolic Dysfunction",317,2004-08-01,2006-06-01,Novartis
NCT00170963,Phase 3,NA,Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Valsartan Alone,Valsartan/Amlodipine 160/5 mg or 160/10 mg Versus Valsartan 160 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Valsartan 160 mg Monotherapy,1018,2004-10-01,2005-06-01,Novartis
NCT00174720,Phase 3,NA,Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.,"A Multinational,Multicenter,Randomized,Double-Blind,Placebo-Controlled,Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160 μg Administered Either in a Once-Daily in the Morning Regimen (160 μg qd AM) for 16 Weeks or in a 160 μg qd AM Regimen for 12 Weeks Preceded by a Twice-Daily Regimen (80 μg Bid) for 4 Weeks,or in an 80 μg Bid Regimen for 16 Weeks,in Adults and Adolescents With Mild to Moderate Persistent Asthma Not Treated With Steroids",708,2005-09-01,2007-02-01,Sanofi
NCT00200356,Phase 4,2,Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke,Edaravone-Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) Comparative Post-Marketing Study on Acute Ischemic Stroke,401,2004-08-01,2006-10-01,Mitsubishi Tanabe Pharma Corporation
NCT00200473,Phase 3,NA,A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients,"A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Study of the Effects of Nebivolol on Safety and Efficacy in Patients With Mild to Moderate Hypertension",800,2001-09-01,2003-03-01,Mylan Bertek Pharmaceuticals
NCT00206310,Phase 3,NA,Crestor Versus Placebo in Subjects With Heart Failure,"Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure",5013,2003-09-01,2007-07-01,AstraZeneca
NCT00208312,Phase 3,2,ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI),"A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 Versus Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging",787,2004-04-01,2005-06-01,Gilead Sciences
NCT00219024,Phase 3,NA,Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.,"An 8 Week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension",2775,2004-08-01,2005-06-01,Novartis
NCT00219063,Phase 3,NA,A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.,"A 26 Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing Aliskiren to Ramipril With Optional Addition of Hydrochlorothiazide, Followed by a 4 Week Double-blind, Randomized, Placebo-controlled Withdrawal in Patients With Essential Hypertension",844,2005-02-01,2006-03-01,Novartis
NCT00231530,Phase 3,NA,"A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients on a Controlled Diet",541,2001-01-01,2002-05-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00251576,Phase 3,NA,Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180),"A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary Syndrome Patients Who Have Been Randomized to Receive Enoxaparin or Unfractionated Heparin in Conjunction With Aspirin",4497,1999-11-01,2004-03-23,Merck Sharp & Dohme Corp.
NCT00251719,Phase 3,3,Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis,"A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once-daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis",2054,2005-12-01,2007-01-01,Takeda
NCT00253227,Phase 3,NA,A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease,Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial,387,1997-07-01,1998-12-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00254956,Phase 3,NA,Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma,"A Multi-Center, Multinational, Randomized, Double-Blind, Parallel Group Study of the Effects of Ciclesonide Hfa-Mdi 640 μg/Day and Beclomethasone Hfa-Mdi 640 μg/Day on Lens Opacification in Adult Subjects With Moderate to Severe Persistent Asthma",1568,2004-01-01,2005-06-01,Sanofi
NCT00262600,Phase 3,3,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,"Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)",18113,2005-11-01,NA,Boehringer Ingelheim
NCT00279045,Phase 3,NA,Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide,"A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus",4426,2000-01-03,2006-06-19,GlaxoSmithKline
NCT00281580,Phase 3,16,Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension,"A Randomized, Double-blind, Double-dummy, Placebo-controlled, 4x4 Factorial Design Trial to Evaluate Telmisartan 20, 40 and 80 mg Tablets in Combination With Amlodipine 2.5, 5 and 10 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-study",1461,2006-04-01,NA,Boehringer Ingelheim
NCT00290927,Phase 3,NA,Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus,"Evaluation of Efficacy and Safety of HMR1964 Intensive Therapy in Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled With Oral Hypoglycemic Agents (OHA); OHA Therapy Controlled, Open, Randomized, Parallel Group, Comparative (Superiority), 16-week, Multinational, Multicenter Study",390,2003-12-01,NA,Sanofi
NCT00309751,Phase 3,2,Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia,Study of Pitavastatin Vs. Atorvastatin (Following Up-Titration) in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia,418,2005-12-01,2007-06-01,Kowa Research Europe
NCT00311896,Phase 3,2,Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT),"Multicentric, Randomized, Placebo Controlled and Double-blind Study to Evaluate the Efficacy and Safety of Antithrombotic Prophylaxis With Bemiparin (3,500 UI/Day) in Cancer Patients With a Central Venous Catheter (CVC)(BECAT)",402,2005-07-01,2010-12-01,"Clinica Universidad de Navarra, Universidad de Navarra"
NCT00313209,Phase 3,2,Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127),"Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study",933,2006-04-01,2008-02-01,AstraZeneca
NCT00338143,Phase 3,NA,"A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies","A Phase IIIb, Open-Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies or Have Recently Transitioned From Systemic Therapies",1200,2003-10-01,2004-05-01,"Genentech, Inc."
NCT00349531,Phase 4,NA,A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS,"A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (IRLS) and Sleep Disturbance (MOS Sleep Scale) in Out-patients With Idiopathic Restless Legs Syndrome",369,2006-07-01,NA,Boehringer Ingelheim
NCT00351884,Phase 3,3,Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes,"A Multicenter, Double-blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 MG QD to Placebo as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy",370,2006-05-01,NA,Novartis
NCT00362232,Phase 3,2,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.,"RECORD 4 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled, Double-blind, Randomized Study of BAY59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement",3148,2006-06-01,2008-01-01,Bayer
NCT00362960,Phase 3,NA,Olmesartan Medoxomil and Diabetic Nephropathy,"Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy",300,2003-05-01,2004-09-01,"Daiichi Sankyo, Inc."
NCT00389779,Phase 3,3,DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension,"A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo (Protocol DAR-312)",849,2006-09-01,2009-08-01,Gilead Sciences
NCT00407537,Phase 4,1,Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors,A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice,1531,2007-03-01,2009-10-01,Pfizer
NCT00419744,Phase 3,NA,A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD,"A Phase IIIB, 12-Month, Double-blind, Double-dummy,Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 μg x 2 Actuations Twice-daily and 80/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler® 4.5 μg x 2 Inhalations Twice-daily in COPD Subjects",1200,2007-01-01,2009-08-01,AstraZeneca
NCT00424476,Phase 3,3,A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE),"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)",865,2007-05-01,2010-03-01,Human Genome Sciences Inc.
NCT00454584,Phase 3,3,An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis,"A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis",903,2007-03-01,2009-01-01,"Centocor, Inc."
NCT00463606,Phase 3,3,A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia,"A 12-week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to ABT-335 and Rosuvastatin Monotherapy in Subjects With Type IIa and IIb Dyslipidemia",760,2007-04-01,2008-02-01,AstraZeneca
NCT00482729,Phase 3,2,MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED),"A Randomized, Double-Blind, Active-Comparator Controlled, Clinical Trial to Study the Efficacy and Safety of MK0431A for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM)",1246,2007-06-19,2009-04-27,Merck Sharp & Dohme Corp.
NCT00521742,Phase 3,4,Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease,"A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCl vs Glyburide in the Treatment of Patients With Type 2 (Non-Insulin-Dependent) Diabetes Mellitus and Mild Cardiac Disease (NYHA I)",300,2001-03-01,2003-01-01,Takeda
NCT00532935,Phase 3,2,MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066),"A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of the MK0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patients With Type 2 Diabetes Mellitus",517,2008-01-26,2009-10-23,Merck Sharp & Dohme Corp.
NCT00558428,Phase 3,NA,Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension,"An Eight-week Randomized, 4-arm, Double-blind Study to Compare the Efficacy and Safety of Combinations of Telmisartan 40mg + Amlodipine 5mg Versus Telmisartan 80mg + Amlodipine 5mg Versus Amlodipine 5mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 5mg Monotherapy",1098,2007-10-01,NA,Boehringer Ingelheim
NCT00570986,Phase 3,3,A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",1465,2007-11-01,2009-06-01,AbbVie
NCT00604396,Phase 3,NA,Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes,Safety and Efficacy of Insulin Detemir Combined With OAD Versus Insulin NPH Combined With OAD in Type 2 Mellitus,477,2003-03-01,2004-01-01,Novo Nordisk A/S
NCT00624052,Phase 3,NA,26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension,An Open Label Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 40mg + Amlodipine 10mg or Fixed Dose Combination of Telmisartan 80mg + Amlodipine 10mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension,838,2008-03-01,NA,Boehringer Ingelheim
NCT00627016,Phase 3,2,A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn,"A Phase 3 Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy of TAK-390MR (30 mg QD) Compared to Placebo on Relief of Nocturnal Heartburn in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD)",305,2008-03-01,2009-03-01,Takeda
NCT00628862,Phase 3,3,"Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU","A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-national, Phase III, Efficacy and Safety Study of Inhaled Formoterol 4.5 μg and 9 μg Twice Daily in Japanese and European Patients With Chronic Obstructive Pulmonary Disease (COPD)",613,2007-12-01,2009-04-01,AstraZeneca
NCT00633893,Phase 3,3,Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism,A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism,2711,2008-05-01,2012-08-01,Bristol-Myers Squibb
NCT00634712,Phase 3,2,Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved),Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Preserved Left Ventricular Systolic Function,734,1999-06-01,2003-05-01,AstraZeneca
NCT00641043,Phase 3,2,Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone,"A Randomised, Double-blind, Placebo Controlled, Parallel Group 24 Week Study to Assess the Efficacy and Safety of BI 1356 (5 mg) in Combination With 30 mg Pioglitazone (Both Administered Orally Once Daily), Compared to 30 mg Pioglitazone Plus Placebo in Drug Naive or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control.",389,2008-03-01,NA,Boehringer Ingelheim
NCT00642096,Phase 3,3,Factorial Study of Metoprolol Succinate TOPROL-XL (324A),"A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Factorial Study of Metoprolol Succinate Extended Release Tablets (TOPROL-XL) Hydrochlorothiazide and Their Combination in Patients With Essential Hypertension.",1900,2003-06-01,2004-07-01,AstraZeneca
NCT00654173,Phase 3,3,Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin (SOLAR),"A 12-Week, Randomized, Open-Label, 3 Arm Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin Achieving NCEP ATP III LDL-C Goals in High Risk Subjects With Hypercholesterolaemia in the Managed Care Setting.",4444,2002-06-01,2004-09-01,AstraZeneca
NCT00667407,Phase 3,2,Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma,"A Randomized, Double-Blind Study to Determine the Efficacy of Levalbuterol Versus Racemic Albuterol in the Treatment of Acute Asthma",627,2000-11-01,2002-08-01,Sunovion
NCT00679432,Phase 3,4,(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis,"Efficacy and Safety of New Oral Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg Extended Release Tablet Formulations in Patients With Mild or Moderate, Active Ulcerative Colitis. A Multicenter, Randomized, Double-blind, Double Dummy Comparative Study Versus Placebo, With an Additional Reference Arm Evaluating Asacol® 2400 mg.",510,2008-06-01,2010-06-01,"Valeant Pharmaceuticals International, Inc."
NCT00696436,Phase 3,5,An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.,"A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension",1291,2008-04-01,2009-08-01,Takeda
NCT00698646,Phase 4,3,Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.,"A 16 Week Multi-center, Randomized, Double-blind Study to Evaluate Efficacy and Safety of Valsartan/Hydrochlorothiazide (HCTZ) Combination Therapy Compared to Patients Initiated With Valsartan Monotherapy or Hydrochlorothiazide (HCTZ) Monotherapy in Very Elderly Patients With Essential Hypertension",384,2008-04-01,2009-06-01,Novartis
NCT00699998,Phase 3,2,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed,9326,2008-06-01,2012-04-01,Eli Lilly and Company
NCT00727857,Phase 3,3,Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.,"A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy Compared to Pioglitazone HCl Monotherapy and to Metformin HCl Monotherapy in the Treatment of Subjects With Type 2 Diabetes",600,2007-06-01,2008-08-01,Takeda
NCT00728351,Phase 3,2,Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%),"A Multicenter, Double-blind, Randomized Study to Compare the Efficacy of 24 Weeks Treatment With Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) Versus Metformin Monotherapy (1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy.",317,2008-06-01,NA,Novartis
NCT00760214,Phase 3,3,Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension,"A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential Hypertension",885,2008-01-01,2009-04-01,Takeda
NCT00768300,Phase 3,2,"(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF","ARTEMIS-IPF: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Early Idiopathic Pulmonary Fibrosis (IPF)",494,2008-12-01,2011-02-01,Gilead Sciences
NCT00772538,Phase 3,2,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I),"A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma",459,2008-10-01,NA,Boehringer Ingelheim
NCT00830960,Phase 3,6,A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome,A Comparison of Platelet Inhibition Following Prasugrel or Clopidogrel Administration in Asian Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention,720,2009-02-01,2010-06-01,Eli Lilly and Company
NCT00838916,Phase 3,2,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,"A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.",779,2009-02-01,2013-05-01,GlaxoSmithKline
NCT00845728,Phase 3,2,Exacerbation Study,"A Phase IIIb Multicenter, 52 Week Treatment, Randomized, Blinded, Double Dummy, Parallel Group Efficacy Study Comparing the Effect of Inhaled Indacaterol 150 µg o.d. vs Inhaled Tiotropium 18 µg o.d. on Lung Function, Rate of Exacerbations and Related Outcomes in Patients With COPD",3439,2009-03-01,2012-07-01,Novartis
NCT00847626,Phase 3,11,Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension,"A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of TAK 491 Plus Chlorthalidone Fixed-Dose Combination in Participants With Moderate to Severe Hypertension",1711,2009-01-01,2010-07-01,Takeda
NCT00853827,Phase 3,2,Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients,"A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy",613,2009-03-01,2013-01-01,Novartis
NCT00860288,Phase 2/Phase 3,4,Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes,NA,1988,2009-02-01,2011-03-01,Novartis
NCT00887250,Phase 3,3,A Study to Investigate the Antihypertensive Efficacy of MK0954,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan (MK954, DuP753) in Patients With Mild to",366,1991-12-01,1992-11-01,Merck Sharp & Dohme Corp.
NCT00966004,Phase 3,3,A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder,"Phase III Study of YM178 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients With Overactive Bladder",1139,2009-07-01,2010-02-01,Astellas Pharma Inc
NCT01018173,Phase 3,2,A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease,"A Randomized Double Blind, Placebo-controlled Clinical Trial to Assess the Effects of Taspoglutide (RO5073031) on Cardiovascular Outcomes in Subjects With Inadequately Controlled Type 2 Diabetes and Established Cardiovascular Disease",2118,2010-01-01,2011-01-01,Hoffmann-La Roche
NCT01028391,Phase 3,2,30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064),"A 30-Week Extension to: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus",317,2007-09-01,2009-01-01,Merck Sharp & Dohme Corp.
NCT01069289,Phase 3,2,Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients,"A Phase III, 12-week, Double-blind, Randomised, Parallel-group, Active-controlled, Multinational, Efficacy and Safety Study of Symbicort® Turbuhaler® 160/4.5 μg 2 Inhalations Twice Daily (Bid) Compared to Oxis® Turbuhaler® 4.5 μg 2 Inhalations Twice Daily (Bid) in Patients With Chronic Obstructive Pulmonary Disease",1293,2010-01-01,2011-03-01,AstraZeneca
NCT01076088,Phase 3,6,Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121),"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of Co-administration of Sitagliptin and Metformin in Patients With Type 2 Diabetes Mellitus",744,2010-11-15,2012-12-24,Merck Sharp & Dohme Corp.
NCT01106690,Phase 3,3,The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone),"A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy",344,2010-06-01,2012-07-01,"Janssen Research & Development, LLC"
NCT01131182,Phase 4,2,Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263),"An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting",1147,2010-06-13,2010-11-04,Merck Sharp & Dohme Corp.
NCT01159912,Phase 3,3,Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents,"A Randomised, Double-blind, Double-dummy, Placebo Controlled (With Rescue Medication), Multicenter Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents.",350,2010-06-30,2012-01-16,GlaxoSmithKline
NCT01174693,Phase 4,2,Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping,Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping,795,2010-03-01,2015-03-01,Gangnam Severance Hospital
NCT01323634,Phase 3,2,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease,A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),519,2011-03-18,2011-12-14,GlaxoSmithKline
NCT01425359,Phase 4,2,Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina,"A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects With Chronic Stable Angina and Coronary Artery Disease With a History of Type 2 Diabetes Mellitus",949,2011-09-01,2012-10-01,Gilead Sciences
NCT01516879,Phase 3,2,Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study,"A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-Term Tolerability and Durable Efficacy of AMG 145 (Evolocumab) on LDL-C in Hyperlipidemic Subjects",905,2012-01-05,2013-10-14,Amgen
NCT01538446,Phase 4,2,Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel,"The ANTARCTIC Study - Assessment of a Normal Versus Tailored Dose of Prasugrel After Stenting in Patients Aged > 75 Years to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications",880,2012-03-01,2016-05-01,Assistance Publique - Hôpitaux de Paris
NCT01573143,Phase 4,2,Statin Therapy In Cardiac Surgery,Statin Therapy In Cardiac Surgery,1922,2011-09-01,2014-09-01,University of Oxford
NCT01574651,Phase 3,2,The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD),"A 26-week Treatment, Multicenter, Randomized, Parallel Group, Blinded Study to Assess the Efficacy and Safety of QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Using Tiotropium Plus Formoterol as Control",934,2012-05-01,2013-04-01,Novartis
NCT01603082,Phase 4,2,Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients,"A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention",343,2012-07-01,2014-06-01,AstraZeneca
NCT01623115,Phase 3,2,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy",486,2012-07-01,2014-12-01,Sanofi
NCT01697696,Phase 3,2,Long Term Safety Study of NVA237 vs QAB149 in COPD Patients,"A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation",511,2012-10-01,2014-11-01,Novartis
NCT01711359,Phase 3,3,A Study in Participants With Moderate to Severe Rheumatoid Arthritis,"A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs",588,2012-11-01,2015-08-01,Eli Lilly and Company
NCT01719003,Phase 3,9,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,"A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus",1413,2012-10-01,2014-12-01,Boehringer Ingelheim
NCT01764997,Phase 3,5,An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate,"A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients With Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment With Adalimumab and MTX",776,2013-04-01,2015-01-01,Sanofi
NCT01792518,Phase 3,2,"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin","A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)",360,2013-02-01,2015-12-01,Boehringer Ingelheim
NCT01845025,Phase 4,2,Study of Safety of Foradil in Patients With Persistent Asthma,"A 26 Week, Randomized, Active-controlled Safety Study of Double-blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma.",827,2013-05-01,2016-05-01,Novartis
NCT01869491,Phase 3,2,Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study,"A Multi-centre, Randomised, Double-blind, Two Arm, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Double Action Chewable Tablets in Patients With Gastro-esophageal Reflux Disease",1107,2013-06-01,2014-05-01,Reckitt Benckiser Healthcare (UK) Limited
NCT01870804,Phase 4,2,Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury (PRATO-ACS 2),Impact of Early High-dose Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury in Unselected Patients With Non- ST Elevation Acute Coronary Syndromes Scheduled for Early Invasive Strategy.,760,2013-05-01,2016-09-01,Centro Cardiopatici Toscani
NCT01917331,Phase 3,2,Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD,A Phase 3 Randomised Double Blind Randomised Parallel Multinational Trial Comparing a Fixed Combination of Beclometasone+Formoterol+Glycopyrrolate to Foster® in Patients With Chronic Obstructive Pulmonary Disease,1368,2014-03-01,2016-03-01,Chiesi Farmaceutici S.p.A.
NCT01928771,Phase 3,3,Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma,"A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma",2681,2013-09-19,2016-04-05,AstraZeneca
NCT01930188,Phase 3,4,Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor),1231,2013-12-02,2015-10-12,Novo Nordisk A/S
NCT01970878,Phase 3,4,"Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)","A 28-Week, Multi-Center, Randomized, Double Blind, Parallel-Group, Active-Controlled Safety Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® as an Active Control",892,2013-11-01,2015-03-01,"Pearl Therapeutics, Inc."
NCT02000336,Phase 3,3,Comparison of the Effectiveness of Two Different Dosages of Cortisone Compared to Placebo in Rheumatoid Arthritis,"Comparison of the Efficacy and Safety of Two Different Starting Dosages of Prednisolone in Early Active Rheumatoid Arthritis: a Randomized, Placebo Controlled Trial",386,2014-01-01,2018-06-01,Ruhr University of Bochum
NCT02105948,Phase 3,2,Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients,Study MEA117106: Mepolizumab vs. Placebo as add-on Treatment for Frequently Exacerbating COPD Patients,837,2014-04-15,2017-01-17,GlaxoSmithKline
NCT02132936,Phase 3,4,LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris,LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris,504,2014-06-01,2015-02-01,LEO Pharma
NCT02138916,Phase 3,3,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,"Randomised, Double-blind, 56 Week Placebo-controlled, Parallel Group, Multicentre, Phase 3 Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab in Patients With Moderate to Very Severe COPD With a History of Exacerbations",1656,2014-06-13,2018-04-17,AstraZeneca
NCT02177435,Phase 3,2,Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension,"An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg.",491,1999-02-01,NA,Boehringer Ingelheim
NCT02182479,Phase 3,5,Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients,"Comparison of the Safety and Efficacy of Berodual® Administered Via Respimat® Device (50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide/10 µg Ipratropium Bromide, 1 Puff q.i.d.) With That Administered Via the MDI (50 µg Fenoterol Hydrobromide/21 µg Ipratropium Bromide, 2 Puffs q.i.d.) in Asthma Patients Over a 12-week Period",631,1998-04-01,NA,Boehringer Ingelheim
NCT02207244,Phase 3,3,A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment",992,2014-11-03,2020-07-15,"Janssen Research & Development, LLC"
NCT02207829,Phase 3,2,A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease,"A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg Compared With Tiotropium 18 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",1017,2014-09-01,2015-06-15,GlaxoSmithKline
NCT02229396,Phase 3,3,Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo,"A 28-week, Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study With a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simultaneous Administration of Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg Compared to Exenatide Once Weekly 2 mg Alone and Dapagliflozin Once Daily 10 mg Alone in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin",695,2014-09-04,2017-12-28,AstraZeneca
NCT02375724,Phase 4,2,BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH,"A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL STUDY TO ASSESS THE BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH WHEN ADMINISTERED TO PATIENTS WITH COPD",300,2015-03-01,2015-11-01,AstraZeneca
NCT02597049,Phase 3,3,A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus,"A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus",424,2015-11-01,2017-02-01,Eli Lilly and Company
NCT02607306,Phase 3,3,"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.","A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus",819,2015-11-18,2017-12-22,Novo Nordisk A/S
NCT00000479,Phase 3,4,Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer,Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women,39876,1992-09-01,2005-02-01,Brigham and Women's Hospital
NCT00000542,Phase 3,NA,Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),NA,NA,1993-08-01,2002-03-01,"National Heart, Lung, and Blood Institute (NHLBI)"
NCT00035451,Phase 3,3,Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.,Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.,658,2001-02-01,2003-06-01,Forest Laboratories
NCT00039026,Phase 3,4,Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea,"A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With a Sulfonylurea Alone",377,2002-02-01,2003-08-01,AstraZeneca
NCT00064415,Phase 3,2,"To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD","A Multicenter, Open-Label, Randomized, Active-Controlled, Parallel Group Chronic Safety Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease",799,2002-06-01,2004-12-01,Sunovion
NCT00092144,Phase 3,NA,Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED),"A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral MK0476 Vs Placebo During the Allergy Season in Patients With Seasonal Aeroallergen Sensitivity and Chronic Asthma Which is Also Active During Allergy Season",500,2004-02-26,2004-06-15,Merck Sharp & Dohme Corp.
NCT00092365,Phase 3,NA,A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED),"A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee",413,2003-04-01,2003-11-01,Merck Sharp & Dohme Corp.
NCT00094757,Phase 3,3,An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023),"A Multicenter, Randomized, Double-Blind Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",521,2004-10-01,2005-08-01,Merck Sharp & Dohme Corp.
NCT00095394,Phase 3,2,Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension,The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension,645,2004-09-01,2005-05-01,Bristol-Myers Squibb
NCT00120900,Phase 3,NA,Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee,"A Phase III, 12-week, Multicentre, Double-Blind, Double-Dummy, Randomised, Placebo - and Active Comparator - Contolled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381 XXmg and YYmg Administered Orally Once Daily, in Adults With Osteoarthritis of the Knee",1340,2005-05-01,2007-09-01,GlaxoSmithKline
NCT00121966,Phase 4,NA,South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus,South Danish Diabetes Study: A Prospective Randomised Multi-Centre Study for the Evaluation of the Optimal Pharmacological Antidiabetic Treatment of Type 2 Diabetes Mellitus,400,2003-01-01,2007-07-01,Odense University Hospital
NCT00129805,Phase 3,2,Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS),"Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial",1510,2001-01-01,2004-09-01,Mitsubishi Tanabe Pharma Corporation
NCT00132418,Phase 4,2,Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders,"Double-blind, Randomized, Placebo-controlled Study of Enbrel (Etanercept) in the Treatment of Rheumatoid Arthritis Subjects With Comorbid Disorders",564,2000-04-01,2004-02-01,Amgen
NCT00136799,Phase 3,NA,Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia,Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia,325,2005-06-01,2006-04-01,Novartis
NCT00141141,Phase 4,NA,Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia,"A Phase IV, Multicenter, Randomized, Open Label Study To Evaluate The Efficacy And Safety Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia",383,2004-01-01,2007-04-01,Pfizer
NCT00145236,Phase 3,NA,Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension,"A Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel Group Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension.",300,2001-11-01,2003-08-01,Mylan Bertek Pharmaceuticals
NCT00154271,Phase 4,NA,Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP),Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP),1677,2004-01-01,2005-06-01,Novartis
NCT00168831,Phase 3,3,Tiotropium / Respimat One-Year Study,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mg and 10mg) of Tiotropium Inhalation Solution Delivered by the Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)",1007,2003-02-01,NA,Boehringer Ingelheim
NCT00174330,Phase 4,NA,Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia,"A Multi-Center, Randomized, Open-Label Study To Evaluate Efficacy And Safety Of Dual Therapy With Atorvastatin Plus Amlodipine When Compared Amlodipine Therapy Alone In The Treatment Of Subjects With Concurrent Hyperlipidemia And Hypertension.",330,2005-05-01,2006-02-01,Pfizer
NCT00184600,Phase 3,3,"Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes","A 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin Versus a Twice Daily Insulin Mixture Versus a Meal-time Rapid-Acting Insulin in Subjects With Type 2 Diabetes Inadequately Controlled on Therapy With Oral Agents, and Assessing the Requirement for More Complex Insulin Regimens to Achieve and Maintain Glycaemic Control, Their Efficacy and Durability",708,2004-11-01,2009-08-01,Novo Nordisk A/S
NCT00195663,Phase 3,3,Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis,"A Prospective Multi-Centre Randomised, Double-Blind, Active Comparator-Controlled, Parallel-Groups Study Comparing the Fully Human Monoclonal Anti-TNFα Antibody Adalimumab Given Every Second Week With Methotrexate Given Weekly and the Combination of Adalimumab and Methotrexate Administered Over 2 Years in Patients With Early Rheumatoid Arthritis (PREMIER).",799,2000-12-01,2012-04-01,AbbVie
NCT00219037,Phase 3,NA,Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension,"A 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long Term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension.",1955,2004-06-01,2005-10-01,Novartis
NCT00240448,Phase 4,NA,"A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients","A Randomised, Double-blind, Double-dummy, Placebo-controlled, Forced-titration, Comparison of MICARDIS® HCT (Telmisartan 80 mg / Hydrochlorothiazide 25 mg) Versus DIOVAN® HCT (Valsartan 160 mg / Hydrochlorothiazide 25 mg) Using Seated Trough Cuff Blood Pressure in Patients With Stage 1 and Stage 2 Hypertension",1109,2003-09-01,NA,Boehringer Ingelheim
NCT00251745,Phase 3,3,Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn,A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg Once-Daily (QD) and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD),908,2005-12-01,2006-05-01,Takeda
NCT00252863,Phase 3,NA,DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults,"A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 µg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel-Group, Multicentre Study",1600,2004-12-01,2006-05-01,AstraZeneca
NCT00255151,Phase 3,3,Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis,A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis,451,2006-01-01,2006-11-01,Takeda
NCT00264550,Phase 3,4,An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,"A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Subjects With ActiveRheumatoid Arthritis Despite Methotrexate Therapy",444,2005-12-01,2012-05-01,"Centocor, Inc."
NCT00268632,Phase 3,NA,"IMPACT Study (Improving Measurements of Persistence on ""ACtonel"" Treatment)",A Multicenter Prospective Study to Assess the Impact of Physician's Reinforcement on the Subject's Compliance and Persistence on Treatment Using Feedback on Bone Markers in Previously Undiagnosed Postmenopausal Osteoporotic Women Treated With Risedronate.,NA,1999-08-01,NA,Sanofi
NCT00274274,Phase 4,NA,Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes,"Efficacy and Safety of Insulin Aspart in a Fixed or Flexible Supplementary Insulin Therapy Regimen, With or Without Insulin Detemir in Type 2 Diabetes",373,2005-09-01,2006-11-01,Novo Nordisk A/S
NCT00274599,Phase 4,NA,PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN,"A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group, Multicentre, Forced-Titration, 14-Week Treatment Study Comparing MICARDIS® (Telmisartan 40-80-80 mg, QD) and ALTACE® (Ramipril 2.5-5-10 mg, QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring",812,2002-10-01,NA,Boehringer Ingelheim
NCT00299130,Phase 3,3,A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis,"A Randomized, Placebo Controlled, Double-blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate, Compared to Methotrexate Monotherapy, in Patients With Active Rheumatoid Arthritis",511,2005-10-01,2013-07-01,"Genentech, Inc."
NCT00361894,Phase 3,2,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.,"RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled., Double-blind, Randomized Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.",2531,2006-02-01,2007-01-01,Bayer
NCT00366938,Phase 3,NA,Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).,"A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator",1464,2003-09-01,NA,Novartis
NCT00367211,Phase 3,NA,Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.,"A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.",400,2006-09-01,2007-09-01,POZEN
NCT00381472,Phase 3,NA,Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa,"A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-dopa",393,2003-06-01,2004-12-01,GlaxoSmithKline
NCT00383929,Phase 3,3,Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg,"A Double Blind, Randomised, 3-Arm Parallel Group, Multicentre, 8-Week, Phase III Study to Assess Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) /HCT 32/12.5mg and 32/25mg vs. CC 32mg Alone in Patients With Inadequate BP Control on Monotherapy With CC 32mg",1979,2006-09-01,2007-10-01,AstraZeneca
NCT00386139,Phase 3,NA,A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients,An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy,881,2006-09-01,2007-07-01,Novartis
NCT00393952,Phase 3,5,"New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma","A Randomized, Double-blind, Placebo-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm) 100/10 µg or 250/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Placebo or Fluticasone (250 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent and Adult Patients With Moderate to Severe Asthma",557,2006-06-01,2008-04-01,SkyePharma AG
NCT00395343,Phase 3,2,Sitagliptin Added-on to Insulin Study (0431-051),"A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or In Combination With Metformin)",641,2006-12-11,2008-10-13,Merck Sharp & Dohme Corp.
NCT00403767,Phase 3,2,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,"A Prospective, Randomized, Double-Blind, Parallel-Group, Multicenter, Non-inferiority Study Comparing the Efficacy and Safety of Rivaroxaban (BAY 59-7939) With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation",14269,2006-12-01,2010-09-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00408187,Phase 3,3,"Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients","A Phase III, Randomized, Multicentre, Double-Blind, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients",642,2006-12-01,2008-12-01,Aurinia Pharmaceuticals Inc.
NCT00439855,Phase 4,NA,Enoxaparin Versus Unfractionated Heparin in PCI,Enoxaparin Versus Unfractionated Heparin in PCI,2100,2003-09-01,2006-02-01,Triemli Hospital
NCT00452530,Phase 3,2,Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery,"A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery (The ADVANCE - 2 Study)",3221,2007-06-01,2009-01-01,Bristol-Myers Squibb
NCT00466167,Phase 3,3,Pivotal Study in Advanced Parkinsons Disease Patients,"A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD).",517,2007-04-01,NA,Boehringer Ingelheim
NCT00479362,Phase 4,4,Anticoagulant Therapy During Pacemaker Implantation,Randomized Trial of Uninterrupted Versus Interrupted Anticoagulant Therapy in Patients Undergoing Cardiac Pacing Device Implantation,447,2005-09-01,2012-09-01,University of Turku
NCT00497237,Phase 3,2,Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma,"Prospective, Randomised, Open-label, Multicentre, Active Drug Controlled, Parallel Group Design Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate 400 mcg + Formoterol 24 mcg pMDI Via HFA-134a (Foster™) vs. Fluticasone Propionate 500 mcg + Salmeterol Xinafoate 100 mcg DPI (Seretide Diskus®) in the 6 Months Stepdown Treatment of Adult Patients With Controlled Asthma",382,2007-04-01,2010-03-01,Chiesi Farmaceutici S.p.A.
NCT00510952,Phase 3,2,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE),The PERSISTENT Trial: A Prospective Randomized Trial Comparing Insulin Lispro Protamine Suspension to Insulin Glargine in Patients With Type 2 Diabetes on Anti-hyperglycemic Medications,471,2007-08-01,2008-10-01,Eli Lilly and Company
NCT00518882,Phase 3,2,Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes,"Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes",467,2007-08-01,2009-04-01,Novo Nordisk A/S
NCT00541489,Phase 3,3,Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip,"A 13-Week, Phase 3, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo Bid and Naproxen 500 mg Bid, Controlled Study on the Efficacy on Signs and Symptoms, and Safety of Naproxcinod (HCT3012) 750 mg Bid, in Patients With Osteoarthritis of the Hip",800,2007-06-01,NA,NicOx
NCT00549549,Phase 3,4,Celebrex In Acute Gouty Arthritis Study,"A Phase 3, Randomized, Double-Blind, Multicenter, Active-Controlled Trial To Evaluate The Efficacy And Safety Of Celecoxib (Celebrex®) And Indomethacin In The Treatment Of Moderate To Severe Acute Gouty Arthritis",402,2008-02-01,2009-12-01,Pfizer
NCT00558259,Phase 3,2,Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE,Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.,1353,2007-11-01,NA,Boehringer Ingelheim
NCT00591773,Phase 3,3,Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension,"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Chlorthalidone in Subjects With Essential Hypertension",551,2007-09-01,2009-03-01,Takeda
NCT00634400,Phase 3,2,Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative),Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function,6268,1999-03-01,2003-05-01,AstraZeneca
NCT00635505,Phase 3,3,"Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients","Randomized, Placebo-Controlled, Parallel, Multi-Center, 12-Week Study to Evaluate the Efficacy and Safety of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Adult and Adolescent Asthmatic Patients",300,2007-09-01,2008-08-01,"Amphastar Pharmaceuticals, Inc."
NCT00651651,Phase 3,3,Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5,"A 12 Week Randomized, Double-blind, Double-Dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-Products (Budesonide and Formoterol) in Children (at Least 6years of Age) and Adults With Asthma-SPRUCE 80/4.5",450,2002-08-01,2003-09-01,AstraZeneca
NCT00654225,Phase 3,2,Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS),"A 6-Week, Randomized,Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolaemia in South Asian Subjects.",2340,2002-10-01,2005-03-01,AstraZeneca
NCT00654407,Phase 3,3,Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia,"An Open Label, Randomized, Multi-Center, Phase IIIB, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia.",4875,2001-11-01,2004-09-01,AstraZeneca
NCT00657150,Phase 3,2,Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty,"A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Compared to Subcutaneous 40 mg Enoxaparin Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Arthroplasty Surgery. (RE-NOVATE II)",2055,2008-03-01,NA,Boehringer Ingelheim
NCT00658528,Phase 3,2,Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD),A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD),1061,2008-02-01,2010-01-01,Eisai Inc.
NCT00670501,Phase 3,3,Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis,Effects of LY333334 in the Treatment of Postmenopausal Women With Osteoporosis,1637,1996-08-01,1999-04-01,Eli Lilly and Company
NCT00679484,Phase 3,2,Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24,"A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV)",400,2008-06-01,2009-11-01,"Daiichi Sankyo, Inc."
NCT00683111,Phase 4,2,Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease,Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications in Patients With Acute Coronary Syndrome or Myocardial Infarction,500,2008-07-01,2011-12-01,Ruttonjee Hospital
NCT00697099,Phase 3,2,Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery,"A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery",2326,2008-06-01,2009-06-01,Sanofi
NCT00699192,Phase 3,3,"Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension","A Multicenter, Double-blind, Randomized, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 mg as Compared to Amlodipine/Valsartan 5/40 mg or to Amlodipine 5 mg Once Daily in Elderly Patients With Essential Hypertension Not Adequately Controlled After Four Weeks on Amlodipine 5 mg Once Daily",965,2008-05-01,2009-05-01,Novartis
NCT00705575,Phase 3,2,Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension,"A 12 Week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg Compared to Aliskiren 300 mg in Patients With Stage II Hypertension",688,2008-06-01,2009-04-01,Novartis
NCT00764725,Phase 4,2,Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT),"A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX",487,2002-12-01,2008-12-01,Karolinska Institutet
NCT00782210,Phase 3,3,12 / 48 Week Pivotal PFT vs PBO in COPD I,"Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 mcg [2 Actuations of 2.5 mcg] and 10 mcg [2 Actuations of 5 mcg]) Delivered by the Respimat® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)",625,2008-11-01,NA,Boehringer Ingelheim
NCT00783237,Phase 4,2,Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431),Onset of Action of Mometasone Furoate Nasal Spray vs. Placebo in Induced Allergic Rhinitis,340,2003-12-01,2004-02-21,Merck Sharp & Dohme Corp.
NCT00792818,Phase 3,2,The Efficacy and Safety of Curcuma Domestica Extracts and Ibuprofen in Knee Osteoarthritis,"The Efficacy and Safety of Curcuma Domestica Extracts and Ibuprofen for Therapy of Patients With Knee Osteoarthritis, the Randomized Double-blinded Controlled Trial, Multicenter Study",367,2008-12-01,2012-10-01,Mahidol University
NCT00827411,Phase 4,4,"Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy","Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting",2500,2009-01-01,2013-01-01,Assistance Publique - Hôpitaux de Paris
NCT00838903,Phase 3,4,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus",1049,2009-02-01,2013-04-01,GlaxoSmithKline
NCT00862641,Phase 4,4,A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease,"A Phase 4, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD).",1009,2009-04-01,2009-10-01,Astellas Pharma Inc
NCT00894387,Phase 3,2,"Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure","A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early After Hospitalization for Acute Decompensated Heart Failure",1639,2009-05-01,2012-08-01,Novartis
NCT01018186,Phase 3,2,Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study,"A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects With Asthma",503,2009-10-19,2011-05-12,GlaxoSmithKline
NCT01030081,Phase 4,2,Amlodipine Prevents Morning Blood Pressure Surge Study,A Randomized Controlled Phase Ⅳ Trial With Two Equally Sized Treatment Groups: Amlodipine And Nifedipine GITS,510,2009-10-01,2013-03-01,Shanghai Jiao Tong University School of Medicine
NCT01043666,Phase 3,3,A Study of YM178 in Subjects With Symptoms of Overactive Bladder,"Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder",1126,2009-12-01,2011-09-01,Astellas Pharma Inc
NCT01057251,Phase 4,2,Nebivolol in Patients With Systolic Stage 2 Hypertension,"Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of 5 mg or 20 mg Nebivolol Once Daily on Blood Pressure in Patients With Systolic Stage 2 Hypertension",433,2010-03-01,2011-01-01,Forest Laboratories
NCT01077362,Phase 3,3,A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents,"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha Agent(s)",312,2010-03-01,2012-11-01,"Janssen Research & Development, LLC"
NCT01081834,Phase 3,3,The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise",678,2010-03-01,2012-03-01,"Janssen Research & Development, LLC"
NCT01120691,Phase 3,3,Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations,"A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)",2224,2010-04-01,2012-07-01,Novartis
NCT01121224,Phase 4,2,Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty,CSP #571 - Drug-eluting Stents vs. Bare Metal Stents in Saphenous Vein Graft Angioplasty (DIVA),597,2012-01-01,2016-12-01,VA Office of Research and Development
NCT01137812,Phase 3,2,The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial),"A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy",756,2010-07-01,2012-03-01,"Janssen Research & Development, LLC"
NCT01142726,Phase 3,3,Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis,"A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA",511,2010-12-01,2014-10-01,Bristol-Myers Squibb
NCT01175824,Phase 4,2,Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies,Comparison of Twice-Daily Insulin Lispro Low Mixture Versus Once-Daily Basal Insulin Glargine and Once-Daily Prandial Insulin Lispro as Insulin Intensification Strategies in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine and Metformin and/or Pioglitazone,478,2011-04-01,2012-11-01,Eli Lilly and Company
NCT01183013,Phase 3,7,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","A Randomised, Double-blind Parallel Group Study to Compare the Efficacy and Safety of Initial Combination Therapy With Linagliptin 5 mg + Pioglitazone 15 mg, 30 mg, or 45 mg, vs. Monotherapy With Pioglitazone (15 mg, 30 mg, or 45 mg) or Linagliptin 5 mg Once Daily for 30 Weeks, Followed by a Blinded Trial Period on Linagliptin 5 mg + Pioglitazone 30 or 45 mg Versus Pioglitazone Monotherapy 30 or 45 mg or Linagliptin 5 mg for up to 54 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control on Diet and Exercise",936,2010-08-01,2013-02-01,Boehringer Ingelheim
NCT01204294,Phase 3,7,Comprehensive Add on Study in Japan,"An Open Label, Randomised, Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Background Mono-therapy With an Approved Antidiabetic Drug",574,2010-09-01,2012-01-01,Boehringer Ingelheim
NCT01235130,Phase 3,2,Multi_center Study to Evaluate the Effect of N-3 Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation,"Phase 3 A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Effect of Long-chain N-3 Polyunsaturated Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation",337,2009-03-01,2013-05-01,Montreal Heart Institute
NCT01277822,Phase 4,2,Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399),"The 8 Weeks, Multicenter, Randomized, Double-blind, Clinical Study To Evaluate Efficacy Of Treatment With Losartan/Amlodipine 100/5 mg Combination Compared To Amlodipine 10 mg Monotherapy In Hypertensive Patients Who Are Not Appropriately Respond To Amlodipine 5 mg Monotherapy",334,2011-05-30,2013-04-22,Merck Sharp & Dohme Corp.
NCT01313676,Phase 3,4,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease,16568,2011-01-25,2015-07-15,GlaxoSmithKline
NCT01318083,Phase 2/Phase 3,3,Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan,"A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Sulfonylurea in Subjects With Type 2 Diabetes in Japan",312,2008-08-01,2009-04-01,Takeda
NCT01340768,Phase 3,2,Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262),"An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting",870,2010-06-22,2011-09-21,Merck Sharp & Dohme Corp.
NCT01392326,Phase 3,3,"Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)","A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis",606,2011-09-01,2014-10-01,Novartis
NCT01456611,Phase 3,3,Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%,"A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Evaluate the Clinical Equivalence of Diclofenac Sodium 1% Gel (Anchen Pharmaceuticals, Inc.) With Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis) in Patients With Osteoarthritis of the Knee",749,2011-09-01,2012-04-01,"Anchen Pharmaceuticals, Inc"
NCT01474369,Phase 3,3,Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease,"A Phase 3, Randomized, Double Blind, Placebo Control, Multicenter Study to Evaluate the Efficacy and Safety of TAK- 438 (10 and 20 mg Once-Daily) in Patients With Non-Erosive Gastroesophageal Reflux Disease.",827,2011-12-01,2013-02-01,Takeda
NCT01507831,Phase 3,2,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),"Long-term Safety and Tolerability of SAR236553 (REGN727) in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy: A Randomized, Double-Blind, Placebo-Controlled Study",2341,2012-01-01,2014-11-01,Sanofi
NCT01512446,Phase 3,2,Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy,Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy,436,2012-02-01,2013-03-01,Evangelisches Krankenhaus Lutherhaus gGmbH
NCT01520818,Phase 3,2,Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes,"A Multinational, Randomised, Open-labelled, Parallel Group Four Months Comparison of Twice Daily Biphasic Human Insulin 30 and Thrice Daily Biphasic Insulin Aspart 50 and 70 in Subjects With Type 1 or Type 2 Diabetes",666,2000-03-01,2001-04-01,Novo Nordisk A/S
NCT01646073,Phase 3,2,Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab (Humira®) in Chinese Subjects With Moderate to Severe Plaque Psoriasis",425,2012-08-01,2013-12-01,AbbVie
NCT01708629,Phase 3,4,Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects,A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3,1881,2012-09-01,2015-10-01,Amgen
NCT01733758,Phase 3,4,A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM),"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus",494,2013-02-01,2015-02-01,GlaxoSmithKline
NCT01777269,Phase 4,2,Prospective Sexual Function Study for BPH Subjects,A Prospective Study of Sexual Function in Sexually Active Men Treated for BPH,489,2013-02-18,2016-04-05,GlaxoSmithKline
NCT01855789,Phase 3,3,A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX,"A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy",718,2013-11-07,2016-10-14,Hoffmann-La Roche
NCT01899742,Phase 3,2,The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium,"DB2116960: A Randomized, Double-Dummy, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of UMEC/VI (a Fixed Combination of Umeclidinium and Vilanterol) With Tiotropium In Subjects With COPD Who Continue To Have Symptoms on Tiotropium",497,2014-09-15,2015-07-22,GlaxoSmithKline
NCT02017171,Phase 3,2,A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes,PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D,530,2014-02-01,2019-06-01,Joslin Diabetes Center
NCT02024646,Phase 3,3,Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-2",484,2014-03-01,2015-10-01,Amgen
NCT02029495,Phase 3,3,"Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis","A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-1",478,2014-03-01,2015-10-01,"Valeant Pharmaceuticals International, Inc."
NCT02033889,Phase 3,3,A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy.",621,2013-12-13,2017-08-03,Merck Sharp & Dohme Corp.
NCT02036515,Phase 3,3,Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin",464,2014-03-12,2016-06-06,Merck Sharp & Dohme Corp.
NCT02072434,Phase 3,2,Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation,"A Prospective, Randomized, Open-Label Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial Fibrillation",2199,2014-03-01,2016-02-01,"Daiichi Sankyo, Inc."
NCT02139046,Phase 3,5,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,"A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout",1790,2014-04-01,2015-11-01,Takeda
NCT02159053,Phase 3,3,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis","A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab (150 mg) With and Without a Subcutaneous Loading Regimen to Assess Efficacy, Safety, and Tolerability up to 2 Years in Patients With Active Ankylosing Spondylitis",350,2015-05-18,2018-01-03,Novartis
NCT02177253,Phase 3,5,"Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease","A Comparison of Ipratropium Bromide/Salbutamol (40 mcg / 200 mcg, One Inhalation) Delivered by the Respimat ® Inhaler to COMBIVENT Inhalation Aerosol (Two Inhalations), Ipratropium Bromide Respimat ® and Placebo of Each Formulation in a 12-week, Double-blind, Safety and Efficacy Study in Adults With Chronic Obstructive Pulmonary Disease",1118,2002-10-01,NA,Boehringer Ingelheim
NCT02257385,Phase 3,2,Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium,"Study DB2116961, A Multicentre, Randomised, Blinded, Parallel Group Study to Compare UMEC/VI (Umeclidinium/Vilanterol) in a Fixed Dose Combination With Indacaterol Plus Tiotropium in Symptomatic Subjects With Moderate to Very Severe COPD",967,2014-10-01,2015-05-01,GlaxoSmithKline
NCT02269176,Phase 3,2,Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension,"12 Week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Group Trial Comparing the Efficacy and Safety of 40 & 80 mg Telmisartan and 50 & 100 mg Losartan in the Treatment of 150 Pairs of Primary Hypertension Patients",330,2000-07-01,NA,Boehringer Ingelheim
NCT02347774,Phase 3,3,Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4),"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-4 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer",641,2015-02-01,2015-12-01,Sunovion Respiratory Development Inc.
NCT02357459,Phase 3,3,Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee,"A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee",486,2015-01-01,2016-01-01,"Flexion Therapeutics, Inc."
NCT02388724,Phase 3,2,Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis,"A Randomized, Double-Blind, Double-Dummy Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Compared to Lansoprazole 30 mg in the Treatment of Subjects With Erosive Esophagitis",480,2015-03-16,2017-07-27,Takeda
NCT02460978,Phase 3,3,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,"A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus - Study Two",815,2015-07-08,2018-04-20,AstraZeneca
NCT02694523,Phase 3,2,BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis,"BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)",605,2016-03-01,2017-08-01,AbbVie
NCT00000620,Phase 3,6,Action to Control Cardiovascular Risk in Diabetes (ACCORD),Action to Control Cardiovascular Risk in Diabetes (ACCORD),10251,1999-09-01,2012-12-01,"National Heart, Lung, and Blood Institute (NHLBI)"
NCT00032890,Phase 3,NA,Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT),Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT),1588,2000-04-01,2004-02-01,VA Office of Research and Development
NCT00039013,Phase 3,4,Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin,"A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With Metformin Alone",336,2002-03-01,2003-06-01,AstraZeneca
NCT00042068,Phase 3,NA,A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis,"A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis",1000,2002-06-01,2003-07-01,Boehringer Ingelheim
NCT00053599,Phase 3,NA,Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin to Slow the Progression of Alzheimer's Disease",400,2002-12-01,2007-10-01,National Institute on Aging (NIA)
NCT00063687,Phase 2/Phase 3,NA,Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure,"A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients With NYHA Class III-IV Congestive Heart Failure",400,2003-03-01,2005-06-01,Cardiome Pharma
NCT00064402,Phase 3,5,"Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD","A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease",741,2002-04-01,2004-03-01,Sunovion
NCT00069823,Phase 3,2,Study of Acid Reflux in Asthma,The Study of Acid Reflux in Asthma,403,2003-09-01,2008-05-01,Johns Hopkins Bloomberg School of Public Health
NCT00073177,Phase 3,NA,Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012),"A 24 Week, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Roflumilast (250 mcg or 500 mcg) Daily in Patients With Asthma",819,2003-11-01,NA,AstraZeneca
NCT00077792,Phase 3,NA,Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25),"A Randomized, Double-Blind, Double-Dummy , Parallel Group, Multinational, Clinical Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With Acute ST-Segment Elevation Myocardial Infarction Receiving Fibrinolytic Therapy",20506,2002-10-01,2006-12-01,Sanofi
NCT00092118,Phase 3,2,The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265),"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis",1992,2003-10-01,2004-05-01,Merck Sharp & Dohme Corp.
NCT00092599,Phase 3,NA,Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801),"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.",410,2003-02-01,2004-07-01,Merck Sharp & Dohme Corp.
NCT00092612,Phase 3,NA,Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED),"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.",372,2003-05-01,2004-06-01,Merck Sharp & Dohme Corp.
NCT00092703,Phase 3,NA,Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED),"A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis",6000,2002-06-27,2003-11-01,Merck Sharp & Dohme Corp.
NCT00095550,Phase 3,3,Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension,The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Patients With Moderate Hypertension,496,2004-10-01,2005-06-01,Bristol-Myers Squibb
NCT00105027,Phase 3,6,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema,682,2004-10-01,2009-02-01,The EMMES Corporation
NCT00115622,Phase 3,NA,Study In Adults And Adolescents With Seasonal Allergic Rhinitis,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 14 Days in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis",304,2004-12-01,2005-01-01,GlaxoSmithKline
NCT00121667,Phase 3,4,Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone,"""A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial to Evaluate the Efficacy and Safety of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone""",1462,2005-08-01,2010-02-01,AstraZeneca
NCT00127647,Phase 3,3,An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327),MK0476 Phase III Double-Blind Comparative Study - Allergic Rhinitis,1375,2004-11-01,2005-04-01,Merck Sharp & Dohme Corp.
NCT00144911,Phase 4,1,ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.,"A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol DISKUS® Inhaler Combination Product 250/50mcg Twice Daily With Salmeterol DISKUS® Inhaler 50mcg Twice Daily on the Annual Rate of Moderate/Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",740,2004-10-01,2006-12-01,GlaxoSmithKline
NCT00152386,Phase 3,NA,A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis,"A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate",950,2005-02-01,2006-10-01,UCB Pharma
NCT00171093,Phase 3,NA,A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia,"A 10-12 Week Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of the Combination of Valsartan (320 mg) and Simvastatin (80 mg) Compared to Valsartan (320 mg) and Simvastatin (80 mg) Monotherapies in Essential Hypertension and Hypercholesterolemia",369,2004-09-01,NA,Novartis
NCT00174824,Phase 4,NA,Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients,Evaluation of Diabetic Retinopathy Progression in Subjects With Type 2 Diabetes Mellitus Treated With Insulin,1024,2001-06-01,2007-04-01,Sanofi
NCT00191464,Phase 4,NA,Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes,Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes: A Comparison of Premeal Insulin Lispro Mixtures to Once-Daily Insulin Glargine,320,2003-12-01,2005-09-01,Eli Lilly and Company
NCT00195507,Phase 4,NA,Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis,"A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis",720,2004-12-01,2007-02-01,Wyeth is now a wholly owned subsidiary of Pfizer
NCT00219193,Phase 3,NA,A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients,"An Eight Week, Multicenter Study to Evaluate Efficacy and Safety of the Triple Combo of Aliskiren /Valsartan/HCTZ (300/320/25 mg), Compared to the Double Combos of Aliskiren/HCTZ (300/25 mg) or Valsartan/HCTZ (320/25 mg) in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg",641,2005-10-01,2007-01-01,Novartis
NCT00221156,Phase 3,NA,Acarbose and Secondary Prevention After Coronary Stenting,Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease (ALERT Study),300,2005-05-01,2009-04-01,"Translational Research Informatics Center, Kobe, Hyogo, Japan"
NCT00239369,Phase 3,NA,Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5,A Prospective Randomised Study to Compare a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 25 mg With a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg in Patients With Uncontrolled Hypertension Who Fail to Respond Adequately to Treatment With a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg,713,2005-10-01,2006-08-01,Boehringer Ingelheim
NCT00240474,Phase 4,NA,A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study),"A Comparison of Telmisartan 80 mg + Hydrochlorothiazide 12.5 mg With Amlodipine 10 mg + Hydrochlorothiazide 12.5 mg in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension. A Prospective, Randomised, Open-label, Blinded End-point Evaluation. (ATHOS Study)",1000,2002-12-01,2004-03-01,Boehringer Ingelheim
NCT00241605,Phase 4,NA,AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus,"AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-week Randomized, Open-label, Multicenter Study to Compare the Efficacy and Tolerability of AVANDAMET to Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Control on Submaximal Metformin.",600,2003-06-01,2005-12-01,GlaxoSmithKline
NCT00251901,Phase 3,NA,Chest Pain Pilot Study,A Randomized Double-Blind Placebo-Controlled Multi-Centre Pilot Study to Assess Symptom Response in Subjects With Pain or Discomfort in the Chest Receiving Oral Treatment With Esomeprazole 40 mg Bid for 4 Weeks.,600,2004-05-01,2005-07-01,AstraZeneca
NCT00269191,Phase 3,NA,A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED),"A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 1)",528,2003-02-05,2003-11-21,Merck Sharp & Dohme Corp.
NCT00272805,Phase 3,NA,Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg,"Prospective, Randomized, Controlled Assessment of Once-Daily Controlled Release COREG CR vs Twice-Daily COREG Immediate Release(IR)on Measures of Compliance and Quality of Life in Patients With Heart Failure and Left Ventricular Systolic Dysfunction",400,2005-10-01,2006-07-01,Cardiovascular Clinical Studies
NCT00281593,Phase 3,NA,Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension,"A Randomized, Double-blind, Double-dummy, Placebo-controlled, 3x4 Factorial Design Trial to Evaluate Telmisartan 20 and 80 mg Tablets in Combination With Ramipril 1.25, 10, and 20 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-study",1354,2006-04-01,NA,Boehringer Ingelheim
NCT00283751,Phase 3,NA,Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes,Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine as Add-on to Current Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes,583,2003-03-01,2004-11-01,Novo Nordisk A/S
NCT00289198,Phase 3,2,Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR),"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 6 Weeks in Adult and Adolescent Subjects 12 Years of Age and Older With Perennial Allergic Rhinitis (PAR)",301,2006-02-01,2006-07-01,GlaxoSmithKline
NCT00297102,Phase 3,2,Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124),Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study,1523,2006-02-01,2008-09-01,AstraZeneca
NCT00299104,Phase 3,3,A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis,"A Randomized, Phase 3, Controlled, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate (MTX) Compared to MTX Alone, in Methotrexate-Naive Patients With Active Rheumatoid Arthritis",755,2006-01-01,2013-07-01,"Genentech, Inc."
NCT00314574,Phase 3,2,A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA),"A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects With Moderate to Severe Persistent Asthma Who Are Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists",850,2005-12-01,2009-11-01,"Genentech, Inc."
NCT00321984,Phase 3,3,Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease,A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (30 mg QD and 60 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD),947,2006-06-01,2006-12-01,Takeda
NCT00343252,Phase 3,2,Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis,The Effect of Teriparatide Compared With Risedronate on Back Pain in Postmenopausal Women With Osteoporotic Vertebral Fractures,712,2006-06-01,2010-06-01,Eli Lilly and Company
NCT00355849,Phase 3,3,Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes,"A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients With Type 2 Diabetes Treated With Once-Daily Insulin Glargine",555,2006-08-01,2008-06-01,Eli Lilly and Company
NCT00358436,Phase 3,2,Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD),NA,804,2006-08-01,2008-06-01,AstraZeneca
NCT00359788,Phase 4,NA,A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.,"A Randomized, Double-blind, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium 18 mcg Daily to Combivent MDI 2 Actuations Qid in COPD Patients Previously Prescribed Combivent MDI",349,2006-07-01,NA,Boehringer Ingelheim
NCT00385931,Phase 3,NA,Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin,"A Multi-centre Study to Evaluate the Effects of Valsartan and the Combination of Valsartan and Simvastatin on Blood Pressure (Ambulatory and Std Cuff) and on Biochemical Markers of Endothelial Function (hsCRP, MCP-1, Serum F2 Isoprostanes, PAI-1, tPA, PICP, PIIINP, MMP9, MMP1, TIMP 1), Safety and Tolerability",412,2002-01-01,2003-04-01,Novartis
NCT00399711,Phase 3,NA,Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes,"Repaglinide and Metformin Combination Tablet (NN4440) in a TID Regimen Compared to a BID Regimen and BID Avandamet in Subjects With Type 2 Diabetes: A Twenty-Six Week, Open-Label, Multicenter, Randomized, Parallel Group Trial to Investigate Efficacy and Safety",560,2006-11-01,2007-11-01,Novo Nordisk A/S
NCT00411554,Phase 3,2,A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED),Sitagliptin (MK0431) Phase III Double-blind Comparative Study - Type 2 Diabetes Mellitus -,319,2007-01-01,2007-08-01,Merck Sharp & Dohme Corp.
NCT00413972,Phase 3,4,Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420),"A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Groups Study Comparing the Efficacy and Safety of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia",392,2006-04-01,2006-11-01,Merck Sharp & Dohme Corp.
NCT00418834,Phase 3,2,Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112),"A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg When Added to Atorvastatin 10 mg Versus Titration to Atorvastatin 20 mg and to 40 mg in Elderly Patients With Hypercholesterolemia at High Risk for CHD",1053,2007-01-01,2008-10-01,Merck Sharp & Dohme Corp.
NCT00445770,Phase 3,3,Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis,"A Randomized, Double-Blind, Multicenter, Comparative Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Active Rheumatoid Arthritis",550,2006-07-01,2010-07-01,Pfizer
NCT00476034,Phase 3,NA,Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA),"A 39-week, Double-blind, Active-controlled Extension to CCOX189A2361, a 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator",1312,2003-12-01,NA,Novartis
NCT00479739,Phase 4,1,CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.,"Randomised, Double-blind, Double-dummy, 52-week, Parallel Group Study of a Standard Dosing Regimen With Salmeterol/Fluticasone propionate50/250 Twice Daily Diskus Versus a Symptom-driven, Variable Dosing Regimen With Formoterol/Budesonide Combination 4.5/160 in Adult Asthmatics",700,2002-11-01,2004-07-01,GlaxoSmithKline
NCT00484926,Phase 4,2,Association of Clopidogrel Therapy and Stent Thrombosis,Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events,2000,2007-03-01,2010-03-01,"CardioVascular Research Foundation, Korea"
NCT00502775,Phase 4,NA,Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine,A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis,680,2007-08-01,2007-11-01,GlaxoSmithKline
NCT00503113,Phase 4,3,A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.,"A Randomized, Open Label Study Evaluating the Effect on Renal Function of Intravenous Bonviva Given by Injection or Infusion, Compared With Oral Alendronate, in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.",801,2007-07-01,2010-04-01,Hoffmann-La Roche
NCT00521599,Phase 4,3,A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828),A Study of the Therapeutic Equivalency of MF DPI 100 mcg and 200 mcg Inhalers in Corticosteroid-Dependent Subjects With Moderate Asthma,672,2007-05-01,2009-03-01,Merck Sharp & Dohme Corp.
NCT00521820,Phase 3,2,Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure,"A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCl vs Glyburide in the Treatment of Subjects With Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild to Moderate Congestive Heart Failure",518,2000-06-01,2003-10-01,Takeda
NCT00525512,Phase 4,2,Tiotropium In Exercise,"A Randomized, Double-blind, Placebo-controlled Two-year Trial to Examine the Changes in Exercise Endurance and COPD Treated With Tiotropium Once Daily (EXACTT)",519,2007-08-01,NA,Boehringer Ingelheim
NCT00529451,Phase 3,4,"Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg","An Eight Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension",1613,2007-09-01,2008-07-01,Novartis
NCT00538486,Phase 4,6,"A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients","Which is the Best Treatment for Non-diabetic Hypertension With Obesity: Telmisartan, Amlodipine or Candesartan, Alone or Plus MEtformin? (HOT-ACME 1)",360,2008-02-01,2009-06-01,Third Military Medical University
NCT00552370,Phase 4,5,Glycemic Optimization Treatment Study,"A Randomized, Open-Label, Parallel-Design Trial. Glycemia Optimization Treatment: Safety of Glucose Control Using Dosing Algorithms With Lantus®(Insulin Glargine [rDNA Origin[) in Adult Individuals With Type 2 Diabetes.",5062,2003-03-01,2005-03-01,Sanofi
NCT00568295,Phase 3,3,A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee,A Four-Week Comparative Study Evaluating Acetaminophen Extended Release (3900 mg/Day) and Rofecoxib (12.5 mg/Day and 25 mg/Day)in the Treatment of Osteoarthritis of the Knee,403,1999-10-01,2000-10-01,Johnson & Johnson Consumer and Personal Products Worldwide
NCT00573508,Phase 4,2,Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 4, Multi-center Study of VESIcare® (Solifenacin Succinate) in Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life VIBRANT: VESIcare® Investigation of BotheR And Quality of Life iN subjecTs With OAB",768,2007-08-01,2008-07-01,Astellas Pharma Inc
NCT00591253,Phase 3,3,Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension,"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Black Subjects With Essential Hypertension",413,2007-10-01,2009-04-01,Takeda
NCT00605020,Phase 3,NA,Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes,Comparison of Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus,719,2003-12-02,2005-03-03,Novo Nordisk A/S
NCT00631917,Phase 4,2,A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension,"A 54 Week, Randomized, Double-blind, Parallel-group, Multicenter Study Evaluating the Long-term Gastrointestinal (GI) Safety and Tolerability of Aliskiren (300 mg) Compared to Ramipril (10 mg) in Patients With Essential Hypertension",774,2008-02-01,2009-09-01,Novartis
NCT00643799,Phase 4,3,Safety and Efficacy of Celecoxib Versus Naproxen in the 6-Month Treatment of Knee Osteoarthritis,"A Randomized, Multicenter, Double-Blind, Double-Dummy Study Comparing the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Naproxen 500 mg Twice Daily in the 6-Month Treatment of Subjects With Osteoarthritis of the Knee",586,2004-03-01,2005-01-01,Pfizer
NCT00653965,Phase 3,2,Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP),"A 6-Week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolaemia in Hispanic Subjects.",3000,2003-05-01,2005-02-01,AstraZeneca
NCT00654381,Phase 3,4,Japanese P III vs Voglibose and Placebo,"A Double-blind Phase III Study to Evaluate the Efficacy of BI 1356 5 mg and 10 mg vs. Placebo for 12 Weeks and vs. Voglibose 0.6 mg for 26 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control, Followed by an Extension Study to 52 Weeks to Evaluate Long-term Safety",561,2008-04-01,NA,Boehringer Ingelheim
NCT00659750,Phase 3,2,To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402),"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray (200 mg Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older",418,2003-12-01,2005-04-01,AstraZeneca
NCT00664560,Phase 3,3,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,"Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Study Evaluating the Efficacy of PN400 (VIMOVO) Twice Daily (Bid) and Celecoxib Once Daily (qd) in Patients With Osteoarthritis of the Knee",614,2008-04-01,2009-01-01,POZEN
NCT00701090,Phase 3,2,A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED),"A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin",1035,2008-05-01,2009-10-01,Merck Sharp & Dohme Corp.
NCT00772577,Phase 4,2,Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension,"An 8-Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension",386,2008-08-01,2009-03-01,Novartis
NCT00792636,Phase 4,3,"A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period","Assessment of the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet Treatment on Blood Pressure When Administered Intermittently for Six Months for the Acute Treatment of Migraine Attacks, With or Without Aura, in Adults",407,2008-11-01,2009-11-01,GlaxoSmithKline
NCT00819741,Phase 4,2,Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs,"A 16-week, Open-label, Multicentre, Randomised, Parallel Study to Evaluate Efficacy and Safety of Repaglinide and Metformin Combination Therapy Compared to Repaglinide Monotherapy in Chinese OAD Naive Type 2 Diabetic Patients",433,2009-02-01,2009-11-01,Novo Nordisk A/S
NCT00843154,Phase 3,2,Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure,Effects Of Candesartan Cilexetil vs Standard Therapy on Serum Levels of Brain Natriuretic Peptide in Patients Suffering From Chronic Heart Failure With Depressed and Preserved Systolic Function,571,2005-12-01,2008-07-01,Takeda
NCT00843492,Phase 3,2,A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery,"A Multicentre, Randomized, Open-label Study to Evaluate the Efficacy andSafety of Fondaparinux Versus Low Molecular Weight Heparin(Nadroparin) in Patients Requiring Rigid or Semi-rigid Immobilization for at Least 21 Days and up to 45 Days Because of Isolated Non-surgical Below-Knee Injury",1351,2008-12-01,2010-06-01,GlaxoSmithKline
NCT00846365,Phase 3,3,Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension,"A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCT® (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension",1085,2009-03-01,2010-06-01,Takeda
NCT00848354,Phase 4,2,Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy,"A Randomized, Open-label Study In The Latin America Region Comparing The Safety And Efficacy Of Etanercept With Conventional Dmard Therapy In Subjects With Rheumatoid Arthritis.",429,2009-06-01,2013-04-01,Pfizer
NCT00853658,Phase 3,3,Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure,"A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).",7064,2009-03-01,2015-10-01,Novartis
NCT00877929,Phase 3,2,Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus,"An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 + Amlodipine 10mg Versus Amlodipine 10 mg Monotherapy as First Line Therapy in Type 2 Diabetes Patients With Hypertension.",706,2009-02-01,NA,Boehringer Ingelheim
NCT01005901,Phase 3,2,"A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo","A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease",1324,2009-10-01,2010-12-01,Novartis
NCT01046110,Phase 3,2,Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin,A Trial Comparing Efficacy and Safety of NN1250 With Sitagliptin in Insulin Naive Subjects With Type 2 Diabetes (BEGIN™ : EARLY),458,2010-01-01,2010-11-01,Novo Nordisk A/S
NCT01047501,Phase 3,3,Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL),Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500 mg/dL) Despite Statin Therapy,702,2009-12-01,NA,Amarin Pharma Inc.
NCT01089725,Phase 3,5,Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study,"Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee",385,2010-03-01,2010-11-01,Pfizer
NCT01106677,Phase 3,4,The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial),"A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy",1284,2010-05-01,2012-05-01,"Janssen Research & Development, LLC"
NCT01110200,Phase 4,2,Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study,"A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization",639,2010-04-30,2012-05-08,GlaxoSmithKline
NCT01128894,Phase 3,2,A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.,"A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus",841,2010-05-01,2011-09-01,GlaxoSmithKline
NCT01156571,Phase 3,2,A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX),A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX),11145,2010-09-01,2012-12-01,The Medicines Company
NCT01176968,Phase 4,2,Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction,"A Double-blind, Randomized, Placebo-controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction",1012,2010-09-01,2012-10-01,Pfizer
NCT01177813,Phase 3,5,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 and Sitagliptin Administered Orally Over 24 Weeks, in Drug naïve Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Diet and Exercise",986,2010-07-01,NA,Boehringer Ingelheim
NCT01208181,Phase 3,4,"A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)","A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK‑0663/Etoricoxib in Patients With Rheumatoid Arthritis",1404,2010-09-01,2014-07-01,Merck Sharp & Dohme Corp.
NCT01225562,Phase 3,3,"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin","A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction",21379,2010-10-01,2014-12-01,AstraZeneca
NCT01324362,Phase 4,2,GSK BHR Study (Sont - Second Study),"A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Sameterol DISKUS Twice Daily or Fluticasone Propionate DISKUS Twice Daily (or Placebo Twice Daily if Asymptomatic)",446,2003-01-01,2004-10-01,GlaxoSmithKline
NCT01329029,Phase 4,2,Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS),"Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 µg Versus Placebo. The REACT Trial",1945,2011-05-01,2014-05-01,AstraZeneca
NCT01331837,Phase 4,2,A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors,A Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) in Comparison With Etanercept (ETA) on the Rate of Cardiovascular Events in Patients With Moderate to Severe Rheumatoid Arthritis (RA),3080,2011-08-02,2016-03-25,Hoffmann-La Roche
NCT01335464,Phase 3,2,Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients,"A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)",515,2011-04-01,2013-10-01,Boehringer Ingelheim
NCT01366209,Phase 3,2,Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF),"A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)",555,2011-06-01,2014-02-01,"Genentech, Inc."
NCT01392677,Phase 3,2,Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea,"A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study With a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Once Daily in Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and Sulfonylurea",311,2011-10-01,2013-08-01,AstraZeneca
NCT01443845,Phase 4,2,Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS),Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS),2354,2011-09-30,2016-01-31,AstraZeneca
NCT01460342,Phase 3,2,Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Study to Evaluate the Efficacy and Safety of Tadalafil Once-a-day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia",610,2011-12-01,2012-10-01,Eli Lilly and Company
NCT01474512,Phase 3,4,A Phase 3 Study in Participants With Moderate to Severe Psoriasis,"A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis",1296,2011-11-01,2018-11-01,Eli Lilly and Company
NCT01522521,Phase 3,2,Study of AK156 in Primary Osteoporosis Patients,Phase 3 Study of AK156 in Primary Osteoporosis Patients,600,2012-02-01,2015-01-01,Asahi Kasei Pharma Corporation
NCT01528254,Phase 4,2,VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus,"A 5-year Study to Compare the Durability of Glycemic Control of a Combination Regimen With Vildagliptin & Metformin Versus Standard-of-care Monotherapy With Metformin, Initiated in Treatment-naïve Patients With Type 2 Diabetes Mellitus",2005,2011-11-03,2019-04-18,Novartis
NCT01532648,Phase 3,2,Randomized Placebo Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 mg in Patients With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA).,NA,509,2012-02-01,2013-11-01,"Valeant Pharmaceuticals International, Inc."
NCT01584232,Phase 3,2,A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus,A Phase 3 Study of LY2189265 Compared to Insulin Glargine in Patients With Type 2 Diabetes Mellitus on a Sulfonylurea and/or Biguanide,361,2012-04-01,2013-07-01,Eli Lilly and Company
NCT01597245,Phase 3,5,A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis",1224,2012-05-01,2019-07-01,Eli Lilly and Company
NCT01615198,Phase 3,2,Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension,"A 14 Week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension",588,2012-08-01,2013-07-01,Novartis
NCT01617434,Phase 3,2,The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes,The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes,451,2012-09-01,2013-10-01,Novo Nordisk A/S
NCT01646177,Phase 3,4,A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3),"A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period",1346,2012-07-01,2019-08-01,Eli Lilly and Company
NCT01661322,Phase 3,2,Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke,Safety and Efficacy of Intensive Versus Guideline Antiplatelet Therapy in High Risk Patients With Recent Ischaemic Stroke or Transient Ischaemic Attack: a Randomised Controlled Trial,3096,2009-04-01,2016-09-01,University of Nottingham
NCT01682863,Phase 3,3,A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation,A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation,614,2012-10-01,2014-06-01,Novartis
NCT01721057,Phase 3,3,A Study in Moderate to Severe Rheumatoid Arthritis Participants,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis",684,2012-12-01,2014-12-01,Eli Lilly and Company
NCT01727141,Phase 3,4,"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.","A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.",1042,2012-11-01,2014-02-01,Novartis
NCT01908140,Phase 3,2,Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD),"A Randomised, Double-blind, Double-dummy, Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Twice-daily Aclidinium Bromide/Formoterol Fumarate Compared With Twice-daily Salmeterol/Fluticasone Propionate for 24 Weeks Treatment in Symptomatic Patients With Chronic Obstructive Pulmonary Disease (COPD)",933,2013-09-01,2014-08-01,AstraZeneca
NCT01930682,Phase 4,2,EARLY Routine Catheterization After Alteplase Fibrinolysis vs. PPCI in ST-Segment-Elevation MYOcardial Infarction,"EARLY Routine Catheterization or Rescue Angioplasty After Alteplase Fibrinolysis vs. Primary Angioplasty in Acute ST-elevation MYOcardial Infarction: An Open, Prospective, Randomized, Multicentre Trial",344,2014-01-13,2016-09-12,RenJi Hospital
NCT02064868,Phase 3,2,Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients,"A Multicenter, Prospective, Randomized, Open-label Study to Assess the Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients",2653,2014-01-31,2017-04-25,Novartis
NCT02065791,Phase 3,2,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy",4462,2014-02-17,2019-06-28,"Janssen Research & Development, LLC"
NCT02079727,Phase 3,3,Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA,"A Multicentre, Comparative, Randomised, Double-blind, Double-dummy Clinical Trial on the Efficacy and Safety of Condrosulf Versus Celebrex and Versus a Placebo in the Treatment of Knee Osteoarthritis",604,2014-06-12,2016-06-16,IBSA Institut Biochimique SA
NCT02175355,Phase 3,5,Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH),"A Randomised, Double- Blind, Placebo-controlled, 6 Week Parallel-group Trial on the Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan 20 mg, 40 mg or 80 mg, p.o. Once Daily) or Hydrochlorothiazide 12.5 mg p.o. Once Daily in the Management of Patients With Isolated Systolic Hypertension (ISH). (ARAMIS - Study = Angiotensin II Receptor Antagonist Micardis in Isolated Systolic Hypertension)",1039,1999-10-01,NA,Boehringer Ingelheim
NCT02229383,Phase 3,2,Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glargine Compared to Placebo Added to Titrated Basal Insulin Glargine in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine With or Without Metformin",464,2014-09-06,2016-08-29,AstraZeneca
NCT02296138,Phase 3,2,Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.,"A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD. [DYNAGITO]",7903,2015-01-13,2017-03-29,Boehringer Ingelheim
NCT02345161,Phase 3,2,A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"A Phase III, 24 Week, Randomized, Double Blind, Double Dummy, Parallel Group Study (With an Extension to 52 Weeks in a Subset of Subjects) Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning Via a Dry Powder Inhaler With Budesonide/Formoterol 400mcg/12mcg Administered Twice-Daily Via a Reservoir Inhaler in Subjects With Chronic Obstructive Pulmonary Disease",1811,2015-01-01,2016-04-01,GlaxoSmithKline
NCT02477969,Phase 3,3,Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating PEGylated Loxenatide Injection（PEX168）Combined With Metformin in the Treatment of Type 2 Diabetes Mellitus",587,2014-02-27,2017-06-01,"Jiangsu Hansoh Pharmaceutical Co., Ltd."
NCT02681094,Phase 3,3,"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes","A Multi-Center, Randomized, Double-Blind, Active-Controlled , Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin 5mg Co-administered With Dapagliflozin 5mg Compared to Saxagliptin 5mg or Dapagliflozin 5mg All Given as Add-on Therapy to Metformin inPatients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Alone",906,2016-02-26,2017-06-21,AstraZeneca
NCT02906917,Phase 3,2,A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification,This Trial is Conducted Globally. The Aim of This Trial is to Compare the Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification.,534,2016-09-20,2017-12-24,Novo Nordisk A/S
NCT00038077,Phase 3,NA,Reversal of Ventricular Remodeling With Toprol-XL,NA,300,2001-08-01,2003-09-01,AstraZeneca
NCT00086502,Phase 3,2,Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Therapy",353,2004-06-01,2005-11-01,Merck Sharp & Dohme Corp.
NCT00092755,Phase 3,NA,An Investigational Drug in Patients With Osteoarthritis (0663-073),"A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 2)",548,2003-04-09,2003-11-13,Merck Sharp & Dohme Corp.
NCT00092781,Phase 3,NA,A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED),"A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 2)",500,2004-03-01,2005-02-01,Merck Sharp & Dohme Corp.
NCT00099242,Phase 3,NA,Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease,Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease,1040,2003-11-01,2006-01-01,Novartis
NCT00109382,Phase 2/Phase 3,4,Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER),Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER),500,2003-05-01,2007-02-01,University of Calgary
NCT00120289,Phase 3,2,Niacin Plus Statin to Prevent Vascular Events,AIM HIGH: Niacin Plus Statin to Prevent Vascular Events,3414,2005-09-01,2012-12-01,Axio Research. LLC
NCT00131664,Phase 3,3,Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study),"Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin: A 48-week Randomized, Open-label, Multicentre Phase IIIB Study to Compare the Effectiveness of Combination Therapy to Monotherapy in Type 2 Diabetes Mellitus Patients",391,2005-09-01,2008-01-01,Canadian Heart Research Centre
NCT00131846,Phase 4,2,Diuretics In the Management of Essential Hypertension (DIME) Study,Effect of Low Dose Thiazide Diuretics on New Onset Type 2 Diabetes in Patients With Essential Hypertension,1130,2004-04-01,2013-11-01,Kyoto University
NCT00141453,Phase 3,2,ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial,CS-866DM Phase 3 Clinical Study: A Double-Blind Controlled Trial in Patients With Diabetic Nephropathy and Overt Proteinuria Secondary to Type 2 Diabetes Mellitus,577,2003-04-01,2009-01-01,"Daiichi Sankyo, Inc."
NCT00145925,Phase 3,2,Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes,ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation,11140,2001-06-01,2008-03-01,The George Institute
NCT00146341,Phase 3,NA,Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg,"An Eight Week Randomized, Double-Blind, Double-Dummy Study Comparing a Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg to Telmisartan 80mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80mg.",345,2005-04-01,2006-09-01,Boehringer Ingelheim
NCT00160602,Phase 3,NA,A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis,"A Phase III Multi-center, Double-blind, Placebo-controlled, Parallel Group 24-Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.",590,2005-06-01,2006-09-01,UCB Pharma
NCT00161070,Phase 4,NA,ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial,ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial,4500,1997-07-01,2006-12-01,UMC Utrecht
NCT00169819,Phase 4,NA,EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study,A Randomized Trial Comparing Same Day Discharge and a Single Bolus of Abciximab to Overnight Hospitalization and Bolus + Perfusion Abciximab After Uncomplicated Trans-Radial Coronary Artery Stenting,1000,2003-10-01,2006-04-01,Laval University
NCT00197080,Phase 3,NA,Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome,"A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome",380,2005-06-01,2006-01-01,GlaxoSmithKline
NCT00219102,Phase 3,NA,"A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients","A 12-week, Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy & Safety of Aliskiren in Patients With Diabetes & Hypertension Not Adequately Responsive to the Combination of Valsartan 160 mg & Hydrochlorothiazide 25 mg",336,2005-06-01,2007-05-01,Novartis
NCT00219128,Phase 3,NA,"A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.","An Eight-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing Aliskiren 150 mg, 300 mg, and 600 mg to Placebo in Patients With Essential Hypertension",671,2004-11-01,2005-06-01,Novartis
NCT00235014,Phase 4,4,A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT),A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT),1204,1997-03-01,NA,Abbott
NCT00236431,Phase 3,NA,A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment,A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease,1063,2001-05-01,2003-12-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00239538,Phase 4,NA,SMOOTH - Blood Pressure Control in Diabetic/Obese Patients,"Prospective, Randomized, Open-label, Blinded Endpoint, Forced Titration Study to Compare Telmisartan Combined With HCTZ (80mg/12.5mg), to Valsartan Combined With HCTZ (160mg/12.5mg), for the Control of Mild-to-moderate Hypertension in Obese Patients With Type 2 Diabetes Mellitus Using ABPM.",840,2003-01-01,2004-12-01,Boehringer Ingelheim
NCT00262054,Phase 4,2,Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3),"Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3",4570,2005-11-01,2008-05-01,Deutsches Herzzentrum Muenchen
NCT00272012,Phase 3,2,"OPAL - Insulin Glulisine, Diabetes Mellitus",Efficacy and Safety of Insulin Glulisine Given as a Single Injection at Breakfast + Insulin Glargine+OAD (Oral Antidiabetic Drug) vs Insulin Glulisine Given as a Single Injection at Main Meal+Insulin Glargine+OAD in Type 2 Diabetic Patients for Which Glycemic Control is Suboptimal Using Insulin Glargine+ OAD Alone,396,2004-07-01,NA,Sanofi
NCT00272701,Phase 4,NA,Esomeprazole in PPI Failures - IMPROVE,"A Randomised, Open, Phase IV, Parallel Group Multicentre Study to Evaluate a Change of Management in Gastroesophageal Reflux Disease (GERD) Patients by Treatment With Esomeprazole 40 mg or Any Other Proton Pump Inhibitor (PPI), After Initial Treatment Failure, in Ordinary Clinical Practice During 4 Weeks.",450,2005-12-01,2007-02-01,AstraZeneca
NCT00274547,Phase 3,NA,Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD),"A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Proportion of Patients Experiencing an Exacerbation and Proportion of Patients Hospitalized for an Exacerbation Over 6 Months During Treatment With Tiotropium 18 Mcg Capsule Once Daily in Patients With COPD in a Veterans Affairs Setting",1829,2001-09-01,NA,Boehringer Ingelheim
NCT00274560,Phase 3,NA,A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.,"A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol in a 12 Week, Randomized, Double-Blind, Double-Dummy Parallel Group Study in Patients With Chronic Obstructive Pulmonary Disease (COPD).",653,2002-05-01,NA,Boehringer Ingelheim
NCT00333489,Phase 4,NA,Comparative Study of Valsartan and Amlodipine Versus Amlodipine Alone in Hypertension,"A National, Multicentric and Comparative Study to Evaluate Efficacy and Tolerability of the Association of Valsartan and Amlodipine Versus Amlodipine Alone in the Treatment of Essential Arterial Hypertension - Stages I and II (Mild to Moderate).",551,2004-03-01,2005-04-01,Novartis
NCT00348712,Phase 3,2,Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes,Efficacy and Safety of Inhaled Pre-prandial Human Insulin Plus Metformin Versus Rosiglitazone Plus Metformin in Type 2 Diabetes,301,2006-10-30,2008-03-05,Novo Nordisk A/S
NCT00359112,Phase 3,1,AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes,"A Randomised, Multi-Centre, Phase IV, Double-Blind, Parallel Group Study Comparing the Effects of 52 Weeks Administration of AVANDAMET and Metformin Plus Sulphonylurea on Change in HbA1c From Baseline in Overweight Type 2 Diabetics Poorly Controlled on Metformin.",544,2004-02-01,NA,GlaxoSmithKline
NCT00363857,Phase 3,NA,A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome,"A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS)",360,2003-08-01,2004-05-01,GlaxoSmithKline
NCT00381485,Phase 3,3,Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED),"A 12-Week Efficacy and Safety Study of Two Doses of Mometasone Furoate/Formoterol Combination Formulation Compared With Mometasone Furoate Monotherapy, in Persistent Asthmatics Previously Treated With High-Dose Inhaled Glucocorticosteroids",834,2006-07-01,2008-01-01,Merck Sharp & Dohme Corp.
NCT00388882,Phase 4,NA,Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.,"A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI",327,2006-10-01,NA,Boehringer Ingelheim
NCT00393471,Phase 3,NA,Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.,A Double-Blind Study Evaluating the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Comparison to Etanercept Alone or Methotrexate Alone in Rheumatoid Arthritis Patients.,615,2000-10-01,2001-10-01,Wyeth is now a wholly owned subsidiary of Pfizer
NCT00402233,Phase 4,4,"A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients","A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Efficacy Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over a 12-week Treatment Phase in Early Parkinson's Disease Patients (PramiBID)",312,2006-11-01,NA,Boehringer Ingelheim
NCT00409643,Phase 3,NA,Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients,"A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients",1259,2004-01-01,2004-07-01,Novartis
NCT00409851,Phase 3,NA,One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension,"A 52 Week, Open Label Extension to the Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients.",1293,2003-04-01,2005-03-01,Novartis
NCT00420927,Phase 4,5,Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis,"A Multicenter, Randomized, Double-Period, Double − Blind Study to Determine the Optimal Protocol for Treatment Initiation With Methotrexate and Adalimumab Combination Therapy in Patients With Early Rheumatoid Arthritis (OPTIMA)",1032,2006-12-01,2010-07-01,Abbott
NCT00452348,Phase 4,2,A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma,"A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects With Asthma",628,2007-05-01,2009-04-01,GlaxoSmithKline
NCT00457002,Phase 3,2,Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness,"A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization.",6758,2007-06-01,2011-05-01,Bristol-Myers Squibb
NCT00473655,Phase 4,NA,Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients,"A Double-blind, Double Dummy, Phase IV, Randomized, Multicenter, Parallel Group, Placebo Controlled Trial to Evaluate the Effect of Rosuvastatin on Triglycerides Levels in Mexican Hypertriglyceridemic Patients",334,2007-01-01,2009-02-01,AstraZeneca
NCT00479713,Phase 3,2,A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED),"A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combo Tab Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg in Patients With Primary High Cholesterol and High Cardiovascular Risk Not Controlled With a Prior Statin Treatment",618,2007-02-01,2008-03-01,Merck Sharp & Dohme Corp.
NCT00490958,Phase 4,2,Telmisartan in Haemodialysis Patients With Chronic Heart Failure,Effects Of Telmisartan Added To Angiotensin Converting Enzyme Inhibitors On Mortality And Morbidity In Haemodialysed Patients With Chronic Heart Failure: A Double-Blind Placebo-Controlled Trial,351,1999-01-01,2005-06-01,"University of Campania ""Luigi Vanvitelli"""
NCT00494312,Phase 4,2,Safety Study of Pioglitazone Compared To Glyburide on Liver Function,"A Randomized, Comparator Controlled, Double-Blind Study of the Liver Safety of Pioglitazone HCl vs Glyburide With Metformin and Insulin as Part of Step Therapy in Subjects With Type 2 (Non-Insulin Dependent) Diabetes",2120,2000-10-01,2005-06-01,Takeda
NCT00494871,Phase 3,2,Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation,Evaluation of the Efficacy and Safety of Rivaroxaban (BAY59-7939) for the Prevention of Stroke and Non-central Nervous System Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation,1280,2007-06-01,2010-01-01,Bayer
NCT00536731,Phase 3,3,Symbicort Rapihaler Therapeutic Equivalence Study,"A 6-week, Phase III, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy and Safety of 2 Actuations Symbicort®pMDI® 40/2.25 μg Twice Daily Compared With 1 Inhalation Symbicort Turbuhaler® 80/4.5 μg Twice Daily and 1 Inhalation Pulmicort®Turbuhaler® 100 μg Twice Daily",742,2007-09-01,2008-04-01,AstraZeneca
NCT00548808,Phase 4,2,A Study for Type 2 Diabetic Patients,Comparison of Insulin Lispro Low Mixture With Insulin Glargine When Initiating and Intensifying Insulin Therapy As Required in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Oral Antihyperglycemic Medication,426,2007-11-01,2009-08-01,Eli Lilly and Company
NCT00591578,Phase 3,3,Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension,"A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Subjects With Essential Hypertension",984,2007-12-01,2010-03-01,Takeda
NCT00651118,Phase 3,4,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,"Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis",832,2008-03-01,2008-07-01,Meda Pharmaceuticals
NCT00658775,Phase 3,2,"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)","A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)",1069,2008-02-01,2010-01-01,Eisai Inc.
NCT00696631,Phase 3,2,European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure,Antiarrhythmic Trial With Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease,653,2002-06-01,2003-08-01,Sanofi
NCT00710580,Phase 3,3,Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",350,2008-07-01,2009-04-01,AbbVie
NCT00733902,Phase 3,4,Tanezumab in Osteoarthritis of the Knee,"A Phase 3 Randomized, Double Blind, Placebo-Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee",697,2008-09-01,2009-11-01,Pfizer
NCT00734474,Phase 2/Phase 3,9,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin",1202,2008-08-01,2012-07-01,Eli Lilly and Company
NCT00790907,Phase 4,3,Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS),FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8),3235,2009-02-01,2010-05-01,GlaxoSmithKline
NCT00822211,Phase 3,3,Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy,"A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy",404,2008-12-01,2009-12-01,Novartis
NCT00822536,Phase 4,2,Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation,Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation,1798,2009-01-01,2014-09-01,Assistance Publique - Hôpitaux de Paris
NCT00830063,Phase 3,4,Tanezumab In Osteoarthritis Of The Knee (2),"A Phase 3 Randomized, Double Blind Placebo And Naproxen Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee",848,2009-05-01,2010-07-01,Pfizer
NCT00849056,Phase 3,2,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes Mellitus",310,2009-01-01,2013-01-01,GlaxoSmithKline
NCT00861926,Phase 3,2,Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics,"48-week,Multinational,Randomized,Double-blind,2-parallel Groups,Comparing the Efficacy of Foster for Maintenance and Reliever Versus Fixed-dose Foster for Maintenance Plus Salbutamol as Reliever in Asthmatics >=18 Years of Age",2079,2009-03-01,2011-04-01,Chiesi Farmaceutici S.p.A.
NCT00862394,Phase 3,4,"A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma","A 12-week, Multinational, Randomised, Double Blind, Double Dummy, 4-arm Parallel-group Study Comparing the Efficacy and Safety of CHF 1535 (Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate) 100 + 6 μg/Actuation Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate) 100 + 6 μg/Actuation, Via HFA Pressurised Inhalation Solution, in Moderate to Severe Symptomatic Asthmatic Patients Aged ≥ 12 Years Under Treatment With Inhaled Corticosteroids",783,2009-02-01,2010-01-01,Chiesi Farmaceutici S.p.A.
NCT00872586,Phase 3,2,"Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension","A Randomized, Double-blind, Double-dummy, Multicenter Clinical Trial to Evaluate the Additional Efficacy and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension, Who Fail to Attain the Blood Pressure Goals With Olmesartan Medoxomil 20mg Monotherapy",304,2006-08-01,2007-08-01,"Daiichi Sankyo, Inc."
NCT00894868,Phase 4,2,Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure,"A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of 52 Weeks Treatment With Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure",798,2009-05-01,2012-08-01,Novartis
NCT00953147,Phase 3,3,A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older,"A 6-Month Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Once Daily Ciclesonide HFA Nasal Aerosol (80 and 160 μg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older",1110,2009-08-01,2010-05-01,Sunovion
NCT00956644,Phase 3,2,Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy,Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Amlodipine Monotherapy in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy,406,2009-07-01,2010-08-01,Sanofi
NCT00963599,Phase 3,4,Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117),"A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients With Seasonal Allergic Rhinitis-Fall Study",907,1999-09-01,1999-11-01,Merck Sharp & Dohme Corp.
NCT00984659,Phase 4,3,Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease,Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease,366,2009-10-29,2010-07-01,GlaxoSmithKline
NCT00986154,Phase 3,2,Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).,"A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).",8292,2009-10-01,2013-04-01,"Daiichi Sankyo, Inc."
NCT01006603,Phase 4,2,"Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin","A 52-Week, Randomised, Double Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Monotherapy",957,2009-10-01,2012-06-01,AstraZeneca
NCT01063920,Phase 2/Phase 3,2,Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®,"A Double-Blind, Double-Dummy, Randomized, Active-Comparator, Non-Inferiority Study of LT-NS001 Versus Naprosyn® for Twelve Weeks in Osteoarthritis Patients to Compare Endoscopic Gastric Ulcer Rates",534,2010-02-01,2010-11-01,Logical Therapeutics
NCT01107886,Phase 4,2,Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications,"A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes",18206,2010-05-01,2013-05-01,AstraZeneca
NCT01139762,Phase 3,2,A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms,"A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia",696,2010-09-01,2012-05-01,Eli Lilly and Company
NCT01147250,Phase 3,2,Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide),"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome",6068,2010-06-01,2015-02-01,Sanofi
NCT01172808,Phase 3,4,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I,"A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma",1071,2010-08-01,2012-11-01,Boehringer Ingelheim
NCT01182441,Phase 3,2,Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy,Prospective Randomized Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy,475,2010-11-01,2017-08-01,Boston Scientific Corporation
NCT01186146,Phase 4,2,Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE),Optimal Duration of Clopidogrel Therapy After Drug-Eluting Stent Implantation to Reduce Late Coronary Arterial Thrombotic Events,5000,2010-08-01,2013-10-01,"CardioVascular Research Foundation, Korea"
NCT01188928,Phase 3,4,LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs),"A Phase 3 Study Comparing Once Daily Treatment With Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension With Betamethasone 0.5 mg/g (as Dipropionate) in the Topical Suspension Vehicle, Calcipotriol 50 mcg/g in the Topical Suspension Vehicle and the Topical Suspension Vehicle Alone in Subjects With Psoriasis Vulgaris on Non-scalp Regions of the Body (Trunk and/or Limbs)",1152,2010-09-01,2011-03-01,LEO Pharma
NCT01205932,Phase 3,4,Dose-confirmatory Bridging Study in Total Hip Replacement,"Randomized, Double-blind, Parallel-group, Active-controlled, Dose-confirmatory Bridging Study of Rivaroxaban (BAY59-7939) 5 to 10 mg Once-daily Regimen With a Reference Drug of Enoxaparin in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement",402,2010-09-01,2011-08-01,Bayer
NCT01214239,Phase 3,2,"Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control","A Randomized, db, Placebo Controlled Parallel Group Efficacy and Safety Study Over 24 Weeks in T2D Patients in China",300,2010-10-01,NA,Boehringer Ingelheim
NCT01215097,Phase 3,2,Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy,"A Randomized, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 Over 24 Weeks in T2D Patients With Insufficient Glycaemic Control Despite Metformin Therapy",306,2010-10-01,2012-04-01,Boehringer Ingelheim
NCT01336023,Phase 3,3,"Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes","A 26 Week Randomised, Parallel Three-arm, Open-label, Multi-centre, Multinational Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide Versus Insulin Degludec or Liraglutide Alone, in Subjects With Type 2 Diabetes Treated With 1-2 Oral Anti-diabetic Drugs (OADs)With a 26 Week Extension",1663,2011-05-23,2012-11-22,Novo Nordisk A/S
NCT01371058,Phase 4,3,Study of Policosanol to Improve Platelet Reactivity After Percutaneous Coronary Stent Implantation (PCI),Study of Policosanol to Improve High on Clopidogrel Platelet Reactivity After Percutaneous Coronary Stent Implantation(Spirit),350,2011-03-01,2013-09-01,Shenyang Northern Hospital
NCT01437540,Phase 3,2,Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,"A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",590,2011-09-19,2013-04-30,AstraZeneca
NCT01438814,Phase 4,2,Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control,"A Randomised, Double-blind, Double-dummy, Active-comparator Controlled Study Investigating the Efficacy and Safety of Linagliptin Co-administered With Metformin QD at Evening Time Versus Metformin BID Over 14 Weeks in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control",689,2011-11-01,2013-03-01,Boehringer Ingelheim
NCT01451203,Phase 3,2,Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors",319,2011-10-11,2014-10-20,Astellas Pharma Inc
NCT01471340,Phase 4,2,A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241),"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma (Protocol No. P06241 Also Known as P202)",11744,2012-01-09,2016-11-30,Merck Sharp & Dohme Corp.
NCT01508026,Phase 3,8,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension","A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed Dose Combination in Patients With Stage 1 or 2 Essential Hypertension",4161,2012-01-01,2013-05-01,Forest Laboratories
NCT01590797,Phase 3,2,A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy, Alone or in Combination With Metformin",467,2012-07-10,2014-06-25,Merck Sharp & Dohme Corp.
NCT01602003,Phase 3,3,Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes,"A Multicenter, Multinational, Randomized, Active-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone",425,2009-12-01,2012-05-01,LG Life Sciences
NCT01691521,Phase 3,3,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma,"MEA115588 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma",580,2012-10-08,2014-01-18,GlaxoSmithKline
NCT01782326,Phase 3,2,"QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)","A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. (FLAME).",3362,2013-07-01,2015-09-01,Novartis
NCT01787188,Phase 3,3,Study of Meloxicam Capsules to Treat Osteoarthritis Pain,"A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Fixed-Dose, Parallel-Group, Efficacy, and Safety Study of Meloxicam SoluMatrix™ Capsules in Patients With Pain Due to Osteoarthritis of the Knee or Hip",403,2013-02-01,2013-10-01,"Iroko Pharmaceuticals, LLC"
NCT01808118,Phase 4,3,Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis,"A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis",673,2013-05-01,2017-02-01,AbbVie
NCT01879410,Phase 3,2,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD",700,2013-06-13,2014-01-09,GlaxoSmithKline
NCT01928628,Phase 3,3,Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients,"A Randomized, Multicenter, Parallel Design Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Who Are Not Adequately Controlled on Lercanidipine 10mg Monotherapy.",449,2012-05-01,NA,LG Life Sciences
NCT02006732,Phase 3,4,Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2),"A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",809,2013-11-01,2014-11-01,Boehringer Ingelheim
NCT02007720,Phase 3,2,"Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF","A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients",873,2014-03-12,2017-06-16,Novartis
NCT02058368,Phase 3,2,"Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia","A Randomized, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride (0.5mg) and Tamsulosin (0.2mg) With Tamsulosin (0.2mg) Monotherapy, Administered Once Daily for 2 Years, on the Improvement of Symptoms and Health Outcomes in Men With Moderate to Severe Benign Prostatic Hyperplasia",609,2014-02-10,2017-03-03,GlaxoSmithKline
NCT02141854,Phase 3,5,Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma,"A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy",882,2014-06-01,2015-09-01,Teva Pharmaceutical Industries
NCT02149199,Phase 3,3,A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.,A Clinical Study Comparing Symbicort® 'as Needed' With Terbutaline 'as Needed' and With Pulmicort® Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma.,3850,2014-07-07,2017-08-02,AstraZeneca
NCT02164513,Phase 3,3,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease",10359,2014-06-30,2017-07-17,GlaxoSmithKline
NCT02172586,Phase 4,4,Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients,"A PROBE (Prospective, Randomised, Open-label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80 mg Once Daily Compared With Losartan 50-100 mg Once Daily Over a Period of 12 Weeks, and of Telmisartan 80 mg + HCTZ 12.5 mg Once Daily Compared With Losartan 100 mg Once Daily + HCTZ 12.5 mg Once Daily Over a Period of Further 12 Weeks in Mild to Moderate Hypertensive Patients (Grade 1 and Grade 2 WHO-ISH Guidelines 1999)",363,2000-01-01,NA,Boehringer Ingelheim
NCT02173782,Phase 3,4,Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD),"A Randomized, Placebo-controlled, Within-device, Double-blind Tri-national Study to Compare the Safety and Efficacy of Berodual® Administered Via the Respimat® Device (50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide/10 µg Ipratropium Bromide, 1 Puff q.i.d) With That Administered Via the MDI (50 µg Fenoterol Hydrobromide/21 µg Ipratropium Bromide, 2 Puffs q.i.d) in COPD Patients Over a 12-week Period",892,1998-02-01,NA,Boehringer Ingelheim
NCT02276222,Phase 3,2,A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD,"A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-5 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)",1087,2014-10-01,2016-02-01,Sunovion Respiratory Development Inc.
NCT02414958,Phase 3,3,Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2),"A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to inSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)",730,2015-06-30,2017-10-23,Boehringer Ingelheim
NCT02483169,Phase 4,4,PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study,Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol,800,2009-06-01,2016-12-01,Asan Medical Center
NCT02489968,Phase 3,4,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus,"A Phase III, Randomised, Double-blind, Parallel Group, 24-week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and Linagliptin 5 mg Fixed Dose Combination Compared With Empagliflozin 10 mg Plus Placebo and a 52-week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 25 mg and Linagliptin 5 mg Fixed Dose Combination Compared With Empagliflozin 25 mg Plus Placebo in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16-week Treatment With Empagliflozin (10 mg or 25 mg) Alone Once Daily.",889,2015-05-12,2017-06-16,Boehringer Ingelheim
NCT02528201,Phase 4,3,A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis,"A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis",330,2002-09-01,2004-11-01,Pfizer
NCT02706847,Phase 3,4,A Study to Compare ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs,"A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)",499,2016-03-15,2020-08-06,AbbVie
NCT02706951,Phase 3,4,A Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY),"A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib ABT-494 Monotherapy to Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to MTX",648,2016-03-02,2020-10-20,AbbVie
NCT02761252,Phase 4,3,Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma,Bilastine and Montelukast in Patients With Seasonal Allergic Rhinoconjunctivitis and Asthma: Efficacy of Concomitant Administration - the SKY Study,453,2016-04-01,2016-11-24,Menarini International Operations Luxembourg SA
NCT02808767,Phase 4,2,Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction,Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction,1226,2013-01-01,2017-05-01,Faculty Hospital Kralovske Vinohrady
NCT00000539,Phase 3,NA,Arterial Disease Multifactorial Intervention Trial (ADMIT),NA,NA,1992-09-01,1999-03-01,"National Heart, Lung, and Blood Institute (NHLBI)"
NCT00046228,Phase 3,3,A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse),"A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.",2461,2002-08-01,2008-01-01,"Centocor, Inc."
NCT00060918,Phase 4,NA,Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension,"A Randomized, Double-Blind, Multicenter Study Comparing the Glycemic Control Characteristics of Carvedilol and Metoprolol in Hypertensive Patients With Type II Diabetes Mellitus.",1210,2001-06-01,2004-04-01,GlaxoSmithKline
NCT00071331,Phase 3,NA,EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan,"Protocol 156-03-236: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure",3600,2003-09-01,2006-07-01,"Otsuka Pharmaceutical Development & Commercialization, Inc."
NCT00080275,Phase 3,NA,Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS),An Open-Label Evaluation of the Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients With Dyslipidemia (OCEANS),600,2004-03-01,NA,Kos Pharmaceuticals
NCT00082407,Phase 3,2,Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin,"Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin",505,2003-11-01,2008-07-01,AstraZeneca
NCT00090168,Phase 3,NA,Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED),A Multicenter Study to Assess the Cholesterol Lowering Level of Switching to an Investigational Drug Compared to Doubling the Dose of an Investigational Drug in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease,435,2004-01-27,2004-11-10,Merck Sharp & Dohme Corp.
NCT00092989,Phase 3,2,"Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)","A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Patients With Acute Asthma",650,2004-07-01,2007-03-01,Merck Sharp & Dohme Corp.
NCT00094770,Phase 3,2,An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024),"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy",1172,2004-09-01,2007-05-01,Merck Sharp & Dohme Corp.
NCT00121446,Phase 2/Phase 3,NA,Which Therapy for Acute Heart Attacks? (The WEST Study),Which Early ST Elevation Myocardial Infarction Therapy? The WEST Study,300,2003-07-01,NA,University of Alberta
NCT00141960,Phase 2/Phase 3,NA,Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease,"YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease",480,2005-09-01,NA,Astellas Pharma Inc
NCT00152984,Phase 4,NA,Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma,"A 12-week Randomised, Double Blind, Placebo Controlled, Parallel Group Trial Evaluating the Efficacy and Safety of Inhaled Tiotropium 18μg q.d. in Patients With COPD and a Concomitant Diagnosis of Asthma",472,2004-12-01,2006-04-01,Boehringer Ingelheim
NCT00163202,Phase 4,NA,Comparative Atorvastatin Pleiotropic Effects,"A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis",330,2002-06-01,2005-08-01,Pfizer
NCT00168857,Phase 4,NA,"A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)","A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS® (Telmisartan) 80 mg Versus COZAAR® (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)",860,2003-07-01,NA,Boehringer Ingelheim
NCT00182403,Phase 3,NA,Fixed Dose Heparin Study,Fixed Dose Unfractionated Heparin for Initial Treatment of Venous Thromboembolism,866,1998-09-01,2004-05-01,McMaster University
NCT00208299,Phase 3,2,ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI),"A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 Versus Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging",1231,2003-10-01,2006-08-01,Gilead Sciences
NCT00234871,Phase 4,2,"Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)","A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy",357,2004-01-01,NA,Abbott
NCT00251134,Phase 3,2,OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial Infarction,"OMEGA: A Prospective, Randomised, Double-Blind, Placebo-Controlled Multicentre Study in Patients Who Survived Acute Myocardial Infarction to Investigate the Efficacy and Safety of 1 Gram Ω-3-Fatty Acid Ethyl Esters (Ω-3FAE) Daily Versus Placebo to Reduce the Risk of Sudden Cardiac Death.",3800,2003-10-01,2008-09-01,Stiftung Institut fuer Herzinfarktforschung
NCT00251693,Phase 3,3,Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis,"A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once- Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis",2038,2005-12-01,2007-01-01,Takeda
NCT00259376,Phase 3,2,American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm,American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS),629,2001-11-01,2003-09-01,Sanofi
NCT00262236,Phase 3,NA,Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension,"A Twelve-week, Randomized, Double-blind, Parallel-group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Atenolol in Patients With Essential Hypertension",693,2005-11-01,2006-08-01,Novartis
NCT00266227,Phase 3,2,A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Retreatment With Rituximab in Subjects With Rheumatoid Arthritis Receiving Background Methotrexate",559,2006-01-01,NA,"Genentech, Inc."
NCT00287729,Phase 3,2,Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis,"A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis",344,2006-04-01,2008-11-01,"Genentech, Inc."
NCT00296530,Phase 4,NA,Study Of Patients With Allergic Rhinitis And Asthma,"A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID",600,2005-09-01,2007-07-01,GlaxoSmithKline
NCT00301392,Phase 4,1,Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT),Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT),1240,2006-04-01,2012-06-01,Tokyo University
NCT00316095,Phase 3,NA,Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia,"Reduced Factorial Design, Randomized, Double Blind Trial Comparing Combinations of Telmisartan 20 or 80 mg and Simvastatin 20 or 40 mg With Single Component Therapies in the Treatment of Hypertension and Dyslipidemia",1695,2006-04-01,2007-08-01,Boehringer Ingelheim
NCT00356096,Phase 4,NA,Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances,"A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome Associated With Mood Disturbances",404,2006-07-01,NA,Boehringer Ingelheim
NCT00359762,Phase 3,2,Exenatide Versus Glimepiride in Patients With Type 2 Diabetes,Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study),1029,2006-09-01,2011-03-01,AstraZeneca
NCT00363896,Phase 3,2,A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD),Clinical Trial Assessing Efficacy and Safety of LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients,843,2006-07-01,2008-05-01,AstraZeneca
NCT00365352,Phase 3,3,XP13512 vs. Placebo in Patients With Restless Legs Syndrome.,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.",325,2006-08-01,2007-12-01,"XenoPort, Inc."
NCT00375284,Phase 4,NA,A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS,"A Phase IV Randomised, Double-blind, Active and Placebo-controlled, 6-week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (Mirapex®) in Patients With Idiopathic Restless Legs Syndrome",404,2006-09-01,NA,Boehringer Ingelheim
NCT00384085,Phase 4,3,"Insulin Glargine ""All to Target"" Trial","All to Target Trial Lantus® (Insulin Glargine) With Stepwise Addition of APIDRA® (Insulin Glulisine) or Lantus With One Injection of Apidra vs a Twice-Daily Premixed Insulin Regimen (Novolog® Mix 70/30) in Adult Subjects With Type 2 Diabetes Failing Dual or Triple Therapy With Oral Agents: a 64-week, Multi-center, Randomized, Parallel, Open-label Clinical Study.",588,2006-05-01,2010-03-01,Sanofi
NCT00391443,Phase 3,2,BUILD 3: Bosentan Use in Interstitial Lung Disease,"Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.",616,2007-02-01,2010-07-01,Actelion
NCT00399724,Phase 4,NA,A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus,"A Multicentre, Multinational, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 2 Diabetes Mellitus.",7376,2002-03-01,2003-08-01,Sanofi
NCT00410410,Phase 3,3,A Study of Abatacept in Patients With Active Ulcerative Colitis,"A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Ulcerative Colitis (UC) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy",591,2006-12-01,2009-11-01,Bristol-Myers Squibb
NCT00418548,Phase 3,NA,Study Comparing Etanercept 50 mg Once Weekly to 25 mg Twice Weekly in Patients With Ankylosing Spondylitis,"A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly Compared With 25 mg Twice Weekly in Subjects With Ankylosing Spondylitis",350,2004-06-01,2005-02-01,Wyeth is now a wholly owned subsidiary of Pfizer
NCT00430677,Phase 2/Phase 3,4,Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis,"A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects With Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE)",423,2007-06-01,2011-08-01,Bristol-Myers Squibb
NCT00432796,Phase 3,2,PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.,A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2),1473,2006-12-01,2017-12-01,Lawson Health Research Institute
NCT00435448,Phase 3,NA,Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia,"A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia",480,2005-06-01,2006-12-01,Threshold Pharmaceuticals
NCT00467376,Phase 3,2,"Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus","12-week, Multicenter, Controlled, Open, 3:1 Randomized, Parallel Clinical Trial Comparing Insulin Glulisine With Regular Human Insulin (Insulin Lispro) Injected Subcutaneously in Subjects With Type 1 or 2 Diabetes Mellitus Also Using Lantus (Insulin Glargine)",485,2007-01-01,NA,Sanofi
NCT00469092,Phase 4,2,Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes,"A Multi-national, Open-labelled, Randomised, Parallel Group, 4 Week run-in and 26 Weeks Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Insulin naïve Subjects With Type 2 Diabetes",480,2007-05-01,2008-04-01,Novo Nordisk A/S
NCT00479401,Phase 3,3,"Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients","A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD).",539,2007-05-01,NA,Boehringer Ingelheim
NCT00496470,Phase 4,2,Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.,"A 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, Study to Evaluate Efficacy and Safety of Budesonide/Formoterol (Symbicort Turbuhaler®) 320/9 µg One Inhalation Twice Daily on Top of Tiotropium (Spiriva®) 18 µg One Inhalation Once Daily",660,2007-05-01,2008-06-01,AstraZeneca
NCT00568984,Phase 4,NA,Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes,Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes Mellitus,324,2002-11-21,2003-11-10,Novo Nordisk A/S
NCT00623623,Phase 3,2,STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction,STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms,1891,2008-03-01,2012-09-01,Boehringer Ingelheim
NCT00637949,Phase 3,2,Safety of Lumiracoxib in Patients With Osteoarthritis,"A 6-Week Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Parallel Group Clinical Saftey Study to Evaluate Incidence of Predefined Gastrointestinal Adverse Events and Peripheral Edema in Subjects With Primary Osteoarthritis Treated With COX189 400 mg o-do Using Rofecoxib 25 mg o.d. as a Comparator",309,2000-12-01,2001-03-01,Novartis
NCT00647270,Phase 3,3,"Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing","A Multi-center, Randomized, Double-blind,Placebo-controlled Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing",420,2007-12-01,2009-04-01,Abbott
NCT00649389,Phase 3,4,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,"A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension",2500,2008-05-01,2009-12-01,"Daiichi Sankyo, Inc."
NCT00650455,Phase 4,3,Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients,"Clinical Protocol for a Multicenter, Double-Blind, Randomized, Placebo Controlled, Comparison of the Efficacy and Safety of Bextra® (Valdecoxib) 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe RA Population",489,2003-02-01,2005-01-01,Pfizer
NCT00702325,Phase 4,2,Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans,"A 12-wk, Rand., Double-blind, Double Dummy, Multi-ctr., Phase IV Study Comparing Efficacy and Safety of SYMBICORT® pMDI 160/4.5 ug x 2 Actuations Twice Daily Versus Pulmicort® (Budesonide Inhalation Powder DPI) 180 ug x 2 Inhalations Twice Daily, in Adult and Adolescent African American Subjects With Asthma",311,2008-06-01,2009-09-01,AstraZeneca
NCT00717457,Phase 3,3,"A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.","Randomized, Active Controlled, Open Label Study to Compare Taspoglutide vs Exenatide as add-on Treatment to Metformin and/or Thiazolidinediones in Patients With Type 2 Diabetes Mellitus",1189,2008-07-01,2011-03-01,Hoffmann-La Roche
NCT00736879,Phase 3,4,Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes,"A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise",497,2008-09-22,2009-12-29,AstraZeneca
NCT00739596,Phase 4,2,Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans,"An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension",332,2008-07-01,2009-03-01,Novartis
NCT00740883,Phase 3,2,"Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. ""PADIS-PE"" Study.","Eighteen Months of Oral Anticoagulant Therapy Versus Placebo After 6 Six Months of Anticoagulation for a First Episode of Idiopathic Pulmonary Embolism: a Multicentre Double-blind Randomized Controlled Trial. ""PADIS-PE"" Study.",374,2007-07-01,2016-10-01,"University Hospital, Brest"
NCT00751114,Phase 4,2,Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients,Superiority Study of Insulin Glargine Over Sitagliptin in Insulin-naïve Patients With Type 2 Diabetes Treated With Metformin and Not Adequately Controlled,515,2008-11-01,2011-07-01,Sanofi
NCT00809926,Phase 4,2,8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension,"An 8-week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Efficacy and Safety of Valsartan Administered in Combination With Aliskiren (160/150 mg, 320/300 mg) Versus Valsartan Alone (160 mg, 320 mg) in Patients With Stage 2 Hypertension",451,2009-01-01,2009-07-01,Novartis
NCT00814268,Phase 4,2,COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke,"COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial",358,2008-12-01,2012-05-01,Sanofi
NCT00814307,Phase 3,4,"A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis","Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis",611,2009-02-01,2010-06-01,Pfizer
NCT00827242,Phase 3,2,Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia",325,2009-01-01,2009-11-01,Eli Lilly and Company
NCT00839800,Phase 3,2,Study to Investigate the Efficacy of Symbicort® SMART.,"A Comparison of Symbicort® SMART (160/4.5μg) and Symbicort® Turbuhaler 160/4.5 μg, Plus Terbutaline Turbuhaler 0.4 mg as Needed, for Treatment of Asthma - a 12-month, Randomized, Double-blind, Parallel Group, Active-controlled, Multinational Phase III Study in Asthmatic Patients From 16 Years",2091,2009-02-01,2011-02-01,AstraZeneca
NCT00861757,Phase 3,4,Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia,"A Phase 3, Randomized, Double Blind, Placebo and Tamsulosin Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil Once a Day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia",612,2009-03-01,2010-06-01,Eli Lilly and Company
NCT00864097,Phase 3,4,Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip,"A Phase 3, Randomized, Double-Blind, Controlled, Multi-Center Study Of The Analgesic Efficacy And Safety Of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip",607,2009-08-01,2010-11-01,Pfizer
NCT00879970,Phase 4,5,Thiazolidinedione Intervention With Vitamin D Evaluation,AVANDIA CV Outcomes Study: Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo-Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In People With Type 2 Diabetes at Risk For Cardiovascular Disease,1332,2009-05-01,2010-11-01,GlaxoSmithKline
NCT00883168,Phase 3,4,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,"Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis",1791,2009-04-01,2009-07-01,Meda Pharmaceuticals
NCT00925600,Phase 3,2,Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss,"A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy",769,2009-11-30,2016-05-12,Amgen
NCT00936897,Phase 3,2,A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates,A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates,833,2009-07-01,2012-01-01,Amgen
NCT00949884,Phase 4,3,Olmesartan Comparison to Losartan in Hypertensive Subjects,"A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects",941,2009-08-01,2010-01-01,"Daiichi Sankyo, Inc."
NCT00957554,Phase 3,2,Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy,Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy,435,2009-07-01,2010-09-01,Sanofi
NCT00986050,Phase 4,4,Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction,A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study,907,2006-01-01,2009-07-01,Catharina Ziekenhuis Eindhoven
NCT01010971,Phase 3,3,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol (160 μg Once Daily and 80 μg Once Daily) for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older",671,2009-12-01,2010-02-01,Sunovion
NCT01033825,Phase 3,7,Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis,"A 6-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety and Efficacy Study of the Potential Inhibitory Effects on the Hypothalamic-Pituitary-Adrenal Axis of Ciclesonide HFA Nasal Aerosol and Ciclesonide Aqueous Nasal Spray in Subjects 12 Years and Older With Perennial Allergic Rhinitis",310,2010-01-01,2010-05-01,Sunovion
NCT01059812,Phase 3,2,A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes,A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™: INTENSIFY ALL),424,2010-02-01,2010-12-01,Novo Nordisk A/S
NCT01064687,Phase 3,4,A Study in Participants With Type 2 Diabetes Mellitus,"A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)",978,2010-02-01,2012-05-01,Eli Lilly and Company
NCT01069003,Phase 4,3,"EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events","EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Antiplatelet Therapy (DAPT) Drug Regimen",2272,2010-04-01,2014-04-01,Medtronic Vascular
NCT01074268,Phase 3,2,Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes,NN1250-3585: A Trial Investigating the Efficacy and Safety of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen / NN1250-3725: An Extension Trial to NN1250-3585 Investigating Safety and Efficacy of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen (BEGIN™: BB T1),456,2010-02-01,2010-12-01,Novo Nordisk A/S
NCT01089127,Phase 3,6,Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD),"A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Different Doses of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease, Using Salmeterol as an Active Control",552,2010-03-01,2010-07-01,Novartis
NCT01164501,Phase 3,3,Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment,"A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control",741,2010-07-01,2012-07-01,Boehringer Ingelheim
NCT01167010,Phase 3,3,"A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma","A Phase III, Randomized, Non-inferiority, Open-label, Comparative Study Between Foraseq® Inhalation Capsules, Eurofarma's Single Formoterol / Budesonide Inhalation Capsule and Single Alenia® Inhalation Capsule in Asthmatic Patients",552,2011-04-01,2012-02-01,Eurofarma Laboratorios S.A.
NCT01218009,Phase 3,2,A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing,A Multi-Center 52-Week Study to Assess the Safety of an Albuterol Dry-powder Inhaler in Subjects With Asthma,331,2010-10-01,2010-12-01,Teva Pharmaceutical Industries
NCT01302691,Phase 3,2,MK-0954E Study in Participants With Hypertension (MK-0954E-357),"A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With Losartan and Amlodipine Co-administration",327,2011-01-01,2012-04-01,Merck Sharp & Dohme Corp.
NCT01313637,Phase 3,4,A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD,"A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease",1493,2011-03-01,2012-04-19,GlaxoSmithKline
NCT01347580,Phase 4,2,A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI),"A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.",1875,2011-09-01,2013-11-01,AstraZeneca
NCT01392573,Phase 3,2,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes,"A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes",413,2011-11-28,2012-10-04,Novo Nordisk A/S
NCT01461369,Phase 3,3,Study of Diclofenac Capsules to Treat Osteoarthritis Pain,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group, Efficacy and Safety Study of Diclofenac [Test] Capsules in Subjects With Osteoarthritis of the Knee or Hip",305,2011-10-01,2012-10-01,"Iroko Pharmaceuticals, LLC"
NCT01467323,Phase 3,2,Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes,"An Open-labelled, Randomised, Parallel Group, Multicentre, Multinational Efficacy and Safety Comparison of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30/70 as Meal Related Insulin in a Twice Daily Regimen in Type 1 and Type 2 Diabetic Subjects",303,1998-04-01,1998-09-01,Novo Nordisk A/S
NCT01494987,Phase 3,2,Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus",431,2012-01-01,2013-08-01,Gilead Sciences
NCT01498679,Phase 3,2,Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.,"A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily for 12 Weeks in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With Low to Mid-strength Inhaled Corticosteroid or Low-strength Combination Therapy.",311,2012-01-01,2013-07-01,GlaxoSmithKline
NCT01498822,Phase 4,2,Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy,"A Multi-Center, Open-label, Randomized Study to Evaluate the Long Term Effectiveness of Levetiracetam as Monotherapy in Comparison With Oxcarbazepine in Subjects With Newly or Recently Diagnosed Partial Epilepsy",353,2011-06-01,2014-07-01,UCB Pharma
NCT01521923,Phase 3,3,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis","A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis",359,2012-01-01,2015-09-01,UCB Pharma
NCT01555138,Phase 4,2,Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.),"A Randomized, Double-blind, Parallel-group, 26-week Study Comparing the Efficacy and Safety of Indacaterol (Onbrez® Breezhaler® 150 mcg o.d.) With Salmeterol/Fluticasone Propionate (Seretide® Accuhaler® 50 mcg/500 mcg b.i.d.) in Patients With Moderate Chronic Obstructive Pulmonary Disease",581,2012-02-01,2014-02-01,Novartis
NCT01623596,Phase 4,2,Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.,"A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)",881,2012-06-08,2015-07-13,Novartis
NCT01644188,Phase 3,2,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),"A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 Versus Ezetimibe in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy",720,2012-08-01,2015-07-01,Sanofi
NCT01696058,Phase 3,2,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,"A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]",1137,2012-09-01,2013-10-01,Boehringer Ingelheim
NCT01722331,Phase 3,3,"A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)","A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)",772,2012-12-01,2019-10-01,Merck Sharp & Dohme Corp.
NCT01729559,Phase 4,2,Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin,Venous Thromboembolic Prophylaxis After Major Trauma: A Randomized Controlled Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin,495,2012-11-01,2014-10-01,Scripps Health
NCT01734785,Phase 3,3,Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes,"A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.",607,2013-01-01,2015-03-01,Boehringer Ingelheim
NCT01758380,Phase 4,2,Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan,"A Double Blind, Double Dummy, Randomised, Multi-centre Study to Assess the Tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan",557,2013-01-01,2013-09-01,Novartis
NCT01772134,Phase 3,3,Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks,"A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks With COPD",617,2013-01-01,2013-07-22,GlaxoSmithKline
NCT01809327,Phase 3,5,"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise","A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise",1186,2013-06-04,2014-12-02,"Janssen Research & Development, LLC"
NCT01860976,Phase 3,2,Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis,A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis,489,2013-06-05,2020-07-06,Bristol-Myers Squibb
NCT01957163,Phase 3,3,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","A Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 1",619,2013-10-01,2014-04-01,GlaxoSmithKline
NCT01959451,Phase 4,2,Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial,Platelet Function Guided Prasugrel Therapy in ACS Patients Undergoing PCI,2600,2013-09-01,2017-06-01,Klinikum der Universitaet Muenchen
NCT01970475,Phase 3,2,Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis,"A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis",526,2013-10-01,2014-11-01,Amgen
NCT02031640,Phase 3,5,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma,"A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma",1113,2013-12-01,2014-12-01,Teva Pharmaceutical Industries
NCT02128932,Phase 3,3,Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes,1089,2014-08-04,2015-09-03,Novo Nordisk A/S
NCT02139644,Phase 3,5,Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma,"A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Low-dose or or Mid-dose Inhaled Corticosteroid Therapy",787,2014-06-01,2015-09-01,Teva Pharmaceutical Industries
NCT02183064,Phase 3,2,"Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis","A Multi-Center, Randomized, Parallel-Group, Open-Label Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis of the Hip, Knee, Hand or Spine",1309,1998-10-01,NA,Boehringer Ingelheim
NCT02203032,Phase 3,3,A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab,"A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab",872,2014-10-07,2016-05-24,"Janssen Research & Development, LLC"
NCT02207231,Phase 3,3,A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis,"Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis",837,2014-11-26,2020-07-20,"Janssen Research & Development, LLC"
NCT02207374,Phase 3,3,A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes,Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Who Are Insufficiently Controlled on Diet/Exercise Therapy or OAD Monotherapy,601,2014-08-04,2016-02-27,Novo Nordisk A/S
NCT02242318,Phase 4,3,Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring,"A Prospective, Randomised, Double-blind, Double-dummy Trial to Compare the Efficacy of Micardis® (Telmisartan) (80 mg p.o. Once Daily) and Valsartan (160 mg p.o. Once Daily) in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring",440,2001-09-01,NA,Boehringer Ingelheim
NCT02305381,Phase 3,4,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes,397,2014-12-01,2015-11-21,Novo Nordisk A/S
NCT02550288,Phase 3,5,A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383),"A Phase III, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy and Safety of MK-0653C in Japanese Patients With Hypercholesterolemia",309,2015-09-29,2016-05-30,Merck Sharp & Dohme Corp.
NCT02666664,Phase 3,2,Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony),"A Randomized, Double-blind, Placebo-controlled, Multicenter Long-term Safety and Tolerability Study of ETC-1002 in Patients With Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy",2233,2016-01-01,2018-05-01,Esperion Therapeutics
NCT02684370,Phase 3,3,BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis,BI 655066/ABBV-066 (Risankizumab) Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1),500,2016-02-01,2017-08-01,AbbVie
NCT02749994,Phase 3,6,A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study),NA,396,2016-04-01,2017-02-01,IlDong Pharmaceutical Co Ltd
NCT02916602,Phase 3,2,A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605,"A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605",340,2015-04-01,2016-09-01,Hanmi Pharmaceutical Company Limited
NCT02967224,Phase 4,2,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to ""Standard of Care"" Basal Insulins in Insulin Naïve Patients Initiating Insulin","A Twenty-six Week, Randomized, Open-label, 2-Arm Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes Benefit of Toujeo® Compared to ""Standard of Care"" Insulin for Initiating Basal Insulin in Insulin Naïve Patients With Uncontrolled Type 2 Diabetes Mellitus, With 6-Month Extension",705,2015-11-05,2017-10-16,Sanofi
NCT00007670,Phase 3,NA,"Does Gabapentin and Lamotriginel Have Significantly Fewer Side-Effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.",CSP #428 - Treatment of Seizures in the Elderly Population,720,1998-01-01,2003-03-01,VA Office of Research and Development
NCT00060931,Phase 4,NA,Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension,"A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvedilol and Metoprolol on Glycemic Control in Hypertensive Patients With Type II Diabetes Mellitus.",501,2001-06-01,2004-04-01,GlaxoSmithKline
NCT00073827,Phase 3,3,"Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma","An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma",445,2002-05-01,2003-01-01,Sunovion
NCT00077753,Phase 4,NA,EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization,"A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization",4726,2002-02-01,2007-02-01,Sanofi
NCT00081731,Phase 3,2,Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions,Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL),947,2004-04-01,2013-09-01,Baim Institute for Clinical Research
NCT00087516,Phase 3,4,Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021),"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK0431 Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",741,2004-06-01,2007-02-01,Merck Sharp & Dohme Corp.
NCT00091949,Phase 3,2,Insulin Resistance Intervention After Stroke Trial,Insulin Resistance Intervention After Stroke (IRIS) Trial,3876,2005-02-01,2015-11-01,Yale University
NCT00092027,Phase 3,NA,A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219),"A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Compare the Safety and Tolerability of an Oral Buffered Solution of Alendronate Sodium 70 mg Once-Weekly Versus Placebo for the Treatment of Osteoporosis in Postmenopausal Women",454,2003-03-19,2004-03-15,Merck Sharp & Dohme Corp.
NCT00092885,Phase 3,NA,An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269),"A Multicenter, Double-Blind, Randomized Study Investigating the Clinical Effect of Montelukast on Allergic Rhinitis in Patients With Seasonal Allergic Rhinitis and Chronic Asthma",831,2003-03-01,2003-10-01,Merck Sharp & Dohme Corp.
NCT00094458,Phase 3,3,Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC,"Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE� (Infliximab) and REMICADE Plus Azathioprine to Azathioprine in the Treatment of Patients With Crohn's Disease Naive to Both Immunomodulators and Biologic Therapy",508,2005-03-01,2009-12-01,"Centocor Ortho Biotech Services, L.L.C."
NCT00099944,Phase 3,3,Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes,Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes,515,2004-05-01,2005-10-01,Novartis
NCT00106366,Phase 3,NA,Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes,Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes,389,2005-03-01,2005-12-01,Novo Nordisk A/S
NCT00111449,Phase 3,NA,Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis,A Phase 3 Multicenter Study to Assess the Efficacy and Safety of Etanercept 50 mg Twice Weekly in Psoriasis,600,2003-06-01,NA,Amgen
NCT00122382,Phase 3,2,Remission and Joint Damage Progression in Early Rheumatoid Arthritis,"A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate",1052,2005-07-01,2009-02-01,Bristol-Myers Squibb
NCT00136045,Phase 3,NA,Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Four-arm Parallel-group Trial to Investigate the Efficacy and Safety of Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome",549,2005-05-01,2006-08-01,UCB Pharma
NCT00148408,Phase 4,NA,Trial of Asthma Patient Education (TAPE),Trial of Asthma Patient Education (TAPE),600,2003-12-01,2005-12-01,American Lung Association Asthma Clinical Research Centers
NCT00153088,Phase 4,NA,INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy,"A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study -",527,2003-01-01,2005-11-01,Boehringer Ingelheim
NCT00163475,Phase 3,NA,Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015),The MOVE-study: Morning Versus Evening Administration of 500 mcg Roflumilast Once Daily for 6 Weeks in Patients With Asthma,511,2004-05-01,2005-08-01,AstraZeneca
NCT00174915,Phase 3,5,"Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.","A Phase 3, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout.",1072,2003-02-01,2004-04-01,Takeda
NCT00187408,Phase 4,NA,The D-KAF (Dalteparin in Knee-to-Ankle Fracture) Trial,Clinically-Important Venous Thromboembolism Following Lower Extremity Fractures: Epidemiology & Prevention,700,2002-08-01,2007-01-01,Sunnybrook Health Sciences Centre
NCT00216593,Phase 3,NA,Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study,"Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study.",415,2003-12-01,2008-03-01,"Janssen Pharmaceutica N.V., Belgium"
NCT00224120,Phase 3,2,A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo,"A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Evaluation of the Efficacy and Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia",462,2005-05-01,2006-05-01,Watson Pharmaceuticals
NCT00230698,Phase 3,NA,A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure,Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures,451,1995-11-01,2002-08-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00232596,Phase 3,2,Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",306,2005-09-01,2008-01-01,GlaxoSmithKline
NCT00242775,Phase 3,NA,"Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg","Efficacy and Safety of Symbicort ®Turbuhaler® 160/4.5 µg/Inhalation, Two Inhalations Twice Daily Plus As-needed Compared With Seretide™ Diskus™ 50/500 µg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation As-needed - a 6-month, Randomised, Double-blind, Parallel-group, Active Controlled, Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma (AHEAD).",2100,2005-05-01,2006-05-01,AstraZeneca
NCT00243178,Phase 3,2,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W),"A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation",6706,2003-07-01,2005-09-01,Sanofi
NCT00244426,Phase 3,2,S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation,II Italian Study on Atrial Fibrillation (S.I.F.A. II): Prevention of Thromboembolic Events in Patients With Non Valvular Atrial Fibrillation.,1372,2000-12-01,2008-04-01,Pfizer
NCT00249249,Phase 3,NA,Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels,Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia,830,2005-10-01,2006-11-01,Kowa Research Europe
NCT00252785,Phase 3,NA,Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients,"An 8-week, Randomised, Double Blind, Parallel-group, Multi-centre, Phase III Study Comparing the Efficacy and Safety of Symbicort® Turbuhaler® 160/4.5 µg Twice Daily and Pulmicort® Turbuhaler® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Patients With Asthma",340,2005-10-01,2006-11-01,AstraZeneca
NCT00270374,Phase 3,1,"A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (Nesiritide) Compared With Nitroglycerin Therapy for Symptomatic Decompensated CHF, The VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure",498,1999-10-01,2000-08-01,"Scios, Inc."
NCT00274079,Phase 4,NA,SPIRIVA in Ususal Care,"A Randomised, Double-blind, Parallel Group, 12 Week Study, Comparing the Effect of Once Daily Tiotropium Lactose Capsule With Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD), naïve to Anticholinergic Agents in Addition to Receiving Their Usual COPD Care",395,2002-10-01,2003-10-01,Boehringer Ingelheim
NCT00325403,Phase 3,2,FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH),"A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension",349,2006-10-01,2011-04-01,United Therapeutics
NCT00329602,Phase 4,2,Long-term Study Of Ropinirole In Restless Legs Syndrome,A Parallel Group Study to Evaluate the Efficacy and Safety of Ropinirole for 26 Weeks and to Further Evaluate the Incidence of Augmentation and Rebound for a Further 40 Weeks Open-label Extension Treatment Period in Subjects Suffering From Moderate to Severe Restless Legs Syndrome.,404,2006-03-01,2008-09-01,GlaxoSmithKline
NCT00335699,Phase 4,NA,Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome,"A 6-Week, Randomised, Open-Label, Parallel Group, Multi-Centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Non-Diabetic Metabolic Syndrome Subjects With Raised LDL-C",370,2005-08-01,2007-01-01,AstraZeneca
NCT00377637,Phase 3,4,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,"A Prospective, Randomized, Active Controlled, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Mycophenolate Mofetil (MMF) in Inducing Response and Maintaining Remission in Subjects With Lupus Nephritis.",370,2005-07-01,2010-03-01,Hoffmann-La Roche
NCT00383435,Phase 3,5,Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED),"A Randomized, 26-Week, Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension, of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD",1055,2006-10-01,2010-07-01,Merck Sharp & Dohme Corp.
NCT00383578,Phase 3,2,Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes,"A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 mg qd or Metformin 1500 mg Daily in Elderly Drug Naive Patients With Type 2 Diabetes",335,2006-09-01,NA,Novartis
NCT00386100,Phase 4,2,A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin,"A Randomized, Parallel Group, Double-blind, Multi-center Study Comparing the Efficacy and Safety of AVANDAMET and Metformin After 80 Weeks of Treatment.",688,2006-10-01,2009-09-01,GlaxoSmithKline
NCT00387517,Phase 3,NA,Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension,An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (150/25 mg and 300/25 mg) in Comparison With HCTZ 25 mg in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg Monotherapy,726,2006-10-01,2007-08-01,Novartis
NCT00400153,Phase 3,3,Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD),Safety and Efficacy of Combivent Respimat in Chronic Obstructive Pulmonary Disease (COPD),1480,2006-11-01,NA,Boehringer Ingelheim
NCT00401596,Phase 3,NA,A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO),"A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Subjects Already Treated With Other Therapies (ALTO)",1899,2000-07-01,2002-07-01,"Genentech, Inc."
NCT00403910,Phase 3,NA,Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study,Phase 3 Study Of Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure,500,2002-09-01,2006-07-01,Heart Care Foundation
NCT00405418,Phase 4,2,Lantus Versus Levemir Treat-To-Target,Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir.,973,2006-11-01,NA,Sanofi
NCT00419952,Phase 3,2,A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.,"A 52-week, Randomised, Double-blind, Parallel-group, Multi-centre, Phase IIIB Study Comparing the Long Term Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily to Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily in Adult/Adolescent (≥12 Years) African American Subjects With Asthma",742,2007-02-01,2009-11-01,AstraZeneca
NCT00448461,Phase 4,2,Antithrombotic Regimens and Outcome,Comparison of Bivalirudin and Unfractioned Heparin in Elective Percutaneous Coronary Interventions,850,2007-03-01,2008-06-01,Careggi Hospital
NCT00476268,Phase 3,3,Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma,A 24-week Phase III Study to Evaluate the Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler HFA 134a-pMDI in Adult Patients With Moderate to Severe Persistent Asthma,824,2004-02-01,2005-01-01,Chiesi Farmaceutici S.p.A.
NCT00486343,Phase 4,2,Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS,"A Randomized, Double-Blind, Placebo Controlled Study of Zileuton CR Tablets Versus Placebo in Adult Patients With Poorly Controlled Asthma Patients on Moderate Dose Inhaled Corticosteroids (ICS)",400,2007-07-01,2008-06-01,Critical Therapeutics
NCT00496769,Phase 3,2,A Phase III Study of Apixaban in Patients With Atrial Fibrillation,Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial,6421,2007-08-31,2017-04-13,Bristol-Myers Squibb
NCT00500955,Phase 3,NA,Rosiglitazone on Microalbuminuria in Type 2 Diabetics,A Study to Evaluate the Efficacy of Rosiglitazone (BRL-049653) on Reduction of Microalbuminuria in Subjects With Type 2 Diabetes Mellitus,336,2000-04-01,2004-06-01,GlaxoSmithKline
NCT00538902,Phase 2/Phase 3,3,Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate,"A Multi-center Randomized, Phase 2/3, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Safety and Efficacy of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate",302,2007-08-01,2009-12-01,Abbott
NCT00546754,Phase 3,2,BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333),"BP-EASE-A 12-Week, Multicenter, Open-Label, Randomized, Controlled Trial To Compare The Effectiveness of Losartan 50 mg/HCTZ 12.5 mg Titrated as Needed to Losartan 100 mg/HCTZ 25 mg or Valsartan 160 mg/HCTZ 25 mg, in Patients With Essential Hypertension Who Have Not Achieved Target Blood Pressure With",808,2007-05-01,2009-05-01,Merck Sharp & Dohme Corp.
NCT00546832,Phase 3,3,Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial II,The Efficacy and Safety of TDS-943 in the Treatment of Osteoarthritis of the Knee: Pivotal Study II,650,2007-10-01,2008-11-01,Mika Pharma GmbH
NCT00552058,Phase 3,2,Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease,"Phase IIIb, Multinational, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-Tumor Necrosis Factor(TNF)-Alpha Monoclonal Antibody, Administered in Subjects With Moderately to Severely Active Crohn's Disease.",439,2008-03-01,2009-11-01,UCB Pharma
NCT00638807,Phase 4,2,Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen,"A Double-Blind, Placebo Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen",388,2003-12-01,2004-07-01,Pfizer
NCT00659594,Phase 3,2,"Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older",500,2004-11-01,2005-09-01,AstraZeneca
NCT00659841,Phase 3,2,"To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray (200µg Once Daily) in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 12 Years and Older",302,2003-12-01,2005-02-01,AstraZeneca
NCT00660179,Phase 3,3,Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension",742,2008-05-01,2012-04-01,Actelion
NCT00691964,Phase 3,3,Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",347,2008-05-01,2009-03-01,AbbVie
NCT00721760,Phase 3,2,Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery,"A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery",1003,2008-07-01,2009-10-01,Sanofi
NCT00731692,Phase 3,3,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.","A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis",970,2008-07-28,2015-06-22,Novartis
NCT00739973,Phase 3,9,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,"An 8-week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Amlodipine in Patients With Essential Hypertension",2694,2008-09-01,2009-05-01,Novartis
NCT00744471,Phase 3,4,Tanezumab in Osteoarthritis Of The Hip,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Hip",627,2008-11-01,2010-06-01,Pfizer
NCT00754988,Phase 3,4,A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.,"A Multicenter, Randomized, Double-dummy, Placebo and Active-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Sitagliptin and Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin.",666,2008-10-01,2011-03-01,Hoffmann-La Roche
NCT00763451,Phase 3,4,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 in Two Titration Regimens on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin",484,2008-09-01,2011-01-01,Sanofi
NCT00787605,Phase 4,2,Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus,An 8-week Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to Amlodipine (10 mg) in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus,860,2008-11-01,2010-01-01,Novartis
NCT00797316,Phase 4,2,Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension,"An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Forced-titration Study to Evaluate the Efficacy and Safety of Aliskiren Plus HCTZ Compared to Aliskiren Monotherapy in Metabolic Syndrome Patients With Stage 2 Hypertension",532,2008-11-01,2009-12-01,Novartis
NCT00819104,Phase 4,5,"A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components","A Five-arm, Randomised, Open Label, Multi-centre, Prospective Study to Compare the Efficacy, Safety and Tolerability of Metoprolol XL Plus Amlodipine Combination (Selomax TM) With Metoprolol XL and Amlodipine as Individual Components in Management of Hypertension in Indian Patients.",402,2008-11-01,2009-08-01,AstraZeneca
NCT00853385,Phase 3,5,"A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis","Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate",717,2009-05-01,2011-03-01,Pfizer
NCT00859898,Phase 3,3,Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes,"A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin 10 mg Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control",1093,2009-04-01,2010-05-01,AstraZeneca
NCT00912964,Phase 3,3,A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,"A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder",2030,2009-04-28,2010-04-27,Astellas Pharma Inc
NCT00968812,Phase 3,3,CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride,"A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy",1452,2009-09-01,2013-01-01,"Janssen Research & Development, LLC"
NCT00996281,Phase 3,2,Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension,"A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension",837,2009-10-01,2011-11-01,Takeda
NCT01001494,Phase 3,3,Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients,Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),828,2009-10-01,2010-11-01,AstraZeneca
NCT01045707,Phase 3,2,"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes",NN5401-3590: A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™ : START 1) / NN5401-3726: An Extension Trial Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subjects With Type 2 Diabetes (BOOST™: START 1),530,2010-01-01,2010-10-01,Novo Nordisk A/S
NCT01071122,Phase 4,3,FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry),"A Prospective, Open-label, Active-controlled, Randomized Study Comparing Nifedipine GITS Versus Valsartan Versus a Combination of Both on Central Blood Pressure in Inadequately Controlled Essential Hypertension.",365,2010-01-01,2012-02-01,Bayer
NCT01076647,Phase 3,2,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,"A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)",467,2010-03-01,2010-12-01,Novo Nordisk A/S
NCT01106534,Phase 4,2,XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort,XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT),870,2009-08-01,2015-07-01,Abbott Vascular
NCT01119859,Phase 4,2,A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis,"A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis",326,2010-05-01,2012-01-01,Hoffmann-La Roche
NCT01120717,Phase 3,2,A Study to Assess the Long-term Safety of QVA149,"A Multicener, Randomised, Double-blind, Placebo-controlled Study, to Assess the Long Term Safety of 52 Weeks Treatment With QVA149 (110 ug Indacaterol/50ug Glycopyrrolate) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",339,2010-04-01,2011-12-01,Novartis
NCT01165138,Phase 3,3,Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,"HZA106827: A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Parallel Group Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder Alone in the Treatment of Persistent Asthma in Adults and Adolescents",612,2010-08-20,2011-10-19,GlaxoSmithKline
NCT01181102,Phase 3,2,"A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty","A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS E-3 Trial)",716,2009-03-01,2010-02-01,"Daiichi Sankyo, Inc."
NCT01208207,Phase 3,4,A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108),"A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis",1015,2010-09-01,2014-11-01,Merck Sharp & Dohme Corp.
NCT01264939,Phase 3,2,"A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists","A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists",336,2011-02-01,2012-11-01,"Genentech, Inc."
NCT01302054,Phase 4,2,"A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.",A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multicentre Study Of Fesoterodine 8 Mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4 Mg Extended Release (ER).,990,2011-05-01,2012-05-01,Pfizer
NCT01321255,Phase 3,2,Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.,Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug,2118,2012-01-01,2014-06-01,Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
NCT01397890,Phase 4,2,Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD),"A Randomised, Parallel-group, Open-label, Multicentre, 3-month Phase IV, Efficacy and Tolerability Study of Budesonide/Formoterol (Symbicort® Turbuhaler® 160/4.5μg/Inhalation, 2 Inhalations Twice Daily) Added to Tiotropium (SpirivaTM 18 μg/Inhalation, 1 Inhalation Once Daily) Compared With Tiotropium (SpirivaTM18 μg/Inhalation, 1 Inhalation Once Daily) Alone in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients",793,2011-07-01,2013-06-01,AstraZeneca
NCT01413958,Phase 3,2,Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1),"A Randomized, Placebo-Controlled Trial to Evaluate the Effects of Phenylephrine HCl 30 mg Extended-Release Tablets on Nasal Congestion in Subjects With Allergic Rhinitis",575,2011-08-01,2011-10-01,Bayer
NCT01415518,Phase 4,2,Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients,"Efficacy and Tolerability Study of Symbicort Turbuhaler(160/4.5µg/Inhalation,2inhalations Twice Daily) Added to Atrovent (20µg/Inhalation, 2 Inhalations 4 Times Daily)+Theophylline SR(0.1g/Tablet,1 Tablet p.o. Twice Daily) Compared With Atrovent+Theophylline SR in Severe COPD Patients.",581,2011-09-01,2012-12-01,AstraZeneca
NCT01430260,Phase 4,3,Omnaris Versus Levocetirizine Phase 4 Study,"A Multi-center, Open, Randomized, Three-arm, Parallel-group, Phase IV Study to Compare the Efficacy of Ciclesonide Nasal Spray and Levocetirizine, Alone and in Combination for the Patient With Allergic Rhinitis",349,2011-01-01,2012-07-01,"Handok Pharmaceuticals Co., Ltd."
NCT01431287,Phase 3,5,Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),"A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD) [TOnado TM 2]",2539,2011-09-01,2013-11-01,Boehringer Ingelheim
NCT01472757,Phase 2/Phase 3,4,Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma,"A Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of VR506 Inhaled From a New Inhaler in Adolescent and Adult Subjects With Asthma",374,2011-10-01,2013-05-01,Vectura Limited
NCT01500278,Phase 4,4,Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate,"A Multicenter, Single-blind, Randomized Parallel-group Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis Responding Inadequately to Methotrexate",915,2011-12-01,2016-01-01,UCB Pharma
NCT01525290,Phase 3,2,Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke,"Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke: a Randomised, Double-blind, Placebo-controlled Trial",501,2012-09-01,2018-05-01,Universitätsklinikum Hamburg-Eppendorf
NCT01618162,Phase 3,2,The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy,The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy,435,2012-08-29,2013-10-23,Novo Nordisk A/S
NCT01632163,Phase 3,2,Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin,"A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Metformin",447,2012-10-01,2015-05-01,Sanofi
NCT01661634,Phase 3,2,Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure,"Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure [TRUE-AHF]",2157,2012-07-01,2016-03-01,Cardiorentis
NCT01668667,Phase 4,4,Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome Post Marketing Commitment Study,"A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)",501,2012-06-01,NA,"XenoPort, Inc."
NCT01674647,Phase 3,2,Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion,"A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion",1504,2012-10-01,2014-01-01,Bayer
NCT01696110,Phase 4,3,BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.,Bivalirudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin Undergoing Angioplasty (BRIGHT):a Randomised Controlled Trial,2194,2012-08-01,2014-07-01,Shenyang Northern Hospital
NCT01709864,Phase 3,2,NVA237 Versus Placebo 12-week Efficacy Study,"A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients",440,2012-11-01,2013-10-01,Novartis
NCT01709903,Phase 3,2,"A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149","A 26-week Treatment Randomized, Double-blind, Double Dummy, Parallel-group Study to Assess the Efficacy and Safety of QVA149 (Indacaterol / Glycopyrronium Bromide) Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe COPD",744,2012-11-01,2014-02-01,Novartis
NCT01767519,Phase 3,3,A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,NA,356,2013-03-01,2015-03-01,Allergan
NCT01769378,Phase 3,2,Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8),"A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8)",300,2013-01-01,2014-12-01,Eli Lilly and Company
NCT01778049,Phase 3,8,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,"A Phase III, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Linagliptin 5 mg Compared to Placebo, Administered as Oral Fixed Dose Combination With Empagliflozin 10 mg or 25 mg for 24 Weeks, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks of Treatment With Empagliflozin 10 mg or 25 mg on Metformin Background Therapy",708,2013-01-01,2015-03-01,Boehringer Ingelheim
NCT01817764,Phase 3,2,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"DB2114930: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD",707,2013-03-01,2013-10-25,GlaxoSmithKline
NCT01849289,Phase 3,2,A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes,A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes (BEGIN™: ONCE),833,2013-06-02,2014-05-15,Novo Nordisk A/S
NCT01946620,Phase 3,3,A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD,"A Randomised, Double-blind, Double Dummy, Parallel Group Study Comparing Fluticasone Propionate / Formoterol Fumarate (Flutiform®) 250/10 µg (2 Puffs BID) and Flutiform® 125/5 µg (2 Puffs BID) Versus Formoterol Fumarate Dihydrate (Atimos®) 12 µg (1 Puff BID) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).",1767,2013-10-01,2016-05-01,Mundipharma Research Limited
NCT01964352,Phase 3,4,Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1),"A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",813,2013-11-01,2014-11-01,Boehringer Ingelheim
NCT01999218,Phase 3,3,Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002),"A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin",1326,2013-12-16,2017-04-18,Merck Sharp & Dohme Corp.
NCT02014467,Phase 3,2,Denosumab China Phase III Study,"A Twelve-Month Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Denosumab in Chinese Postmenopausal Women With Osteoporosis at Increased Risk of Fracture",486,2014-01-01,2015-08-01,GlaxoSmithKline
NCT02064439,Phase 3,3,Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism),Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism,3365,2014-03-05,2016-11-04,Bayer
NCT02094963,Phase 4,2,Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management,"A Randomized, Open-label, Parallel Group, Multicenter Phase IV Study to Assess Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management:TICAKOREA Trial",800,2014-07-05,2020-06-01,Asan Medical Center
NCT02100228,Phase 4,2,"Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)",A Phase IV Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-Valvular Atrial Fibrillation Undergoing Cardioversion,1500,2014-07-01,2017-02-01,Pfizer
NCT02105974,Phase 3,2,Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD),A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared With Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),1621,2014-04-07,2015-07-08,GlaxoSmithKline
NCT02145468,Phase 3,2,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP Kinase as a TherapeUtic Target and moDify Outcomes After an Acute Coronary syndromE (LATITUDE)-TIMI 60.,3503,2014-06-03,2015-12-14,GlaxoSmithKline
NCT02152371,Phase 3,2,A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes,"A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg With Placebo on Glycemic Control in Patients With Type 2 Diabetes on Basal Insulin Glargine",300,2014-05-01,2015-10-01,Eli Lilly and Company
NCT02175771,Phase 3,8,Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma,A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma,758,2014-07-01,2015-07-01,Teva Pharmaceutical Industries
NCT02200653,Phase 4,4,A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM),"A Prospective, Randomised, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDIS® (Telmisartan) (40 or 80 mg p.o. Once Daily) and COZAAR® / LORZAAR® (Losartan) (50 or 100 mg p.o. Once Daily) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (TOPAS STUDY = Telmisartan and LOsartan ComParative ABPM Study)",387,2000-05-01,NA,Boehringer Ingelheim
NCT02205606,Phase 3,6,Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia,"A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1306 Tablet in Patients With Primary Hypercholesterolemia",412,2014-06-01,2015-04-01,Hanmi Pharmaceutical Company Limited
NCT02294227,Phase 3,3,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis","A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)",341,2015-05-29,2017-12-25,Novartis
NCT02463071,Phase 3,3,AZD0585 Phase III Long-term Study in Japan,"A Randomised, Double-blind, Placebo Controlled, Parallel Group, Phase III Long-term Study to Evaluate Efficacy and Safety of 12 Weeks and 52 Weeks of AZD0585 Administration, Respectively, in Japanese Patients With Hyperlipidemia Accompanied by Hypertriglyceridemia.",886,2015-06-10,2017-03-11,AstraZeneca
NCT02498509,Phase 3,3,Clinical Trial to Evaluate the Efficacy and Safety of CKD-342,"A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Concomitant Mometasone Furoate and Levocabastine HCl in Perennial Allergic Rhinitis Patients",459,2015-05-01,2016-05-01,Chong Kun Dang Pharmaceutical
NCT02504268,Phase 3,4,Effects of Abatacept in Patients With Early Rheumatoid Arthritis,"A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive",1490,2015-08-31,2020-03-20,Bristol-Myers Squibb
NCT02580591,Phase 3,4,Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3),"A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-3)",977,2015-10-12,2017-09-20,Boehringer Ingelheim
NCT00000558,Phase 3,NA,Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE),NA,NA,1995-11-01,2005-06-01,"National Heart, Lung, and Blood Institute (NHLBI)"
NCT00035984,Phase 3,4,Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus,"A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Twice Daily in Subjects With Type 2 Diabetes Mellitus Treated With Metformin and a Sulfonylurea",734,2002-05-01,2003-08-01,AstraZeneca
NCT00048932,Phase 3,3,A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis,NA,1795,2002-12-01,2009-10-01,Bristol-Myers Squibb
NCT00051558,Phase 3,2,Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis,Comparison of the Effects of Teriparatide With Those of Alendronate Sodium on Lumbar Spine Bone Mineral Density in Glucocorticoid-Induced Osteoporosis,428,2002-11-01,2008-01-01,Eli Lilly and Company
NCT00071721,Phase 3,2,Valproate in Dementia (VALID),"A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)",313,2003-10-01,2009-12-01,Alzheimer's Disease Cooperative Study (ADCS)
NCT00092014,Phase 3,2,A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211),"A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis",1053,2002-09-01,2004-04-01,Merck Sharp & Dohme Corp.
NCT00092209,Phase 3,NA,Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302),"A Randomized, Placebo-Controlled, Double-Blind, Parallel Study of the Anti-Hypertensive Efficacy and Safety of Losartan Monotherapy as Compared to HCTZ Monotherapy and to the Combination of Losartan and HCTZ in Japanese Patients With Essential Hypertension",840,2002-04-01,2002-11-01,Merck Sharp & Dohme Corp.
NCT00092716,Phase 3,NA,Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025),"A Multicenter, Double-Blind, Randomized, Parallel Group, 28-Week Study to Evaluate the Efficacy and Safety of Ezetimibe and Simvastatin Co-administration Versus Atorvastatin in Patients With Hypercholesteremia",655,2002-05-01,2003-04-01,Merck Sharp & Dohme Corp.
NCT00099918,Phase 3,NA,Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes,Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes,717,2004-05-01,2005-09-01,Novartis
NCT00102882,Phase 4,NA,Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate,"Randomized, Double-Blind Comparison of Advair 100/50 BID vs Salmeterol BID vs Albuterol QID in Subjects With ARG/ARG Genotype 12 Years of Age and Older With Presistent Asthma on Short-Acting Beta2-Agonists Alone",547,2004-10-01,2007-01-01,GlaxoSmithKline
NCT00115492,Phase 4,NA,Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations,"A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50mcg BID With Salmeterol Diskus 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease",797,2004-12-01,2007-06-01,GlaxoSmithKline
NCT00134160,Phase 4,2,OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study,The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk,1000,2005-08-01,2010-05-01,OSCAR Study
NCT00135993,Phase 3,NA,Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome",811,2005-05-01,2006-11-01,UCB Pharma
NCT00138619,Phase 3,NA,Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes,Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes,478,2004-11-01,2007-04-01,Novartis
NCT00168779,Phase 4,NA,"Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension","A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.",1185,2005-09-01,2006-07-01,Boehringer Ingelheim
NCT00170989,Phase 3,NA,Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone,Comparison of the Combination of Valsartan 320 mg Plus Hydrochlorothiazide 12.5 mg and Valsartan 320 mg Plus Hydrochlorothiazide 25 mg to Valsartan 320 mg in Mild to Moderate Hypertensive Patients Not Adequately Controlled With Valsartan 320 mg,2714,2004-09-01,2005-07-01,Novartis
NCT00171275,Phase 4,NA,Fluvastatin in the Therapy of Acute Coronary Syndrome,Fluvastatin in the Therapy of Acute Coronary Syndrome,1000,2003-11-01,NA,Novartis
NCT00174993,Phase 3,2,Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes,PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy,4373,2001-05-01,2005-01-01,Takeda
NCT00191282,Phase 4,2,Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes,Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D),1116,2002-10-01,2007-10-01,Eli Lilly and Company
NCT00202566,Phase 3,NA,Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris,"Evaluation of the Anti-anginal Efficacy and Safety of Oral Administration of Ivabradine Compared to Placebo on Top of Background Therapy With Atenolol in Patients With Stable Angina Pectoris. A Four-month Randomised Double-blind, Parallel Group International Multicentre Study.",750,2005-06-01,2007-10-01,Servier
NCT00222573,Phase 4,NA,Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction,Clopidogrel Or Metoprolol in Myocardial Infarction Trial,46000,1999-07-01,2005-02-01,University of Oxford
NCT00236665,Phase 3,NA,A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension",531,2001-03-01,2002-06-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00242294,Phase 2/Phase 3,NA,Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06),A Confirmatory Study of APTA-2217 in Patients With Chronic Obstructive Pulmonary Disease (A Placebo-controlled Double-blind Comparative Study),570,2004-11-01,2007-03-01,AstraZeneca
NCT00242944,Phase 4,2,Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS),Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome,307,2005-11-01,2008-03-01,Kyoto University
NCT00249873,Phase 3,2,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A),"A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation",7554,2003-06-01,2009-03-01,Sanofi
NCT00260923,Phase 3,NA,A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing an Eight-week Treatment of Aliskiren 75 mg, 150 mg and 300 mg to Placebo in Patients With Essential Hypertension",641,2005-11-01,2006-11-01,Novartis
NCT00265096,Phase 3,3,A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously in Subjects With Active Psoriatic Arthritis",407,2005-12-01,2012-01-01,"Centocor, Inc."
NCT00267176,Phase 4,NA,Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension,"A 4-week, Multicentre, Randomized, Double-blind, Double-dummy, Parallel Group Ambulatory Blood Pressure Monitoring Study to Investigate Whether Treatment With Lumiracoxib 100 mg Once Daily Results in an Improved 24-hour Blood Pressure Profile Compared to Ibuprofen 600 mg Three Times a Day in Osteoarthritis Patients With Controlled Hypertension",1020,2005-11-01,NA,Novartis
NCT00268216,Phase 3,NA,Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD),"A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease (COPD) Over 3 Years of Treatment",6228,2000-09-01,2005-11-01,GlaxoSmithKline
NCT00271557,Phase 3,NA,A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels,"A Randomized, Open-Label, Active-Controlled, Multicenter Phase III Safety Study of Two Doses of NATRECOR hBNP (Nesiritide) Administered as a Continuous Infusion in the Treatment of Decompensated CHF",305,1997-01-01,1997-12-01,"Scios, Inc."
NCT00274573,Phase 3,NA,Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity,Acute and Long-term Effects of Once Daily Oral Inhalation of Tiotropium 18 Mcg Dry Powder Inhalation Capsules in a Placebo Controlled Parallel Group Design Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity,1639,2002-03-01,NA,Boehringer Ingelheim
NCT00274638,Phase 4,NA,PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM),"A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group 6-week Treatment Study Comparing Telmisartan Combined With Hydrochlorothiazide (40 mg/12.5 mg or 80 mg/12.5 mg) Tablets With Losartan Combined With Hydrochlorothiazide (50 mg/12.5 mg) Tablets Using Ambulatory Blood Pressure Monitoring in Patients With Mild-to-Moderate Hypertension",805,2002-07-01,NA,Boehringer Ingelheim
NCT00296387,Phase 3,NA,Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome,Comparison of the Effects Noted in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With acUte Coronary Syndrome - CENTAURUS,1160,2006-01-01,2007-10-01,AstraZeneca
NCT00296491,Phase 4,4,Study Of Allergic Rhinitis In Patients Who Also Have Asthma,"A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID",725,2005-09-01,2007-10-01,GlaxoSmithKline
NCT00297063,Phase 3,NA,BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-,Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus (Monotherapy) - Double-Blind Comparative Study of Rosiglitazone Maleate vs. Pioglitazone Hydrochloride and Placebo -,350,2006-01-01,2007-05-01,GlaxoSmithKline
NCT00306696,Phase 4,NA,Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.,A Randomised Study Examining the Effect of Different Diuretics on Fluid Balance in Diabetics Treated With Avandia,388,2002-10-01,2004-01-01,GlaxoSmithKline
NCT00311740,Phase 3,NA,A Study of VAH631 in Patients With Essential Hypertension (Factorial Study),"A Multi-center, Factorial Study to Evaluate Efficacy & Safety of 8 Wks Treatment With VAH631 [Valsartan (40 & 80 mg) and Hydrochlorothiazide (6.25 & 12.5 mg) Combined & Alone in Essential Hypertensive Patients] - Double-blind Study of VAH631 in Patients With Essential Hypertension (Factorial Study)",582,2006-03-01,2006-09-01,Novartis
NCT00319995,Phase 3,NA,Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED),Efficacy and Safety of Combination Loratadine/Montelukast QD vs Pseudoephedrine and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis,1095,2006-03-01,2006-06-28,Merck Sharp & Dohme Corp.
NCT00325442,Phase 3,2,FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH),"A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects With Pulmonary Arterial Hypertension",354,2006-10-01,2010-12-01,United Therapeutics
NCT00330460,Phase 3,2,"A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.","A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Denisty",1189,2006-05-01,2008-01-01,Amgen
NCT00335166,Phase 3,3,SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease,"A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.",330,2006-11-01,2008-02-01,Solvay Pharmaceuticals
NCT00343551,Phase 3,2,Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.,"A Nine-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg Compared to Irbesartan 300 mg and Ramipril 10 mg in the Setting of a Missed Dose in Patients With Essential Hypertension",654,2006-05-01,NA,Novartis
NCT00347100,Phase 4,2,Insulin Glargine in Type 2 Diabetic Patients,Treatment of Early Insulinization With Glargine in Type 2 Diabetes Patients Uncontrolled on Sulfonylurea or Metformin Monotherapy,387,2006-06-01,NA,Sanofi
NCT00361959,Phase 4,NA,SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease,"Multicentre, Randomised, Double-Blind, Double Dummy, Parallel Group, 104-week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE*) 50/500mcg Delivered Twice Daily Via the DISKUS*/ACCUHALER* Inhaler With Tiotropium Bromide 18 mcg Delivered Once Daily Via the HandiHaler Inhalation Device on the Rate of Health Care Utilisation Exacerbations in Subjects With Severe Chronic Obstructive Pulmonary Disease (COPD)",1270,2003-06-01,2006-02-01,GlaxoSmithKline
NCT00368134,Phase 3,NA,To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes,"A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Compare the Effects of 12 Weeks Treatment With Vildagliptin 50 mg Bid to Voglibose 0.2 mg Tid in Patients With Type 2 Diabetes",370,2006-08-01,NA,Novartis
NCT00373451,Phase 4,2,Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome,"Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Abciximab And Bivalirudin in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Interventions (ISAR-REACT-4)",1721,2006-07-01,2011-07-01,Deutsches Herzzentrum Muenchen
NCT00377819,Phase 3,2,Study of Transitioning From Alendronate to Denosumab,A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women With Low Bone Mineral Density,504,2006-09-01,2008-07-01,Amgen
NCT00382096,Phase 3,4,Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes,"A Randomized, Double-blind, Active-controlled, Multicenter Study to Compare the Effect of 24 Weeks Treatment With a Fixed Combination Therapy of Vildagliptin and Metformin to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes",1179,2006-09-01,2008-06-03,Novartis
NCT00383721,Phase 3,5,Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED),"A Randomized, 26-Week, Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension, of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD",1196,2006-09-01,2010-07-01,Merck Sharp & Dohme Corp.
NCT00404820,Phase 3,2,Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis,"A Multi-center, Randomized, Open-label, Controlled, One-year Trial to Measure the Effect of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteopenia and Osteoporosis",604,2006-10-01,2008-12-01,Novartis
NCT00423319,Phase 3,2,Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3),"A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The Advance-3 Study Apixaban Dosed Orally Versus Anticoagulation With Injectable Enoxaparin to Prevent Venous Thromboembolism)",5407,2007-03-01,2009-09-01,Bristol-Myers Squibb
NCT00439647,Phase 3,2,Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis,"A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men",1199,2006-12-01,2010-10-01,Novartis
NCT00439777,Phase 3,2,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism,4833,2007-03-01,2011-12-01,Bayer
NCT00441350,Phase 3,2,Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension,Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Patients With Essential Hypertension,1004,2007-07-01,2008-05-01,Menarini Group
NCT00449930,Phase 3,2,Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049),"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control",1050,2007-03-01,2008-07-25,Merck Sharp & Dohme Corp.
NCT00567996,Phase 3,3,Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control,"A 26-week Treatment, Multi-center, Randomized, Double-blind, Double- Dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, and Safety of Indacaterol (150 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Salmeterol (50 µg b.i.d.) as an Active Control",1002,2007-11-01,NA,Novartis
NCT00589927,Phase 4,2,Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent,Comparison of Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Implantation For Long Coronary Lesions,486,2007-12-01,2010-02-01,"CardioVascular Research Foundation, Korea"
NCT00600626,Phase 3,NA,Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes,Comparison of Basal Bolus Treatment With Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes Mellitus,394,2004-01-01,2004-07-01,Novo Nordisk A/S
NCT00616772,Phase 3,2,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects With Type IIb Dyslipidemia With Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial,682,2008-02-01,2012-09-01,AbbVie
NCT00621140,Phase 3,2,Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control,"A Randomised, Double-blind, Placebo-controled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug Naive or Previously Treated (6 Weeks Washout) Type 2 Diabetic Patients With Insufficient Glycemic Control",503,2008-02-01,NA,Boehringer Ingelheim
NCT00626197,Phase 3,2,A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG),"A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus",381,2008-02-01,2013-10-01,"Genentech, Inc."
NCT00642187,Phase 3,2,New Version Pulmicort Turbuhaler USA Adults,A Placebo-controlled Comparison of the Efficacy and Safety of the Current US Version of Pulmicort (Budesonide) Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Adults Currently Treated With Inhaled Steroids.,525,2002-07-01,2004-10-01,AstraZeneca
NCT00652002,Phase 3,3,Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5,"A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5",450,2002-07-01,2004-01-01,AstraZeneca
NCT00657943,Phase 4,6,The Copenhagen Insulin and Metformin Therapy Trial,"The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial",415,2008-04-01,2012-12-01,Steno Diabetes Center
NCT00660517,Phase 3,4,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,"Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Astelin Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis",607,2007-12-01,2008-04-01,Meda Pharmaceuticals
NCT00679731,Phase 3,2,A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis,"A Phase 3, Multicenter, Randomized, Double-blind Study Comparing the Safety Efficacy of ABT-874 to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis",317,2008-04-01,2009-11-01,AbbVie
NCT00715624,Phase 3,2,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin","A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin",496,2008-07-01,2011-02-01,Sanofi
NCT00722371,Phase 3,7,MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2),"A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",1615,2008-09-05,2011-03-25,Merck Sharp & Dohme Corp.
NCT00725036,Phase 3,NA,Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 Diabetes,"A 24-month Multicentre, Open-label, Randomised, Parallel Group, Long Term Safety Trial Comparing Intensive Treatment of Pulmonary Inhaled Human Insulin With Insulin Aspart Administered s.c., Both in Combination With NPH, in Subjects With Type 1 Diabetes",305,2002-09-02,2004-12-14,Novo Nordisk A/S
NCT00765674,Phase 3,4,Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension,"An 8 Week, Double-blind, Randomized, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate to Severe Hypertension",1191,2008-09-01,2009-08-01,Novartis
NCT00813995,Phase 3,2,A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074),"A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy",395,2008-12-09,2010-08-09,Merck Sharp & Dohme Corp.
NCT00849095,Phase 3,2,Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma,As Needed Budesonide/Formoterol Combination Versus Regular Budesonide/Formoterol Combination Plus as Needed Terbutaline in Mild-Moderate Persistent Asthma,860,2009-04-01,2013-05-01,Università degli Studi di Ferrara
NCT00866658,Phase 3,2,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)","A Randomized, Double-Blind, Placebo-Controlled, 2-arm Parallel-group, Multicenter Study With a 24-Week Treatment Period Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Sulfonylurea",311,2009-03-01,2010-06-01,Sanofi
NCT00882440,Phase 3,7,A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011),"A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Different Doses of DuP 753 (MK0954)",576,1990-12-01,1992-01-01,Merck Sharp & Dohme Corp.
NCT00900731,Phase 3,2,A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD),"A 12-week Treatment, Multicenter, Randomized, Parallel-group, Blinded, Double-dummy Study to Compare the Efficacy and Safety of Indacaterol (150 µg Once Daily [od]) Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD",1598,2009-06-01,2010-03-01,Novartis
NCT00922480,Phase 3,2,Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients,"A Randomized, Double-blind, Losartan-controlled, Parallel Group Comparison Dose Titration Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan 60mg~120mg in Patients With Mild to Moderate Essential Hypertension",506,2008-12-01,2009-09-01,"Boryung Pharmaceutical Co., Ltd"
NCT00929110,Phase 3,3,"1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)","A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease",1066,2009-06-01,2011-04-01,Novartis
NCT00963469,Phase 3,3,Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240),"A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis Over a 4-Week Treatment Period-Fall 2001",1079,2001-08-01,2001-11-01,Merck Sharp & Dohme Corp.
NCT00965549,Phase 4,2,Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients,Comparison of a Basal Plus One Insulin Regimen (Insulin Glargine/Insulin Glulisine) With a Biphasic Insulin Regimen (Insulin Aspart/Insulin Aspart Protamine 30/70) in Type 2 Diabetes Patients Following Basal Insulin Optimisation,463,2009-07-01,2012-12-01,Sanofi
NCT00978627,Phase 3,2,Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes,"NN5401-3594: A 26-week, Open-labelled, Two-arm, Parallel, Randomised Trial Comparing Efficacy and Safety of NN5401 Once Daily Plus Insulin Aspart vs. Basal-bolus Treatment With Insulin Detemir Plus Insulin Aspart in Subjects With Type 1 Diabetes / NN5401-3645: An Extension Trial Comparing Safety and Efficacy of NN5401 Plus Meal-time Insulin Aspart for the Remaining Meals With Insulin Detemir Plus Meal-time Insulin Aspart in Type 1 Diabetes (BOOST™: T1)",548,2009-08-01,2010-05-01,Novo Nordisk A/S
NCT00985621,Phase 3,4,Tanezumab In Osteoarthritis Of The Hip Or Knee,"A Phase 3 Randomized, Double-Blind, Placebo- And Oxycodone-Controlled, Multicenter Study Of The Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip",600,2009-10-01,2010-12-01,Pfizer
NCT01009463,Phase 3,4,A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),HZC102871: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD),1626,2009-09-25,2011-10-31,GlaxoSmithKline
NCT01017952,Phase 3,4,A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD),1635,2009-09-25,2011-10-17,GlaxoSmithKline
NCT01033071,Phase 3,3,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.,"A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension",1071,2010-01-01,2010-11-01,Takeda
NCT01042392,Phase 4,4,Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients,Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients,506,2009-11-01,2011-01-01,Novartis
NCT01042977,Phase 3,2,Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease,"A 24-week, Multicentre, Randomised, Double-blind,Age-stratified, Placebo Controlled Phase III Study With an 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care",964,2010-03-01,2012-12-01,AstraZeneca
NCT01061671,Phase 3,2,Simvastatin Therapy for Moderate and Severe COPD,Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE),885,2010-03-01,2014-01-01,University of Minnesota - Clinical and Translational Science Institute
NCT01079130,Phase 3,6,Efficacy and Safety of Different Doses of Indacaterol,"A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Different Doses of Indacaterol in Adult Patients With Persistent Asthma, Using Salmeterol as an Active Control",511,2010-02-01,NA,Novartis
NCT01098539,Phase 3,2,A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.,"A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Renal Impairment",507,2010-05-01,2012-11-01,GlaxoSmithKline
NCT01167153,Phase 4,2,Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients,"A 12 Weeks, Multi-center, Open Label, Randomized, Active Drug Parallel Control Trial to Compare the Effectiveness of Valsartan/Amlodipine and Nifedipine in Treating Chinese Hypertensive Patients Not Respond to Mono Antihypertensive Treatment",564,2010-05-01,2011-04-01,Novartis
NCT01233622,Phase 3,2,Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride,"A Multi-center, Randomized, Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin 50 mg Bid as add-on Therapy to Metformin Plus Glimepiride in Patients With Type 2 Diabetes",317,2010-10-01,2011-11-01,Novartis
NCT01237223,Phase 3,6,Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension,"An 8-week Double-blind, Multicenter, Randomized, 6-arm, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in Patients With Essential Hypertension",1342,2010-10-01,2011-05-01,Novartis
NCT01243424,Phase 3,2,CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes,"A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.",6072,2010-10-26,2019-03-01,Boehringer Ingelheim
NCT01287039,Phase 3,2,A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma,"A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma",489,2011-04-01,2014-03-01,Teva Pharmaceutical Industries
NCT01294592,Phase 4,2,Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement,Comparative Efficacy of Dutasteride Plus Tamulsoin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice With Step-up Therapy to Tamsulosin in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement.,742,2010-12-01,2013-10-01,GlaxoSmithKline
NCT01316900,Phase 3,4,24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease,A Multicenter Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GW642444 and With Tiotropium Over 24 Weeks in Subjects With COPD,846,2011-03-01,2012-04-24,GlaxoSmithKline
NCT01345253,Phase 3,2,GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia,GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia,709,2011-05-23,2018-09-28,GlaxoSmithKline
NCT01357642,Phase 3,3,Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients,"Epinephrine Inhalation Aerosol USP, an HFA-MDI: Clinical Study-C For Evaluation Of Efficacy And Safety In Asthma Patients",373,2011-07-01,2011-12-01,"Amphastar Pharmaceuticals, Inc."
NCT01377012,Phase 3,3,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents","A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents (CAIN457F2302) and a Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis (CAIN457F2302E1)",637,2011-08-30,2015-09-09,Novartis
NCT01431274,Phase 3,5,Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),"A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD). [TOnado TM 1]",2624,2011-09-01,2013-09-01,Boehringer Ingelheim
NCT01436110,Phase 3,3,Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma,"A Randomised, Double-blind, Double-dummy, Placebo Controlled Multi-centre Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Inhalation Powder and Fluticasone Propionate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents Not Currently Treated With Inhaled Corticosteroids",351,2011-09-01,2012-09-01,GlaxoSmithKline
NCT01498653,Phase 3,2,Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry,"A Randomised, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily Compared to Fluticasone Propionate Delivered Twice Daily in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With High-strength Inhaled Corticosteroids or Mid-strength ICS/LABA Combination Therapy.",313,2012-01-01,2013-02-01,GlaxoSmithKline
NCT01502774,Phase 3,2,Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients,Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients,970,2011-04-01,2015-02-01,Hospices Civils de Lyon
NCT01508936,Phase 3,2,Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma,"A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma",511,2012-02-01,2013-08-01,Teva Pharmaceutical Industries
NCT01510769,Phase 3,3,Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat,"A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum Uric Acid and Resolving Tophi in Subjects With Tophaceous Gout",330,2012-01-01,2014-06-01,"Ardea Biosciences, Inc."
NCT01519674,Phase 4,3,Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin,"A 24 Week Randomised, Open Label, 3 Parallel-group Comparison of Once and Twice Daily Biphasic Insulin Aspart (BIAsp) 30 Plus Sitagliptin and Twice Daily BIAsp 30, All in Combination With Metformin in Insulin naïve Type 2 Diabetic Subjects Inadequately Controlled on Sitagliptin and Metformin",582,2012-06-01,2013-10-01,Novo Nordisk A/S
NCT01519791,Phase 3,2,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis","A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis",880,2012-01-01,2015-09-01,UCB Pharma
NCT01524289,Phase 3,2,Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020),"A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia",306,2012-02-03,2018-10-20,Merck Sharp & Dohme Corp.
NCT01525615,Phase 3,3,A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD,"A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Effect of 12 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 µg and 5/5 µg) Delivered by the Respimat® Inhaler, on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD)[Torracto (TM)]",404,2012-02-01,2013-09-01,Boehringer Ingelheim
NCT01555164,Phase 3,2,A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects With Type 2 Diabetes Mellitus",442,2012-06-01,2013-10-01,Gilead Sciences
NCT01648582,Phase 3,3,A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus,"The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea",774,2012-07-01,2014-12-01,Eli Lilly and Company
NCT01695239,Phase 3,4,A Study of Ixekizumab in Participants With Active Psoriatic Arthritis,"A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis",417,2012-12-01,2017-09-01,Eli Lilly and Company
NCT01703221,Phase 3,3,Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020),"A Phase III, Multicenter, Randomized, Placebo- and Sitagliptin-controlled, Parallel-group, Double-blinded Study and Subsequent Open-label, Extension Study to Assess the Safety and Efficacy of MK-3102 in Japanese Patients With Type 2 Diabetes Mellitis Who Have Inadequate Glycemic Control on Diet/Exercise Therapy",414,2012-10-24,2014-04-25,Merck Sharp & Dohme Corp.
NCT01709110,Phase 4,2,VERtebral Fracture Treatment Comparisons in Osteoporotic Women,Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures,1366,2012-10-01,2016-07-01,Eli Lilly and Company
NCT01710358,Phase 3,3,A Study in Moderate to Severe Rheumatoid Arthritis,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy",1307,2012-10-01,2015-09-01,Eli Lilly and Company
NCT01720446,Phase 3,4,Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes,"A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)",3297,2013-02-21,2016-03-15,Novo Nordisk A/S
NCT01752634,Phase 3,4,"Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis","A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis",399,2013-04-01,2019-01-01,Novartis
NCT01813435,Phase 3,2,GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation,Comparative Effectiveness of 1 Month of Ticagrelor Plus Aspirin Followed by Ticagrelor Monotherapy Versus a Current-day Intensive Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Intervention With Bivalirudin and BioMatrix Family Drug-eluting Stent Use,16000,2013-05-01,2018-05-01,ECRI bv
NCT01876368,Phase 3,2,Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan,"A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan",376,2013-09-01,2014-08-01,Novartis
NCT01959529,Phase 3,2,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,7637,2013-10-29,2016-10-16,Novo Nordisk A/S
NCT01991795,Phase 3,2,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study)",19349,2012-01-18,2018-11-26,AstraZeneca
NCT01994226,Phase 4,2,Colchicine Or Naproxen Treatment for ACute gouT,"Multi-centre, Open-label, Active-comparator, Pragmatic Clinical Trial of Low-dose Colchicine Versus Naproxen in Patients With Acute Gout.",399,2014-01-01,2016-03-01,Keele University
NCT02019472,Phase 3,3,A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis,"A Multicenter, Randomized, Double-blind, Parallel Group Study of Sirukumab Monotherapy Compared With HUMIRA® Monotherapy Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis",559,2014-04-04,2016-08-17,"Janssen Research & Development, LLC"
NCT02119286,Phase 3,3,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2","A Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2",620,2013-10-01,2014-04-01,GlaxoSmithKline
NCT02155660,Phase 3,4,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,"A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations.",2255,2014-06-25,2018-04-09,AstraZeneca
NCT02243176,Phase 4,2,"24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy","SMART Study - A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With Type 2 Diabetes Mellitus (T2D) Inadequately Controlled With Metformin Monotherapy",689,2014-09-01,2015-09-01,AstraZeneca
NCT02294279,Phase 4,2,The Evaluation of FeNO for Predicting Response to ICS in Subjects With Non-specific Respiratory Symptoms,The Evaluation of FeNO for Predicting Response to an Inhaled Corticosteroid in Subjects With Non-specific Respiratory Symptoms,360,2014-05-01,2016-08-01,Research in Real-Life Ltd
NCT02301975,Phase 3,3,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma","A Randomized, Double-blind, Double-dummy, Parallel Group, Multicenter Study of Once Daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, Twice Daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Twice Daily Fluticasone Propionate 250 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents Already Adequately Controlled on Twice-daily Inhaled Corticosteroid and Long-acting beta2 Agonist",1526,2015-03-01,2016-11-25,GlaxoSmithKline
NCT02346240,Phase 3,4,Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO),"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis",559,2015-02-11,2018-12-03,UCB Pharma
NCT02384941,Phase 3,3,"Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy","A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy",793,2015-03-01,2017-02-01,Sanofi
NCT02414854,Phase 3,4,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),"A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma",1902,2015-04-27,2017-11-23,Sanofi
NCT02467920,Phase 4,2,Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM,"Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Switching Premix Human Insulin to Aspart30 in T2DM With Inadequate Glycaemic Control on Premixed Human Insulin and Metformin: a Randomized, Open, Parallel Trial",349,2015-08-01,2017-12-01,Huazhong University of Science and Technology
NCT02501161,Phase 3,2,A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus,A Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus,1000,2016-01-08,2018-10-03,Novo Nordisk A/S
NCT02630706,Phase 3,3,A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Monotherapy",506,2015-12-16,2017-12-27,Merck Sharp & Dohme Corp.
NCT02675426,Phase 3,4,A Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone,"A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs",662,2015-12-17,2020-08-06,AbbVie
NCT02849080,Phase 3,2,Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.,Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus,500,2016-09-20,2019-03-31,Novo Nordisk A/S
NCT00000614,Phase 3,NA,Prevention of Recurrent Venous Thromboembolism (PREVENT),NA,NA,1998-09-01,2004-08-01,"National Heart, Lung, and Blood Institute (NHLBI)"
NCT00041938,Phase 3,2,Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial,Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial,2305,2002-10-01,2014-07-01,Columbia University
NCT00086515,Phase 3,2,Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED),"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy",701,2004-06-30,2007-02-02,Merck Sharp & Dohme Corp.
NCT00092586,Phase 3,NA,Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040),"A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/Day When Added to Ongoing Therapy With a Statin Versus Statin Therapy Alone, in Patients With Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol Level",2904,2002-09-01,2003-10-01,Merck Sharp & Dohme Corp.
NCT00093158,Phase 3,NA,Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS),The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation,13800,2003-08-01,2007-01-01,The Medicines Company
NCT00102440,Phase 3,3,Febuxostat Versus Allopurinol Control Trial in Subjects With Gout,"A Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout",760,2002-07-01,2004-02-01,Takeda
NCT00106535,Phase 3,3,A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA),"A Randomized, Double-blind Study of Safety and Prevention of Structural Joint Damage During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis",1196,2005-01-01,2012-07-01,Hoffmann-La Roche
NCT00117780,Phase 4,NA,Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes,Comparison of Efficacy and Safety of Insulin Detemir Once or Twice Daily in a Basal-Bolus Regimen With Insulin Aspart in Patients With Type 1 Diabetes,520,2005-06-01,2006-10-01,Novo Nordisk A/S
NCT00133198,Phase 3,NA,Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS),"A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Trial Comparing Fixed Doses of 0.25 mg, 0.50 mg and 0.75 mg Pramipexole (Mirapex®) Administered Orally to Investigate the Safety and Efficacy in Patients With Idiopathic Restless Legs Syndrome for 12 Weeks",345,2004-04-01,2005-02-01,Boehringer Ingelheim
NCT00133250,Phase 4,2,Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3),Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3),800,2003-06-01,2008-03-01,Deutsches Herzzentrum Muenchen
NCT00138541,Phase 3,NA,Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes,Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes,440,2004-10-01,2006-04-01,Novartis
NCT00141102,Phase 4,2,Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis,"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events",4484,2005-10-01,2009-05-01,Pfizer
NCT00184561,Phase 4,NA,Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes,Change in HbA1c With Biphasic Insulin Aspart 70/30 in Two Different Treatment Regiments in Subjects With Type 2 Diabetes Inadequately Controlled With Oral Anti-diabetic Drug Therapy.,321,2005-07-01,2006-07-01,Novo Nordisk A/S
NCT00207766,Phase 3,NA,A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease,"ACCENT II - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long Term Treatment of Patients With Fistulizing CROHN'S Disease",306,2000-06-01,2006-08-01,"Centocor, Inc."
NCT00220220,Phase 3,NA,Amlodipine as Add-on to Olmesartan in Hypertension,Efficacy and Safety of Amlodipine Used as Add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy,429,2005-04-01,2007-04-01,"Daiichi Sankyo, Inc."
NCT00221104,Phase 3,2,Japan Statin Treatment Against Recurrent Stroke (J-STARS),Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke,1578,2004-03-01,NA,"Translational Research Informatics Center, Kobe, Hyogo, Japan"
NCT00231556,Phase 3,NA,A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy,"A Randomized, Double-Blind, Parallel-Group, Monotherapy Study to Compare the Safety and Efficacy of Two Doses of Topiramate in the Treatment of Newly Diagnosed or Recurrent Epilepsy",750,1999-07-01,2003-09-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00237237,Phase 3,NA,Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes,Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes,588,2005-10-01,NA,Novartis
NCT00264537,Phase 3,4,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,"A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Methotrexate-naive Subjects With Active Rheumatoid Arthritis",637,2005-12-01,2012-06-01,"Centocor, Inc."
NCT00265083,Phase 3,3,A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalpha MonoclonalAntibody, Administered Subcutaneously, in Subjects With Active Ankylosing Spondylitis",356,2005-12-01,2012-01-01,"Centocor, Inc."
NCT00269893,Phase 3,3,"A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty","A Phase III Double-Blind, Placebo-Controlled Multicenter Study of Abciximab In Patients Undergoing High Risk Coronary Angioplasty (EPIC)",2038,1991-11-01,1992-11-01,"Centocor, Inc."
NCT00286468,Phase 3,3,Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With a Sulfonylurea in Subjects With Type 2 Diabetes",500,2006-04-01,2007-06-01,Takeda
NCT00287716,Phase 3,3,Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis,"A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis",435,2006-07-14,2008-11-10,"Genentech, Inc."
NCT00311363,Phase 3,2,"Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.",A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome.,327,2006-04-01,2007-11-01,"XenoPort, Inc."
NCT00359905,Phase 3,3,Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH,"Evaluation of the Efficacy and Safety of Silodosin vs. Tamsulosin and Placebo in the Treatment of the Signs and Symptoms of BPH. Multicentre, Randomised, Double-Blind, Controlled Trial With an Optional Long-Term, Open-Label Extension Phase.",1228,2006-05-01,2008-01-01,Recordati Industria Chimica e Farmaceutica S.p.A.
NCT00379288,Phase 3,4,Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139),A 1-Year Safety Study of Medium and High Doses of Mometasone Furoate/Formoterol Combination Formulation and Medium and High Doses of Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Medium to High Doses of Inhaled Glucocorticosteroids,404,2006-06-01,2007-11-01,Merck Sharp & Dohme Corp.
NCT00397657,Phase 4,2,Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis,ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS),400,2006-11-01,2009-10-01,Walter Reed Army Medical Center
NCT00399464,Phase 3,NA,Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia,Efficacy and Safety of SL77.0499-10 10mg Once Daily in Comparison With Placebo and Tamsulosin Hydrochloride 0.2mg in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia (BPH).,1177,2006-11-01,2007-10-01,Sanofi
NCT00413049,Phase 3,2,Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension,"A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Amlodipine 5 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Amlodipine 5 mg Monotherapy",698,2007-01-01,2007-11-01,Novartis
NCT00447915,Phase 3,3,Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis,Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis - Comparative Study With Sodium Risedronate Hydrate(RIS) With Vertebral Fracture as an Index -,1265,2007-03-01,2011-12-01,Chugai Pharmaceutical
NCT00451360,Phase 3,NA,Chondromodulating Effect of Diacerein in Osteoarthritis of the Hip,Evaluation of the CHOndromodulating Effect of DIAcerein in Osteoarthritis of the Hip. ECHODIAH.,500,1993-03-01,1997-04-01,Laboratoires NEGMA
NCT00453063,Phase 3,2,Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED),Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis,426,2007-03-01,2007-06-01,Merck Sharp & Dohme Corp.
NCT00504127,Phase 3,4,Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee,"A Phase 3, 53 Weeks Study on Analgesic Efficacy and Safety of Naproxcinod (HCT 3012): 26-Week, Randomized, Parallel-Group, Double-Blind, Placebo (13 Weeks)- and Naproxen (26 Weeks)-Controlled, Multicenter Study of Naproxcinod (375 mg Bid and 750 mg Bid) With a 26-Week Naproxen-Controlled Safety Follow-up in Subjects With Osteoarthritis of the Knee, and a 1-week Post-treatment Safety Follow-up",1020,2007-04-01,NA,NicOx
NCT00525824,Phase 3,NA,"12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe","A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD",1743,2007-08-01,2008-09-01,AstraZeneca
NCT00526474,Phase 3,2,Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50)",26449,2007-09-01,2011-12-01,Merck Sharp & Dohme Corp.
NCT00527943,Phase 3,2,Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)",12944,2007-12-01,2011-07-01,Merck Sharp & Dohme Corp.
NCT00541450,Phase 3,2,A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED),"A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of Sitagliptin and MK0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patients With Type 2 Diabetes Mellitus",492,2008-01-15,2010-01-16,Merck Sharp & Dohme Corp.
NCT00552097,Phase 3,2,Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578),Effect of Combination Ezetimibe and High-Dose Simvastatin vs Simvastatin Alone on the Atherosclerotic Process in Subjects With Heterozygous Familial Hypercholesterolemia (The ENHANCE Trial),720,2002-06-01,2006-04-25,Merck Sharp & Dohme Corp.
NCT00626535,Phase 3,2,"A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)","A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)",500,2003-03-01,2004-02-01,AstraZeneca
NCT00654537,Phase 3,4,"STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges","A 6 Week Open Label, Dose Comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Subjects With Hypercholesterolemia.",5625,2001-04-01,2004-10-01,AstraZeneca
NCT00663260,Phase 2/Phase 3,3,Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2/3 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control",631,2008-06-01,2011-06-01,AstraZeneca
NCT00679380,Phase 3,4,(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis,"Efficacy and Safety of Oral Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg Extended Release Tablets in Patients With Mild or Moderate Active Ulcerative Colitis. A Multicentre, Randomised, Double-Blind, Double-Dummy, Comparative Study Versus Placebo With an Additional Reference Arm Evaluating Entocort®EC",514,2008-06-01,2010-04-01,"Valeant Pharmaceuticals International, Inc."
NCT00679588,Phase 3,2,Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery,"A Multinational, Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery",4413,2008-04-01,2010-08-01,Sanofi
NCT00700817,Phase 3,5,"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus","The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Extension",665,2008-06-01,2010-06-01,Novo Nordisk A/S
NCT00707031,Phase 3,2,"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","A Randomized, Open-label, Active-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 Versus Exenatide on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin",639,2008-06-01,2010-11-01,Sanofi
NCT00718224,Phase 3,2,Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery,"A Multinational, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of Semuloparin (AVE5026) With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery",1150,2008-07-01,2009-05-01,Sanofi
NCT00751751,Phase 3,2,Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly,Comparison of the Efficacy of Olmesartan Medoxomil Versus Losartan on Diastolic Blood Pressure in Elderly and Very Elderly Patients With Essential Hypertension.,441,2003-06-01,2005-06-01,"Daiichi Sankyo, Inc."
NCT00776984,Phase 3,2,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II),"A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma",453,2008-10-01,NA,Boehringer Ingelheim
NCT00782509,Phase 3,3,12 / 48 wk Pivotal PFT vs PBO in COPD II,"Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 mcg [2 Actuations of 2.5 mcg] and 10 mcg [2 Actuations of 5 mcg]) Delivered by the Respimat® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD",644,2009-02-01,NA,Boehringer Ingelheim
NCT00783718,Phase 3,2,Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis,"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients With Moderate to Severe Ulcerative Colitis",895,2009-01-01,2012-03-01,"Millennium Pharmaceuticals, Inc."
NCT00790023,Phase 3,3,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis,"A Randomized, Multicenter, Double Blind, Placebo Controlled, Parallel Group, Phase III Clinical Trial to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol (160 μg Once Daily and 80 μg Once Daily) for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older.",707,2008-11-01,2009-02-01,Sunovion
NCT00791999,Phase 2/Phase 3,4,Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA),"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Pharmacokinetics and Safety of CDP870 as add-on Medication to MTX in Japanese Active RA Patients Who Have an Incomplete Response to MTX.",316,2008-11-01,2011-01-01,"Otsuka Pharmaceutical Co., Ltd."
NCT00792805,Phase 3,3,Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD),"A Phase III, 26-week Multicenter Randomized Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (150 and 300 µg Once Daily [od]) in Patients With Chronic Obstructive Pulmonary Disease (COPD)",563,2008-11-01,2010-02-01,Novartis
NCT00812955,Phase 3,4,"Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (""Bad Cholesterol"") and Triglycerides","An 8-Week, Multicenter, Randomized, Double-blind, Four-arm, Parallel-group Study Comparing the Safety and Efficacy of ABT-143 to Simvastatin in Subjects With Hypercholesterolemia",474,2008-11-01,2009-06-01,AstraZeneca
NCT00855582,Phase 3,3,A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil 2.5 and 5 mg Once Daily Dosing for 12 Weeks for the Treatment of Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia in Men With Both Erectile Dysfunction and Benign Prostatic Hyperplasia",606,2009-03-01,2010-07-01,Eli Lilly and Company
NCT00864812,Phase 4,2,Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea,"A Randomized, Open Label, Multicenter, Phase 4 Study for the Comparison of Efficacy of Tiotropium Plus Salmeterol/ Fluticasone Propionate Compared With Tiotropium Alone in COPD Patients",509,2009-03-01,2010-03-01,The Korean Academy of Tuberculosis and Respiratory Diseases
NCT00888355,Phase 3,4,MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension,"A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Losartan Given Once or Twice Daily in Patients With Mild to Moderate Hypertension",428,1992-05-01,1993-02-01,Merck Sharp & Dohme Corp.
NCT00909480,Phase 4,2,Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes,"A 26 Week Randomised, Multinational, Open Labelled, 2 Armed, Parallel Group, Treat-to-target Once Daily Treatment Trial With Insulin Detemir Versus Insulin Glargine, Both in Combination With Metformin in Subjects With Type 2 Diabetes",457,2009-05-01,2010-06-01,Novo Nordisk A/S
NCT00930670,Phase 4,8,Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects,Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects,320,2009-06-01,2011-12-01,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
NCT00942994,Phase 4,2,Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension,"An 8-week Multicenter, Randomized, Double-blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren/Amlodipine/HCTZ Compared to Aliskiren/Amlodipine in US Minority Patients With Stage 2 Hypertension",412,2009-06-01,NA,Novartis
NCT00958269,Phase 3,5,Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment,"A Randomized, Double-Blind, Placebo- and Sitagliptin-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment Including Subjects on Hemodialysis",360,2009-08-01,2011-11-01,Phenomix
NCT00974571,Phase 3,3,Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246),"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis",1365,2001-11-01,2002-05-01,Merck Sharp & Dohme Corp.
NCT00982228,Phase 3,2,Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes,"NN1250-3583: A 52 Week Randomised, Controlled, Open Label, Multicentre, Multinational, Parallel, Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (BEGIN™: BB T1 LONG) / NN1250-3644: An Extension Trial to Trial NN1250-3583 Comparing Safety and Efficacy of NN1250 With Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin, in Type 1 Diabetes (BEGIN™: T1)",629,2009-09-01,2010-11-08,Novo Nordisk A/S
NCT00982644,Phase 3,2,Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes,"NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)",1030,2009-09-01,2010-12-01,Novo Nordisk A/S
NCT01001208,Phase 3,2,The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis",478,2009-11-01,2011-02-01,Amgen
NCT01018511,Phase 3,4,Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms,"A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg and Tamsulosin Hydrochloride OCAS 0.4 mg Monotherapy, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) With a Substantial Storage Component",1334,2010-01-01,2011-03-01,Astellas Pharma Inc
NCT01032629,Phase 3,3,CANVAS - CANagliflozin cardioVascular Assessment Study,"A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus",4330,2009-12-09,2017-02-22,"Janssen Research & Development, LLC"
NCT01059136,Phase 3,2,Aldosterone Blockade Early After Acute Myocardial Infarction,Aldosterone Lethal Effects Blocked in AMI Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up: THE ALBATROSS TRIAL,1603,2010-02-01,2014-08-01,Assistance Publique - Hôpitaux de Paris
NCT01068665,Phase 3,2,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: LOW VOLUME),460,2010-03-01,2010-11-01,Novo Nordisk A/S
NCT01126580,Phase 3,3,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3),The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3),807,2010-05-01,2012-06-01,Eli Lilly and Company
NCT01151137,Phase 3,2,Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy,"A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors",3236,2010-07-01,2011-09-01,Sanofi
NCT01167881,Phase 3,2,Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes,"A Phase III Randomised, Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 10773 Compared to Glimepiride Administered Orally During 104 Weeks With a 104 Week Extension Period in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Metformin Treatment",1549,2010-08-01,2015-08-01,Boehringer Ingelheim
NCT01178073,Phase 3,3,A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),"AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)",610,2010-10-01,2014-07-31,GlaxoSmithKline
NCT01241591,Phase 3,4,"A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis","A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis",1101,2010-11-01,2013-01-01,Pfizer
NCT01242527,Phase 2/Phase 3,4,Epanova® for Lowering Very High Triglycerides,Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia,399,2011-01-01,2012-04-01,AstraZeneca
NCT01318135,Phase 2/Phase 3,4,Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan,"A Long-term, Open-label Extension Study to Investigate the Long-term Safety of Alogliptin When Used in Combination With Sulfonylurea or Metformin in Subjects With Type 2 Diabetes in Japan",576,2009-01-01,2010-04-01,Takeda
NCT01335477,Phase 3,2,Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II,"A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)",551,2011-05-01,2013-10-01,Boehringer Ingelheim
NCT01343004,Phase 3,3,Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women,"A Randomized, Double-blind, Placebo-Controlled, Comparative Multicenter Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women With Severe Osteoporosis and at Risk of Fracture",2463,2011-04-01,2014-10-01,"Radius Health, Inc."
NCT01408303,Phase 3,3,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,"A 6-Week, Randomized, Double-Blind, Placebo(Olive Oil)-Controlled Study to Assess the Efficacy and Safety of Add-On Epanova® to Statin Therapy in Subjects With Persistent Hypertriglyceridemia and High Risk for Cardiovascular Disease",646,2011-08-01,2012-06-01,AstraZeneca
NCT01442038,Phase 3,2,Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects With a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention With Incomplete Revascularization",2651,2011-10-01,2015-02-01,Gilead Sciences
NCT01458574,Phase 3,3,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis","A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis",593,2012-07-20,2016-05-27,Pfizer
NCT01484496,Phase 3,2,A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE),"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects With Systemic Lupus Erythematosus (SLE)",839,2011-11-16,2015-10-01,GlaxoSmithKline
NCT01499368,Phase 3,3,"A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients","A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients",495,2011-11-01,2012-11-01,"Boryung Pharmaceutical Co., Ltd"
NCT01545388,Phase 3,3,Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136),"A Phase III, Randomized, Placebo and Active-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of the Addition of Metformin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Sitagliptin Monotherapy",337,2012-02-23,2013-03-12,Merck Sharp & Dohme Corp.
NCT01577082,Phase 3,2,Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients,"A 12-week, Multinational, Multicentre, Randomised, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of CHF 1535 200/6µg Versus Beclomethasone Dipropionate in Adult Asthmatic Patients Not Adequately Controlled on High Dose of Inhaled Corticosteroids or on Medium Dose of Inhaled Corticosteroids Plus Long-acting β2 Agonists",542,2012-04-01,2012-11-01,Chiesi Farmaceutici S.p.A.
NCT01599104,Phase 3,3,Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension,"A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension",1161,2012-06-01,2013-04-01,Novartis
NCT01606761,Phase 3,3,"A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)","A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy",878,2012-08-06,2016-01-12,"Janssen Research & Development, LLC"
NCT01664247,Phase 3,2,The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification,The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification,346,2012-10-01,2013-12-31,Novo Nordisk A/S
NCT01709513,Phase 3,3,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)","A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins",314,2012-09-01,2017-05-01,Regeneron Pharmaceuticals
NCT01877668,Phase 3,5,Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis",422,2014-01-20,2015-12-18,Pfizer
NCT01907854,Phase 4,2,Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin,Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin,407,2013-12-01,2015-06-01,Novo Nordisk A/S
NCT01969708,Phase 3,2,Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2),"Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.",362,2014-09-01,2019-03-01,The EMMES Corporation
NCT02177396,Phase 3,2,MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring,A Prospective Randomized Open-Label Blinded End Point (PROBE) Trial Comparing MICARDIS® (Telmisartan) (80 mg QD) and Valsartan (80 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring.,426,1998-04-01,NA,Boehringer Ingelheim
NCT02349295,Phase 3,3,A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis,"A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis",363,2014-12-01,2019-06-01,Eli Lilly and Company
NCT02376790,Phase 3,3,Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis,"A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis",851,2015-03-03,2018-07-06,Amgen
NCT02494284,Phase 4,2,Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation,Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation : STAMP-DES Trial,364,2015-12-22,2017-02-13,Asan Medical Center
NCT02531035,Phase 3,2,A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes",1405,2015-09-01,2017-04-01,Sanofi
NCT02607865,Phase 3,4,Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes,Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes,1860,2016-02-15,2018-03-26,Novo Nordisk A/S
NCT02796677,Phase 3,4,AMPLIFY - D6571C00001 Duaklir USA Phase III Study,"A 24 Week Treatment, Multicenter, Randomized, Double Blinded, Double Dummy, Parallel-group, Clinical Trial Evaluating the Efficacy and Safety of Aclidinium Bromide 400 μg/Formoterol Fumarate 12 μg Fixed-dose Combination BID Compared With Each Monotherapy (Aclidinium Bromide 400 μg BID and Formoterol Fumarate 12 μg BID) and Tiotropium 18 μg QD When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.",1595,2016-07-05,2017-06-09,AstraZeneca
NCT02835534,Phase 4,2,The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI,"The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute ST Elevation Myocardial Infarction(STEMI): a Multi-center, Randomized, Open, Parallel, Non-inferiority, Active Controlled Trial",6200,2016-05-01,2019-01-01,"Guangzhou Recomgen Biotech Co., Ltd."
NCT02937701,Phase 3,2,Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab,"A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects With Moderate to Severe Rheumatoid Arthritis",558,2016-10-10,2018-08-02,Amgen
NCT00000476,Phase 3,NA,Digitalis Investigation Group (DIG),NA,NA,1990-06-01,1998-06-01,"National Heart, Lung, and Blood Institute (NHLBI)"
NCT00036439,Phase 3,NA,A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Active Ulcerative Colitis,"A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis",364,2002-02-01,2007-01-01,"Centocor, Inc."
NCT00038961,Phase 3,2,A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).,"A Multicenter, Randomized, Double-blind, Parallel Group Trial to Demonstrate the Efficacy of Fondaparinux Sodium in Association With Intermittent Pneumatic Compression (IPC) Versus IPC Used Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdomi",1309,2001-11-01,2004-10-01,GlaxoSmithKline
NCT00064428,Phase 3,4,OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction,An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction.,12092,2003-08-01,2006-02-01,GlaxoSmithKline
NCT00087529,Phase 2/Phase 3,2,A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis,"A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis",439,2004-06-01,NA,"Genentech, Inc."
NCT00090103,Phase 3,3,Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment,"A Randomized, Double-blind, Parallel Group Study to Investigate the Efficacy and Safety of Treatment With Dutasteride (0.5mg) and Tamsulosin (0.4mg), Administered Once Daily for 4 Years, Alone and Combination, on the Improvement of Symptoms and Clinical Outcome in Men With Moderate to Severe Symptomatic Benign Prostatic Hyperplasia",4844,2003-11-01,2009-04-01,GlaxoSmithKline
NCT00092638,Phase 3,NA,An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED),"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.",450,2003-05-01,2004-08-01,Merck Sharp & Dohme Corp.
NCT00092768,Phase 3,NA,A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED),"A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 1)",500,2004-03-01,2005-02-01,Merck Sharp & Dohme Corp.
NCT00096980,Phase 4,NA,A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies,"An Open Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneously Administered Efalizumab Used in Combination With Topical Psoriasis Therapies for Prolonged Maintenance Treatment",300,2001-02-01,2004-05-01,"Genentech, Inc."
NCT00097084,Phase 3,NA,Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes,Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes,324,2004-09-01,2005-12-01,Novo Nordisk A/S
NCT00099866,Phase 3,2,Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes,Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes,570,2004-01-01,2005-08-01,Novartis
NCT00099892,Phase 3,NA,Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes,Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes,544,2004-05-01,2005-09-01,Novartis
NCT00101751,Phase 4,NA,INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study,"Efficacy and Safety of a Standard Titration Algorithm Coupled With a Conventional Dietary Intervention or Intensive Dietary Intervention Versus a Standard Titration Algorithm, Alone, in Patients With Type 2 Diabetes Initiating NovoLog® Mix 70/30 Therapy",4877,2004-10-01,2006-06-01,Novo Nordisk A/S
NCT00101803,Phase 3,NA,Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes,Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes,527,2005-01-01,2006-01-01,Novartis
NCT00102388,Phase 3,2,Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes,Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes,1092,2005-01-01,NA,Novartis
NCT00103857,Phase 3,7,MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036),"A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",1208,2005-03-17,2008-02-21,Merck Sharp & Dohme Corp.
NCT00110240,Phase 3,NA,Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes,Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes,594,2005-04-01,2006-10-01,Novartis
NCT00120003,Phase 3,2,Scandinavian Candesartan Acute Stroke Trial (SCAST),Scandinavian Candesartan Acute Stroke Trial,2500,2005-06-01,2010-09-01,Oslo University Hospital
NCT00125918,Phase 3,5,PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension,"PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment in Patients With Pulmonary Arterial Hypertension",406,2005-08-01,2007-08-01,Eli Lilly and Company
NCT00138567,Phase 3,NA,Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes,Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes,530,2005-01-01,2006-08-01,Novartis
NCT00138580,Phase 3,NA,Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes,Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes,345,2004-11-01,2006-04-01,Novartis
NCT00139386,Phase 4,2,Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial,Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation,1119,2005-10-01,2012-04-01,Kumamoto University
NCT00145327,Phase 3,3,Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis),"A 3-year, Double-blind Extension to CZOL446H2301 to Evaluate the Long-term Safety and Efficacy of Zoledronic Acid in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D",2456,2005-05-01,2009-11-01,Novartis
NCT00151827,Phase 3,2,Olmesartan Medoxomil in Hypertension and Renal Impairment,Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment,393,2003-08-01,2005-07-01,"Daiichi Sankyo, Inc."
NCT00168792,Phase 4,NA,A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI),"A Phase IIIb - IV, Randomised, Open Label Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early PCI as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction. ASSENT 4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction.)",1671,2003-11-01,NA,Boehringer Ingelheim
NCT00174668,Phase 3,2,"Insulin Glulisine in Diabetes Mellitus, Type 2","52-week, Open, Randomized, Multinational, Multicenter Clinical Trial Comparing Insulin Glulisine in Combination With Insulin Glargine in an Intensified Insulin Regimen to a Two-injection Conventional Insulin Regimen in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control Pretreated With a Two-injection Conventional Insulin Therapy",311,2004-11-01,NA,Sanofi
NCT00175032,Phase 3,2,A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin,"A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taking Low Dose Aspirin",1045,2003-07-01,2004-07-01,Takeda
NCT00186901,Phase 3,2,A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors,Diminished Bone Mineral Density in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Severity-Adapted Clinical Trial,429,2000-07-01,2011-09-01,St. Jude Children's Research Hospital
NCT00195494,Phase 4,4,Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis,"A 24-Month,Randomized,Double-Blind,Two-Period Study to Evaluate the Efficacy and Safety of the Combination of Etanercept and Methotrexate and Methotrexate Alone in Subjects With Early Rheumatoid Arthritis",542,2004-11-01,2008-03-01,Wyeth is now a wholly owned subsidiary of Pfizer
NCT00195702,Phase 3,6,Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Rheumatoid Arthritis Patients Currently Receiving Treatment With Methotrexate",619,2000-02-01,2010-08-01,Abbott
NCT00207662,Phase 3,NA,A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease,"ACCENT I - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn's Disease",580,2000-07-01,2005-11-01,"Centocor, Inc."
NCT00212667,Phase 3,NA,Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan,Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan,650,2002-08-01,NA,Ono Pharmaceutical Co. Ltd
NCT00220233,Phase 3,NA,Olmesartan as an Add-on to Amlodipine in Hypertension,Add-on Study of Olmesartan Medoxomil in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Amlodipine 5 mg Alone,632,2005-04-01,2007-08-01,"Daiichi Sankyo, Inc."
NCT00222261,Phase 4,2,Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.,Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.,1001,2003-04-01,2010-07-01,Oslo University Hospital
NCT00229424,Phase 3,3,Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -,Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -,325,2005-04-01,2007-01-01,"Taiho Pharmaceutical Co., Ltd."
NCT00232050,Phase 3,NA,Study of Omalizumab in Moderate to Severe Bronchial Asthma,Study of Omalizumab in Moderate to Severe Bronchial Asthma,327,2002-10-01,2005-05-01,Novartis
NCT00242411,Phase 4,NA,MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults,"A Comparison of the Efficacy of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 Inhalation b.i.d. Plus As-needed) and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults. A Randomized, Open, Parallel-group, Multicentre 26-weeks Study",1900,2004-09-01,2006-10-01,AstraZeneca
NCT00249795,Phase 3,2,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I),"A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation",9016,2003-06-01,2009-08-01,Sanofi
NCT00250679,Phase 3,3,Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease,"Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel Group Long-Term Safety Study of 15 μg and 25 μg Arformoterol Tartrate Inhalation Solution BID in Subjects With Chronic Obstructive Pulmonary Disease",443,2005-10-01,2007-10-01,Sunovion
NCT00252668,Phase 4,NA,Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects,"An Open-Label, Multicentre, Extension Study of the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects",300,2004-06-01,2005-09-01,Wyeth is now a wholly owned subsidiary of Pfizer
NCT00253188,Phase 3,NA,A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease,"Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease",653,1997-02-01,1998-12-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00257686,Phase 3,6,Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly Patients,"Study Of Pitavastatin 1 Mg Vs. Pravastatin 10 Mg, Pitavastatin 2 Mg Vs. Pravastatin 20 Mg And Pitavastatin 4 Mg Vs. Pravastatin 40 Mg (Following Up-Titration) In Elderly Patients With Primary Hypercholesterolemia Or Combined Dyslipidemia",962,2005-09-01,2006-05-01,Kowa Research Europe
NCT00273299,Phase 3,NA,Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension,A 6-Week Study to Evaluate the Combination of Valsartan/HCTZ (160/12.5mg With Forced Titration to Maximum Dose of 320/25mg) Compared to Valsartan Monotherapy (160mg With Forced Titration to 320mg) as Initial Therapy in Patients With Severe Hypertension,607,2005-11-01,2006-07-01,Novartis
NCT00274014,Phase 3,NA,Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory Disorders,Effects of Inhaled Tiotropium Bromide on Severity of Airflow Obstruction During Long-term Treatment in Patients With Moderately Severe Copd. Impact on Severity and Incidence of Exacerbations.,1000,2000-10-01,2003-10-01,Boehringer Ingelheim
NCT00277394,Phase 4,2,Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis,Safety Profile of Innohep Versus Subcutaneous Unfractionated Heparin in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis,541,2005-12-01,2008-07-01,LEO Pharma
NCT00285519,Phase 4,NA,Japan Morning Surge-1 Study,"The Effects of Controlling Morning Hypertension on Target Organ Damage With Adrenergic Blockers, Based on Self-Measured Morning Blood Pressure Readings",600,2003-08-01,2005-08-01,Japan Heart Foundation
NCT00289848,Phase 3,2,MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040),"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",530,2006-03-01,2007-03-01,Merck Sharp & Dohme Corp.
NCT00309738,Phase 3,2,Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin,Study of Pitavastatin Vs. Simvastatin (Following Up-Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia and 2 or More Risk Factors for Coronary Heart Disease,355,2005-09-01,2006-10-01,Kowa Research Europe
NCT00309777,Phase 3,4,Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin,Study of Pitavastatin Vs. Simvastatin (Following Up-Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia,857,2005-09-01,2006-10-01,Kowa Research Europe
NCT00318422,Phase 3,NA,Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes,Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes.,1041,2006-05-01,2007-05-01,Novo Nordisk A/S
NCT00322257,Phase 3,2,Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes,"Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy",596,2006-05-01,2008-04-02,Novo Nordisk A/S
NCT00327145,Phase 3,NA,A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy,"A Double-blind, Randomized, Multicenter Study to Evaluate the Effectiveness of the Combination of Valsartan & Amlodipine in Hypertensive Patients Not Controlled on Monotherapy",894,2006-03-01,2007-01-01,Novartis
NCT00327418,Phase 4,NA,CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events,A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS),2800,1997-01-01,2004-02-01,Pfizer
NCT00332020,Phase 3,2,"Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement","RECORD 2 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Hip Replacement.",2457,2006-02-01,2007-06-01,Bayer
NCT00353912,Phase 3,NA,Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension,"A 12-week, Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combo Based Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension",571,2006-06-01,2007-04-01,Novartis
NCT00365950,Phase 4,NA,3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE,Clinical Trial of Two Durations of Warfarin Therapy in the Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism,2400,1999-09-01,2003-12-01,British Thoracic Society
NCT00376272,Phase 3,2,GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence,"Randomized, Prospective, Parallel Group, Placebo-Controlled, Multi-Center Study on the Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence",1442,2004-11-01,2008-03-01,Gruppo di Ricerca GISSI
NCT00379249,Phase 3,NA,Rosuvastatin ORBITAL Germany,Effects of a Twelve Months ROSUVASTATIN Treatment Plus Additional Care (Drug Intake Adherence and Lifestyle Enhancing Initiatives ) Compared to ROSUVASTATIN Treatment Alone on Long-Term Disease-Related Costs in Patients With an Indication for Statin Treatment According to the Joint European Guidelines,8000,2002-02-01,2004-02-01,AstraZeneca
NCT00383240,Phase 3,4,Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED),A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Medium-Dose Inhaled Glucocorticosteroids,781,2006-09-01,2008-09-01,Merck Sharp & Dohme Corp.
NCT00385138,Phase 3,2,Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.,"A Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervention (PCI).",5364,2006-09-01,2010-06-01,The Medicines Company
NCT00395512,Phase 3,4,Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus,"A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 Plus Pioglitazone HCl (Actos®), SYR-322 Alone or Pioglitazone HCl Alone in Subjects With Type 2 Diabetes",655,2006-11-01,2008-02-01,Takeda
NCT00396227,Phase 3,2,Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone,"A Multi-center, Randomized, Open-label, Active Controlled, Parallel Arm Study to Compare the Efficacy of 12 Weeks of Treatment With Vildagliptin 100 mg, qd to Thiazolidinedione (TZD) as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy in a Community-based Practice Setting.",2665,2006-10-01,NA,Novartis
NCT00406419,Phase 3,3,A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE),"A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment",1015,2006-12-01,2015-04-01,"Genentech, Inc."
NCT00414609,Phase 3,2,Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE),"A 36-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Including a 2 Year Extension Study to Evaluate Efficacy and Safety of Aliskiren on the Prevention of Left Ventricular Remodeling in High Risk Post-acute Myocardial Infarction Patients When Added to Optimized Standard Therapy",820,2006-12-01,2011-07-01,Novartis
NCT00430729,Phase 3,NA,Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112),Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52 Weeks Double Blind Study With 500mcg Roflumilast Once Daily Versus Placebo. Ratio-Study.,1100,2003-01-01,NA,AstraZeneca
NCT00451412,Phase 3,2,A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients,"A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients",3254,2007-01-01,2009-06-01,Novartis
NCT00452699,Phase 4,2,A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma,"A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects With Asthma",621,2007-05-01,2009-05-01,GlaxoSmithKline
NCT00463866,Phase 4,2,Local Phase 4 Pan-European SMART Study,NA,8424,2007-03-01,2008-12-01,AstraZeneca
NCT00480805,Phase 3,NA,HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED),HYZAAR Versus Ramipril Diabetic Patients,312,2001-08-08,2002-10-16,Merck Sharp & Dohme Corp.
NCT00542087,Phase 3,NA,Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED),"A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Etoricoxib 60 mg and Diclofenac Sodium 150 mg in Patient With Osteoarthritis of the Knee or Hip",516,2002-03-22,2002-12-20,Merck Sharp & Dohme Corp.
NCT00553267,Phase 3,NA,Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension,"An Eight-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy",947,2007-11-01,NA,Boehringer Ingelheim
NCT00624338,Phase 2/Phase 3,3,Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE),"A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)",461,2008-01-01,2012-10-01,EMD Serono
NCT00628342,Phase 4,3,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)",600,2003-04-01,2003-08-01,AstraZeneca
NCT00641056,Phase 3,2,Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3),Efficacy of Once-Weekly Exenatide Long-Acting Release and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea,467,2008-04-01,2009-11-01,AstraZeneca
NCT00641914,Phase 4,2,Inhaled Steroid Treatment as Regular Therapy in Early Asthma,Inhaled Steroid Treatment As Regular Therapy in Early Asthma. A Study on the Effect of Early Intervention With Long-Term Inhaled Budesonide (Pulmicort Turbuhaler ® ) in Newly Diagnosed Asthma.,6800,1996-10-01,2003-02-01,AstraZeneca
NCT00687973,Phase 4,2,Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg,Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg,393,2008-01-01,2009-01-01,Novartis
NCT00696241,Phase 3,5,Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension,"A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension",1275,2007-06-01,2008-10-01,Takeda
NCT00754403,Phase 4,2,Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects on Glycemic Control With Concomitantly Administered Pioglitazone HCl and Metformin HCl Extended Release (Fortamet®) in Subjects With Type 2 Diabetes",312,2005-07-01,2006-10-01,Takeda
NCT00783224,Phase 3,4,A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512),Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis,351,2005-09-01,2005-12-01,Merck Sharp & Dohme Corp.
NCT00810199,Phase 3,2,A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment,Randomized Placebo-controlled Study of Two Treatment Strategies Based on Tocilizumab (TCZ) With or Without Methotrexate (MTX) and Possible Addition of Other Disease-modifying Anti-rheumatic Drugs (DMARDs) in Patients...,556,2009-03-01,2013-01-01,Hoffmann-La Roche
NCT00831441,Phase 3,2,Phase III Acute Coronary Syndrome,"Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome",7484,2009-03-01,2011-03-01,Bristol-Myers Squibb
NCT00859183,Phase 4,3,Oral Sirolimus for In-Stent Restenosis,"A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Impact of Oral Sirolimus on Restenosis Prevention in Patients With In-Stent Restenosis.",300,2001-10-01,2004-03-01,Deutsches Herzzentrum Muenchen
NCT00862420,Phase 3,2,Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease,"A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg/Day Versus Ticlopidine 200 mg/Day in Patients With Peripheral Arterial Disease - With Extended Treatment of Clopidogrel 75 mg/Day for 40 Weeks",431,2009-02-01,2011-05-01,Sanofi
NCT00917254,Phase 2/Phase 3,4,Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery,"Phase II/III Study of YM150 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients Undergoing Elective Total Knee Replacement Surgery -",369,2009-05-01,2010-01-01,Astellas Pharma Inc
NCT00931710,Phase 4,2,Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension,"A 12-week Multicenter, Randomized, Double-blind, Parallel-group, Active-control Study to Evaluate the Antihypertensive Efficacy and Safety of Valsartan/Amlodipine-based Regimen Versus a Losartan-based Regimen in Patients With Stage 2 Systolic Hypertension",488,2009-07-01,2010-01-01,Novartis
NCT00954447,Phase 3,2,Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes,"A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of Linagliptin (5 mg), Administered Orally Once Daily for at Least 52 Weeks in Type 2 Diabetic Patients in Combination With Basal Insulin Therapy",1263,2009-08-01,NA,Boehringer Ingelheim
NCT00960661,Phase 3,2,"A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes","A Randomized Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes Who Were Previously Treated by Basal Insulin Glargine With Either Metformin or Metformin and Sulfonylurea",1036,2009-09-01,2012-08-01,AstraZeneca
NCT01045161,Phase 3,3,"Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)","A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose",544,2009-03-01,2011-06-01,AstraZeneca
NCT01068600,Phase 3,2,Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Indacaterol in Patients With Chronic Obstructive Pulmonary Disease",318,2010-01-01,NA,Novartis
NCT01068678,Phase 3,2,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM),460,2010-02-01,2010-11-01,Novo Nordisk A/S
NCT01087723,Phase 3,2,European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial,"Multi-centre, Multi-national, Prospective, Randomised, Open-label, Comparison of Bivalirudin to Other Guideline Based Current Therapies (Excluding Bivalirudin)",2198,2010-03-01,2014-08-01,The Medicines Company
NCT01106014,Phase 3,2,Selexipag (ACT-293987) in Pulmonary Arterial Hypertension,"A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension",1156,2009-12-01,2014-10-01,Actelion
NCT01106651,Phase 3,3,A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy",716,2010-06-01,2013-05-01,"Janssen Research & Development, LLC"
NCT01114880,Phase 3,2,Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis,"A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis",344,2010-01-01,2011-02-01,Abbott
NCT01118312,Phase 4,2,Study of Asthma and Nasal Steroids,Study of Asthma and Nasal Steroids for the American Lung Association-Airways Clinical Research Centers,388,2010-09-01,2015-06-01,JHSPH Center for Clinical Trials
NCT01130246,Phase 3,2,VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome,VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes,5189,2010-05-01,2012-03-01,Anthera Pharmaceuticals
NCT01209702,Phase 3,5,A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs,"A Ph II/III Seamless, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Reduction in Signs and Symptoms and Inhibition of Structural Damage During Treatment With Tocilizumab Versus Placebo in Patients With Ankylosing Spondylitis Who Have Failed Non-steroidal Anti-inflammatory Drugs and Are naïve to TNF Antagonist Therapy NSAIDs",306,2010-09-01,2011-12-01,Hoffmann-La Roche
NCT01212770,Phase 3,4,PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis and a Qualifying Psoriasis Lesion",505,2010-09-30,2017-02-09,Celgene
NCT01296412,Phase 3,2,Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403),"A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy",653,2011-03-11,2012-02-29,Merck Sharp & Dohme Corp.
NCT01306214,Phase 3,3,Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus,"A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) During 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control on MDI Insulin Regimen Alone or With Metformin",566,2011-02-01,2013-04-01,Boehringer Ingelheim
NCT01318070,Phase 2/Phase 3,3,Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan,"A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan",339,2007-11-01,2008-10-01,Takeda
NCT01345916,Phase 3,3,Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients,"A Phase 3,8-week Clinical Trial to Test the Efficacy of CHF1535 Via NEXT DPI® Versus Same Dose of CHF1535 pMDI and Beclomethasone DPI 100µg on PEF in Adult Asthmatic Patients After 1 Month of Treatment With FOSTER®",932,2011-03-01,2011-08-01,Chiesi Farmaceutici S.p.A.
NCT01376245,Phase 3,2,A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD,A 24-week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder Delivered Once Daily Via a Dry Powder Inhaler Compared With Placebo in Subjects of Asian Ancestry With Chronic Obstructive Pulmonary Disease,646,2011-04-01,2012-09-01,GlaxoSmithKline
NCT01422876,Phase 3,5,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"A Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Oral Administration of BI 10773 25 mg/Linagliptin 5 mg and BI 10773 10 mg/Linagliptin 5 mg Fixed Dose Combination Tablets Compared With the Individual Components (BI 10773 25 mg, BI 10773 10 mg, and Linagliptin 5 mg) for 52 Weeks in Treatment naïve and Metformin Treated Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control",1405,2011-08-01,2013-09-01,Boehringer Ingelheim
NCT01462942,Phase 3,5,Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination,Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-dose Combinations Compared With Individual Components and Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.,2443,2011-10-01,2013-01-01,AstraZeneca
NCT01470053,Phase 3,3,Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis,"A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Mometasone Furoate/Azelastine Hydrochloride Combination Group and Mometasone Furoate and Azelastine Hydrochloride Group 4 Weeks After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Perennial Allergic Rhinitis Patient.",347,2011-03-01,2012-11-01,"Hanlim Pharm. Co., Ltd."
NCT01493531,Phase 3,3,Combining Lesinurad With Allopurinol in Inadequate Responders,"A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol",610,2011-12-01,2014-07-01,"Ardea Biosciences, Inc."
NCT01566604,Phase 3,2,"Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease","A 26-week Treatment, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 (50 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease",460,2012-03-01,2013-06-01,Novartis
NCT01663402,Phase 3,2,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome",18600,2012-10-01,2018-01-23,Sanofi
NCT01708603,Phase 3,4,Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects,A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2,1831,2012-08-01,2015-08-01,Amgen
NCT01714817,Phase 3,2,Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis",695,2013-01-22,2018-05-18,Bristol-Myers Squibb
NCT01730534,Phase 3,2,Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events,"Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes",17276,2013-04-25,2018-07-18,AstraZeneca
NCT01774474,Phase 3,7,PRevention of Macular EDema After Cataract Surgery,PRevention of Macular EDema After Cataract Surgery,1127,2013-07-10,2016-11-04,Maastricht University Medical Center
NCT01850615,Phase 3,2,"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes",323,2013-09-23,2014-11-17,Novo Nordisk A/S
NCT01854658,Phase 3,4,"Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)","A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo",1615,2013-07-01,2015-03-01,"Pearl Therapeutics, Inc."
NCT01860729,Phase 3,2,A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022),"A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C",589,2013-05-01,2015-08-01,Merck Sharp & Dohme Corp.
NCT01870778,Phase 3,2,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients",6566,2013-10-02,2017-02-01,Novartis
NCT01914757,Phase 3,3,Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist,"A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)",2508,2013-08-01,2016-03-01,AstraZeneca
NCT01986855,Phase 3,3,A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Background Antihyperglycemic Therapy",468,2013-12-02,2016-09-28,Merck Sharp & Dohme Corp.
NCT02074982,Phase 3,2,Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis,"A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)",676,2014-02-26,2016-06-29,Novartis
NCT02085161,Phase 3,4,To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways,"An Exploratory, 12 Week, Randomised, Partially Double-blinded, Placebo-controlled Parallel Group Trial to Explore the Effects of Once Daily Treatments of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination or Tiotropium (Both Delivered by Respimat® Inhaler), Supervised Exercise Training and Behavior Modification on Exercise Capacity and Physical Activity in Patients With Chronic Obstructive Pulmonary Disease (COPD)",304,2014-03-01,2015-10-01,Boehringer Ingelheim
NCT02094937,Phase 3,4,A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects,"201135 : A Randomised, Double-blind, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Subjects Stepped Down From a Maintenance Therapy With RELVAR® Inhaler (FF/VI) 100/25 mcg Once-daily in Japanese Subjects",430,2014-03-27,2015-08-28,GlaxoSmithKline
NCT02164864,Phase 3,3,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),"A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus Clopidogrel or Ticagrelor and Aspirin in Patients With Non Valvular Atrial Fibrillation (NVAF) That Have Undergone a Percutaneous Coronary Intervention (PCI) With Stenting",2725,2014-07-22,2017-06-05,Boehringer Ingelheim
NCT02172573,Phase 3,3,Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease,"A Double-blind, Placebo-controlled, Randomised, Multicenter Trial to Compare the Safety and Efficacy of Oral Administration of Pramipexole up to 4.5mg and Bromocriptine up to 22.5mg Combined With L-dopa in Advanced Parkinson's Disease",315,1999-04-01,NA,Boehringer Ingelheim
NCT02177500,Phase 3,2,Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy,"An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 40 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 40 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 40 mg",327,2000-01-01,NA,Boehringer Ingelheim
NCT02181998,Phase 3,2,A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting,"A Phase IIIb-IV, Randomised, Open Label Trial on Efficacy and Safety of 2 Parallel Groups: Full Dose Tenecteplase Combined With Unfractionated Heparin or Enoxaparin in Acute Myocardial Infarction in the Prehospital Setting (ASSENT 3 Plus) ASSENT 3 Plus Was a Satellite Study to ASSENT 3 (Main Study) ASSENT (ASsessment of the Safety and Efficacy of New Thrombolytic Regimens)",1606,2000-07-01,NA,Boehringer Ingelheim
NCT02194205,Phase 3,4,Comparison of Safety and Efficacy of COMBIVENT HFA to COMBIVENT (CFC) in Patients With Chronic Obstructive Pulmonary Disease (COPD),"A One-year Randomized, Double-blind, Placebo and Active-controlled Parallel Design Safety and Efficacy Comparison of COMBIVENT HFA Inhalation Aerosol to COMBIVENT (CFC) Inhalation Aerosol in Patients With COPD",360,2000-10-01,NA,Boehringer Ingelheim
NCT02227550,Phase 4,2,Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy,"An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation",676,2014-12-01,2017-09-01,Atrial Fibrillation Network
NCT02229227,Phase 3,2,Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus,Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study,814,2014-11-21,2017-07-24,GlaxoSmithKline
NCT02244229,Phase 4,2,Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients,"MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride.",403,1998-04-01,NA,Boehringer Ingelheim
NCT02343926,Phase 3,2,Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin,"A Multicentre, National, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin",443,2014-12-01,2016-04-01,Sanofi
NCT02420262,Phase 3,2,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,506,2015-07-26,2016-10-05,Novo Nordisk A/S
NCT02741245,Phase 3,5,A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832),"A Phase III, Randomized, Active Comparator-controlled, Clinical Trial to Study the Efficacy and Safety of MK-0653H in Japanese Patients With Hypercholesterolemia.",321,2016-06-01,2017-01-01,Merck Sharp & Dohme Corp.
NCT00043784,Phase 3,NA,SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes,"A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting With Acute Coronary Syndromes (ACS)",8000,2001-08-01,NA,Sanofi
NCT00049829,Phase 3,NA,HORIZON-PFT: Pivotal Fracture Trial,HORIZON-PFT: Pivotal Fracture Trial,7700,2002-01-01,NA,Novartis
NCT00073372,Phase 3,NA,A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II),"Abciximab (ReoPro) in Acute Ischemic Stroke: A Phase III, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Trial.",808,2003-10-01,2005-12-01,"Centocor, Inc."
NCT00076076,Phase 3,NA,The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023),"The FLASH Study: A Randomized, Controlled Study of Roflumilast 250 mcg and 500 mcg Versus Placebo in Patients With Asthma",822,2003-12-01,2005-06-01,AstraZeneca
NCT00092625,Phase 3,NA,Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803),"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.",442,2003-03-01,2004-08-01,Merck Sharp & Dohme Corp.
NCT00092651,Phase 3,NA,A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, ""Factorial"" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia",1398,2002-09-01,2003-06-01,Merck Sharp & Dohme Corp.
NCT00118703,Phase 3,NA,Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis,"A 4 Week Randomized, Double Blind, Placebo Controlled Study of GW685698X Aq Nasal Spray 100mcg QD in Adults and Adolescents With Vasomotor Rhinitis",350,2005-07-01,2006-02-09,GlaxoSmithKline
NCT00121641,Phase 3,5,Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise",1035,2005-07-01,2010-02-01,AstraZeneca
NCT00129233,Phase 4,2,Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance,The Novel Antihypertensive Goal Of hYpertension With diAbetes ― Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study,1150,2004-10-01,2013-04-01,Nagoya University
NCT00133692,Phase 4,NA,INVEST: INternational VErapamil SR Trandolapril STudy,INternational VErapamil SR Trandolapril STudy,22000,1997-09-01,2003-02-01,University of Florida
NCT00139815,Phase 3,2,Michelangelo - Oasis 5,"An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes",20078,2003-04-01,2005-12-01,GlaxoSmithKline
NCT00143481,Phase 4,NA,"Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women","A Multi-Center, Double-Phase, Randomized, Double-Blind, Placebo Controlled (12-Week Double-Blind Followed by 12-Week Open-Label) Study Evaluating the Effect of Tolterodine ER on Urgency Urinary Incontinence (UUI), Urgency, Frequency, Sexual Quality of Life and Sexual Function in Women With Overactive Bladder",400,2005-03-01,NA,Pfizer
NCT00144508,Phase 3,2,Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA),"An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA",306,2003-03-01,2006-02-01,Chugai Pharmaceutical
NCT00145210,Phase 3,NA,Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans,"A Double-Blind, Randomized, Placebo- and Active-Controlled, Forced Titration Study Evaluating the Effects of Nebivolol on Blood Pressure and Heart Rate in African American Patients With Hypertension",630,2005-04-01,2007-09-01,Mylan Bertek Pharmaceuticals
NCT00163358,Phase 3,NA,Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132),Efficacy of Ciclesonide and of a Fixed Combination With Fluticasone Propionate and Salmeterol Versus Placebo on Long-term Asthma Control,630,2003-09-01,2005-10-01,AstraZeneca
NCT00168844,Phase 3,3,Tiotropium / Respimat One-Year Study,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mg and 10mg) of Tiotropium Inhalation Solution Delivered by the Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)",983,2003-01-01,NA,Boehringer Ingelheim
NCT00174681,Phase 4,NA,Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes,Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes,390,2003-04-01,NA,Sanofi
NCT00175903,Phase 3,2,Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",1701,2005-02-01,2007-10-01,UCB Pharma
NCT00184665,Phase 3,NA,Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes,2 Year Efficiency and Safety Comparison of Insulin Detemir and NPH Insulin in Type 1 Diabetes.,501,2004-06-01,2006-09-01,Novo Nordisk A/S
NCT00185172,Phase 3,3,Olmesartan in Essential Hypertension,Efficacy and Safety of Olmesartan: Reduction of Blood Pressure in the Treatment of Patients Suffering From Mild to Moderate Essential Hypertension,2333,2002-01-01,2005-06-01,"Daiichi Sankyo, Inc."
NCT00202020,Phase 3,NA,Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke,"Cilostazol Stroke Prevention Study-a Randomized, Double Blind, Double Dummy, Parallel Comparative, Multicenter Clinical Trial",720,2004-05-01,2006-01-01,Otsuka Beijing Research Institute
NCT00216892,Phase 4,NA,Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris,Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris,1032,2005-04-01,2005-12-01,LEO Pharma
NCT00219089,Phase 3,NA,"A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.","An Eight-week, Randomized, Double-blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus",839,2004-11-01,2005-08-01,Novartis
NCT00224107,Phase 3,2,A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo,"A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Evaluation of the Efficacy and Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia",461,2005-05-01,2006-08-01,Watson Pharmaceuticals
NCT00233441,Phase 2/Phase 3,NA,"Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter","Placebo Controlled Double Blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200, or 300 mg OD, With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter",673,2004-12-01,2006-05-01,Sanofi
NCT00236574,Phase 3,NA,A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment,A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease.,974,2001-05-01,2003-11-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00244556,Phase 4,NA,Study Comparing Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Active Rheumatoid Arthritis Despite Current Methotrexate Therapy,A Randomized Comparison of the Safety and Efficacy of Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Patients With Active Rheumatoid Arthritis Despite Current Methotrexate Therapy,300,2003-03-01,2004-05-01,Wyeth is now a wholly owned subsidiary of Pfizer
NCT00246909,Phase 4,NA,Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340),"Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week.",600,2005-11-01,2006-11-01,Takeda
NCT00259792,Phase 3,NA,SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults,"A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26-week, Randomised, Open, Parallel Group Multicentre Study",1000,2004-09-01,2006-01-01,AstraZeneca
NCT00261573,Phase 3,NA,A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia,The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia,593,1998-12-01,2000-12-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00267215,Phase 3,NA,Efficacy and Safety of Lumiracoxib,"A One-week Multicenter, Multiple-dose, Randomized, Double-blind, Double-dummy, Parallel-group Comparison of the Analgesic Efficacy and Safety of Lumiracoxib (COX189), Celecoxib, and Placebo in the Treatment of Osteoarthritis of the Knee",330,2000-11-01,NA,Novartis
NCT00294710,Phase 3,NA,A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine,"A Twenty Six-week, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension",976,2005-03-01,2006-07-01,Novartis
NCT00299013,Phase 3,4,Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis,"A Multicentre, Randomised, Double Blind, Double Dummy, Active Comparator Controlled, Parallel Group Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis",796,2006-03-01,2008-04-01,Alizyme
NCT00301574,Phase 3,NA,An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.,"Placebo-Controlled, Double-Blind Study of Galantamine (R113675) in the Treatment of Alzheimer's Disease.",398,2001-04-01,2004-02-01,Janssen Pharmaceutical K.K.
NCT00307437,Phase 3,3,A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis.",1230,2005-05-01,2011-10-01,"Centocor Research & Development, Inc."
NCT00312104,Phase 3,NA,Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes,Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes.,325,2002-04-01,2003-03-01,Novo Nordisk A/S
NCT00325676,Phase 4,NA,Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342),CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD,639,2006-06-01,NA,Takeda
NCT00328627,Phase 3,12,Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS®), in Subjects With Type 2 Diabetes",1554,2006-05-01,2008-03-01,Takeda
NCT00358176,Phase 3,NA,Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women,"A Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Noninferiority Study Comparing 75mg Risedronate Dosed on 2 Consecutive Days Monthly With 5mg Daily Risedronate in the Treatment of Postmenopausal Osteoporosis as Assessed Over 24 Months.",1231,2004-07-01,2007-03-01,Sanofi
NCT00365170,Phase 4,NA,Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes,"A Randomised, Parallel-group, Open-label, Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen, in the Treatment of Pregnant Women With Type 1 Diabetes, Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes",419,2002-09-01,2005-04-01,Novo Nordisk A/S
NCT00371683,Phase 3,2,Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery,"A Phase 3 Randomized, Double-Blind Active-Controlled (Enoxaparin), Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery",3608,2006-11-01,2008-05-01,Bristol-Myers Squibb
NCT00372216,Phase 3,2,CIPAMI-Study: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction,CIPAMI-Study: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction,337,2006-10-01,2010-01-01,Stiftung Institut fuer Herzinfarktforschung
NCT00383136,Phase 4,2,FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab,FATA: Comparison Between Tirofiban and Abciximab in Facilitated Angioplasty With Stent Implantation: Randomized Multicentre Study,692,2003-06-01,2007-09-01,University of Bologna
NCT00394199,Phase 3,3,Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma,"A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm) 100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (100 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent & Adult Patients With Mild to Moderate Asthma",357,2006-06-01,2008-02-01,SkyePharma AG
NCT00422227,Phase 4,2,Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region,"A Randomized, Open-Label Study in the Asia-Pacific Region Comparing the Safety and Efficacy of Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis",300,2007-06-01,2009-03-01,Wyeth is now a wholly owned subsidiary of Pfizer
NCT00423995,Phase 3,NA,Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822),Study of the Decongestant Effect of the Combination of Loratadine and Montelukast Compared With Placebo in SAR Subjects Exposed to Pollen in an Environmental Exposure Unit,379,2006-11-01,2007-03-10,Merck Sharp & Dohme Corp.
NCT00476996,Phase 3,3,A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT),"A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One Anti-TNF-α Therapy",840,2007-05-01,2019-06-01,"Genentech, Inc."
NCT00485589,Phase 3,2,A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM),"A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab in Combination With Methotrexate (MTX) Compared to MTX Alone in Methotrexate- Naive Patients With Active Rheumatoid Arthritis",613,2007-06-01,2013-08-01,"Genentech, Inc."
NCT00499707,Phase 3,NA,Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects,"A Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Fixed Dose Rosiglitazone/Metformin Combination Therapy Compared to Both Rosiglitazone and Metformin Monotherapies in Drug Naive Type 2 Diabetes Mellitus Subjects",453,2003-10-01,2004-12-01,GlaxoSmithKline
NCT00531817,Phase 3,2,A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis,"A Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Tocilizumab (TCZ) Versus Placebo in Combination With Disease Modifying Antirheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)",619,2007-10-01,2011-03-01,Hoffmann-La Roche
NCT00546507,Phase 3,3,Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I,The Efficacy and Safety of TDS-943 in the Treatment of Osteoarthritis of the Knee: Pivotal Study I,650,2007-10-01,2008-10-01,Mika Pharma GmbH
NCT00560417,Phase 3,2,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide,A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide,339,2007-11-01,2009-12-01,Eli Lilly and Company
NCT00571649,Phase 3,2,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,"Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study",8101,2007-12-01,2010-11-01,Bayer
NCT00591266,Phase 3,3,"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension","A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Amlodipine 5 mg in Subjects With Essential Hypertension",566,2007-10-01,2009-04-01,Takeda
NCT00602472,Phase 3,2,BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes,"A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg) Administered Orally Once Daily Over 24 Weeks, With an Open-label Extension to One Year (Placebo Patients Switched to BI 1356), in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With a Sulphonylurea",1058,2008-02-01,NA,Boehringer Ingelheim
NCT00604253,Phase 3,NA,Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone,Comparison of Efficacy and the Safety of Insulin Detemir and Insulin NPH as add-on to Current OHA Therapy in Subjects With type2 Diabetes Mellitus,362,2003-12-01,2005-05-01,Novo Nordisk A/S
NCT00620542,Phase 3,4,CRESTOR Athero Imaging Head to Head IVUS Study,Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN),2333,2008-01-01,2011-06-01,AstraZeneca
NCT00646594,Phase 3,2,Atlantis Symbicort,"A Two Stage Randomized, Open-Label, Parallel Group, Phase III, Multicenter, 7 Month Study to Assess the Efficacy & Safety of SYMBICORT pMDI Adminstered Either as Fixed or as an Adjustable Regimen Versus a Fixed Regimen of Advair in Subjects 12 Yrs of Age and Older With Asthma.",1200,2003-11-01,2005-01-01,AstraZeneca
NCT00649025,Phase 3,3,A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults,"A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10ug Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (250ug Twice Daily) Alone in SkyePharma HFA pMDI and Flovent® HFA pMDI in Adolescent and Adult Patients With Moderate to Severe Asthma",438,2008-03-01,2008-10-01,SkyePharma AG
NCT00664534,Phase 4,2,Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast,Comparison of Premixed Insulin Lispro Low-Mixture and Mid-Mixture Regimens With Separate Basal and Bolus Insulin Injections in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Oral Therapy Who Consume Light Breakfast,344,2008-04-01,2010-11-01,Eli Lilly and Company
NCT00751829,Phase 3,2,Isolated Systolic Hypertension in the Elderly and Very Elderly,Comparison of the Efficacy of Olmesartan Medoxomil Versus Nitrendipine on Systolic Blood Pressure in Elderly and Very Elderly Patients With Isolated Systolic Hypertension,417,2003-07-01,2005-02-01,"Daiichi Sankyo, Inc."
NCT00766545,Phase 3,2,Cilostazol Stroke Prevention Study : A Placebo-Controlled Double-Blind Trial for Secondary Prevention of Cerebral Infarction.,Cilostazol Stroke Prevention Study : A Placebo-Controlled Double-Blind Trial for Secondary Prevention of Cerebral Infarction.,1095,1992-04-01,1997-03-01,"Otsuka Pharmaceutical Co., Ltd."
NCT00777946,Phase 3,3,Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone,"A Randomized, Eight-week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (300/5 mg and 300/10 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy",818,2008-10-01,2009-05-01,Novartis
NCT00789750,Phase 3,2,Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus,"A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of WELCHOL as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus (T2DM)",562,2009-04-01,2012-07-01,"Daiichi Sankyo, Inc."
NCT00792727,Phase 3,2,HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Four-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee",380,2007-09-01,2008-05-01,"Hisamitsu Pharmaceutical Co., Inc."
NCT00821977,Phase 2/Phase 3,3,Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes,NA,338,2008-11-01,2010-10-01,Novartis
NCT00823992,Phase 3,2,A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Taspoglutide on Glycemic Control, and Its Safety and Tolerability, in Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy.",305,2009-01-01,2010-05-01,Hoffmann-La Roche
NCT00846586,Phase 3,2,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,"A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease",1134,2009-03-01,2010-03-01,Novartis
NCT00849017,Phase 3,3,Safety and Efficacy Study of Albiglutide in Type 2 Diabetes,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus",309,2009-01-01,2013-02-01,GlaxoSmithKline
NCT00856206,Phase 3,2,Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE),"A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate- Lowering Therapy",1315,2009-03-01,2011-01-01,Regeneron Pharmaceuticals
NCT00872001,Phase 3,2,The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED),The Effect Of Acadesine On Clinically Significant Adverse Cardiovascular and Cerebrovascular Events In High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction in Cardiovascular Events by AcaDesine in Subjects Undergoing CABG),3080,2009-04-01,2010-10-01,Merck Sharp & Dohme Corp.
NCT00885352,Phase 3,2,Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128),"A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Metformin and Pioglitazone",313,2009-04-15,2010-11-10,Merck Sharp & Dohme Corp.
NCT00902538,Phase 3,6,Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension,Add-on Study of Hydrochlorothiazide in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Olmesartan/Amlodipine Alone,2204,2009-04-01,2010-10-01,"Daiichi Sankyo, Inc."
NCT00911547,Phase 3,4,The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029),"A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 2-Period, Parallel-Group Study to Assess the Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients",642,1995-03-01,1996-05-01,Merck Sharp & Dohme Corp.
NCT00926289,Phase 4,2,Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension,"A Randomised, Double-blind, Double Dummy, Active Controlled, Parallel Group, Forced Titration Study to Compare the Fixed-dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 25mg (T80/HCTZ25) Versus Telmisartan 80mg (T80) Monotherapy as First Line Therapy in Patients With Grade 2 or Grade 3 Hypertension (Systolic Blood Pressure (SBP) >=160 mmHg and Diastolic Blood Pressure (DBP) >=100 mmHg)",894,2009-06-01,NA,Boehringer Ingelheim
NCT00929864,Phase 3,2,Abatacept Versus Adalimumab Head-to-Head,"A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis",869,2009-10-01,2012-11-01,Bristol-Myers Squibb
NCT00935532,Phase 3,2,Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus,Parallel Group Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus Treated With Oral Antidiabetic(s),427,2009-07-01,2011-07-01,AstraZeneca
NCT00970489,Phase 3,2,Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation,(OPERA)Randomized Clinical Trial to Examine Whether Peri-operative Intake of n-3 Polyunsaturated Fatty Acids Will Reduce the Occurrence of Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery,1516,2010-08-01,2012-06-01,Brigham and Women's Hospital
NCT00970632,Phase 3,3,A Study of Tadalafil in Men With Benign Prostatic Hyperplasia,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia",511,2009-10-01,2011-01-01,Eli Lilly and Company
NCT00972283,Phase 3,2,Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes,"NN1250-3582: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin ± Treatment With Metformin, ± Pioglitazone in Subjects With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment/NN1250-3667: An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin ± OADs in Type 2 Diabetes (BEGIN™: BB)",1006,2009-09-01,2010-10-28,Novo Nordisk A/S
NCT00976391,Phase 3,2,A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine,"A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared With the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus",586,2009-09-01,2012-05-01,GlaxoSmithKline
NCT00993109,Phase 4,2,Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension,"Randomized,Open-label,Parallel Design Comparator Study of Effect of Nifedipine GITS/OROS (Adalat) 30 mg in Combination With Valsartan (Diovan) 80 mg Compared to Valsartan (Diovan) 160 mg Monotherapy in Patients Whose Blood Pressure is Not Well Controlled by Valsartan 80 mg Alone",360,2010-02-01,2011-05-01,Bayer
NCT01009086,Phase 3,3,A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis,"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis",615,2009-12-01,2013-05-01,"Janssen Research & Development, LLC"
NCT01021735,Phase 4,2,Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy,Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy,302,2010-04-01,2015-04-01,University of Glasgow
NCT01031680,Phase 3,2,"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension","A 24-week, Multicentre, Randomised, Double-blind, Age-stratified, Placebo Controlled, Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Pts With T2DM, CV Disease and Hypertension Who Exhibit Inadequate Glycaemic Control on Usual Care",922,2010-02-01,2012-12-01,AstraZeneca
NCT01051011,Phase 3,3,A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy,"A Multi-center, Randomized, Open-label, Active-controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin-naive Type 2 Diabetic Patients Inadequately Controlled With Metformin and Sulphonylurea Combination Therapy.",370,2010-01-01,2010-12-01,Hoffmann-La Roche
NCT01054885,Phase 3,6,Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD),A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD),1226,2009-10-19,2011-02-08,GlaxoSmithKline
NCT01059799,Phase 3,2,Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes,A Pan Asian Trial Comparing Efficacy and Safety of Insulin NN1250 and Insulin Glargine as Add on to OAD(s) in Subjects With Type 2 Diabetes (BEGIN™: ONCE ASIA),435,2010-02-01,2010-12-16,Novo Nordisk A/S
NCT01075282,Phase 3,3,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2),"A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride",810,2010-02-01,2012-11-01,Eli Lilly and Company
NCT01076075,Phase 3,2,A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229),"A Phase III, Randomized, Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on a Sulfonylurea in Combination With Metformin",427,2010-06-03,2012-01-19,Merck Sharp & Dohme Corp.
NCT01121835,Phase 4,2,Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study,"A 24-week, Open, Multicenter, Comparative Study of 2 Strategies (Including Insulin Glargine Versus Premixed Insulin) for the Therapeutic Management of Patients With Type 2 Diabetes Failing Oral Agents",934,2010-02-01,2012-03-01,Sanofi
NCT01175811,Phase 4,2,A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus,A Comparison of Premixed and Basal-Bolus Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Twice-daily Premixed Insulin,402,2011-02-01,2012-11-01,Eli Lilly and Company
NCT01181167,Phase 3,2,"A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty","A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-5 Trial)",610,2009-05-01,2010-03-01,"Daiichi Sankyo, Inc."
NCT01181895,Phase 3,3,Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma,"A Randomized, Double-blind, Double-dummy, Parallel-group, Placebo Controlled (on Inhaled Corticosteroid Medication), Multicenter Study to Evaluate the Efficacy and Safety of Vilanterol Inhalation Powder (GW642444) and Salmeterol, Compared With Placebo in the Treatment of Persistent Asthma in Adults and Adolescents Uncontrolled on Inhaled Corticosteroids",348,2010-09-01,2011-08-26,GlaxoSmithKline
NCT01290874,Phase 3,2,Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT),Blacks and Exacerbations on LABA vs. Tiotropium (BELT),1071,2011-01-01,2013-07-01,Brigham and Women's Hospital
NCT01462266,Phase 3,2,Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Alone or in Combination With Metformin",660,2012-01-13,2013-06-07,Merck Sharp & Dohme Corp.
NCT01462929,Phase 3,3,Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),"A Multiple Dose, Double-blind, Double-dummy, Placebo Controlled, Parallel Clinical Trial to Assess the Efficacy and Safety of Twice Daily Inhaled Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",414,2011-11-01,2012-05-01,AstraZeneca
NCT01486940,Phase 3,2,Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes,"A Multi-centre, Multinational, Open-labelled, Randomised, Parallel-Group Comparison of Insulin Detemir Plus Insulin Aspart With NPH Insulin Plus Human Soluble Insulin in Subjects With Type 1 Diabetes on a Basal-Bolus Regimen",598,2002-03-01,2002-10-01,Novo Nordisk A/S
NCT01499953,Phase 3,2,Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux,Superficial Vein Thrombosis (SVT) Treated for Forty-five Days With Rivaroxaban Versus Fondaparinux,472,2012-04-01,2016-06-01,GWT-TUD GmbH
NCT01519518,Phase 4,2,How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention,A Randomised Controlled Trial to Compare Unfractionated Heparin Versus Bivalirudin in the Treatment of Patients With a Clinical Diagnosis of ST-Segment Elevation Myocardial Infarction Events - For Planned Management With Primary PCI,1829,2012-02-01,2013-12-01,Liverpool Heart and Chest Hospital NHS Foundation Trust
NCT01556997,Phase 3,3,Perindopril Amlodipine for the Treatment of Hypertension,"Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension",837,2012-02-01,2013-02-01,Symplmed Pharmaceuticals LLC
NCT01610037,Phase 3,3,Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation,A Placebo and Active Controlled Study to Assess the Long-term Safety of Once Daily QVA149 for 52 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate to Severe Airflow Limitation,1215,2012-10-01,2015-02-01,Novartis
NCT01633112,Phase 4,3,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,"A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis",1064,2012-08-09,2018-04-30,Novartis
NCT01712516,Phase 3,4,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation","A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",1001,2012-12-01,2014-02-01,Novartis
NCT01717300,Phase 3,3,A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021),"A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C",459,2012-11-06,2014-10-29,Merck Sharp & Dohme Corp.
NCT01732770,Phase 4,2,Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis,A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates,643,2012-11-01,2015-01-01,Amgen
NCT01758198,Phase 4,2,Abatacept Post-marketing Clinical Study in Japan,"A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate vs. Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate",405,2013-04-11,2016-12-26,Bristol-Myers Squibb
NCT01777334,Phase 3,2,The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD,"A Multicenter, Trial Comparing the Efficacy and Safety of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily With Tiotropium 18 mcg Once Daily Over 24 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",905,2013-01-23,2013-09-24,GlaxoSmithKline
NCT01822808,Phase 3,2,Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure,"A Prospective, Placebo-controlled, Double-blind, Randomized Study to Compare Hydralazine-isosorbide-dinitrate(HYIS) Versus Placebo on Top of Std Care in African Patients With Acute Heart Failure (AHF) and Left Ventricular Dysfunction",500,2013-01-01,2016-07-01,University of Cape Town
NCT01880216,Phase 3,2,Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT,"A Multinational, Multicentre, Randomized, Open, Parallel Group Study on the Efficacy and Safety of Bemiparin Sodium (LMWH) Compared to Enoxaparin Sodium (LMWH) in the Treatment of Acute Deep Vein Thrombosis (DVT)",312,2013-06-01,2015-05-01,Berlin-Chemie AG Menarini Group
NCT01882439,Phase 3,4,Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor",395,2013-08-01,2016-04-01,Pfizer
NCT01966107,Phase 4,2,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,"Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD)",3635,2013-10-16,2017-09-29,AstraZeneca
NCT01976208,Phase 2/Phase 3,2,Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma,"A Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Anti-IgE Monoclonal Antibody Injection(Omalizumab) in Patients With Allergic Asthma",630,2010-12-01,2015-12-01,Shanghai Zhangjiang Biotechnology Limited Company
NCT02099110,Phase 3,5,"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy",1233,2014-04-22,2016-05-26,Merck Sharp & Dohme Corp.
NCT02104674,Phase 3,3,A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT PATIENTS WITH MILD TO MODERATE ASTHMA",313,2014-06-01,2016-05-01,Hoffmann-La Roche
NCT02105961,Phase 3,3,Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD),Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level,674,2014-04-24,2017-01-16,GlaxoSmithKline
NCT02121613,Phase 4,3,PERmixon® in LUTS Evaluation Study (PERLES),PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia,833,2014-04-01,2016-06-01,Pierre Fabre Medicament
NCT02177461,Phase 4,4,Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension,"A PROBE (Prospective, Randomised, Open-Label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80mg Once Daily Compared With 10-20 mg Enalapril Once Daily Over a Period of 24 Weeks in Elderly Patients With Blood Hypertension",374,2000-04-01,NA,Boehringer Ingelheim
NCT02254291,Phase 3,3,A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes,"Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily, Both as Monotherapy in Japanese Subjects With Type 2 Diabetes",308,2014-10-02,2015-11-11,Novo Nordisk A/S
NCT02281318,Phase 3,2,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control,"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control",556,2014-12-11,2016-06-10,GlaxoSmithKline
NCT02453685,Phase 4,2,A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients,"A 32-week Randomised, Multinational, Treat-to-target, Open Label, Parallel Group Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp) 30 and Basal-bolus Therapy With Insulin Glargine and Insulin Aspart in Insulin naïve Type 2 Diabetic Patients Inadequately Controlled on Oral Anti-diabetic Therapy",335,2015-09-01,2016-09-01,Novo Nordisk A/S
NCT02584855,Phase 3,3,A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis,"A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis",400,2015-11-01,2018-10-01,Eli Lilly and Company
NCT02672852,Phase 3,2,BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment,BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance),500,2016-02-29,2018-08-03,AbbVie
NCT02730377,Phase 4,2,Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes,Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting,1994,2016-03-28,2019-08-12,Novo Nordisk A/S
NCT02738632,Phase 3,2,Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients,"Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by Telmisartan/Amlodipine Combination",300,2015-05-01,2016-08-01,IlDong Pharmaceutical Co Ltd
NCT02906930,Phase 3,4,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only.,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only.,703,2016-09-20,2017-12-08,Novo Nordisk A/S
NCT03021187,Phase 3,4,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin,"Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin. A 52-week, Randomised, Double-blind, Placebo-controlled Trial (PIONEER 8 - Insulin add-on)",720,2017-02-02,2018-08-23,Novo Nordisk A/S
NCT00000609,Phase 3,NA,Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT),NA,NA,1997-05-01,2005-04-01,"National Heart, Lung, and Blood Institute (NHLBI)"
NCT00034840,Phase 4,NA,Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose,"A Prospective, Randomized, Double-Blind, Forced Titration Trial to Compare the Efficacy of MICARDIS® (Telmisartan 80 mg p.o. Once Daily) and Diovan® (Valsartan 160 mg p.o. Once Daily) Using Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Hypertension After Missing One Dose",490,2001-10-01,2002-08-01,Boehringer Ingelheim
NCT00046748,Phase 3,NA,Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma,"Ph III, 28-wk, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess Efficacy, Safety, Tolerability of SC Omalizumab in Adults and Adolescents w/ Severe Persist. Allergic Asthma & Are Inadequately Controlled Despite GINA (2002) Step 4 Tx",484,2001-12-01,2004-04-01,Novartis
NCT00059306,Phase 3,2,Secondary Prevention of Small Subcortical Strokes Trial,Secondary Prevention of Small Subcortical Strokes (SPS3) Trial,3020,2003-02-01,2012-04-01,University of British Columbia
NCT00079638,Phase 4,NA,Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL,Comparative Efficacy Evaluation of Lipid Levels When Treated With Niaspan and Statin or Other Lipid-Modifying Therapies,300,2004-04-01,2005-05-01,Kos Pharmaceuticals
NCT00089804,Phase 3,3,Study of LJP 394 in Lupus Patients With History of Renal Disease,"A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300 mg and 900 mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease",943,2004-10-01,2009-02-01,La Jolla Pharmaceutical Company
NCT00092690,Phase 3,NA,MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED),"A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Hypercholesterolemia",1902,2003-06-01,2004-03-01,Merck Sharp & Dohme Corp.
NCT00093899,Phase 3,NA,A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED),A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia,611,2004-11-01,2005-09-01,Merck Sharp & Dohme Corp.
NCT00097786,Phase 3,4,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,"A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT)",9306,2002-01-01,2009-10-01,Novartis
NCT00099853,Phase 3,3,Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes,Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes,362,2004-05-01,2008-01-01,Novartis
NCT00102466,Phase 3,2,Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes,Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes,1007,2005-01-01,2009-01-01,Novartis
NCT00106340,Phase 3,2,Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes,Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes,3118,2005-03-01,NA,Novartis
NCT00109408,Phase 3,2,A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis,"A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Monotherapy Versus Methotrexate Monotherapy in Patients With Moderate to Severe Active Rheumatoid Arthritis",673,2005-07-01,2007-12-01,Hoffmann-La Roche
NCT00110435,Phase 3,NA,A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077),"A Multicenter, Randomized, Double-blind, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypercholesterolemia",1229,2005-05-01,2005-12-01,Merck Sharp & Dohme Corp.
NCT00153062,Phase 4,4,PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes,"PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis",20332,2003-08-01,NA,Boehringer Ingelheim
NCT00163527,Phase 3,NA,Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013),"A 24-Week, Double-Blind, Parallel Group, Placebo and Active Controlled Study to Investigate the Efficacy and Safety of Daily Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Chronic Asthma",2054,2003-04-01,2005-11-01,AstraZeneca
NCT00166530,Phase 4,2,EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089),"A Prospective Randomized Open Label Blinded Endpoint Multicenter Study in Patients With Coronary Artery Disease to Assess the LDL Lowering Effect of Switching to Ezetimibe (+) Simvastatin for Cholesterol Lowering, Compared the Dose of the Statin Used.",367,2005-11-01,2007-02-01,Merck Sharp & Dohme Corp.
NCT00175019,Phase 3,3,Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010,"A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout",1086,2003-07-01,2007-02-01,Takeda
NCT00202878,Phase 3,2,IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103),"A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)",18144,2005-10-17,2014-09-18,Merck Sharp & Dohme Corp.
NCT00203658,Phase 4,NA,Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin,"LITE Study, Appendix A (HOME-LITE), Amendment 6",400,1997-04-01,2000-10-01,University of Calgary
NCT00206167,Phase 3,NA,A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD,"A 12-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid Compared to Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD",1600,2005-04-01,2007-09-01,AstraZeneca
NCT00219115,Phase 3,NA,A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg,A 12-week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of the Combination Aliskiren With HCTZ Compared to Irbesartan or Amlodipine With HCTZ or HCTZ Alone in Hypertensive Patients With BMI ≥ 30 kg/m2 Not Adequately Responsive to HCTZ 25 mg,493,2005-01-01,2006-03-01,Novartis
NCT00219141,Phase 3,3,Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension,"A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension",460,2005-10-01,2007-11-01,Novartis
NCT00219180,Phase 3,NA,Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure,"An 8-week Multi-center, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren (150 mg and 300 mg) Administered Alone and in Combination With Valsartan (160 mg and 320 mg) in Patients With Hypertension",1797,2005-06-01,2006-09-01,Novartis
NCT00237887,Phase 3,NA,Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis,"A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects With Moderate to Severe Chronic Plaque Psoriasis",1212,2004-12-01,NA,Abbott
NCT00238784,Phase 3,NA,SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults,"A Comparison of Symbicort® Single Inhaler Therapy (Symbicort® 200 Turbuhaler® 1 Inhalation b.i.d. Plus as Needed) & Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents & Adults-a 26-Week, Randomised, Open-Label, Parallel Group, Multicentre Study",1300,2004-05-01,2005-10-01,AstraZeneca
NCT00252824,Phase 3,NA,STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma,"A Comparison of the Efficacy of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 Inhalation b.i.d. Plus As-needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26 Weeks, Randomised, Open-label, Parallel-group, Multicentre Study",1000,2005-07-01,2006-12-01,AstraZeneca
NCT00271817,Phase 3,5,To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED),"Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia",1220,2005-12-01,2008-02-01,Merck Sharp & Dohme Corp.
NCT00274612,Phase 4,NA,Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM,A Prospective Randomised Open- Label Blinded-Endpoint (PROBE) Trial Comparing Telmisartan (MICARDIS®) (40-80-80mg QD) and Ramipril (2.5-5--10mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. PRISMA = Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM,801,2002-10-01,2003-11-01,Boehringer Ingelheim
NCT00276484,Phase 3,2,To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090),"A Multicenter, Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at High Risk for CHD Not Adequately Controlled on Atorvastatin 40 Mg",579,2006-02-01,2008-03-01,Merck Sharp & Dohme Corp.
NCT00295633,Phase 3,3,A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone,"A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS477118) in Combination With Thiazolidinedione Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone",565,2006-03-01,2008-10-01,AstraZeneca
NCT00314860,Phase 3,NA,RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole,"A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)",568,2006-02-01,2006-12-01,GlaxoSmithKline
NCT00328692,Phase 3,2,PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects With Acute Heart Failure Syndrome and Renal Impairment Who Are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy",932,2006-08-01,2009-07-01,"NovaCardia, Inc."
NCT00343980,Phase 3,2,Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes,Safety and Efficacy of Inhaled Pre-prandial Human Insulin Plus Glimepiride Versus Rosiglitazone Plus Glimepiride in Type 2 Diabetes,363,2006-10-10,2008-03-10,Novo Nordisk A/S
NCT00346216,Phase 4,3,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen",24081,2006-10-04,2016-04-12,Pfizer
NCT00347360,Phase 3,2,The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial,"A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment With 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG CR) or 10mg, 20mg, or 40mg QD Doses of Lisinopril (Zestril) or a Combination of One of the Doses of Each Medication",654,2006-07-01,2008-04-01,GlaxoSmithKline
NCT00361530,Phase 3,2,Carotid Intima-media Thickness in Japan Statin Treatment Against Recurrent Stroke(J-STARS Echo),Effect of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) Reductase Inhibitor Upon Carotid Intima-media Complex Thickness in the Post-ischemic Patients With Hyperlipidemia During the Prospective Study of J-STARS.,854,2004-03-01,NA,"Translational Research Informatics Center, Kobe, Hyogo, Japan"
NCT00373685,Phase 4,2,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),"Gastrointestinal (GI) Randomized Event And Safety Open-Label NSAID Study (GI-Reasons): A Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS) In Osteoarthritis Patients",8067,2006-10-01,2010-11-01,Pfizer
NCT00375388,Phase 3,NA,"The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial",Study of Metformin HCL in Patients With Type 2 Diabetes Intensively Treated With Insulin: a Treatment Strategy for Insulin Resistance in Type 2 Diabetes Mellitus: a Randomized Controlled Trial,400,1998-01-01,2002-10-01,"Bethesda General Hospital, Hoogeveen"
NCT00377858,Phase 4,2,Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX),Comparison of Two Approaches to Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control on Oral Therapy: Comparison of Premixed Insulin Lispro Mid Mixture With Separate Basal and Bolus Insulin Injections,484,2006-08-01,2008-09-01,Eli Lilly and Company
NCT00382889,Phase 3,NA,As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma,"Multinational, Double Blind, Randomised, Parallel Group Study on the Therapeutic Efficacy and Safety of Beclomethasone Dipropionate 250 mg Combined With Salbutamol 100 mg in the Treatment of Patients With Mild Persistent Asthma.",480,2002-08-01,2004-09-01,Chiesi Farmaceutici S.p.A.
NCT00384215,Phase 4,NA,Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin,"Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin: a Randomized, Open, Parallel Study",352,2001-12-01,2005-02-01,Sanofi
NCT00384930,Phase 2/Phase 3,5,Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia",1058,2006-08-01,2008-10-01,Eli Lilly and Company
NCT00405717,Phase 4,NA,Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel,Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention,1300,2006-02-01,2008-05-01,Shenyang Northern Hospital
NCT00408629,Phase 3,2,Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis",518,2006-11-01,2010-03-01,Abbott
NCT00412984,Phase 3,2,Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation,"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation",18201,2006-12-01,2011-06-01,Bristol-Myers Squibb
NCT00424268,Phase 3,2,Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128),"Effect of Roflumilast in COPD Patients Treated With Tiotropium. A 24-week, Double-blind Study With 500 µg Roflumilast Once Daily Versus Placebo. The HELIOS Study",743,2007-01-01,2008-07-01,AstraZeneca
NCT00433966,Phase 3,2,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS™) or Uncoated Bare Metal Stent (EXPRESS2™),3602,2005-03-01,2010-11-01,"Cardiovascular Research Foundation, New York"
NCT00442546,Phase 3,3,Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement,"A Multicenter, Double-Blind Randomized, Placebo-Controlled Study Of The Efficacy And Safety Of Pregabalin In The Treatment Of Subjects With Post-Operative Pain Following Total Knee Arthroplasty (TKA)",307,2007-05-01,2008-12-01,Pfizer
NCT00445276,Phase 4,NA,Symptomatic Efficacy of Diacerein in Knee Osteoarthritis,Efficacy Study of Diacerein in the Symptomatic Treatment of Knee Osteoarthritis,500,2005-11-01,2006-09-01,Laboratoires NEGMA
NCT00477295,Phase 3,2,"A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy","A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",583,2007-05-01,2011-01-01,Eisai Inc.
NCT00494013,Phase 3,2,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY),Treat-to-Target Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Comparator) in Basal Therapy for Patients With Type 2 Diabetes Mellitus,442,2007-08-01,2008-09-01,Eli Lilly and Company
NCT00545324,Phase 4,NA,First Step With Singulair® Therapy (0476-323),"A 12 Week Multicenter, Open-Label, Randomized, Observational Study Comparing Singulair® 10 Mg As Controller Monotherapy In Adults With Mild Asthma ""To Low Dose"" Inhaled Corticosteroid Treatment",399,2002-09-01,2003-12-01,Merck Sharp & Dohme Corp.
NCT00590174,Phase 4,2,Clopidogrel Use and Long-term Safety After Drug-Eluting Stents Implantation,"Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events",1175,2007-10-01,2010-04-01,"CardioVascular Research Foundation, Korea"
NCT00614380,Phase 3,NA,Open Label Study Telmisartan and Amlodipine in Hypertension,An Open Label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Combination of Telmisartan 40mg + Amlodipine 5mg or the Combination of Telmisartan 80mg + Amlodipine 5mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension.,976,2008-01-01,NA,Boehringer Ingelheim
NCT00620867,Phase 4,3,Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States),A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee,393,2002-10-01,2003-03-01,Pfizer
NCT00624065,Phase 3,2,Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure,"COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing the Proportion of Subjects With Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either Carvedilol CR + Lisinopril or Lisinopril Monotherapy",348,2008-03-01,2008-08-01,GlaxoSmithKline
NCT00628758,Phase 3,2,A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma,"A Comparison of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5mg, 1 Inhalation Two Times a Day (b.i.d.) Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults a -26-week, Randomized, Open-label, Parallel-group, Multicentre Study",430,2005-12-01,2008-09-01,AstraZeneca
NCT00641602,Phase 4,2,"A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis","A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis.",1000,2002-12-01,2003-08-01,AstraZeneca
NCT00641680,Phase 3,3,Rhinocort Aqua Versus Placebo and Fluticasone Propionate,"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-group, Phase IIIb Study to Assess the Efficacy, Safety & Product Attributes of Rhinocort Aqua(Budesonide) Versus Placebo and FluticasonePropionate as an Active Comparator in Patients 12yrs Age &Older With SeasonalAllergicRhinitis",750,2003-04-01,2003-07-01,AstraZeneca
NCT00643201,Phase 3,2,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism,5614,2008-07-01,2013-03-01,Bristol-Myers Squibb
NCT00654498,Phase 3,2,Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS),"A Randomized, Double-blind, Placebo Controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally q.n. to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks",306,2008-04-01,2009-06-01,Boehringer Ingelheim
NCT00658632,Phase 3,2,Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD),A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD),1397,2008-02-01,2009-09-01,Eisai Inc.
NCT00667797,Phase 4,2,Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects,Pharmacoeconomic Outcomes of Levalbuterol and Racemic Albuterol in Inpatients Requiring Nebulization (POLARIS),486,2003-03-01,2005-05-01,Sunovion
NCT00697151,Phase 4,2,Patent Foramen Ovale in Cryptogenic Stroke Study,Patent Foramen Ovale in Cryptogenic Stroke Study,630,1993-06-01,2000-06-01,Columbia University
NCT00707993,Phase 3,2,Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects With Type 2 Diabetes",441,2008-06-01,2010-08-01,Takeda
NCT00714961,Phase 3,2,Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction,"A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy",3491,2003-02-01,2005-01-01,Sanofi
NCT00734318,Phase 3,4,Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma,"A Double Blind, Double Dummy, Randomised, Multicentre, Four Arm Parallel Group Study to Assess the Efficacy and Safety of FlutiForm® pMDI 250/10µg (2 Puffs Bid) vs Fluticasone pMDI 250µg (2 Puffs Bid) Plus Formoterol pMDI 12µg (2 Puffs Bid) Administered Concurrently in Adult Subjects With Severe Persistent, Reversible Asthma.",1667,2008-09-01,2009-10-01,Mundipharma Research Limited
NCT00740792,Phase 3,4,A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,"Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis.",776,2008-08-01,2008-11-01,Meda Pharmaceuticals
NCT00770653,Phase 3,2,Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.,Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia,305,2007-04-01,2009-05-01,Takeda
NCT00772174,Phase 3,2,Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes,"Double-blind, Randomized, Multicenter, Parallel-Group Study to Evaluate the Effects of Pioglitazone on Metabolic Syndrome in Patients With Type 2 Diabetes Treated With Metformin",418,2007-01-01,2008-02-01,Takeda
NCT00796653,Phase 3,4,Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II,"A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)",937,2009-01-01,NA,Boehringer Ingelheim
NCT00802373,Phase 3,2,Solifenacin Succinate Versus Tolterodine 4mg Once Daily,"Solifenacin in a Flexible Dose Regimen With Tolterodine as an Active Comparator in a Double-blind, Double-dummy, Randomised Overactive Bladder Symptom Trial",1355,2003-07-01,2004-10-01,Astellas Pharma Inc
NCT00821093,Phase 3,2,Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD),"A 12 Week Treatment, Multi-center, Randomized, Parallel Group, Double Blind, Double Dummy Study to Assess the Superiority of Indacaterol (150 µg o.d.) Via a SDDPI in Patients With Moderate to Severe COPD, Using Salmeterol (50 µg b.i.d.) as an Active Comparator Delivered Via a DISKUS Inhaler",1123,2009-01-01,2009-10-01,Novartis
NCT00829660,Phase 4,2,Acarbose Cardiovascular Evaluation Trial,"A Long-term, Multicentre, Double-blind, Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary Syndrome Who Have Impaired Glucose Tolerance",6526,2009-02-17,2017-04-18,University of Oxford
NCT00848081,Phase 3,2,A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Efficacy of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant Alpha1-Adrenergic Blocker Therapy",318,2009-03-01,2009-12-01,Eli Lilly and Company
NCT00856544,Phase 3,4,"A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications","Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS",795,2009-05-01,2011-01-01,Pfizer
NCT00856986,Phase 3,5,The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes,"The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes. A 26 Week, Randomised, Open-label, Parallel-group, Multicentre, Multinational Trial With a 26 Week Extension",987,2009-03-01,2010-11-01,Novo Nordisk A/S
NCT00870467,Phase 3,6,A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis,"A Phase 3 Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Comparing Adalimumab and Placebo in Adult Japanese Subjects With Rheumatoid Arthritis",334,2009-03-01,2011-08-01,Abbott
NCT00877383,Phase 3,2,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,"A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease",1142,2009-04-01,2010-02-01,Novartis
NCT00909597,Phase 3,3,A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes,"A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea",756,2009-05-01,2010-11-01,Hoffmann-La Roche
NCT00909779,Phase 3,2,Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects,A Large Simple Safety Study of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease,841,2009-06-01,2012-06-01,Sunovion
NCT00913120,Phase 2/Phase 3,4,Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery,"Phase II/III Study of YM150 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients Undergoing Elective Total Hip Replacement Surgery",610,2009-05-01,2010-03-01,Astellas Pharma Inc
NCT00919711,Phase 3,2,Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy,A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel® Therapies in Postmenopausal Women Transitioned From Weekly or Daily Alendronate Therapy,870,2009-09-01,2012-03-01,Amgen
NCT00949442,Phase 4,2,Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment,Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled,708,2009-07-01,2012-07-01,Sanofi
NCT00950794,Phase 4,2,Study of Salmeterol (SN408D) for Adult Asthma,Study of Salmeterol (SN408D) for Adult Asthma - Clinical Study of Salmeterol Compared With Hokunalin (Tulobuterol) Tape -,367,2003-09-01,2005-02-01,GlaxoSmithKline
NCT00975286,Phase 3,2,24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine,"A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin",446,2009-10-01,2011-08-01,Sanofi
NCT01009580,Phase 3,2,Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes,"A 26-week, Randomised, Open-labelled, Two-arm, Parallel-group, Treat-to-target Trial Comparing Efficacy and Safety of Soluble Insulin Analogue Combination (SIAC) Twice Daily (BID) With Biphasic Insulin Aspart (BIAsp) 30 BID, With or Without Metformin, With or Without DPP-4 Inhibitor, With or Without Pioglitazone in Subjects With Type 2 Diabetes in Inadequate Glycaemic Control on Once or Twice Daily Premixed or Self-mixed Insulin Regimen With or Without OADs (BOOST™: Intensify Premix 1)",447,2009-11-01,2010-08-01,Novo Nordisk A/S
NCT01029886,Phase 3,2,Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes,Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes and Inadequate Glycemic Control Treated With Lifestyle Modification and Oral Antidiabetic Medications,912,2010-01-01,2011-04-01,AstraZeneca
NCT01035255,Phase 3,2,This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure,"A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction",8442,2009-12-01,2014-05-01,Novartis
NCT01068652,Phase 4,2,"Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs","Effect of 50-week Treatment With Stepwise Insulin Intensification of Basal-bolus Insulin Analogues (Insulin Detemir and Aspart) or Biphasic Insulin Aspart 30 (NovoMix 30) All in Combination With Fixed Dose of Metformin on Glycaemic Control (Measured as HbA1c) in Subjects With Type 2 Diabetes. Open Labelled, Randomized, Two-arm, Parallel Group, Multi-centre, Multi-national Trial",403,2010-03-01,2012-05-01,Novo Nordisk A/S
NCT01123980,Phase 4,2,Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment,"An Open-labelled, Randomised, Parallel Group, 3 Week run-in and 24 Week Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Chinese and Japanese Insulin Naive Subjects With Type 2 Diabetes",521,2010-05-01,2011-06-01,Novo Nordisk A/S
NCT01154036,Phase 3,8,MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162),"A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin",1547,2010-07-01,2012-10-01,Merck Sharp & Dohme Corp.
NCT01185938,Phase 4,2,Statin Contrast Induced Nephropathy Prevention,Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention; PRATO-ACS Trial,500,2010-07-01,2012-10-01,Centro Cardiopatici Toscani
NCT01197534,Phase 3,3,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.,"(OSKIRA-2): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to DMARDs",913,2010-09-01,2013-03-01,AstraZeneca
NCT01197755,Phase 3,3,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist,"(OSKIRA-3): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With Inadequate Response to a TNF-alpha Antagonist",323,2010-09-01,2013-02-01,AstraZeneca
NCT01202903,Phase 3,2,Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy,"A 24-week, Phase III Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study of Xolair® (Omalizumab) in Patients With Moderate to Severe Persistent Allergic Asthma Who Remain Not Adequately Controlled Despite GINA (2009) Step 4 Therapy",616,2010-09-01,2013-10-01,Novartis
NCT01210001,Phase 3,3,Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin,"A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Trial of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite a Background Therapy of Pioglitazone Alone or in Combination With Metformin",499,2010-09-01,NA,Boehringer Ingelheim
NCT01270464,Phase 3,3,A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma,"A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma",315,2011-02-01,2013-09-01,Teva Pharmaceutical Industries
NCT01388361,Phase 3,3,Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin,"A Trial Comparing the Efficacy and Safety of Adding Liraglutide Versus Addition of Insulin Aspart With the Largest Meal to Insulin Degludec, Both in Combination With Metformin, in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification (BEGIN™: VICTOZA® ADD-ON)",413,2011-09-01,2012-07-01,Novo Nordisk A/S
NCT01394952,Phase 3,2,Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND),The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND),9622,2011-07-01,2018-07-01,Eli Lilly and Company
NCT01395745,Phase 3,2,CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus,"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus",442,2013-02-01,2016-10-01,Anthera Pharmaceuticals
NCT01437397,Phase 3,5,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD).",1692,2011-09-01,2013-02-01,AstraZeneca
NCT01510158,Phase 3,3,Combining Lesinurad With Allopurinol in Inadequate Responders,"A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol.",607,2012-01-01,2014-08-01,"Ardea Biosciences, Inc."
NCT01548001,Phase 4,3,Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis,"A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis",910,2012-05-01,2017-01-01,"Jiangsu Simcere Pharmaceutical Co., Ltd."
NCT01576419,Phase 3,2,"Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients","Double Blinded, Randomized, Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients",309,2010-01-01,2011-09-01,"PMG Pharm Co., Ltd"
NCT01578850,Phase 4,2,Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening,"A Randomized, Double-blind Placebo-controlled Study Of The Maintenance Of Efficacy Of Etanercept Plus Dmard(s) Compared With Dmard(s) Alone In Subjects With Rheumatoid Arthritis After Achieving An Adequate Response With Etanercept Plus Dmard(s)",491,2012-07-01,2015-03-01,Pfizer
NCT01590771,Phase 3,2,A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy, Alone or in Combination With Metformin",498,2012-07-09,2014-06-24,Merck Sharp & Dohme Corp.
NCT01698320,Phase 3,2,Safety Study of Albuterol Spiromax® in Subjects With Asthma,A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma,364,2012-10-01,2013-12-01,Teva Pharmaceutical Industries
NCT01715298,Phase 3,2,NVA237 BID Versus Placebo Twelve-week Efficacy Study,"A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients",432,2012-11-01,2013-12-01,Novartis
NCT01730053,Phase 3,6,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),"A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin Versus Ezetimibe Added-on to Rosuvastatin Versus Rosuvastatin Dose Increase in Patients Who Are Not Controlled on Rosuvastatin",305,2012-11-01,2014-05-01,Regeneron Pharmaceuticals
NCT01772147,Phase 3,2,Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.,"A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.",608,2013-01-01,2013-08-01,GlaxoSmithKline
NCT01785472,Phase 3,3,Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension,"A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Patients With Essential Hypertension",1438,2013-04-01,2014-08-01,Novartis
NCT01822899,Phase 3,2,A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"DB2116134: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD",717,2013-04-04,2013-10-07,GlaxoSmithKline
NCT01867125,Phase 3,3,A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication",1081,2013-07-31,2017-01-02,Hoffmann-La Roche
NCT01911364,Phase 3,3,Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease,A 52-wk Randomized Double Blind Parallel Trial: Combination of Beclometasone+Formoterol+Glycopyrrolate vs Tiotropium and vs Combination of Beclometasone+Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease,3686,2014-01-01,2016-03-01,Chiesi Farmaceutici S.p.A.
NCT01973231,Phase 4,2,Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes,Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes,404,2013-10-01,2014-11-01,Novo Nordisk A/S
NCT02049814,Phase 4,2,Efficacy and Safety of Voglibose Compared With Acarbose in Patients With Type 2 Diabetes,"Efficacy and Safety of Voglibose Compared With Acarbose in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone: a Randomized, Open-label, Non-inferiority Study",494,2014-06-01,2016-06-01,Takeda
NCT02054897,Phase 3,4,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes,388,2014-02-03,2015-05-08,Novo Nordisk A/S
NCT02072330,Phase 2/Phase 3,5,Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.,"A Randomized, Double-Blind, Multicenter, Phase 2/3 Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB (Fix-dose Combination of Azilsartan and Amlodipine) and Hydrochlorothiazide in Comparison With TAK-536CCB or Hydrochlorothiazide Monotherapy in Patients With Grade I or II Essential Hypertension",353,2013-03-01,2013-12-01,Takeda
NCT02104804,Phase 3,2,Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control,"A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Chinese Subjects in China With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Insulin Alone or on Insulin in Combination With Metformin",953,2014-05-07,2016-02-26,AstraZeneca
NCT02168842,Phase 3,2,Efficacy of Isradipine in Early Parkinson Disease,Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease,336,2014-09-01,2019-03-01,University of Rochester
NCT02172287,Phase 3,3,"Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)","A Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in a Six-Month, Double-Blind, Double-Dummy, Safety and Efficacy Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)",623,1999-02-01,NA,Boehringer Ingelheim
NCT02173691,Phase 3,3,Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD),"A Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in a Six-Month, Double-Blind, Double-Dummy, Safety and Efficacy Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)",584,1999-02-01,NA,Boehringer Ingelheim
NCT02183701,Phase 3,2,Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension,A Prospective Randomised Open-Label Blinded Endpoint Trial Comparing Telmisartan 80 mg and Losartan 50 mg + Hydrochlorothiazide 12.5 mg (Fixed Dose Combination) in Patients With Mild-to-Moderate Essential Hypertension Using Ambulatory Blood Pressure Monitoring,715,1998-04-01,NA,Boehringer Ingelheim
NCT02224157,Phase 3,2,A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma,A Clinical Study Comparing Symbicort 'as Needed' With Pulmicort Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma,4215,2014-11-28,2017-08-16,AstraZeneca
NCT02244255,Phase 4,2,FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia,"An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia",1993,1998-08-01,NA,Boehringer Ingelheim
NCT02246920,Phase 3,3,"Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients","A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Nasal Spray, 50 mcg With Flonase® Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis",1110,2014-03-01,2014-09-01,Teva Pharmaceuticals USA
NCT02311231,Phase 4,2,Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART,"Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform",6012,2014-06-01,2017-03-01,Uppsala University
NCT02438787,Phase 3,3,A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Subjects With Active Radiographic Axial Spondyloarthritis",315,2015-07-31,2017-08-31,"Janssen Research & Development, LLC"
NCT02441218,Phase 3,2,Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study,NA,6505,2006-09-01,2010-04-01,Servier
NCT02561806,Phase 3,2,A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis,"A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis",300,2015-10-01,2017-10-01,Eli Lilly and Company
NCT02684357,Phase 3,3,BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis,BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2),500,2016-02-01,2017-09-01,AbbVie
NCT02836873,Phase 3,2,Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment,A Double Blind Placebo Controlled Study to Evaluate the Effect of Bexagliflozin Tablets on Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment,300,2016-09-01,2018-02-01,Theracos
NCT02860624,Phase 3,2,Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients,"Efficacy and Safety of Ilaprazole for GERD: A Randomized, Double-Blind, Esomeprazole-Controlled, Phase 3, Multicenter Trial in China",550,2011-12-01,NA,Livzon Pharmaceutical Group Inc.
NCT02890173,Phase 3,3,Study of CS-3150 in Patients With Essential Hypertension,A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study),1001,2016-09-01,2017-07-11,"Daiichi Sankyo, Inc."
NCT00000569,Phase 3,2,Lung Health Study II,The Chronic Obstructive Pulmonary Disease Early Intervention Trial,1116,1993-09-01,1999-05-01,University of Minnesota - Clinical and Translational Science Institute
NCT00006305,Phase 3,4,Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes,Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes,2368,2000-09-01,2009-03-01,University of Pittsburgh
NCT00027066,Phase 3,2,Warfarin Versus Aspirin Recurrent Stroke Study,A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke,2206,1993-06-01,2001-11-01,Columbia University
NCT00046254,Phase 3,NA,Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture,NA,2127,2002-02-01,2007-02-01,Novartis
NCT00090298,Phase 3,NA,Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058),"A Multicenter, Randomized, Double-Blind Study to Evaluate the Lipid-Altering Efficacy and Safety of the Ezetimibe/Simvastatin Combination Tablet Versus Rosuvastatin in Patients With Primary Hypercholesterolemia",2815,2004-04-01,2004-12-01,Merck Sharp & Dohme Corp.
NCT00106847,Phase 3,NA,A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance InfliximabTherapy in Patients With Plaque-Type Psoriasis",683,2003-01-01,2005-07-01,"Centocor, Inc."
NCT00109317,Phase 3,NA,A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy,"A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy",686,2002-09-01,2003-02-01,"Genentech, Inc."
NCT00132717,Phase 3,NA,A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808),"An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination Tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Coronary Event",450,2005-01-01,2007-06-01,Merck Sharp & Dohme Corp.
NCT00135096,Phase 3,2,Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin,"APIDRA® (Insulin Glulisine) Administered Premeal vs Postmeal in Adult Subjects With Type 2 Diabetes Mellitus Receiving LANTUS® (Insulin Glargine) as Basal Insulin: a Multicenter, Randomized, Parallel, Open Label Clinical Study",345,2004-08-01,2007-07-01,Sanofi
NCT00135876,Phase 3,NA,Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients,A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE),512,2002-10-01,2006-11-01,Ontario Clinical Oncology Group (OCOG)
NCT00140946,Phase 4,NA,A Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients (0476-075),"A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Two-Period, Parallel-group Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients.",546,1998-03-01,2000-10-01,Merck Sharp & Dohme Corp.
NCT00143377,Phase 4,NA,Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB,"A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial To Evaluate The Effectiveness Of Detrusitol Sr 4mg On Patient's Perception Of Bladder Condition (PPBC).",600,2004-09-01,2005-10-01,Pfizer
NCT00145730,Phase 4,NA,Prevention of Ectopic Bone Related Pain and Disability After Hip Replacement Surgery With Peri-Operative Ibuprofen,A Multicentre Randomised Placebo-Controlled Trail of Ibuprofen for the Prevention of Ectopic Bone-Related Pain and Disability After Elective Hip Replacement Surgery (HIPAID),1000,2002-02-01,2004-05-01,The George Institute
NCT00149227,Phase 4,2,Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study),Add-on Effects of Valsartan on Morbi- Mortality in High Risk Hypertension,3031,2004-01-01,2009-01-01,Kyoto Prefectural University of Medicine
NCT00170378,Phase 4,NA,The Use of Low Molecular Weight Heparin in Traumatic Brain Injury,The Use of Low Molecular Weight Heparin in Traumatic Brain Injury,300,2002-12-01,2005-08-01,Minneapolis Medical Research Foundation
NCT00172081,Phase 3,2,TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis,"An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis",2532,2000-04-01,2003-11-01,Shire
NCT00190580,Phase 4,2,Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease,Effects of Valsartan on the Progression of Renal and Cardiovascular Disease - Kanagawa Valsartan Trial (KVT),312,2003-02-01,2008-04-01,KVT-Study Group
NCT00234897,Phase 4,NA,Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis,Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO),1938,2004-08-01,NA,Abbott
NCT00235248,Phase 3,2,Aortic Arch Related Cerebral Hazard Trial (ARCH),Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery,350,2002-02-01,2012-07-01,Assistance Publique - Hôpitaux de Paris
NCT00236392,Phase 3,NA,"A Study of Efficacy and Safety of ""On-demand"" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)","Double-Blind Placebo-Controlled Randomized Withdrawal Trial Assessing the Efficacy and Tolerability of ""On-Demand"" Maintenance Therapy With 10mg o.d. Rabeprazole for 6 Months in Non-Erosive Reflux Disease Patients With Complete Symptom Relief After 4 Week Open Acute Phase",422,2001-10-01,2002-10-01,"Janssen Pharmaceutica N.V., Belgium"
NCT00241488,Phase 3,NA,DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia,": An Open-Label, Randomised, Multi-Centre, Phase IIIb/IV, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin and Atorvastatin in Subjects With Type IIa and IIb Hypercholesterolaemia (DISCOVERY)",1362,2003-06-01,2007-02-01,AstraZeneca
NCT00251641,Phase 3,2,The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED),"An Open-Label, Randomized Efficacy and Safety Study of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis",868,2005-09-01,2008-06-01,Merck Sharp & Dohme Corp.
NCT00251823,Phase 3,NA,Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI),The Safety and Efficacy of Eptifibatide-Facilitated Percutaneous Coronary Angioplasty Versus Primary Percutaneous Coronary Angioplasty Alone,400,2005-07-01,2008-09-01,Ottawa Heart Institute Research Corporation
NCT00253214,Phase 3,NA,Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation,Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation,973,2001-03-01,2002-07-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00255164,Phase 3,3,Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis,A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis,451,2006-01-01,2006-11-01,Takeda
NCT00259766,Phase 3,NA,SHARE - Symbicort and Health Economics in a Real Life Evaluation,"Symbicort and Health Economics in a Real Life Evaluation - SHARE - A Randomised, Open-Label, Parallel-Group, Multicentre Study to Assess the Asthma-Related Health-Care Costs, in Ordinary Clinical Practice During 12 Months",1970,2004-04-01,2007-05-01,AstraZeneca
NCT00264212,Phase 4,NA,AMISH : Aprovel for Management of Isolated Systolic Hypertension,A Multicentre Prospective Randomized Open-Label 12-Week Study With Blinded Evaluation Comparing the Efficacy and Safety of Irbesartan and Irbesartan-Hydrochlorothiazide Fixed Combination With Amlodipine and Amlodipine Plus Hydrochlorothiazide in Elderly Patients With Isolated Systolic Hypertension,436,2004-08-01,NA,Sanofi
NCT00269906,Phase 3,2,"A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty",Chimeric Anti-Platelet Therapy (Abciximab) in Unstable Angina Refractory to Standard Medical Therapy Trial (CAPTURE),1265,1993-05-01,1995-12-01,"Centocor, Inc."
NCT00277264,Phase 3,NA,Spiriva® Assessment of FEV1 (SAFE),"Spiriva® Assessment of FEV1 (SAFE). The Effect of Inhaled Tiotropium Bromide (18 Mcg Once Daily) on the Change in FEV1 During Long-term Treatment in Patients With COPD. A One-year Parallel Group, Double-blind, Randomised, Placebo-controlled Study",914,2002-01-01,2004-05-01,Boehringer Ingelheim
NCT00321737,Phase 3,3,Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis,A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.,445,2006-05-01,2007-05-01,Takeda
NCT00325806,Phase 4,NA,Ramipril - Hypertension,Prevention of Hypertension in Patients With High-Normal Blood Pressure With the Angiotensin-Converting-Enzyme-Inhibitor Ramipril - a Randomised Prevention Trial of the German Hypertension League.,1008,2000-05-01,2005-08-01,Sanofi
NCT00334386,Phase 4,NA,Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.,"Multicentre, Multinational, Parallel, Randomised, Double Blind Clinical Trial, to Evaluate the Non-inferiority of PR Torasemide Versus IR Torasemide in Patients With Mild or Moderate Arterial Hypertension.",388,2005-04-01,2006-02-01,Ferrer Internacional S.A.
NCT00348504,Phase 3,NA,"Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.","Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.",1300,2003-03-01,2005-06-01,Abbott
NCT00354939,Phase 4,NA,Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement,"10-week, Open, National, Multicenter Clinical Trial to Evaluate the Safety of Insulin Glargine in Type 2 Diabetes Mellitus Patients, on Intensified Conventional Therapy (ICT)",480,2003-10-01,2004-03-01,Sanofi
NCT00361699,Phase 3,2,hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP),Effect of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) Reductase Inhibitor Upon the Serum High Sensitive CRP in the Post-ischemic Patients With Hyperlipidemia During the Prospective Study of J-STARS.,1095,2004-03-01,NA,"Translational Research Informatics Center, Kobe, Hyogo, Japan"
NCT00379769,Phase 3,4,RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes,"A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and Glycaemia",4447,2001-04-01,2008-12-01,GlaxoSmithKline
NCT00393458,Phase 3,4,"Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control","A 52-week Treatment, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (300 and 600 µg Once Daily) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 µg Twice Daily) as an Active Control",1732,2006-10-01,2008-07-01,Novartis
NCT00393991,Phase 3,4,"Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma","A Randomized, Double-blind, Placebo-controlled, Parallel, Stratified, Multi-center, 12-Week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm)100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI)With the Administration of Placebo or Fluticasone (100 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent and Adult Patients With Mild to Moderate Asthma",475,2006-07-01,2008-04-01,SkyePharma AG
NCT00396357,Phase 3,2,Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone,"A Multicenter, Double-blind, Randomized Parallel-group, Study to Demonstrate the Effect of 24 Weeks Treatment With Vildagliptin 100 mg qd as add-on to Metformin 500 mg Bid Compared to Metformin 1000 mg Bid in Patients With Type 2 Diabetes Inadequately Controlled on Metformin 500 mg Bid Monotherapy",914,2006-10-01,NA,Novartis
NCT00404547,Phase 4,2,Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102),"An Open-Label Randomized, Multicenter Study in Patients With Asthma to Evaluate the Effectiveness of Alvesco® (Ciclesonide) Compared to Asthma Usual Care in a Primary Practice Setting",1121,2006-11-01,2008-12-01,AstraZeneca
NCT00419757,Phase 3,2,"An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma","A 12-week, Randomised, Double Blind, Active-controlled, Multi-centre, Phase IIIB Study Comparing the Efficacy and Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily Versus Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily, in Adult/Adolescent (> 12 Yrs) Hispanic Subjects With Asthma",558,2007-01-01,2008-06-01,AstraZeneca
NCT00421122,Phase 3,3,Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD,"A 6-Month, Phase IIIA, Multi-Center,Randomised,Double-Blind, Double-Dummy, Parallel-Group Study of the Efficacy and Safety of Symbicort® Turbuhaler®+ Bricasol® pMDI Compared With Pulmicort® Turbuhaler®+Bricasol® pMDI in Chinese Patients With COPD",315,2006-09-01,2007-11-01,AstraZeneca
NCT00435461,Phase 4,NA,Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine,A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis,1000,2006-12-20,2007-02-28,GlaxoSmithKline
NCT00438451,Phase 4,3,Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs,"A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy.",361,2007-01-01,2011-08-01,Johannes Gutenberg University Mainz
NCT00439244,Phase 3,3,Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis,"A One-year Partial Double-blinded, Randomized, Multi-center, Multi-national Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis",412,2006-12-01,2009-02-01,Novartis
NCT00439738,Phase 4,2,Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults,"A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients",412,2006-12-01,NA,Novartis
NCT00447759,Phase 4,2,The Standard Care Versus Celecoxib Outcome Trial,Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's,7300,2007-06-01,2015-08-01,University of Dundee
NCT00454896,Phase 3,2,A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB),"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5mg and 10mg VESIcare® for the Treatment of Urgency Associated With Overactive Bladder",739,2004-05-01,2005-09-01,Astellas Pharma Inc
NCT00481364,Phase 3,2,Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease in Hemodialysis Patients,"Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease: Prospective, Randomized, Controlled Study",446,2006-11-01,2008-12-01,Ege University
NCT00562289,Phase 3,3,Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence,Closure of Patent Foramen Ovale or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence,664,2007-12-01,2016-12-01,Assistance Publique - Hôpitaux de Paris
NCT00637273,Phase 3,3,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)","A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release(Once Weekly) to Those of Sitagliptin and a Thiazolidinedione in Subjects With Type 2 Diabetes Mellitus Treated With Metformin",514,2008-01-01,2009-07-01,AstraZeneca
NCT00641537,Phase 3,5,CLARITY Extension Study,"A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects With Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)",867,2008-02-01,2011-12-01,EMD Serono
NCT00644735,Phase 4,2,"Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed","Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed.",750,2002-12-01,2004-01-01,AstraZeneca
NCT00652392,Phase 3,2,Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM,"A 12 Week, Randomized, Double-Blind, Double-Dummy, Placebo and Active-controlled Study of Symbicort pMDI Administered Once Daily in Adults and Adolescents With Asthma - STEM",750,2003-04-01,2004-06-01,AstraZeneca
NCT00653744,Phase 3,2,Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES),"A 6-Week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects. (ARIES)",1700,2002-03-01,2004-03-01,AstraZeneca
NCT00662909,Phase 3,3,A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,"A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder",2149,2008-03-28,2009-04-22,Astellas Pharma Inc
NCT00680953,Phase 3,3,Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis,"A Randomized, Double-Blind, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of Denosumab in Japanese Osteoporotic Subjects With Prevalent Fragility Vertebral Fracture(s)",1262,2008-05-01,2012-07-01,"Daiichi Sankyo, Inc."
NCT00688701,Phase 3,4,GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 12-week Study Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Not Treated With Antidiabetic Agents",361,2008-05-01,2009-12-01,Sanofi
NCT00740714,Phase 3,3,Effects of Coenzyme Q10 (CoQ) in Parkinson Disease,Effects of Coenzyme Q10 in Parkinson Disease - Phase III,600,2008-12-01,2011-08-01,Weill Medical College of Cornell University
NCT00741715,Phase 3,15,Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia,"A Multicenter, Randomized, Placebo-controlled, ""Factorial"" Design, 12-month Study to Evaluate the Efficacy and Safety of AVE5530 25 mg/Day and 50 mg/Day Co-administered With All Registered Atorvastatin Strengths Ranging From 10 mg to 80 mg in Patients With Primary Hypercholesterolemia",1736,2008-08-01,2009-06-01,Sanofi
NCT00750113,Phase 4,3,Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.,A Multicenter Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control and Beyond: Comparison of Two Treatment Strategies.,405,2007-10-01,2009-08-01,Bayer
NCT00783744,Phase 3,2,Insulin Glargine Combination Therapies in Type II Diabetics,"28-week, Open, Randomized, Multinational, Multicenter Clinical Trial to Compare Efficacy and Safety of Combination Therapy of Glimepiride Plus Metformin Plus HOE901 Insulin Analogue Versus a Two-injection Conventional Therapy With Premixed Insulin NPH 30/70 Bid in Type 2 Diabetes Mellitus Patients Poorly Controlled With Oral Antidiabetic Drug Treatment.",375,2001-12-01,NA,Sanofi
NCT00790205,Phase 3,2,Sitagliptin Cardiovascular Outcomes Study (MK-0431-082),"TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control",14671,2008-12-10,2015-03-30,Merck Sharp & Dohme Corp.
NCT00809965,Phase 3,3,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,"A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome",15526,2008-11-01,2011-09-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00818883,Phase 3,2,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension,"A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension",609,2009-02-01,2009-11-01,Takeda
NCT00853957,Phase 4,2,Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension,"An 8-week Multicenter, Randomized, Double-blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine (150/5 mg, 300/10 mg) Versus Amlodipine Alone (5 mg, 10 mg) in African American Patients With Stage 2 Hypertension",443,2009-02-01,2009-08-01,Novartis
NCT00856284,Phase 3,3,Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus,"A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination With Metformin in Subjects With Type 2 Diabetes",2639,2009-03-01,2012-10-01,Takeda
NCT00960141,Phase 3,3,A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED),"A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis-Fall Study",829,2000-08-01,2000-11-01,Merck Sharp & Dohme Corp.
NCT00979901,Phase 3,4,Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED),"A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Seasonal Allergic Rhinitis--Spring Study",1577,2000-03-01,2000-05-01,Merck Sharp & Dohme Corp.
NCT01001572,Phase 3,3,Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension,"A Multi-national, Multi-center, Double-blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 160/5 mg to Valsartan 160 mg Alone in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 160 mg Monotherapy",932,2009-09-01,2010-05-01,Novartis
NCT01022762,Phase 4,2,Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment,"A 16-week, Multicentre, Randomised, Open-label, Parallel Group Study to Investigate the Efficacy and Safety Profiles of Repaglinide Monotherapy Compared to Gliclazide Monotherapy in Chinese Antidiabetic-naïve Subjects With Type 2 Diabetes",440,2009-11-01,2010-11-01,Novo Nordisk A/S
NCT01023581,Phase 3,7,Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes",784,2009-11-01,2011-06-01,Takeda
NCT01038427,Phase 3,3,A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis,"A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Mometasone Nasal Spray (Lek Pharmaceuticals) With NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis",1103,2009-12-01,2010-02-01,Sandoz
NCT01117350,Phase 4,2,Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure,"A 24-week, Multicenter, International, Randomized (1:1), Parallel-group, Open-label, Comparative Study of Insulin Glargine Versus Liraglutide in Insulin-naïve Patients With Type 2 Diabetes Treated With Oral Agents and Not Adequately Controlled, Followed by a 24-week Extension Period With Insulin Glargine for Patients Not Adequately Controlled With Liraglutide",978,2010-07-01,2013-03-01,Sanofi
NCT01155466,Phase 3,5,A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938),"A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3;Protocol No. P04938)",778,2010-07-14,2012-12-20,Merck Sharp & Dohme Corp.
NCT01177384,Phase 3,2,Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130),"A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Acarbose Monotherapy",380,2011-01-25,2013-03-25,Merck Sharp & Dohme Corp.
NCT01189890,Phase 3,2,Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251),"A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control",480,2010-08-16,2012-10-31,Merck Sharp & Dohme Corp.
NCT01197521,Phase 3,3,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.,"(OSKIRA-1): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate",923,2010-09-01,2012-11-01,AstraZeneca
NCT01202188,Phase 3,5,"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","A 26-week Treatment Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled (Open Label) Study to Assess the Efficacy, Safety and Tolerability of QVA149 (110/50 μg q.d.) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",2144,2010-09-01,2012-03-01,Novartis
NCT01243177,Phase 3,2,Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",888,2011-04-01,2015-08-01,UCB Pharma
NCT01263925,Phase 3,2,Prostaglandin E1 in Outpatients With Intermittent Claudication,Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication,561,2001-04-01,2011-04-01,UCB Pharma
NCT01293097,Phase 4,2,Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI,Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention(PCI),2884,2010-06-01,2011-10-01,Peking University First Hospital
NCT01294462,Phase 3,2,Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS),"A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes(ACS) for Whom PCI is Planned",801,2011-02-01,2012-07-01,AstraZeneca
NCT01315249,Phase 3,2,QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD),"A 26-week Treatment, Multi-center, Randomized, Doubleblind, Double Dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",523,2011-03-01,2012-03-01,Novartis
NCT01327846,Phase 3,4,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),"A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP",10067,2011-04-11,2019-12-02,Novartis
NCT01349777,Phase 4,2,Effectiveness of Clopidogrel Resinate in PCI(PRIDE),Effectiveness of Clopidogrel Resinate(PRegrel®) in Patients Undergoing Percutaneous Coronary Intervention Compared With ClopiDogrEl Bisulfate(Plavix®),1056,2010-03-15,2017-03-14,"CardioVascular Research Foundation, Korea"
NCT01368536,Phase 4,3,Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes,"A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes",975,2011-05-01,2012-02-01,Novartis
NCT01370005,Phase 3,3,12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus,"A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus",825,2011-06-01,2012-07-01,Boehringer Ingelheim
NCT01458951,Phase 3,2,"A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis","A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.",547,2012-06-01,2015-06-01,Pfizer
NCT01459367,Phase 3,3,Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis,"A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg Once-Daily) Compared to AG-1749 (15 mg Once-Daily) in a 24-week Maintenance Treatment in Patients With Healed Erosive Esophagitis (EE).",607,2011-10-01,2013-03-01,Takeda
NCT01483560,Phase 3,2,REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL),Phase 3 Study of Metformin in Adults With Type 1 Diabetes,502,2011-12-01,2017-04-18,University of Glasgow
NCT01498003,Phase 4,2,Tirofiban in Stenting for Long Coronary Lesion,Safety and Efficacy of Peri-procedural Use of Tirofiban in Elective Percutaneous Coronary Intervention for Long Coronary Lesions With Overlapping Drug-Eluting Stent,748,2011-11-01,2014-06-01,Shanghai Jiao Tong University School of Medicine
NCT01512979,Phase 4,2,"Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes","A 24-week, Randomized, Double-blind, Active-controlled, Parallel Group Trial to Assess the Superiority of Oral Linagliptin and Metformin Compared to Linagliptin Monotherapy in Newly Diagnosed, Treatment-naïve, Uncontrolled Type 2 Diabetes Mellitus Patients",316,2012-01-01,2013-04-01,Boehringer Ingelheim
NCT01513460,Phase 3,3,"Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease","A Multicenter, Randomized, Blinded, Active-controlled, Parallel-group Study to Compare the Efficacy, Tolerability and Safety of NVA237 Compared to Tiotropium Added on to Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease",773,2012-04-01,2013-12-01,Novartis
NCT01613326,Phase 3,2,"Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","A 12-week Treatment, Randomized, Blinded, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of NVA237 (50 µg o.d.) Compared to Tiotropium (18 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease (COPD)",657,2012-06-01,2013-01-01,Novartis
NCT01636713,Phase 3,3,A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD,"A 24-week Randomised, Double-blind and Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",581,2012-07-01,2013-10-01,GlaxoSmithKline
NCT01676116,Phase 3,2,The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy,The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III -GLP-1 Switch),438,2012-08-01,2014-03-01,Novo Nordisk A/S
NCT01721044,Phase 3,3,A Moderate to Severe Rheumatoid Arthritis Study,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors",527,2013-01-01,2014-09-01,Eli Lilly and Company
NCT01730040,Phase 3,7,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),"A Randomized, Double-Blind Study of the Efficacy and Safety of Alirocumab Added on to Atorvastatin Versus Ezetimibe Added on to Atorvastatin Versus Atorvastatin Dose Increase Versus Switch to Rosuvastatin in Patients Who Are Not Controlled on Atorvastatin",355,2012-10-01,2014-05-01,Regeneron Pharmaceuticals
NCT01890122,Phase 3,4,Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin and Metformin Fixed Dose Combination, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes Mellitus",647,2013-09-01,2015-10-01,Takeda
NCT01947491,Phase 3,4,"A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis",NA,394,2013-11-01,2015-01-01,"Promius Pharma, LLC"
NCT01989468,Phase 3,3,24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis,"A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3 Years in Subjects With Active Psoriatic Arthritis",414,2014-04-10,2018-01-22,Novartis
NCT02022930,Phase 3,3,Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis,"A Multi-center, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Hydros and Hydros-TA Joint Therapies for Management of Pain Associated With Osteoarthritis in the Knee",510,2014-01-01,2016-06-01,"Carbylan Therapeutics, Inc."
NCT02152605,Phase 3,2,A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"A 12 Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects With COPD",498,2014-09-01,2015-03-05,GlaxoSmithKline
NCT02177409,Phase 3,2,Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension,"A Prospective Randomized Open-Label, Blinded-Endpoint (PROBE) Trial Comparing MICARDIS® (Telmisartan) (80 mg QD) and Amlodipine (5 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring.",431,1998-04-01,NA,Boehringer Ingelheim
NCT02348723,Phase 4,2,Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT),Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial),678,2015-04-28,2016-11-14,Boehringer Ingelheim
NCT02396732,Phase 4,2,Aspirin and Enoxaparin for VTE in Trauma,The Role Of Combined Therapy With Aspirin and Enoxaparin In Prevention Of Venous Thromboembolism In Trauma Patients: A Randomized-Controlled Trial,800,2016-02-01,2018-05-01,University of Miami
NCT02413398,Phase 3,2,A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase III Study to Evaluate the Glycemic Efficacy and Renal Safety of Dapagliflozin in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment (CKD 3A) Who Have Inadequate Glycemic Control.",323,2015-06-15,2017-11-07,AstraZeneca
NCT02421510,Phase 3,3,"Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy","A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy",782,2015-05-01,2017-07-01,Sanofi
NCT02446990,Phase 3,2,Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure,Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double-blind Placebo-controlled International Multicenter Study. Study Assessing the Morbi-mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease,19102,2009-09-01,2014-01-01,Servier
NCT02552212,Phase 3,2,Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS,"Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation",317,2015-09-01,2020-04-01,UCB Pharma
NCT02579850,Phase 3,2,2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients,"52-week, Double Blind, Randomized, 2 Active Parallel Arms Study of Fixed Combination CHF 5993 Administered vs Ultibro® in COPD Patients",1532,2015-05-29,2017-07-10,Chiesi Farmaceutici S.p.A.
NCT02762578,Phase 3,2,Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes,A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes BOOST: INTENSIFY PREMIX/ALL 2,543,2016-05-03,2017-06-19,Novo Nordisk A/S
NCT00051285,Phase 3,2,"ESSENTIAL-""The Studies of Oral Enoximone Therapy in Advanced Heart Failure""","ESSENTIAL Protocol No. My-021 and Protocol No. My-026, Each Titled: A Phase III, Randomized, Double-Blind, Multicenter, Parallel Group, Placebo-Controlled Study of Oral Enoximone vs. Placebo in Advanced Chronic Heart Failure Subjects",1800,2002-02-01,2005-06-01,Gilead Sciences
NCT00091598,Phase 3,NA,ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH),"ARIES 1 and ARIES 2: Ambrisentan in PAH - A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension",372,2004-01-01,2006-02-01,Gilead Sciences
NCT00093925,Phase 3,2,Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC),Evaluation of Clevidipine in the Postoperative Treatment of Hypertension Assessing Safety Events (With Nicardipine as Active Comparator) (ECLIPSE-NIC),739,2004-05-01,2006-09-01,The Medicines Company
NCT00095147,Phase 3,5,Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis,"A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination With Methotrexate in Controlling Disease Activity in Subjects With Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate",431,2005-02-01,2009-07-01,Bristol-Myers Squibb
NCT00096603,Phase 3,NA,A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g,"An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g",450,2002-10-01,2004-07-01,"Genentech, Inc."
NCT00097591,Phase 3,2,A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention,A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention,13619,2004-11-01,2007-07-01,Eli Lilly and Company
NCT00108823,Phase 3,NA,The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121),"A 24-week, Double Blind, Randomized Study to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Parameters Indicative of Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease",550,2004-10-01,NA,AstraZeneca
NCT00133003,Phase 4,2,"Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)","Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)",2022,2003-03-01,2006-01-01,Deutsches Herzzentrum Muenchen
NCT00142584,Phase 3,2,Evaluation of the Long-Term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension,"An Open-Label, Randomized Study Evaluating the Long-Term Effects of Metoprolol Versus Nebivolol as Monotherapy or in Combination With Amlodipine or Hydrochlorothiazide for the Treatment of Patients With Hypertension",1000,2005-08-01,2008-03-01,Mylan Bertek Pharmaceuticals
NCT00170950,Phase 3,2,Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension,"A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension",11506,2003-10-01,2008-05-01,Novartis
NCT00171002,Phase 3,NA,Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Amlodipine Alone,A Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of Valsartan/Amlodipine 160/10 mg Versus Amlodipine 10 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Amlodipine 10 mg Monotherapy,936,2004-11-01,2005-06-01,Novartis
NCT00219973,Phase 3,NA,"CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)","Multicentric, Rand., D-b, Pbo Controlled Clinical Trial to Evaluate the Efficacy and the Safety of the Thromboprophylaxis With Bemiparin 3,500 IU/d for 28 Days Compared to 8 Days, in Patients Undergoing Oncological Abdominal/ Pelvic Surgery",526,2005-05-01,2009-04-01,Rovi Pharmaceuticals Laboratories
NCT00231738,Phase 4,NA,Protective Effect of EPA on Cardiovascular Events,Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS),18000,1996-11-01,2004-11-01,Kobe University
NCT00243724,Phase 3,NA,HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease,"An Open-Label, Parallel-Group, Multi-Centre Study to Determine the Effect of Treatment With Esomeprazole for Six Months on Histological Markers of Esophageal Epithelial Acid-Related Disease in Patients With Upper GI Symptoms.",350,2005-04-01,2007-06-01,AstraZeneca
NCT00244387,Phase 3,NA,"Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa","A Multi-centre, Multi-national, Phase 3, Randomized, Double-blind, Double-dummy, 3- Arm Parallel Group, Placebo- and Pramipexole- Controlled Trial of the Efficacy and Safety of Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa",506,2004-03-01,2005-07-01,UCB Pharma
NCT00244842,Phase 3,4,Randomized Placebo-Controlled Study of ISA247 in Plaque Psoriasis,"A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients",451,2004-12-01,2005-10-01,Aurinia Pharmaceuticals Inc.
NCT00269867,Phase 3,5,Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis,"A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment",428,1997-03-01,2000-03-01,"Centocor, Inc."
NCT00272090,Phase 3,NA,Insulin Glargine in Type 1 Diabetes Mellitus,Italian Experience Trial for the Implementation of the Use of Lantus in Basal - Bolus Regimen in Type I Diabetes Mellitus Patients.,489,2002-11-01,2005-12-01,Sanofi
NCT00273026,Phase 4,NA,Study In Asthma Control,"An Open-label, Multi-centre, Randomized, Parallel Group Clinical Effectiveness Study to Determine the Level of Asthma Control in Adolescent and Adult Patients With ADVAIR Versus Usual Care for 24 Weeks.",680,2004-11-01,NA,GlaxoSmithKline
NCT00273052,Phase 3,2,COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension,"A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG- MR) With Metoprolol Succinate (TOPROL XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients",514,2006-01-01,2007-12-01,GlaxoSmithKline
NCT00305162,Phase 3,2,A Clinical Trial to Demonstrate the Efficacy of Cangrelor,A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI).,8882,2006-04-01,2010-06-01,The Medicines Company
NCT00331604,Phase 3,3,Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes,"Inhaled Pre-prandial Human Insulin With the AERx® iDMS Versus s.c. Insulin Aspart in Type 2 Diabetes: A 104 Week, Open-label, Multicenter, Randomised, Trial Followed by a 12 Week Re-randomised Extension to Investigate Safety and Efficacy",618,2006-08-31,2008-05-05,Novo Nordisk A/S
NCT00344110,Phase 3,NA,Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension,"A Randomized, Double-blind, Placebo and Active-controlled, Multicenter, Parallel-group Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg to Evaluate Efficacy, Safety and Pharmacokinetics in Patients With Mild to Moderate Essential Hypertension",768,2006-06-01,2007-04-01,Novartis
NCT00367315,Phase 3,NA,Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA),"A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator",1684,2003-09-01,NA,Novartis
NCT00368277,Phase 3,2,"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly","A 36 Week Randomized, Double-blind, Parallel Group, Multi-center, Active-controlled, Optional Titration Study Comparing an Aliskiren-based Regimen to a Ramipril-based Regimen in Patients ≥ 65 Years Old With Systolic Essential Hypertension",901,2006-09-01,2008-02-01,Novartis
NCT00368979,Phase 3,2,Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects,"Clinical Evaluation of Dutasteride in Benign Prostatic Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparative Study of GI198745 (Dutasteride) in Subjects With Benign Prostatic Hyperplasia.",378,2006-02-01,2007-12-01,GlaxoSmithKline
NCT00377676,Phase 3,2,Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes,"A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability During Treatment of Type 2 Diabetes (T2DM) With Usual Diabetes Therapy (UDT) and Either Cycloset or Placebo",3095,2004-07-01,2007-01-01,VeroScience
NCT00393718,Phase 3,2,Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes,Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes,400,2006-11-01,2008-05-01,Novo Nordisk A/S
NCT00395603,Phase 3,NA,Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122),Compare Ezetimibe 10mg and Simvastatin 40mg vs Atorvastatin 80mg Daily in Subjects With Cardiovascular Heart Disease and/or Diabetes Mellitus With Uncontrolled Lipids on Statin Therapy,550,2006-09-01,2007-06-01,Merck Sharp & Dohme Corp.
NCT00400777,Phase 4,NA,"Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension","An Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy of the Combination of Valsartan and Hydrochlorothiazide and Amlodipine in Hypertensive Patients Not Controlled With Valsartan and Hydrochlorothiazide",460,2006-08-01,2008-06-01,Novartis
NCT00409760,Phase 3,NA,Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension.,"A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients.",1930,2003-01-01,2004-02-01,Novartis
NCT00417222,Phase 3,2,Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan,Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial),1145,2006-11-01,2013-12-01,Tohoku University
NCT00425373,Phase 2/Phase 3,9,Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension,"A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of 8-week Treatment With Valsartan (40 and 80 mg) and Amlodipine (2.5 and 5 mg) Combined and Alone in Essential Hypertensive Patients",1474,2006-11-01,2008-03-01,Novartis
NCT00430248,Phase 3,3,Efficacy and Safety of Oral Febuxostat in Participants With Gout,"A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.",2269,2007-02-01,2008-03-01,Takeda
NCT00443690,Phase 3,2,Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms, Diuresis, Renal Function, and Clinical Outcomes in Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring Intravenous Therapy",480,2007-08-01,2009-01-01,"NovaCardia, Inc."
NCT00454662,Phase 4,2,Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study),Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study),5141,2007-04-01,2011-09-01,COLM Study Research Organization
NCT00474045,Phase 3,2,Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes,"A Randomised, Parallel-group, Open-labelled, Multinational Trial Comparing the Efficacy and Safety of Insulin Detemir (Levemir®) Versus Human Insulin (NPH Insulin), Used in Combination With Insulin Aspart as Bolus Insulin, in the Treatment of Pregnant Women With Type 1 Diabetes",470,2007-05-01,2010-08-01,Novo Nordisk A/S
NCT00484198,Phase 3,4,"Randomized, Double-Blind Active Comparator-Controlled Study of Rivoglitazone in Type 2 Diabetes Mellitus","A Randomized, Double-blind, Placebo and Active Comparator-Controlled, Parallel-Group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus",1820,2007-04-01,2009-02-01,"Daiichi Sankyo, Inc."
NCT00487539,Phase 2/Phase 3,4,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis",1065,2007-08-01,2010-10-01,"Janssen Research & Development, LLC"
NCT00489736,Phase 3,2,Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation,"Randomized Double Blind Trial to Evaluate the Efficacy and Safety of Dronedarone (400mg BID) Versus Amiodarone (600mg Daily for 28 Days, Then 200mg Daily Thereafter) for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation (AF)",504,2007-06-01,2008-10-01,Sanofi
NCT00529529,Phase 3,3,Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma,"A 26-week Treatment, Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group Study to Assess the Safety of Indacaterol (300 and 600 µg o.d.) in Patients With Moderate to Severe Persistent Asthma, Using Salmeterol (50 µg b.i.d.) as an Active Control",805,2007-09-01,2008-08-01,Novartis
NCT00535405,Phase 3,5,A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128),"A Multicenter, Randomized, Double-Blind, Parallel, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at High or Moderately High Risk for Coronary Heart Disease",1289,2007-11-01,2009-03-01,Merck Sharp & Dohme Corp.
NCT00541697,Phase 3,NA,Eze/Simva Switch Study in Diabetics (0653A-807),"A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination Tablets Ezetimibe/Simvastatin (10mg/20mg) and Ezetimibe/Simvastatin (10mg/40mg) Compared to Atorvastatin 20mg in Patients With Type II Diabetes.",648,2005-01-19,2005-10-14,Merck Sharp & Dohme Corp.
NCT00542555,Phase 3,4,Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee,"301: A Phase 3 Study of the Analgesic Efficacy and Safety of HCT 3012: A Parallel, Randomized, Double Blind, 13 Week Placebo and Naproxen Controlled, Multicenter Study of HCT 3012 (375 mg Bid and 750 mg Bid) in Patients With Osteoarthritis of the Knee, Followed by Its Extension (301E): A Parallel, Randomized, Open-Label, Multicenter, 52-Week Follow-up Safety Study of HCT 3012 (375 mg Bid and 750 mg Bid) in Subjects With Osteoarthritis of the Knee",918,2005-12-01,2007-09-01,NicOx
NCT00565409,Phase 4,3,Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis,"A Randomized, Double-Blind Study Comparing the Safety & Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, & Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis",834,2008-03-01,2011-05-01,Pfizer
NCT00580840,Phase 4,3,Dosing Flexibility Study in Patients With Rheumatoid Arthritis,"A Phase IIIb Open-label run-in Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety/Efficacy of Certolizumab Pegol Administered Concomitantly With Stable-dose Methotrexate in Patients With Active Rheumatoid Arthritis.",333,2007-12-01,2011-03-01,UCB Pharma
NCT00604344,Phase 3,NA,Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes,"A 48-week, Randomised, Multi-centre, Openlabelled, Parallel-group Trial to Compare the Efficacy and the Safety of NN304 (Insulin Detemir) and NPH Human Insulin in Subjects With Insulin Requiring Diabetes Mellitus on a Basal-bolus Regimen",401,2003-04-01,2005-03-01,Novo Nordisk A/S
NCT00633932,Phase 3,3,Reflux Esophagitis Phase III Study (Initial Treatment),"A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg and 40 mg Once Daily Oral Administration With Omeprazole 20 mg Once Daily Oral Administration in Patients With Reflux Esophagitis",602,2007-12-01,2008-12-01,AstraZeneca
NCT00634309,Phase 3,2,Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added),Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Depressed Left Ventricular Systolic Function,597,1999-06-01,2003-05-01,AstraZeneca
NCT00640627,Phase 4,2,Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen,"A Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex® (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen",380,2003-12-01,2004-09-01,Pfizer
NCT00645268,Phase 4,3,"A Multicenter, Double-Blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes","A Multicenter, Double-Blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Viagra® (Sildenafil Citrate) on the PRN Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes",300,2002-12-01,2004-01-01,Pfizer
NCT00648141,Phase 3,3,Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis,"A 12-Week Symptomatic Effect Evaluation to Compare Celecoxib 200 mg QD, Celecoxib 200 mg BID and Diclofenac 75 mg SR BID in Patients With Ankylosing Spondylitis",458,2003-01-01,2005-01-01,Pfizer
NCT00653341,Phase 3,2,Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s),Target Glycemic Control and the Incidence of Symptomatic Nocturnal Hypoglycemia in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or NPH Human Insulin.,764,2000-01-01,2001-10-01,Sanofi
NCT00673790,Phase 4,3,The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose,Blood Pressure and Metabolic Effects of Nebivolol Compared With Hydrochlorothiazide and Placebo in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose,543,2008-05-01,NA,Forest Laboratories
NCT00673920,Phase 3,3,A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy,"A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy",314,2008-04-01,2009-10-01,"Genentech, Inc."
NCT00676338,Phase 3,4,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)","Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes",820,2008-11-01,2011-01-01,AstraZeneca
NCT00683618,Phase 3,3,Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia,"A Randomised, Double-blind Trial to Compare the Efficacy of Rosuvastatin 5 and 10 mg to Atorvastatin 10 mg in the Treatment of High Risk Patients With Hypercholesterolemia Followed by an Open Label Treatment Period With Rosuvastatin Up-titrated to the Maximum Dose of 20 mg for Those Patients Who do Not Achieve Goal",934,2008-05-01,2009-07-01,AstraZeneca
NCT00706134,Phase 3,4,"Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study","An Eight-week Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal",756,2008-05-01,2009-04-01,Novartis
NCT00722852,Phase 3,2,Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee,"Multicentre, Randomized, Double-blind, Placebo-controlled Study of Safety and Efficacy of Epicutaneously Applied Diractin® (Ketoprofen in Transfersome® Gel) for the Treatment of Osteoarthritis of the Knee",555,2008-06-01,2009-04-01,IDEA AG
NCT00734630,Phase 4,2,Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients,"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Nebivolol Added To Antihypertensive Treatment With Lisinopril or Losartan in Patients With Hypertension.",491,2008-08-01,2010-05-01,Forest Laboratories
NCT00744926,Phase 3,3,A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide Compared to Placebo, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise",373,2008-08-01,2010-04-01,Hoffmann-La Roche
NCT00765830,Phase 3,2,Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension),"A 28 Week Extension to a 24 Week Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of Vildagliptin (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency",349,2008-09-01,2011-04-01,Novartis
NCT00794157,Phase 3,3,Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD),"A 12-week Treatment, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (150 and 300 µg Once Daily [od]) in Patients With Chronic Obstructive Pulmonary Disease (COPD)",347,2008-11-01,2009-10-01,Novartis
NCT00809354,Phase 3,5,Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip,"A Phase 3, Multi-Center, Randomized, Double-Blind, Controlled Study Of The Long-Term Analgesic Efficacy And Safety of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip",2720,2009-02-01,2010-10-01,Pfizer
NCT00821834,Phase 3,2,Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned,"A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg Once Daily With a 300 mg Loading Dose Versus Ticlopidine 100 mg Twice Daily in Patients With Stable Angina or Old (Healed) Myocardial Infarction to Which Percutaneous Coronary Intervention is Being Planned - With Extended Treatment of Clopidogrel 75 mg Once Daily for 40 Weeks in a Patients' Subset",1003,2008-12-01,2010-08-01,Sanofi
NCT00862251,Phase 3,3,Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED),"A Randomized, Double-Blind, Active-Controlled Study of Patients With Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled With Simvastatin or Atorvastatin: Comparison of Switching to Combination Tablet Ezetimibe/Simvastatin Versus Switching to Rosuvastatin or Doubling the Statin Dose",808,2009-04-01,2011-03-01,Merck Sharp & Dohme Corp.
NCT00865020,Phase 4,2,Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal,"A Twelve-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Prolonged Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg in Mild to Moderate Hypertensive Patients With the 24-hour Ambulatory Blood Pressure Measurement After 1 Week of Treatment Withdrawal Study Acronym: ASSERTIVE - AliSkiren Study of Profound antihypERtensive Efficacy in hyperTensIVE Patients",822,2009-03-01,2010-06-01,Novartis
NCT00887978,Phase 3,2,Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension,"A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension",310,2009-06-01,2011-07-01,United Therapeutics
NCT00900146,Phase 2/Phase 3,5,"Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients","Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study",556,2009-04-01,2010-11-01,Novartis
NCT00929851,Phase 3,2,BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate),"a 48-week, Double Blind, Randomized, Multinational, Multicentre, ""Fixed Combination"" Beclomethasone Dipropionate Plus Formoterol Fumarate Versus Formoterol in Patients With Severe Chronic Obstructive Pulmonary Disease",1199,2009-10-01,2012-07-01,Chiesi Farmaceutici S.p.A.
NCT00953212,Phase 3,4,Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery,"A Randomized Controlled Trial to Compare Prophylaxis With Oral Ascorbic Acid, Oral Amiodarone or Both in Combination With Beta Blockers to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery",304,2009-08-01,2012-02-01,Maine Medical Center
NCT00972738,Phase 3,3,Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235),"A Multi-Center, Double-blind, Randomized, Parallel-Group Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis-Spring 2001 Study",1214,2001-04-01,2001-07-01,Merck Sharp & Dohme Corp.
NCT01007435,Phase 3,4,A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis,"A Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission and Prevention of Structural Joint Damage During Treatment With Tocilizumab (TCZ), as a Monotherapy and in Combination With Methotrexate (MTX), Versus Methotrexate in Patients With Early, Moderate to Severe Rheumatoid Arthritis",1162,2009-10-31,2014-01-28,Hoffmann-La Roche
NCT01013532,Phase 4,4,PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage,"A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and Cardiovascular Events and to Compare the Preventive Effect of Probucol in the Same Patient Group With Non-drug User Group for the Prevention of Cardiovascular Events",1600,2009-06-01,2016-12-01,Asan Medical Center
NCT01039688,Phase 3,3,"Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX","Phase 3 Randomized, Double-Blind Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Compared To Methotrexate In Methotrexate-Naive Patients With Rheumatoid Arthritis",968,2010-01-01,2013-03-01,Pfizer
NCT01079234,Phase 3,3,Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes,"A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)",493,2010-03-01,2011-05-01,Novo Nordisk A/S
NCT01086384,Phase 3,2,Asthma Exacerbation Study,"A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma",2020,2010-02-22,2011-09-15,GlaxoSmithKline
NCT01087788,Phase 3,7,Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis,"Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Adult-Onset Active and Progressive Psoriatic Arthritis (PsA)",409,2010-03-01,2015-08-01,UCB Pharma
NCT01101009,Phase 4,2,Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure,Efficacy of Sevikar® Compared to the Combination of Perindopril/ Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension-,486,2010-04-01,2012-12-01,"Daiichi Sankyo, Inc."
NCT01159600,Phase 3,4,Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes,"A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea",1504,2010-07-01,NA,Boehringer Ingelheim
NCT01179048,Phase 3,2,Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results,"A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events",9340,2010-08-31,2015-12-17,Novo Nordisk A/S
NCT01192724,Phase 4,2,Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation,A Trial of Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients With Long or Multi-vessel Coronary Artery Disease Underwent Biolimus-Eluting Stent Implantation,630,2010-03-01,2012-12-01,Yonsei University
NCT01224366,Phase 3,2,Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus,"A 24-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus.",448,2010-09-01,2011-10-01,Novartis
NCT01285323,Phase 3,2,A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma,"A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma",464,2011-03-01,2014-04-01,Teva Pharmaceutical Industries
NCT01287117,Phase 3,4,A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment,"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)",319,2011-02-01,2012-10-01,"Genentech, Inc."
NCT01292473,Phase 3,4,"A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)","A Phase III, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine Treatment (H1)",323,2011-03-01,2012-06-01,"Genentech, Inc."
NCT01323621,Phase 3,2,Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),512,2011-03-18,2012-01-24,GlaxoSmithKline
NCT01459809,Phase 3,3,Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients,"A Multinational, Open Label, Randomized, Active-controlled, 3-arm Parallel Group, 24-week Study Comparing the Combination of Glimepiride and Metformin Versus Glimepiride and Metformin Alone in Patients With Type 2 Diabetes",538,2012-02-01,2014-01-01,Sanofi
NCT01465763,Phase 3,2,"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis","A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis",614,2012-04-01,2015-05-01,Pfizer
NCT01572792,Phase 3,5,"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)","A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",921,2012-04-01,2013-06-01,AstraZeneca
NCT01604278,Phase 3,2,"Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","A 12-week Multi-center, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of the Co-administration of NVA237 + Indacaterol Once Daily vs. Indacaterol Once Daily in Patients With Moderate to Severe COPD",449,2012-05-01,2013-01-01,Novartis
NCT01644500,Phase 3,3,A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus,"The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus",737,2012-07-01,2014-08-01,Eli Lilly and Company
NCT01706198,Phase 3,2,"An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma","A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler Compared With Usual Maintenance Therapy in Subjects With Asthma",4232,2012-11-01,2016-12-16,GlaxoSmithKline
NCT01787396,Phase 3,3,Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d,"A Multicenter, Randomized, Active-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d Compared With Either Monotherapy in Treatment naïve Patients With Type 2 Diabetes",433,2013-04-01,2015-03-01,LG Life Sciences
NCT01813422,Phase 3,2,GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound,"A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization",970,2013-04-18,2016-07-29,Amgen
NCT01838850,Phase 3,2,"Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy","A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Triple Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg, Amlodipine 5mg and Hydrochlorothiazide 12.5mg in Patients With Hypertension Not Controlled With Dual Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg and Hydrochlorothiazide 12.5mg",344,2013-04-01,2014-08-01,"Daiichi Sankyo, Inc."
NCT01897532,Phase 4,2,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk",7003,2013-07-10,2018-01-18,Boehringer Ingelheim
NCT01952145,Phase 3,2,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch),557,2013-09-20,2014-11-04,Novo Nordisk A/S
NCT01975246,Phase 3,2,Add-on to Micamlo BP Trial,An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Amlodipine 5 mg,309,2013-11-01,2014-07-01,Boehringer Ingelheim
NCT02068443,Phase 3,3,Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy,"A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Comparative Study When Metformin Hydrochloride 500 mg is Added on to SYR-322 25 mg in Type 2 Diabetic Patients",374,2014-02-01,2015-02-01,Takeda
NCT02072226,Phase 3,2,A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke,"A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)",313,2014-05-31,2017-03-22,"Genentech, Inc."
NCT02151851,Phase 3,2,A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis,"A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel Group, Randomized 24-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol (CZP) as Additional Medication to Methotrexate in Chinese Subjects With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate",431,2014-06-01,2016-06-01,UCB Pharma
NCT02177344,Phase 3,4,Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease,"A Six Month, Randomized, Double-blind (Within Formulation), Multiple Dose Trial to Compare the Safety and Efficacy of 20 mcg and 40 mcg of Ipratropium Bromide, as Delivered by the RESPIMAT Device, to 18 mcg ATROVENT® Inhalation Aerosol (x 2 Puffs) and Respective Placebos in Adults, With Chronic Obstructive Pulmonary Disease",646,1998-08-01,NA,Boehringer Ingelheim
NCT02178137,Phase 4,3,Effect of Interventions on the Progression of Knee Osteoarthritis,"Effect of Interventions on Progression of Knee Osteoarthritis - a Comparison of Effect of Glucosamine/Chondroitin or Diacerin Vs Placebo: Measured by Clinical, Radiological and Biochemical Parameters",322,2014-06-01,2017-10-01,Indus Hospital
NCT02183220,Phase 3,4,Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache,"A Randomised, Double Blind, Placebo- and Active-controlled Parallel Group Study Investigating the Efficacy and Tolerability of Metamizol 0.5 g and 1.0 g in Patients With Episodic Moderate Tension Headache.",417,1998-10-01,NA,Boehringer Ingelheim
NCT02245672,Phase 3,3,MGR001 / Advair Diskus Local Equivalence Study in Asthma,"A Randomized, Double-blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to Advair Diskus Administered Via Oral Inhalation in Adult Asthma Patients",2725,2014-10-01,2015-07-01,Mylan Inc.
NCT02268214,Phase 3,3,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,"A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus",833,2014-11-11,2017-08-25,AstraZeneca
NCT02273050,Phase 3,3,Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control,"A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control",1136,2014-12-01,2016-08-01,AstraZeneca
NCT02305849,Phase 3,3,A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment,"Phase III Study of ASP015K - A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to MTX",519,2014-07-25,2017-11-28,Astellas Pharma Inc
NCT02446912,Phase 3,3,Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus,"A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus",460,2015-06-09,2018-07-13,AstraZeneca
NCT02495324,Phase 4,3,Fimasartan Achieving SBP Target (FAST) Study,"A Randomized, Double-blind, Active Control, 3-parallel Group, Forced Titration, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Fimasartan Versus Valsartan Monotherapy in Patients With Mild to Moderate Essential Hypertension",369,2015-06-01,2017-05-01,"Boryung Pharmaceutical Co., Ltd"
NCT02513160,Phase 3,4,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) at 320 or 640 mcg/Day in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma",713,2015-09-30,2016-03-31,Teva Pharmaceutical Industries
NCT02532855,Phase 3,2,A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838),"A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea",614,2015-10-20,2017-10-10,Merck Sharp & Dohme Corp.
NCT02551575,Phase 2/Phase 3,3,Efficacy and Safety of Traditional Chinese Medicine (TCM) Comprehensive Therapy in Patients With Rheumatoid Arthritis,"Efficacy and Safety of Qingre Huoxue Comprehensive Therapy in the Treatment of Rheumatoid Arthritis (RA): A Randomized, Double-blind, Double-dummy, Multi-center Trial",468,2014-11-01,2017-12-01,Guang'anmen Hospital of China Academy of Chinese Medical Sciences
NCT02551874,Phase 3,2,"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin","A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin With or Without Sulfonylurea Therapy",651,2015-10-20,2017-11-09,AstraZeneca
NCT02629159,Phase 3,3,A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate,"A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)",1629,2015-12-01,2021-01-21,AbbVie
NCT02967211,Phase 4,2,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to ""Standard of Care"" Basal Insulin in Patients Already Using Basal Insulin","A Twenty-six Week, Randomized, Open-label, 2-arm Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes Benefit of Transition to Toujeo Compared to ""Standard of Care"" Insulin in Basal Insulin Treated Patients With Uncontrolled Type 2 Diabetes Mellitus, With Six-Month Extension",609,2015-12-21,2017-10-20,Sanofi
NCT03220425,Phase 3,2,Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.,"A Six Month, Multi-centre, Open-label, Parallel Efficacy and Safety Comparison of Insulin Detemir and NPH Insulin in Subjects With Type 1 Diabetes on a Basal-bolus Regimen.",752,2001-02-01,2001-11-12,Novo Nordisk A/S
NCT00000478,Phase 3,NA,Asymptomatic Cardiac Ischemia Pilot (ACIP) Study,NA,NA,1990-11-01,1997-06-01,"National Heart, Lung, and Blood Institute (NHLBI)"
NCT00000530,Phase 3,NA,Raynaud's Treatment Study (RTS),NA,NA,1992-09-01,1998-06-01,"National Heart, Lung, and Blood Institute (NHLBI)"
NCT00004817,Phase 3,NA,Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures,NA,385,1991-02-01,NA,Office of Rare Diseases (ORD)
NCT00032786,Phase 3,NA,Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease,"A Phase 3, International, Multicenter, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Antegren (Natalizumab) in Maintaining Clinical Response and Remission in Subjects With Crohn's Disease",NA,2002-03-01,2004-03-01,Biogen
NCT00032799,Phase 3,NA,Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease,"A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease",905,2001-12-01,2003-09-01,Biogen
NCT00074542,Phase 3,NA,An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease,"A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease",364,2002-09-01,2005-01-01,Tillotts Pharma AG
NCT00077779,Phase 3,NA,Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease,"A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease",854,2003-07-01,NA,Abbott
NCT00077805,Phase 4,NA,PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin),"An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke",NA,2003-08-01,NA,Sanofi
NCT00078611,Phase 3,NA,A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease,"A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous Antegren(TM) (Natalizumab) in Subjects With Moderately to Severely Active Crohn's Disease With Elevated C-Reactive Protein",462,2004-03-01,2005-03-01,Biogen
NCT00090116,Phase 3,NA,The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease,"A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's Type",400,2003-03-01,2005-03-01,Forest Laboratories
NCT00091429,Phase 3,NA,Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine,"A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Ranolazine SR at a Dose of 1000 mg Twice a Day in Patients With Chronic Angina Who Remain Symptomatic Despite Treatment With Amlodipine 10 mg Once a Day",500,2004-08-01,2005-02-01,Gilead Sciences
NCT00099268,Phase 3,2,Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy,"A Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy",747,2004-09-01,2008-11-01,Novartis
NCT00099788,Phase 3,2,Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes,"A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multinational, Clinical Trial to Evaluate the Efficacy and Safety of Ranolazine vs Placebo in Patients With Non-ST Segment Elevation Acute Coronary Syndromes",6560,2004-10-01,2007-02-01,Gilead Sciences
NCT00105300,Phase 3,NA,Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderate to Severe Crohn's Disease Who Have Lost Response or Are Intolerant to Infliximab",300,2004-10-01,NA,Abbott
NCT00120328,Phase 3,NA,"To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy","ASCEND - A Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Effect of the Endothelin Receptor Antagonist Avosentan on Time to Doubling of Serum Creatinine, End Stage Renal Disease or Death in Patients With Type 2 Diabetes Mellitus and Diabetic Nephropathy",2364,2005-07-01,2007-02-01,Speedel Pharma Ltd.
NCT00130208,Phase 3,2,Effect of Sulodexide in Early Diabetic Nephropathy,The Collaborative Study Group Trial: The Effect of Sulodexide in Patients With Type 2 Diabetes and Microalbuminuria,1000,2005-08-01,2008-02-01,Keryx Biopharmaceuticals
NCT00136019,Phase 3,NA,SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization",400,2004-03-01,2006-08-01,UCB Pharma
NCT00136773,Phase 4,NA,Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus,Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus,332,2003-04-01,2005-11-01,Novartis
NCT00138723,Phase 3,NA,"Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome","A Phase 3, Parallel Group, Randomized, Double-Blind, Placebo Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome",NA,2003-10-01,2005-02-01,Pfizer
NCT00141232,Phase 4,NA,Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes,"A Multicentre, Randomised, Double Blind Placebo Controlled Trial Evaluating Atorvastatin in Factorial With Omega-3 Fatty Acids Cardiovascular Risk Reduction in Patients With Type 2 Diabetes",810,2004-11-01,2006-07-01,Pfizer
NCT00143221,Phase 4,NA,Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH),"A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Flexible Dose Study With and Open-Label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States",350,2004-03-01,2005-05-01,Pfizer
NCT00143507,Phase 3,2,The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction,Effects of Ivabradine on Cardiovascular Events in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction. A Three-year Randomised Double-blind Placebo-controlled International Multicentre Study.,10917,2004-12-01,2008-02-01,Servier
NCT00143520,Phase 2/Phase 3,NA,Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes,"A Randomized, Double-blind, Double-dummy, Placebo-controlled 26-week Dose-response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects With Type 2 Diabetes",441,2004-12-01,2005-12-01,"Daiichi Sankyo, Inc."
NCT00147719,Phase 3,NA,WelChol® With Metformin in Treating Patients With Type 2 Diabetes,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Monotherapy or Metformin Therapy in Combination With Other Oral Anti-Diabetic Agents",300,2004-06-01,2006-07-01,"Daiichi Sankyo, Inc."
NCT00147758,Phase 3,NA,WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Sulfonylurea Monotherapy or Sulfonylurea Therapy in Combination With Other Oral Anti-Diabetic Agents",400,2004-06-01,2006-08-01,"Daiichi Sankyo, Inc."
NCT00151502,Phase 3,NA,To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.,"An 80-Week, Randomized, Multi-Center, Parallel-Group, Double-Blind Study of the Efficacy and Safety of Atorvastatin 80 MG Plus an Acetylcholinesterase Inhibitor Versus an Acetylcholinesterase Inhibitor Alone in the Treatment of Mild to Moderate Alzheimer's Disease.",600,2002-11-01,2007-07-01,Pfizer
NCT00152425,Phase 3,NA,"Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).","A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Maintenance of Clinical Response to Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed 4-weekly From Weeks 8 to 24), in the Treatment of Patients With Active Crohn's Disease Who Have Responded to Open Induction Therapy (Dosed at Weeks 0, 2 and 4) With CDP870",392,2004-02-01,2005-05-01,UCB Pharma
NCT00152490,Phase 3,NA,"A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)","A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Safety and Efficacy of the Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed at Weeks 0, 2, 4 Then 4-weekly to Week 24), in the Treatment of Patients With Active Crohn's Disease",604,2003-12-01,2005-05-01,UCB Pharma
NCT00152971,Phase 3,3,Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement,"A Phase III, Randomized, Parallel-group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day 1 Followed by 150 mg Day 2-completion, and 110 mg Day 1 Followed by 220 mg Day 2-completion) of Dabigatran Etexilate Administered Orally (Capsules), Compared to Enoxaparin 30 mg Twice a Day Subcutaneous for 12 - 15 Days in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Knee Replacement Surgery",2615,2004-11-01,NA,Boehringer Ingelheim
NCT00153036,Phase 3,NA,Rt-PA in the Treatment of Acute Ischemic Stroke,ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset,821,2003-04-01,NA,Boehringer Ingelheim
NCT00157586,Phase 3,NA,Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND),"A Multicenter, Randomized, Prospective, Double-blind Study to Evaluate the Nephroprotective Effect of Delapril Alone or Combined With Manidipine in Patients With Type 2 Diabetes",342,2002-02-01,2008-06-01,Mario Negri Institute for Pharmacological Research
NCT00162084,Phase 3,NA,A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography,"A Phase 3, Parallel, Double Blind, Multicenter Trial to Examine Inducible Myocardial Perfusion Abnormality Detection With BMS068645 and Adenosine Stress SPECT Compared to Coronary Angiography",2000,2005-04-01,NA,Forest Laboratories
NCT00168818,Phase 3,3,Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery,"A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Replacement Surgery. RE-NOVATE (Extended Thromboembolism Prevention After Hip Surgery)",3494,2004-11-01,NA,Boehringer Ingelheim
NCT00171145,Phase 3,2,A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.,A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.,445,2004-04-01,2004-12-01,Novartis
NCT00171184,Phase 4,2,"Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder","Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder",400,2005-04-01,2006-06-01,Novartis
NCT00171496,Phase 4,2,Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients,"A Six-month Open Label, Multicenter, Randomized Study to Evaluate the Incidence of New Onset Diabetes Mellitus and Glucose Metabolism in Patients Receiving Cyclosporine Microemulsion With C-2 Monitoring Versus Tacrolimus After de Novo Kidney Transplantation",693,2003-10-01,2006-03-01,Novartis
NCT00174759,Phase 3,NA,CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease,"A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.",1460,2004-09-01,NA,Sanofi
NCT00203034,Phase 3,3,Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations,"A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations",472,2000-05-01,2003-01-01,Teva Pharmaceutical Industries
NCT00203060,Phase 3,2,"Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa","A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial For The Efficacy, Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinson's Disease (PD) Patients Not Treated With Levodopa",404,1997-07-01,2000-07-01,Teva Pharmaceutical Industries
NCT00210821,Phase 3,NA,Comparing the Safety and Effectiveness of Topiramate With the Safety and Effectiveness of Amitriptyline in Preventing Migraine Headaches,A Comparison of Topiramate Versus Amitriptyline in Migraine Prophylaxis,347,2004-02-01,2005-11-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00210912,Phase 3,1,A Study of the Effectiveness and Safety of Topiramate Versus Placebo for Preventing Chronic Migraine Headaches,A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Chronic Migraine,328,2003-09-01,2005-04-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00211705,Phase 4,NA,Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study),Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study),8000,1994-02-01,2004-03-01,Mitsukoshi Health and Welfare Foundation
NCT00212732,Phase 3,NA,Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan,Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan,750,2003-10-01,NA,Ono Pharmaceutical Co. Ltd
NCT00212810,Phase 4,NA,Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.,TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study,385,2005-09-01,2007-08-01,"Ortho-McNeil Neurologics, Inc."
NCT00215436,Phase 3,NA,A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD,"A 12-week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg in the Treatment of Patients With Chronic Obstructive Pulmonary Disease",345,2005-03-01,2006-09-01,Dey
NCT00216619,Phase 3,2,The Prolonged Use of Topiramate for Preventing Migraine Headaches,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Investigate the Efficacy and Tolerability of Topiramate in Prolonged Migraine Prevention",834,2003-11-01,2006-08-01,"Janssen Pharmaceutica N.V., Belgium"
NCT00220363,Phase 3,NA,A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome,"A Phase 3, Parallel Group, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome",NA,2004-01-01,2005-02-01,Pfizer
NCT00220415,Phase 3,NA,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization","A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization",NA,2004-05-01,2006-01-01,UCB Pharma
NCT00220961,Phase 3,2,Actos Now for Prevention of Diabetes (ACT NOW),Actos Now for Prevention of Diabetes (ACT NOW),602,2004-01-01,2010-04-01,The University of Texas Health Science Center at San Antonio
NCT00225277,Phase 3,2,Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus,"A Double-Blind, Randomized, Comparator-Controlled Study In Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular Ultrasound",547,2003-07-01,2007-10-01,Takeda
NCT00225589,Phase 3,NA,A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR),"A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)",840,2002-08-01,2006-05-01,AstraZeneca
NCT00231595,Phase 3,NA,A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine",768,2001-03-01,2002-11-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00235716,Phase 3,4,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease","CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)",613,2007-08-01,2012-10-01,VA Office of Research and Development
NCT00236509,Phase 3,NA,A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine",763,2001-02-01,2002-09-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00236561,Phase 3,NA,A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine,"A Randomized, Double-Blind, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prophylaxis of Migraine",786,2001-04-01,2002-12-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00239330,Phase 3,NA,Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy,"An Open-label, Randomised, Multi-centre, Phase IIIb, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin and Atorvastatin in Subjects With Type IIa and IIb Hypercholesterolaemia",824,2003-06-01,2005-02-01,AstraZeneca
NCT00242320,Phase 3,2,Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119),"The JADE Study: A 12-week, Double-blind, Randomized Study to Investigate the Effect of 500 mcg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease",551,2005-08-01,2007-08-01,AstraZeneca
NCT00247247,Phase 4,2,Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.,Efficacy and Tolerability of Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing-Off Phenomenon,300,2002-12-01,2005-06-01,"Orion Corporation, Orion Pharma"
NCT00256204,Phase 3,3,A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease,"A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects",1174,2005-11-01,2009-06-01,Teva Pharmaceutical Industries
NCT00280371,Phase 3,NA,A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPD,"A 12-week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg/0.5 mL Delivered by OMRON MicroAir NE-U22V Nebulizer in the Treatment of Patients With Chronic Obstructive Pulmonary Disease",345,2006-01-01,2007-05-01,Dey
NCT00280696,Phase 3,5,A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures,"A Double-blind, Randomized, Placebo-controlled 5 Parallel Groups, Confirmatory Trial on the Efficacy and Safety of Levetiracetam Used as add-on Therapy at Doses of 0.5 to 3 g/Day in Patients From 16 to 65 Years With Epilepsy With Partial Onset Seizures Under Treatment With 1 to 3 Anti-epileptic Drug(s)",352,2005-11-01,2007-11-01,UCB Pharma
NCT00282932,Phase 4,NA,Detrol LA In Men With Overactive Bladder.,"A Randomized, Double Blind, Placebo Controlled Detrol LA ""Add-On"" To Alpha-Blocker Study In Men With Persistent Overactive Bladder Symptoms Of Urinary Frequency And Urgency With/Without Urgency Incontinence After Previous Monotherapy With Alpha Blocker.",600,2006-01-01,NA,Pfizer
NCT00283335,Phase 3,2,The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol,CSP #363 - The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol,2531,1991-06-01,1999-08-01,VA Office of Research and Development
NCT00286494,Phase 3,3,Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Pioglitazone in Subjects With Type 2 Diabetes Mellitus",493,2006-02-01,2007-08-01,Takeda
NCT00286897,Phase 3,NA,"The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations","A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations",702,2006-02-01,2007-08-01,Eisai Inc.
NCT00291330,Phase 3,2,Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism,"A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication.",2564,2006-02-01,NA,Boehringer Ingelheim
NCT00300196,Phase 3,2,"ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke","ASP II (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute Ischemic Stroke",311,2006-03-01,2008-12-01,Neurobiological Technologies
NCT00300430,Phase 3,3,"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.","A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects With Mixed Dyslipidemia",1911,2006-09-01,NA,Abbott
NCT00300456,Phase 3,6,Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,"A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 and Simvastatin Combination Therapy to ABT-335 and Simvastatin Monotherapy in Subjects With Mixed Dyslipidemia",657,2006-03-01,NA,Abbott
NCT00300469,Phase 3,6,Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,"A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Atorvastatin Calcium Combination Therapy to Fenofibric Acid and Atorvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia",613,2006-03-01,NA,Abbott
NCT00300482,Phase 3,6,Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood,"A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Rosuvastatin Calcium Combination Therapy to Fenofibric Acid and Rosuvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia",1445,2006-03-01,NA,Abbott
NCT00308347,Phase 3,NA,A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED),"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy",1513,1996-05-01,2001-04-01,Merck Sharp & Dohme Corp.
NCT00309244,Phase 3,2,Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up,"A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere /Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up",677,2006-02-01,2008-09-01,Mannkind Corporation
NCT00311402,Phase 3,2,JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme,"JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily",1295,2006-04-01,NA,Boehringer Ingelheim
NCT00313313,Phase 3,3,A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas,"A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Glyburide in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Glyburide Alone",768,2006-04-01,2008-09-01,AstraZeneca
NCT00316082,Phase 3,5,Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise",365,2006-06-01,2008-11-01,AstraZeneca
NCT00322153,Phase 3,2,A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type",677,2005-06-01,2008-01-01,Forest Laboratories
NCT00325390,Phase 3,NA,Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation,Double-Blind Parallel Comparison Study of SR25990C Versus Standard Therapy in Japan(Ticlopidine) in Patients With Acute Coronary Syndrome Without ST-Segment Elevation Who Are Planned for Percutaneous Coronary Intervention,800,2004-07-01,NA,Sanofi
NCT00327015,Phase 3,4,A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,"A Multicenter, Randomized, Double-Blind Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control",1306,2006-05-01,2008-12-01,AstraZeneca
NCT00327691,Phase 4,NA,A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels,"The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD",8600,1998-04-01,2004-08-01,Pfizer
NCT00328523,Phase 3,NA,TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060),Ezetimibe Together With Any Statin Cholesterol Enhancement,1496,2004-06-01,2006-01-01,Merck Sharp & Dohme Corp.
NCT00329173,Phase 3,NA,PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.,"A 6-Week Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-Group Study to Compare the Efficacy and Safety of Rosuvastatin (10 mg) With Atorvastatin (20 mg) in Subjects With Hypercholesterolaemia and Either a History of CHD or Clinical Evidence of CHD",1000,2003-11-01,2004-08-01,AstraZeneca
NCT00329238,Phase 3,2,Secondary Prevention of Venous Thrombo Embolism (VTE).,"A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.",2867,2006-05-01,NA,Boehringer Ingelheim
NCT00330850,Phase 3,NA,An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack,NA,650,2006-05-01,2006-12-01,ProEthic Pharmaceuticals
NCT00331487,Phase 3,2,Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia,Pioglitazone Versus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia,719,2000-09-01,2004-03-01,Takeda
NCT00334958,Phase 3,2,Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures,"A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures",356,2006-02-01,2009-05-01,Eisai Inc.
NCT00337558,Phase 4,2,A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR),"Solifenacin Succinate in a Flexible Dose Regimen With Simplified Bladder Training Versus Solifenacin Succinate in a Flexible Dose Regimen Alone in a Prospective, Randomized, Parallel Group, Overactive Bladder Symptom Study",643,2006-05-01,2007-05-01,Astellas Pharma Inc
NCT00338117,Phase 3,NA,"Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease","A European Multi-Center Study to Determine the Safety and Efficacy of Galanthamine Hydrobromide 40mg/Day (32 mg /Day GAL Base, Tid Dose Regimen) in Patients Diagnosed With Alzheimer-Type Dementia",554,1995-08-01,1997-05-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00348140,Phase 3,3,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease,"A 54 Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE4-stratified Subjects With Mild to Moderate Alzheimer's Disease",1468,2006-07-12,2009-03-20,GlaxoSmithKline
NCT00353587,Phase 2/Phase 3,5,Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin,"Phase 2/3, Randomized, Double-blind, Placebo- and Active Comparator-controlled, Parallel, Multicenter Study to Determine Safety and Efficacy of Metaglidasen in Treatment of Type 2 Diabetes Suboptimally Controlled on Insulin",396,2006-05-01,2007-11-01,"CymaBay Therapeutics, Inc."
NCT00360308,Phase 3,3,"Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations","A Multi-centre, Randomised, Double-blind, Placebo and Entacapone Controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations",723,2006-11-01,2008-04-01,Eisai Inc.
NCT00362323,Phase 3,2,Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFO,"A Randomized, Double-blind Study Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Metformin Alone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Not Appropriately Controlled With a Statin.",482,2006-10-01,2009-03-01,Solvay Pharmaceuticals
NCT00366301,Phase 4,4,The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes,The LANCET Trial: A Randomized Clinical Trial of Lantus for C-reactive Protein Reduction in Early Treatment of Type 2 Diabetes,500,2006-08-01,2009-04-01,Brigham and Women's Hospital
NCT00368108,Phase 3,3,"Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations",752,2006-08-01,2008-01-01,Eisai Inc.
NCT00379899,Phase 4,1,ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis,A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis,360,2006-09-01,2009-11-01,Amgen
NCT00380939,Phase 4,NA,This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.,"A Prospective, Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Atorvastatin Versus Pravastatin on the Progression and Quantification of Coronary Atherosclerotic Lesions as Measured by Intravascular Ultrasound (REVERSAL)",600,1999-04-01,2000-12-01,Pfizer
NCT00402363,Phase 3,2,"Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation",663,2006-11-01,2010-01-01,GlaxoSmithKline
NCT00423085,Phase 3,3,Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease,"A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)",859,2007-01-01,2010-04-01,Novartis
NCT00426751,Phase 3,2,Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI),Eptifibatide Versus Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction,429,2006-10-01,2007-12-01,GlaxoSmithKline
NCT00432276,Phase 3,2,Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus,"A Multicenter, Randomized, Double-Blind Study to Determine the Efficacy and Safety of the Addition of SYR-322 25 mg Versus Dose Titration From 30 mg to 45 mg of Pioglitazone HCl (ACTOS®) in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Control on a Combination of Metformin and 30 mg of Pioglitazone HCl Therapy",803,2007-01-01,2009-06-01,Takeda
NCT00440050,Phase 3,2,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease,402,2007-02-01,2009-05-01,Alzheimer's Disease Cooperative Study (ADCS)
NCT00444925,Phase 3,3,Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB),"12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)",1712,2007-04-01,2008-07-01,Pfizer
NCT00464269,Phase 3,4,"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures",400,2007-09-01,2009-01-01,UCB Pharma
NCT00464308,Phase 4,3,"A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg",The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT),1392,2006-11-01,2008-05-01,Janssen-Cilag Pty Ltd
NCT00475852,Phase 3,2,A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure,"Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF)",7141,2007-05-01,2011-03-01,"Scios, Inc."
NCT00490035,Phase 3,4,"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",399,2007-09-01,2009-02-01,UCB Pharma
NCT00503152,Phase 3,3,Preventing Microalbuminuria in Type 2 Diabetes,"A Prospective, Randomized, Probe Trial to Evaluate Whether, at Comparable Blood Pressure Control, Combined Therapy With the ACEI Benazepril and the ARB Valsartan, Reduces the Incidence of Microalbuminuria More Effectively Than BEN or VAL Alone in Hypertensive Patients With Type 2 Diabetes and High-normal Albuminuria",613,2007-05-01,2016-09-01,Mario Negri Institute for Pharmacological Research
NCT00522379,Phase 3,5,Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch,"A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects With Advanced-stage Parkinson's Disease",514,2007-07-01,2011-07-01,UCB Pharma
NCT00528372,Phase 3,9,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise",1067,2007-09-01,2010-07-01,AstraZeneca
NCT00528879,Phase 3,4,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",915,2007-09-01,2010-05-01,AstraZeneca
NCT00536484,Phase 3,2,Fesoterodine Flexible Dose Study,"A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.",896,2007-08-01,2008-03-01,Pfizer
NCT00537238,Phase 3,2,Pregabalin Versus Levetiracetam In Partial Seizures,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",509,2007-10-01,2012-05-01,Pfizer
NCT00537940,Phase 4,2,Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures,"A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.",484,2008-02-01,2013-07-01,Pfizer
NCT00546637,Phase 3,2,"Fesoterodine ""add-on"" Male Overactive Bladder Study","A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Fesoterodine As An ""Add-On"" Therapy In Men With Persistent Overactive Bladder Symptoms Under Monotherapy Of Alpha Blocker For Lower Urinary Tract Symptoms.",947,2007-11-01,2009-02-01,Pfizer
NCT00551447,Phase 3,NA,A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED),A Comparison of Treatment With Ezetimibe (SCH 58235) and Simvastatin Coadministration Versus Simvastatin in Attaining the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Coronary Heart Disease (CHD) or CHD Risk Equivalent Strata Low-Density Lipoprotein Cholesterol (LDL-c),616,2002-01-01,2003-03-01,Merck Sharp & Dohme Corp.
NCT00555217,Phase 3,2,VA NEPHRON-D: Diabetes iN Nephropathy Study,CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study),1448,2008-07-01,2014-10-01,VA Office of Research and Development
NCT00575588,Phase 3,2,"52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period","A 52-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone.",891,2007-12-01,2010-08-01,AstraZeneca
NCT00596752,Phase 4,2,Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV,"Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV)",840,2004-03-01,2013-07-01,UCB Pharma
NCT00608881,Phase 3,2,Coenzyme Q10 in Huntington's Disease (HD),Coenzyme Q10 in Huntington's Disease (HD),609,2008-03-01,2015-05-01,Massachusetts General Hospital
NCT00611026,Phase 3,3,Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.,"12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder.",2417,2008-02-01,2009-10-01,Pfizer
NCT00614939,Phase 3,2,Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment,"A Short-term 12-Week, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study to Evaluate the Treatment Effect of Saxagliptin Compared With Placebo in Adult Patients With Type 2 Diabetes and Renal Impairment (Moderate, Severe, and End-Stage) With an Additional 40-week, Randomized, Double-blind, Placebo-controlled Long-term Observational Period.",572,2008-01-01,2010-03-01,AstraZeneca
NCT00627640,Phase 3,2,"Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa","A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine",549,2009-02-01,2012-03-01,Newron
NCT00631189,Phase 4,2,Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients,Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Subjects With Type IIa and IIb Hypercholesterolaemia,668,2007-10-01,2008-10-01,AstraZeneca
NCT00639158,Phase 3,2,Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood,"A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 in Combination With Atorvastatin and Ezetimibe to Atorvastatin in Combination With Ezetimibe in Subjects With Combined (Atherogenic) Dyslipidemia",543,2008-02-01,NA,Abbott
NCT00643851,Phase 3,3,An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets,"A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control",994,2008-06-01,2009-08-01,AstraZeneca
NCT00660907,Phase 3,2,Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients,"A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone.",1217,2008-03-01,2013-01-01,AstraZeneca
NCT00660998,Phase 4,2,Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes,"A Rand, db, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Plac in Men With Diabetes Mellitus Type 1 and Erectile Dysfunction",318,2003-02-01,2004-01-01,Bayer
NCT00661362,Phase 3,2,Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes,"A 24-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy",570,2008-06-01,2009-09-01,AstraZeneca
NCT00666458,Phase 3,2,18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D),"18-wk, International, Multi-centre, Randomized, Parallel-group, Double-Blind, Active-Controlled Phase IIIb Study to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin in Comparison With Sitagliptin in Combination With Metformin in Adult Patients With T2D Who Have Inadequate Glycaemic Control on Metformin Alone",822,2008-04-01,2009-03-01,AstraZeneca
NCT00668005,Phase 3,2,Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension,"A Randomized, Double-blind, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administration for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Men With Arterial Hypertension and Erectile Dysfunction",388,2003-02-01,2003-09-01,Bayer
NCT00668109,Phase 3,2,"Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia","A Randomized, Open-label, Multi-center, Parallel Group Study to Investigate the Efficacy and Safety of Vardenafil in Comparison to Tadalafil in Males With Erectile Dysfunction and a Diagnosis of Diabetes, Hypertension or Hyperlipidemia",614,2003-12-01,2004-06-01,Bayer
NCT00673231,Phase 3,4,"Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin","A 24-week International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Patients With Type 2 Diabetes With Inadequate Glycaemic Control on Insulin",1240,2008-04-01,2011-01-01,AstraZeneca
NCT00677807,Phase 3,3,"Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)","A 26-week Extension to a 26-week Treatment, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess Safety, Tolerability and Efficacy of Two Doses of Indacaterol (150 and 300 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease",415,2008-05-01,2009-03-01,Novartis
NCT00679627,Phase 3,2,A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease",2051,2008-06-01,2012-05-01,"Janssen Research & Development, LLC"
NCT00680186,Phase 3,2,Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE),"A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication",2589,2008-04-01,NA,Boehringer Ingelheim
NCT00680745,Phase 3,4,Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients,"A 24-Week,Int.,Rand.,Double-blind,Parallel-group,Multi-centre, Plac.-Controlled Phase III Study With a 24-Wk Ext.Per.to Eval.the Efficacy and Safety of Dapagliflozin in Comb.With Glimepiride (a Sulphonylurea) in Subjects With Type2 Diab.Who Have Inadeq. Glycaemic Control on Glimepiride Therapy Alone",597,2008-04-01,2010-05-01,AstraZeneca
NCT00683878,Phase 3,3,Add-on to Thiazolidinedione (TZD) Failures,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Thiazolidinedione Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone",972,2008-07-01,2010-06-01,AstraZeneca
NCT00685776,Phase 3,2,Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019),"A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease",1623,2008-03-24,2017-11-23,Merck Sharp & Dohme Corp.
NCT00685841,Phase 3,5,A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease",717,2002-02-01,2003-06-01,Sunovion
NCT00698932,Phase 3,2,Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control,"A 24-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise.",568,2008-06-01,2009-10-01,AstraZeneca
NCT00699582,Phase 3,3,To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",389,2008-05-01,2011-01-01,Eisai Inc.
NCT00699972,Phase 3,3,Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",390,2008-06-01,2010-11-01,Eisai Inc.
NCT00700310,Phase 3,4,Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",712,2008-08-01,2010-01-01,Eisai Inc.
NCT00740623,Phase 3,3,"A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.",547,2009-01-01,2010-04-01,SK Life Science
NCT00757588,Phase 3,2,Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin,"A Multicenter, Randomized, Double-Blind, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin Alone or on Insulin in Combination With Metformin",455,2008-11-01,2010-04-01,AstraZeneca
NCT00772603,Phase 3,3,Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures,Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures,366,2008-11-01,2010-11-01,"Supernus Pharmaceuticals, Inc."
NCT00783692,Phase 3,2,Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease,"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease",1116,2008-12-01,2012-05-01,"Millennium Pharmaceuticals, Inc."
NCT00814801,Phase 3,3,An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease,Placebo-controlled Confirmatory Study of Galantamine (R113675) for Alzheimer's Type Dementia,580,2007-02-01,2008-09-01,Janssen Pharmaceutical K.K.
NCT00857649,Phase 3,2,Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease,"A Randomised, Double-Blind, Parallel-Group Study Examining the Efficacy and Safety of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type",369,2003-12-01,2010-09-01,H. Lundbeck A/S
NCT00880620,Phase 3,4,A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease,A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease,381,2009-04-01,2010-11-01,"IMPAX Laboratories, Inc."
NCT00911937,Phase 4,2,A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency,"A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency.",963,2009-08-01,2011-09-01,Pfizer
NCT00928070,Phase 4,2,A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder,"A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Vulnerable Elderly Patients With Overactive Bladder.",566,2009-09-01,2011-09-01,Pfizer
NCT00947843,Phase 4,3,Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents,"Assessment of the Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents : A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial",306,2013-11-01,2016-10-01,Seoul National University Hospital
NCT00957684,Phase 3,5,Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial.",402,2004-07-01,2007-02-01,Bial - Portela C S.A.
NCT00984867,Phase 3,2,Dapagliflozin DPPIV Inhibitor add-on Study,"A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study With 24 Week Extension to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg/Day in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on a DPP-4 Inhibitor Sitagliptin+/-Metformin",833,2009-10-01,2011-09-01,AstraZeneca
NCT00988429,Phase 3,3,Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial",653,2008-12-01,2017-07-01,Bial - Portela C S.A.
NCT01028586,Phase 3,3,"MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)","A Phase III, Double-blind, Placebo-controlled Extension Trial to Investigate the Long-term Efficacy and Safety of Low (50 mg/Day) and High (100 mg/Day) Dose Safinamide, as add-on Therapy in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist",507,2009-10-01,NA,Newron
NCT01049984,Phase 4,2,Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease,"A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease",328,2009-12-01,2012-10-01,Teva Pharmaceutical Industries
NCT01087762,Phase 3,7,Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis,"Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis",325,2010-03-01,2015-08-01,UCB Pharma
NCT01089751,Phase 4,2,Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily,NA,322,2010-03-01,2012-06-01,Allergan
NCT01093534,Phase 4,3,Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.,"A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects With Overactive Bladder and a Diagnosis of Detrusor Overactivity - A Double-blind, Randomised, Placebo-controlled, Parallel Group, Multi-centre Study.",547,2010-01-01,2011-06-01,Astellas Pharma Inc
NCT01095653,Phase 3,3,A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise",1179,2010-06-01,2012-03-01,AstraZeneca
NCT01095666,Phase 3,3,A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",1484,2010-06-01,2013-03-01,AstraZeneca
NCT01099137,Phase 4,2,Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin,The Study About Glucose Lowering Effect of Vildagliptin in Type 2 Diabetes Patients Who Are Uncontrolled With Metformin and a Sulphonylurea,344,2010-01-01,2013-05-01,Seoul National University Bundang Hospital
NCT01132638,Phase 3,2,Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease,"Evaluation of Complete Remission of Erosive Gastroesophageal Reflux Disease Following Four-week Treatment With Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg With Eight-week Extension Treatment in Non-responding Patients - Multicenter, National, Prospective, Randomized, Double-blind, Parallel-group, Phase III",713,2011-08-01,2012-06-01,Takeda
NCT01137474,Phase 3,4,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)",2996,2010-07-01,2013-02-01,AstraZeneca
NCT01187966,Phase 3,3,"Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease","A Phase III, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Patients With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, and/or an Anticholinergic",669,2007-01-01,2009-02-01,Newron
NCT01188824,Phase 4,2,The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study),The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study),801,2010-09-01,2013-07-01,China Medical University Hospital
NCT01195662,Phase 3,2,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication",2245,2010-10-01,2013-02-01,AstraZeneca
NCT01217892,Phase 3,4,Evaluation of Dapagliflozin Taken Twice-daily,"A 16-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Safety and Efficacy of Dapagliflozin 2.5 mg BID, 5 mg BID and 10 mg QD Versus Placebo in Patients With Type 2 Diabetes Who Are Inadequately Controlled on Metformin-IR Monotherapy",400,2010-11-01,2011-08-01,AstraZeneca
NCT01224171,Phase 3,2,Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease,"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease",416,2010-11-01,2012-04-01,"Millennium Pharmaceuticals, Inc."
NCT01227655,Phase 3,3,Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.,"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With ""Wearing-off"" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Study.",427,2011-03-01,2012-07-01,Bial - Portela C S.A.
NCT01228747,Phase 3,2,"A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)","A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Oral Levetiracetam, in Epilepsy Patients Aged ≥16 Years, With Generalized Tonic-clonic (GTC) Seizures",361,2010-10-01,2014-05-01,UCB Pharma
NCT01229735,Phase 4,2,Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures,"A Randomized, Open-label, Parallel Group, Multi-center, Comparative, Phase IV Trial of Levetiracetam (LEV) Versus Topiramate (TPM) as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures",343,2010-11-01,2015-05-01,UCB Pharma
NCT01252056,Phase 4,3,A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy,"A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy",353,2010-03-01,2012-12-01,Otsuka Beijing Research Institute
NCT01252953,Phase 3,2,REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification,"REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease",30624,2011-06-01,2019-04-01,University of Oxford
NCT01261325,Phase 3,3,Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 Years Old) With Partial Onset Seizures",768,2010-12-01,2014-05-01,UCB Pharma
NCT01262677,Phase 3,3,Once-A-Day Pregabalin For Partial Seizures,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures - Protocol A0081194",334,2011-01-01,2012-08-01,Pfizer
NCT01272219,Phase 3,5,Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes,"Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation",3731,2011-06-01,2015-03-02,Novo Nordisk A/S
NCT01283594,Phase 2/Phase 3,5,Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off,"A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off",420,2011-03-01,NA,Biotie Therapies Inc.
NCT01284556,Phase 3,3,Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures,"An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Phenobarbital as Adjunctive Therapy in Participants (> or = 17 to 70 Years Old) With Partial Onset Seizures",314,2010-11-01,2016-04-01,West-Ward Pharmaceutical
NCT01286935,Phase 3,3,18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD,"A Phase III, Double-blind, Placebo-controlled, 18-mon Ext Study Long-term Efficacy & Safety of 50 & 100mg/Day Doses of Safinamide, as add-on Therapy, in Idiopathic PD Pts With Motor Fluctuations, Treated With Levodopa, Who May be Receiving DA, and/or Anticholinergic",544,2007-08-01,2010-08-01,Newron
NCT01291641,Phase 4,3,Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy,"Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study",342,2011-03-01,2017-03-01,Seoul National University Hospital
NCT01300819,Phase 4,2,Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms,"Multicenter, Double-blind, Placebo-controlled, Parallel-group, Phase IV Study to Assess the Effect of Rotigotine on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease",349,2011-02-01,2012-11-01,UCB Pharma
NCT01302067,Phase 4,3,A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine,"A 12-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Trial In Overactive Bladder Subjects To Confirm The Efficacy Of 8 Mg Fesoterodine Compared To 4 Mg Fesoterodine.",2012,2011-05-01,2012-11-01,Pfizer
NCT01313494,Phase 3,2,"A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:","A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial",626,2011-03-01,2012-05-01,AstraZeneca
NCT01353235,Phase 3,2,Oral Prednisolone in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD),A Prospective Randomized Trial of Systemic Corticosteroids (Oral Prednisolone) in Severe Exacerbation of COPD Requiring Ventilatory Assistance,317,2010-04-01,2013-06-01,Hôpital Universitaire Fattouma Bourguiba
NCT01369329,Phase 3,3,A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1),"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)",769,2011-07-01,2013-07-01,"Janssen Research & Development, LLC"
NCT01369342,Phase 3,3,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2),"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)",640,2011-07-01,2014-10-01,"Janssen Research & Development, LLC"
NCT01369355,Phase 3,6,A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI),"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease",1282,2011-09-13,2019-10-21,"Janssen Research & Development, LLC"
NCT01455857,Phase 3,3,A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes,"Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes",460,2013-03-01,2014-09-01,Intarcia Therapeutics
NCT01455870,Phase 3,2,A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes,"A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes",535,2013-05-01,2015-07-01,Intarcia Therapeutics
NCT01455896,Phase 3,2,A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650,"A Randomized, Multi-Center Study to Evaluate Cardiovascular Outcomes With ITCA 650 in Patients Treated With Standard of Care for Type 2 Diabetes",4156,2013-03-01,2016-03-01,Intarcia Therapeutics
NCT01479530,Phase 3,2,Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China,"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China",321,2011-12-01,NA,H. Lundbeck A/S
NCT01488019,Phase 4,2,Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate),"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate) Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",1071,2012-03-01,2016-01-01,Dey
NCT01492361,Phase 3,2,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial),8000,2011-11-01,NA,Amarin Pharma Inc.
NCT01512004,Phase 3,2,Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder,"Phase III Study of Propiverine Hydrochloride Extended-Release Capsule in the Treatment of Overactive Bladder (OAB) in Chinese Population With Urgent Micturition, Frequent Micturition and/or Urge Urinary Incontinence",324,2010-01-01,2011-08-01,Lee's Pharmaceutical Limited
NCT01523301,Phase 4,2,Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients,"Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients",380,2012-04-01,2014-10-01,UCB Pharma
NCT01541956,Phase 4,2,Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION),"An Open-labeled, Randomized, Multicenter, Prospective, Parallel Group, Interventional Study to Demonstrate the Effectiveness of 24 Weeks Treatment With Vildagliptin 50mg Bid as Add on to Metformin 500 mg Bid Compared to Metformin up to 1000 mg Bid in Chinese Patients With Type 2 Diabetes Inadequately Controlled on Metformin 500 mg Bid Monotherapy .",3091,2012-02-01,2013-12-01,Novartis
NCT01568073,Phase 3,3,"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With ""Wearing-off"" Phenomenon","Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With ""Wearing-off"" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo- and Active-controlled, Parallel-group, Multicentre Clinical Study",600,2011-03-01,2013-11-01,Bial - Portela C S.A.
NCT01606007,Phase 3,3,Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes,"A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy With Saxagliptin and Dapagliflozin Added to Metformin Compared to Add-On Therapy With Saxagliptin in Combination With Metformin or Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone.",1282,2012-07-01,2014-01-01,AstraZeneca
NCT01618695,Phase 3,2,A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures,"A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures",465,2012-05-17,2019-09-01,Eisai Inc.
NCT01619059,Phase 3,2,Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes,"A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy With Saxagliptin Added to Dapagliflozin in Combination With Metformin Compared to Therapy With Placebo Added to Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Dapagliflozin",315,2012-06-01,2015-01-01,AstraZeneca
NCT01621178,Phase 3,3,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),"A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease",577,2012-07-01,2016-12-01,Eli Lilly and Company
NCT01624259,Phase 3,2,A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes,"A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide With Once-Daily Liraglutide in Patients With Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation of LY2189265 in Diabetes-6)",599,2012-06-01,2013-11-01,Eli Lilly and Company
NCT01628926,Phase 3,3,A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients,"A Double-Blind, 3-Arm, Parallel Group, Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa",420,2009-06-01,2011-05-01,"Otsuka Pharmaceutical Co., Ltd."
NCT01646255,Phase 3,2,"Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients","A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of The Efficacy And Safety of Rotigotine Transdermal Patch In Chinese Subjects With Advanced-stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled On Levodopa",346,2012-07-01,2014-10-01,UCB Pharma
NCT01646320,Phase 3,2,Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy With Dapagliflozin Added to Saxagliptin in Combination With Metformin Compared to Therapy With Placebo Added to Saxagliptin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Saxagliptin",320,2012-09-01,2015-02-01,AstraZeneca
NCT01652729,Phase 3,3,"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus","A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus",365,2013-02-01,2014-04-01,AstraZeneca
NCT01710657,Phase 3,3,A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontrolled Partial-Onset Seizures With or Without Secondary Generalization",548,2012-09-01,2014-08-01,UCB Pharma
NCT01732822,Phase 3,2,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,"A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)",13885,2012-12-04,2016-09-26,AstraZeneca
NCT01741194,Phase 2/Phase 3,2,AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext,"A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension",418,2013-03-01,2017-04-14,"Accera, Inc."
NCT01763866,Phase 3,24,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,"A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia",2067,2013-01-01,2013-12-01,Amgen
NCT01763918,Phase 3,4,Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects With Heterozygous Familial Hypercholesterolemia",331,2013-02-01,NA,Amgen
NCT01768559,Phase 3,3,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,"A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin",894,2013-01-01,2014-12-01,Sanofi
NCT01776424,Phase 3,3,Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease,A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).,27395,2013-02-28,2021-06-30,Bayer
NCT01777282,Phase 3,5,A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus,"A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus",374,2013-02-23,2015-01-27,GlaxoSmithKline
NCT01794143,Phase 3,4,A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes,Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study,5000,2013-05-01,NA,GRADE Study Group
NCT01798706,Phase 3,2,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients,"A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen",350,2013-06-01,2015-02-01,Sanofi
NCT01908829,Phase 3,3,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),"A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms",2174,2013-07-10,2014-11-25,Astellas Pharma Inc
NCT01937871,Phase 3,3,A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once-Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Erectile Dysfunction",909,2013-09-01,2015-12-01,Eli Lilly and Company
NCT01949948,Phase 3,2,Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke,Randomised Trial of Tenecteplase vs. Alteplase for Recanalisation in Acute Ischemic Stroke,1050,2012-09-01,2016-12-31,Haukeland University Hospital
NCT01954121,Phase 3,2,"Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures","An Open-label, Randomized, Parallel-group, Active-controlled Study Comparing the Efficacy and Safety of Levetiracetam to Carbamazepine Used as Monotherapy in Subjects Newly or Recently Diagnosed as Epilepsy and Partial-onset Seizures",436,2013-09-01,2015-09-01,UCB Pharma
NCT01955161,Phase 3,3,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil",933,2013-10-01,2016-07-01,H. Lundbeck A/S
NCT01963208,Phase 3,2,Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension,"A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults With Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment",405,2013-10-01,2016-10-01,Marinus Pharmaceuticals
NCT01969123,Phase 3,3,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication",474,2013-10-01,2017-01-01,FORUM Pharmaceuticals Inc
NCT01969136,Phase 3,3,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication",403,2013-10-01,2017-01-01,FORUM Pharmaceuticals Inc
NCT01972841,Phase 3,6,"This is a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder",3527,2013-11-05,2015-10-22,Astellas Pharma Inc
NCT01985334,Phase 4,4,Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen,"A Prospective, Multicenter, 12-week, Randomized Open-label Study to Evaluate the Efficacy and Safety of Glycopyrronium (50 Micrograms o.d.) or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination (110/50 Micrograms o.d.) Regarding Symptoms and Health Status in Patients With Moderate Chronic Obstructive Pulmonary Disease (COPD) Switching From Treatment With Any Standard COPD Regimen",4351,2014-06-01,2016-04-01,Novartis
NCT01994720,Phase 3,2,[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES],"A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.",13307,2014-01-07,2016-03-02,AstraZeneca
NCT02006641,Phase 3,3,Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil",858,2014-02-01,2016-12-01,H. Lundbeck A/S
NCT02006654,Phase 3,2,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor,"Randomised, Double-blind, Parallel-group, Placebo-controlled Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor",734,2014-03-01,2017-01-01,H. Lundbeck A/S
NCT02017340,Phase 3,2,A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease,A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease,511,2013-04-24,2016-12-16,"St. James's Hospital, Ireland"
NCT02045862,Phase 3,3,"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder",2084,2014-03-17,2016-09-08,Astellas Pharma Inc
NCT02058147,Phase 3,3,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,"A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)",1170,2014-02-01,2015-06-01,Sanofi
NCT02058160,Phase 3,2,Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes,"A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)",736,2014-01-01,2015-07-01,Sanofi
NCT02080364,Phase 3,2,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,"Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine",800,2015-04-01,2019-01-01,vTv Therapeutics
NCT02104817,Phase 3,2,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH),13086,2014-10-30,2019-10-31,AstraZeneca
NCT02157935,Phase 3,2,Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease,"A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.",2026,2014-06-27,2016-02-08,AstraZeneca
NCT02173457,Phase 3,3,Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients,"Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Sitagliptin-Controlled Trial",738,2014-06-01,2018-09-01,"Chipscreen Biosciences, Ltd."
NCT02284893,Phase 3,2,Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone,"A 26-week International, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3bTrial With a Blinded 26-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone",861,2014-09-01,2016-09-01,AstraZeneca
NCT02294396,Phase 4,4,Post-marketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.,Post-Marketing Study of Mirabegron - Long-term Add-on Therapy With Anticholinergics in Patients With Overactive Bladder Under Treatment With Mirabegron,649,2014-10-28,2016-09-07,Astellas Pharma Inc
NCT02337738,Phase 2/Phase 3,3,A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off",404,2015-01-01,2016-09-01,Takeda
NCT02352363,Phase 3,2,Randomized Safety Study of CVT-301 Compared to an Observational Control Group,"A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease (PD) Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control",408,2015-03-01,2017-05-01,Acorda Therapeutics
NCT02390882,Phase 3,3,A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH,"A Multicenter, Randomized, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With Benign Prostatic Hyperplasia",494,2014-10-01,2015-07-01,Hanmi Pharmaceutical Company Limited
NCT02419612,Phase 3,2,"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial With a Blinded 104-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin ≥1500 mg in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone",444,2015-08-14,2019-08-15,AstraZeneca
NCT02454491,Phase 4,2,Verapamil vs Heparin in Transradial Procedures,Comparison of VERapamil vs. Heparin Therapy on Procedural sUccess During Transradial Coronary Procedures (VERMUT Study),418,2015-05-01,2016-09-01,University Hospital of Ferrara
NCT02465515,Phase 4,2,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus","A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus (HARMONY Outcomes)",9400,2015-07-01,2018-03-22,GlaxoSmithKline
NCT02585778,Phase 3,2,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy",517,2015-10-23,2017-04-03,Sanofi
NCT02623062,Phase 3,2,Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study,"A Multi-centred, Randomised, Double-blind, Two Arms, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Oral Suspension Sachet in Patients With Reflux Disease",644,2013-12-01,2016-05-01,Reckitt Benckiser Healthcare (UK) Limited
NCT02656173,Phase 4,2,"A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)","A Phase 4, Double-Blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With OAB Symptoms, While Taking the Alpha Blocker,Tamsulosin, for BPH",730,2016-01-25,2017-07-21,Astellas Pharma Inc
NCT02963922,Phase 3,2,Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin,Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin,400,2017-02-06,2018-09-25,Novo Nordisk A/S
NCT03006276,Phase 3,2,"Efficacy, Tolerability, and Safety Study of DFN-15",NA,622,2016-12-01,2018-04-01,Dr. Reddy's Laboratories Limited
NCT03009019,Phase 3,2,"Efficacy, Tolerability, and Safety of DFN-15",NA,631,2016-12-01,2018-05-01,Dr. Reddy's Laboratories Limited
NCT03021343,Phase 3,2,Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients,Effect of ColchiciNe on the InciDence of Atrial Fibrillation in Open Heart Surgery Patients: END-AF Trial,360,2012-10-01,2015-02-01,Jordan Collaborating Cardiology Group
NCT00000173,Phase 3,NA,Memory Impairment Study (Mild Cognitive Impairment Study),"A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)",NA,1999-03-31,2004-01-31,National Institute on Aging (NIA)
NCT00000425,Phase 3,NA,Toward Better Outcomes in Osteoarthritis,Toward Better Outcomes in Osteoarthritis (OA): Finding the Appropriate Role for Nonsteroidal Anti-inflammatory Drugs (NSAIDs),900,1996-07-31,2001-04-30,Stanford University
NCT00000480,Phase 3,NA,Multicenter Unsustained Tachycardia Trial (MUSTT),NA,NA,1991-09-30,1996-09-30,"National Heart, Lung, and Blood Institute (NHLBI)"
NCT00035256,Phase 4,NA,Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis,Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis,330,2001-10-31,2005-07-31,Eli Lilly and Company
NCT00067093,Phase 3,NA,Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT),NA,1452,2003-05-31,2005-09-30,Sanofi
NCT00092066,Phase 3,NA,"A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)","A 15-Week, Double-Blind, Randomized, Active-Controlled, Multi-Center Study With 24-Week Extension to Evaluate the Safety, Tolerability, Efficacy of Alendronate 70 mg Plus Vitamin D3 2800 IU Combination Tablet in Men and Postmenopausal Women With Osteoporosis",717,2003-09-24,2004-05-01,Organon and Co
NCT00092079,Phase 3,NA,A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227),"A 15-Week, Double-Blind, Randomized, Active-Controlled, Multi-Center Study With 24-Week Extension to Evaluate the Safety, Tolerability, Efficacy of Alendronate 70 mg Plus Vitamin D3 2800 IU Combination Tablet in Men and Postmenopausal Women With Osteoporosis",652,2004-01-31,2004-11-30,Merck Sharp & Dohme LLC
NCT00097357,Phase 2/Phase 3,8,BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery,"A Phase 2 Randomized, Double-Blinded (BMS-562247 and Enoxaparin), Active-Controlled (Enoxaparin and Warfarin), Parallel-Arm, Dose-Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery",1238,2004-10-31,2005-12-31,Bristol-Myers Squibb
NCT00110474,Phase 3,NA,Glucosamine Unum In Die [Once A Day] Efficacy (GUIDE) Trial: Glucosamine Sulfate in Patients With Knee Osteoarthritis,Efficacy and Safety of Glucosamine Sulfate Versus a Pure Analgesic (Acetaminophen/Paracetamol) and Placebo in Patients Suffering From Osteoarthritis of the Knee,300,2000-05-31,2002-12-31,Rottapharm
NCT00126516,Phase 4,2,Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline,Effects of Angiotensin II Receptor Blockers (ARB) and Angiotensin Converting Enzyme Inhibitors (ACEI) on Progression of Silent Brain Infarction and Cognitive Decline in Japanese Patients With Essential Hypertension in the Elderly,395,2004-05-31,2013-06-30,Nara Medical University
NCT00128024,Phase 4,2,Effects of Early Statin Treatment After Acute Myocardial Infarction (AMI) in Japanese Patients,Effects of Early Statin Treatment on Symptomatic Heart Failure and Ischemic Events After Acute Myocardial Infarction. The MUSASHI-AMI: A Multicenter Randomized Controlled Trial,460,2002-02-28,2006-02-28,Kumamoto University
NCT00134147,Phase 3,NA,A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control,"A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin (Exubera) on Glycemic Control in Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled on a Minimum of Two Oral Anti Diabetic Agents",1100,2005-04-30,2007-05-31,Pfizer
NCT00150410,Phase 3,NA,Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose,"A One-Year, Open, Randomized, Parallel, Three-Arm Study Comparing Exubera® (Insulin Dry Powder Pulmonary Inhaler) vs. Avandia® (Rosiglitazone Maleate) as Add-On Therapy vs. Exubera® Substitution of Sulfonylurea in Patients With Type 2 Diabetes, Poorly Controlled on Combination Sulfonylurea and Metformin Treatment",626,2003-01-31,2007-06-30,Pfizer
NCT00174642,Phase 3,3,Opposing Step-by-step Insulin Reinforcement to Intensified Strategy,Comparison of Three Therapeutic Strategies for Treating Type 2 Diabetes Mellitus Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs,811,2004-12-31,NA,Sanofi
NCT00191425,Phase 4,NA,2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis,"Comparison of a 2-Year Therapy of Teriparatide Alone and Its Sequential Use for 1 Year, With or Without Raloxifene HCl, in the Treatment of Severe Postmenopausal Osteoporosis",810,2002-08-31,2005-11-30,Eli Lilly and Company
NCT00210496,Phase 4,NA,Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine,Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate),406,2005-06-30,2007-06-30,Janssen-Ortho LLC
NCT00247962,Phase 4,2,Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis,"A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis",566,2005-12-31,2008-02-29,Wyeth is now a wholly owned subsidiary of Pfizer
NCT00259610,Phase 4,4,Treatment of Early Aggressive Rheumatoid Arthritis (TEAR),Treatment of Early Aggressive Rheumatoid Arthritis (TEAR),755,2004-05-31,2009-06-30,University of Alabama at Birmingham
NCT00263393,Phase 4,2,Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS),Evaluation of a Primary Health Care Intervention for the Prevention of Cardiovascular Disease in Rural Andhra Pradesh,3712,2005-12-31,2009-06-30,The George Institute
NCT00300118,Phase 3,2,Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD),"Double-blind, Double-dummy, Randomized, Multicentre Study to Compare the Efficacy and Safety of Oral Budesonide (9 mg) and Oral Mesalazine (4.5 g) in Moderately Active Crohn's Disease Patients",311,2004-09-30,2008-05-31,Dr. Falk Pharma GmbH
NCT00314158,Phase 3,3,A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension,NA,523,2005-11-30,2007-01-31,Alcon Research
NCT00329355,Phase 3,NA,Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA),"A Randomized, Double-blind, Single Migraine Attack, Placebo-controlled, Parallel-group Multicenter Study to Evaluate the Efficacy and Tolerability of Trexima (Sumatriptan Succinate.Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women With Dysmenorrhea",351,2006-05-31,2006-11-30,GlaxoSmithKline
NCT00329459,Phase 3,2,"Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea","A Randomized, Double-blind, Single Migraine Attack, Placebo -Controlled, Patallel-group Multicenter Study to Evaluate the Efficacy and Tolerability or Trexima (Sumatriptan Succinate/Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women With Dysmenorrhea",320,2006-05-31,2006-11-30,GlaxoSmithKline
NCT00348452,Phase 3,NA,"A Study Comparing the Effectiveness and Safety of Extended Release Tramadol HCl at 100 mg, 200 mg and 300 mg Doses to Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis (OA)","Double-blind, Randomized, Dose-ranging, Parallel-group Comparison of the Efficacy and Safety of Extended Release Tramadol Hydrochloride (Tramadol HCl ER) 100 mg, 200 mg, 300 mg, Celecoxib 200 mg and Placebo in the Treatment of Osteoarthritis of the Knee and/or Hip.",1000,2002-09-30,2003-08-31,"Bausch Health Americas, Inc."
NCT00370565,Phase 3,NA,Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.,"Efficacy And Safety Of Exubera (Inhaled Insulin) Therapy In Subjects With Type 2 Diabetes Mellitus Not Well Controlled With Combination Oral Agents: A Three-Month, Outpatient, Parallel Comparative Trial.",345,1999-06-30,2000-09-30,Pfizer
NCT00387881,Phase 3,2,TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1),"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Tolerability of TREXIMA* (Sumatriptan Succinate/Naproxen Sodium) for a Single Moderate or Severe Headache in Adults Diagnosed With Probable Migraine Without Aura (ICHD-II 1.6.1) (*TREXIMET)",679,2006-09-30,2008-02-29,GlaxoSmithKline
NCT00389740,Phase 3,NA,A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189),"A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Raloxifene on Bone Mineral Density in Postmenopausal Women With Osteoporosis",400,2001-04-02,2003-01-16,Organon and Co
NCT00393705,Phase 4,2,Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019),A Comparison of Insulin Lispro MM Intensive Mixture Therapy With Progressive Dose-Titration of Insulin Lispro LM or Biphasic Insulin Aspart 30/70,302,2006-10-31,2009-03-31,Eli Lilly and Company
NCT00414973,Phase 3,2,A Study for Patients With Osteoporosis,Comparison of Teriparatide and Calcitonin in the Treatment of Men and Postmenopausal Women With Osteoporosis,364,2006-12-31,2008-07-31,Eli Lilly and Company
NCT00424333,Phase 3,NA,Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes,"Efficacy and Safety of Inhaled Compared With Subcutaneous Human Insulin in an Intensive Insulin Regimen for Subjects With Type 1 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial",320,1999-05-31,2000-10-31,Pfizer
NCT00424437,Phase 3,NA,Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.,"Efficacy and Safety of Inhaled Compared With Subcutaneous Human Insulin Therapy in Subjects With Type 1 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial",320,1999-09-30,2000-09-30,Pfizer
NCT00433732,Phase 3,NA,To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches,"A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy Opf Trexima in the Acute Treatment of Migraine Headaches",1400,2004-08-31,2005-04-30,POZEN
NCT00434083,Phase 3,NA,To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches,"A Double-Blind Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches",1200,2004-07-31,2005-01-31,POZEN
NCT00449787,Phase 4,2,Comparing Naproxen to Sumatriptan for Emergency Headache Patients,A Randomized Clinical Trial to Compare Naproxen and Sumatriptan for Headache Patients Discharged From the Emergency Department (ED),401,2007-03-31,2009-07-31,Montefiore Medical Center
NCT00542633,Phase 3,2,"An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus","An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus",472,2006-12-31,NA,Biodel
NCT00542724,Phase 3,2,"An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus","An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus",462,2006-09-30,NA,Biodel
NCT00562588,Phase 4,NA,EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA,"EARLY: Prospective, Randomised, National, Multi-centre, Open-label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study",551,2007-07-31,NA,Boehringer Ingelheim
NCT00573443,Phase 3,3,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)",326,2007-12-31,2009-09-30,Avanir Pharmaceuticals
NCT00640991,Phase 3,2,REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study),An International Multicentre Randomized Controlled Trial of Intensive Insulin Therapy Targeting Normoglycemia In Acute Myocardial Infarction: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) Pilot Study,500,2008-04-30,2010-06-30,Population Health Research Institute
NCT00652106,Phase 3,3,Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension,NA,432,2003-06-30,2004-03-31,Allergan
NCT00663897,Phase 4,2,Lansoprazole Versus Mosapride for Functional Dyspepsia,A Comparative Study of Lansoprazole and Mosapride for Functional Dyspepsia: Focus on Difference Between Epigastric Pain Syndrome and Postprandial Distress Syndrome,329,2008-05-31,2009-09-30,Lotung Poh-Ai Hospital
NCT00692913,Phase 3,2,A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262),"A Phase III (Phase V Program), Open-Label, Randomized, Referred-Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK -0217A/Alendronate Sodium-70 mg/Vitamin D3 5600 I.U. Combination Tablet on Vitamin D Inadequacy in the Treatment of Osteoporosis in Postmenopausal Women",515,2008-06-30,2010-07-31,Organon and Co
NCT00747110,Phase 3,2,Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC),"Double-blind, Double-dummy, Randomised, Multi-centre, Comparative Phase III Clinical Study on the Efficacy and Tolerability of an 8 Week Oral Treatment With 9 mg Budesonide or 3 g Mesalazine in Patients With Active Ulcerative Colitis",343,2007-10-31,2010-08-31,Dr. Falk Pharma GmbH
NCT00810693,Phase 3,3,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH),"Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)",445,2008-12-31,2012-05-31,Bayer
NCT00856622,Phase 3,3,"A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients","A 6-Month, Randomized, Double-Masked Comparison Of Fixed Combination Of Latanoprost And Timolol With The Individual Components, Continuing Into A 6-Month Open Label Safety Study Of Fixed Combination In Patients With Glaucoma Or Ocular Hypertension.",436,1997-08-31,1999-06-30,Pfizer
NCT00979589,Phase 3,2,Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events,"Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke",5100,2009-12-31,2012-06-30,Beijing Tiantan Hospital
NCT00979628,Phase 4,3,Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM),Basal Bolus Versus Basal Insulin Regimen for the Treatment of Hospitalized Patients With Type 2 Diabetes Mellitus,375,2010-01-31,2012-06-30,Emory University
NCT01021696,Phase 2/Phase 3,5,Pain in Patients With Dementia and Behavioural Disturbances,The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial,352,2009-11-30,2010-10-31,University of Bergen
NCT01194882,Phase 3,2,Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes,Evaluation of Insuman Implantable 400 IU/ml in Patients With Type 1 Diabetes Treated With the Medtronic MiniMed Implantable Pump System Using Insuplant 400IU/ml,479,2010-11-16,2018-02-01,Sanofi
NCT01248468,Phase 4,3,"Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine","A Multi-center, Randomized, Double-blind, Parallel-group Single-dose, Placebo-controlled Study Comparing the Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine.",752,2010-11-30,2011-03-31,Novartis
NCT01342081,Phase 3,3,DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%,"A Double-masked Study of DE-111 Ophthalmic Solution Versus Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocular Hypertension -Phase 3, Confirmatory Study-",489,2011-05-31,NA,"Santen Pharmaceutical Co., Ltd."
NCT01427751,Phase 4,2,Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion,NA,307,2011-10-11,2014-11-04,Allergan
NCT01451398,Phase 3,2,Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus,"A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Prandial Technosphere® Insulin Inhalation Powder Versus Technosphere Inhalation Powder in Insulin Naïve Subjects With Type 2 Diabetes Mellitus Poorly Controlled With Oral Antidiabetic Agents Over a 24 Week Treatment Period",353,2011-11-30,2013-07-31,Mannkind Corporation
NCT01477983,Phase 4,4,Kansai Plus Atrial Fibrillation Trial,Kansai Plus Atrial Fibrillation Trial; UNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate Trial; Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation Trial,2113,2011-11-30,2017-07-31,"Kyoto University, Graduate School of Medicine"
NCT01683331,Phase 4,2,A Clinical Trial to Prevent New Onset Diabetes After Transplantation,A Clinical Trial to Prevent New Onset Diabetes After Transplantation,251,2012-08-31,2018-02-27,University of Michigan
NCT01749904,Phase 3,2,Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension,"A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension.",420,2013-01-31,2015-09-30,Bausch & Lomb Incorporated
NCT01749930,Phase 3,2,Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension,"A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension",420,2013-01-31,2015-05-31,Bausch & Lomb Incorporated
NCT01866163,Phase 3,2,LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris,LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris,426,2013-06-30,2013-11-30,LEO Pharma
NCT01973205,Phase 3,2,Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine,"A Multi-center, Randomized, Double-blind, Parallel-group, Single-dose, Placebo-controlled Study Comparing the Efficacy and Safety of a Combination of Acetaminophen and Aspirin vs Placebo in the Acute Treatment of Migraine",900,2013-10-31,2014-07-31,Novartis
NCT02183688,Phase 3,6,"Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients","A Double-blind, Randomized, Placebo-controlled Clinical Trial to Confirm the Rationale of the ASA + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients",1889,1998-09-30,NA,Boehringer Ingelheim
NCT02207491,Phase 3,2,Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,"A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% Compared to Timolol Maleate Ophthalmic Solution, 0.5% in Patients With Elevated Intraocular Pressure",411,2014-07-31,2015-03-31,Aerie Pharmaceuticals
NCT02207621,Phase 3,3,Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension,"A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% q.d. and b.i.d. Compared to Timolol Maleate Ophthalmic Solution, 0.5% b.i.d. in Patients With Elevated Intraocular Pressure",756,2014-07-31,2016-03-31,Aerie Pharmaceuticals
NCT02558374,Phase 3,2,Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension,"A Double-masked, Randomized, Multi-center, Active-controlled, Parallel Group, 6-month Study With a 3-month Interim Analysis Assessing the Ocular Hypotensive Efficacy and Safety of AR-13324 Ophthalmic Solution, 0.02% QD Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure",708,2015-09-30,2016-12-31,Aerie Pharmaceuticals
NCT02565173,Phase 3,5,Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma,"Phase III Multi-center, Randomized, Double-masked, Active- and Placebo-controlled Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma",303,2015-09-30,2016-11-30,Inotek Pharmaceuticals Corporation
NCT02631551,Phase 3,4,Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR),"A Double-Blind, Randomized, Parallel-Group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose Combination GSP 301 Nasal Spray (NS) Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators) in Subjects (Aged 12 Years and Older) With Seasonal Allergic Rhinitis (SAR)",1180,2016-03-31,2016-07-31,Glenmark Specialty S.A.
NCT02709538,Phase 3,3,Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR),"A Double-Blind, Randomized, Parallel-Group Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Two Placebo Nasal Spray Formulations in Subjects (Aged 12 Years and Older) With Perennial Allergic Rhinitis (PAR)",601,2016-04-30,2017-07-31,Glenmark Specialty S.A.
NCT02870205,Phase 3,4,Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR),"A Double-Blind, Randomized, Parallel-Group Seasonal Allergic Rhinitis (SAR) Study to Evaluate the Efficacy, Safety and Tolerability of GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Olopatadine Hydrochloride Nasal Spray and Mometasone Furoate Nasal Spray) in Adult and Adolescent Subjects (12 Years of Age and Older)",1176,2016-08-31,2017-01-31,Glenmark Specialty S.A.
NCT03049085,Phase 4,2,Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting,"Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting: A Double-blind, Placebo-controlled, Randomized Trial",300,2017-02-01,2019-05-31,Medinet Heart Centre
